POISONS STANDARD FEBRUARY 2019
I, Avi Rebera, as delegate of the Secretary to the Department of Health, make the following Poisons Standard.
Dated 21/12/18
(Signed by)
Avi Rebera
Assistant Secretary
Regulatory Engagement and Planning Branch
Health Products Regulation Group
Department of Health
1. Name
This instrument is the Poisons Standard February 2019.
2. New Poisons Standard
This instrument consists of the Standard for the Uniform Scheduling of Medicines and Poisons No. 23 (the SUSMP 23).
3. Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 February 2019 | 1 February 2019 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
4. Authority
This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989.
5 Repeals
Each instrument that is specified in Schedule 1 to this instrument is repealed as set out in that Schedule.
Schedule 1—Repeals
Note: See section 5.
Poisons Standard October 2018
1 The whole of the instrument
Repeal the instrument
Schedule 2-Standard for the Uniform Scheduling of Medicines and Poisons No. 23
STANDARD FOR THE UNIFORM SCHEDULING OF MEDICINES AND POISONS
No. 23
February 2019
Reasons for scheduling delegates’ final decisions can be accessed from the TGA website, at https://www.tga.gov.au/reasons-scheduling-delegates-final-decisions
Further inquiries in relation to this document should be directed to:
Media Liaison Unit
Australian Government Department of Health
Table of Contents
Table of Contents
INTRODUCTION
PART 1
INTERPRETATION
PART 2
CONTROL ON MEDICINES AND POISONS
SECTION ONE LABELS
SECTION TWO CONTAINERS
SECTION THREE STORAGE
SECTION FOUR DISPOSAL
SECTION FIVE RECORD KEEPING
SECTION SIX SALE, SUPPLY, POSSESSION, or USE
SECTION SEVEN/Appendix I PAINT OR TINTERS
PART 3
MISCELLANEOUS REGULATIONS
SECTION ONE ADVERTISING
SECTION TWO SALE OR SUPPLY
SECTION THREE STORAGE
PART 4
THE SCHEDULES
SCHEDULE 1
SCHEDULE 2
SCHEDULE 3
SCHEDULE 4
SCHEDULE 5
SCHEDULE 6
SCHEDULE 7
SCHEDULE 8
SCHEDULE 9
SCHEDULE 10
PART 5
THE APPENDICES
APPENDIX A – GENERAL EXEMPTIONS
APPENDIX B – SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING
APPENDIX C (see SCHEDULE 10)
APPENDIX D – ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8
APPENDIX E – FIRST AID INSTRUCTIONS FOR POISONS
APPENDIX F – WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS
APPENDIX G – DILUTE PREPARATIONS
APPENDIX H – SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED
APPENDIX I
APPENDIX J – SCHEDULE 7 POISONS REQUIRING ADDITIONAL CONTROLS ON AVAILABILITY AND USE
APPENDIX K – DRUGS REQUIRED TO BE LABELLED WITH A SEDATION WARNING
APPENDIX L – REQUIREMENTS FOR DISPENSING LABELS FOR HUMAN AND VETERINARY MEDICINES
APPENDIX M – ADDITIONAL CONTROLS OR SUPPLY REQUIREMENTS FOR POISONS INCLUDED IN SCHEDULE 3 TO ALLOW THEM TO BE PROVIDED BY A PHARMACIST
INDEX
The Poisons Standard February 2019, which, under section 2 above consists of the Standard for the Uniform Scheduling of Medicines and Poisons No.23 (the Standard, or the SUSMP), is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989, and is a compilation of decisions made under section 52D of the same Act. The SUSMP should be read in conjunction with the Scheduling Policy Framework (SPF) of the Australian Health Ministers' Advisory Council. Further information on the scheduling amendments and the SPF can be accessed at www.tga.gov.au. Refer to Part 1, Interpretation, on page 2 below for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).
The SUSMP serves two key purposes.
Firstly, the SUSMP contains the decisions of the Secretary of the Department of Health or the Secretary's delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.
Secondly, the SUSMP includes provisions for labelling, containers, storage, disposal, record-keeping, sale, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products, for example cosmetics.
The requirements for labelling and containers in the SUSMP are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.
Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in the SUSMP as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons.
The SUSMP is presented with a view to promoting uniform:
- scheduling of poisons throughout Australia;
- signal headings on labels for poisons throughout Australia;
- labelling and packaging requirements for poisons throughout Australia;
- additional controls on the availability and use of poisons in Australia.
The various Commonwealth Acts, legislative instruments and other documents which integrate with the SUSMP include:
- the Agricultural and Veterinary Chemicals Code Act 1994
- the Agricultural and Veterinary Chemicals Code Regulations 1995
- the Therapeutic Goods Act 1989
- Therapeutic Goods Order 69 – General requirements for labels for medicines
- Therapeutic Goods Order 80 – Child-Resistant Packaging Requirements for Medicines
- Therapeutic Goods Order 91 – Standard for labels of prescription and related medicines
- Therapeutic Goods Order 92 – Standard for labels of non-prescription medicines
- the Required Advisory Statements for Medicine Labels (RASML).
CLASSIFICATION
Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.
Schedule 1. | This Schedule is intentionally blank. |
Schedule 2. | Pharmacy Medicine – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person. |
Schedule 3. | Pharmacist Only Medicine – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription. |
Schedule 4. | Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription. |
Schedule 5. | Caution – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label. |
Schedule 6. | Poison – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label. |
Schedule 7. | Dangerous Poison – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply. |
Schedule 8. | Controlled Drug – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence. |
Schedule 9. | Prohibited Substance – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. |
Schedule 10 (previously Appendix C). | Substances of such danger to health as to warrant prohibition of sale, supply and use - Substances which are prohibited for the purpose or purposes listed for each poison. |
PRINCIPLES OF SCHEDULING
Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.
This Standard lists poisons in ten Schedules according to the degree of control recommended to be exercised over their availability to the public.
Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.
For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.
Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this Standard, the method by which it is implemented in the States and Territories may vary.
Schedule 10 (previously Appendix C) contains a list of substances or preparations, the sale, supply or use of which should be prohibited because of their known dangerous properties.
Substances in products which have been considered for scheduling, but have been exempted from this Standard, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).
READING THE SCHEDULES
Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.
Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.
Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.
Where exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.
Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.
Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (‘reverse scheduling’), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.
Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.
It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Part 1, Interpretation, subparagraph 1(2)).
It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.
Finally, when using this Standard to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:
Group | Example |
the parent acid of salts | “oxalic acid” to find sodium oxalate |
the radical of a salt | “chromates” to find potassium chromate |
the element | “arsenic” to find arsenic trioxide |
a chemical group with similar toxicological or pharmacological activity | “hydrocarbons, liquid” to find kerosene |
a pharmacological group | “anabolic steroidal agents” to find “androsterone” |
AVAILABILITY OF POISONS
The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.
These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.
Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not indicate:
- that the poison is available; nor
- that is has been approved or is efficacious for any use that may be specified in a Schedule; nor
- does it negate any obligation for registration of a therapeutic good, or agricultural or veterinary chemical product containing that poison.
PREPARATIONS CONTAINING POISONS LISTED IN TWO OR MORE SCHEDULES
If a preparation contains two or more poisons, the provisions relating to each of the Schedules in which those poisons are included apply.
Where it is not possible to comply both with a provision relating to one of those Schedules and with a provision relating to another of those Schedules, the provision of the more restrictive Schedule applies, unless a contrary intention is indicated in the Schedules or relevant legislation.
The Schedules listed in order of greatest to least restriction on access and availability are 9, 10, 8, 4, 7, 3, 2, 6, 5.
Schedule 1 is not currently in use.
Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this Standard. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.
Appendix | Title | Purpose/ controls imposed |
Appendix A | General exemptions | List of classes of products or uses exempted from this Standard. |
Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |
Appendix C | Appendix is intentionally left blank | See Schedule 10. |
Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |
Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
Appendix G | Dilute preparations | Concentration cut-offs for specified poisons, below which the requirements of the Standard do not apply |
Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |
Appendix I | Appendix is intentionally left blank | |
Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |
Appendix K | Human medicines required to be labelled with a sedation warning | List of human medicines required to be labelled with a warning regarding their sedation potential. |
Appendix L | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |
Appendix M | Additional controls or supply requirements for Poisons included in Schedule 3 to allow them to be provided by a pharmacist | The substance and proposed intervention/additional requirement(s) |
1. (1) In this Standard, unless the contrary intention appears —
“Agricultural chemical” means a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:
a) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing;
b) destroying a plant;
c) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity;
d) modifying an effect of another agricultural chemical;
e) attracting a pest for the purpose of destroying it; or
f) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an agricultural chemical product;
but does not include:
g) a veterinary chemical.
“Agricultural chemical product” has the meaning defined in the Agricultural and Veterinary Chemicals Code Act 1994.
“Animal” means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.
“Animal feed premix” means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.
“Appropriate authority” means:
a) in the Australian Capital Territory, ACT Government Health Directorate;
b) for the purpose of providing an exemption from all or part of Section 1.1 to Section 1.5.3 in Part 2 of this Standard by the Australian Pesticides and Veterinary Medicines Authority, the Chief Executive Officer or their delegate;
c) in New South Wales, the Director-General of the NSW Ministry of Health;
d) in the Northern Territory, the Chief Health Officer of the Department of Health;
e) in Queensland, the Chief Executive of Queensland Health;
f) in South Australia, the Chief Executive of the Department for Health and Ageing;
g) in Tasmania, the Secretary of the Department of Health and Human Services;
h) for the purpose of providing an exemption from all or part of Section 1.1 to Section 1.5.3 of this Standard by the Therapeutic Goods Administration, the National Manager or their delegate;
i) in Victoria, the Secretary to the Department of Health;
j) in Western Australia, the Chief Executive Officer of the Department of Health.
“Approved name” means:
a) in relation to a poison that is for human therapeutic use, the name approved for use by the Therapeutic Goods Administration;
b) in relation to a poison that is for animal or agricultural use, the name approved for use by the Australian Pesticides and Veterinary Medicines Authority;
c) in relation to all other poisons:
i) the name used in an entry in these Schedules; or, if no such name is given,
ii) the English name recommended by Standards Australia as the common name for the poison; or, if no such name is given,
iii) the English name given to the poison by the International Organization for Standardization; or, if no such name is given,
iv) the English name given to the poison by the British Standards Institution; or, if no such name is given,
v) the name that would comply with the requirements of part (a) or (b) of this definition, or, if no such name is given,
vi) the English name given to the poison by the European Committee for Standardization (CEN); or, if no such name is given,
vii) the international non-proprietary name recommended for the poison by the World Health Organization; or, if no such name is given,
viii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the International Cosmetic Ingredient Dictionary & Handbook published by the Personal Care Products Council of America; or, if no such name is given,
ix) the accepted scientific name or the name descriptive of the true nature and origin of the poison.
“Australian Code for the Transport of Dangerous Goods by Road and Rail” means the seventh edition of the document of that name.
“Authorised prescriber” means a registered medical, dental or veterinary practitioner or such other person authorised by the appropriate authority.
“Blood” means whole blood extracted from human donors.
“Blood components” means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.
“Child-resistant closure” means:
a) a closure that complies with the requirements for a child-resistant closure in the Australian Standard AS 1928-2007 entitled Child-resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2003, MOD);
b) a closure approved by an order made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or
c) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”.
See also "Non-access packaging”.
“Child-resistant packaging” means packaging that:
a) complies with the requirements of the Australian Standard AS 1928-2007 entitled Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2003, MOD);
b) is reclosable and complies with the requirements of at least one of the following Standards:
i) the International Organization for Standardization Standard ISO 8317:2003 entitled Child-resistant packaging – Requirements and testing procedures for reclosable packages;
ii) the British Standards Institution Standard BS EN ISO 8317:2004 entitled Child-resistant packaging. Requirements and testing procedures for reclosable packages;
iii) the Canadian Standards Association Standard CSA Z76.1-06 entitled Reclosable Child-Resistant Packages;
iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled Poison prevention packaging standards and Section 1700.20, entitled Testing procedure for special packaging;
c) is approved as child-resistant by any order made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or
d) is in the form of blister or strip packaging in which a unit of use is individually protected until the time of release and that complies with Section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001 entitled Child-resistant packages.
See also "Non-access packaging".
“Compounded” in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.
“Cosmetic” means:
a) a substance or preparation intended for placement in contact with any external part of the human body, including:
i) the mucous membranes of the oral cavity; and
ii) the teeth;
with a view to:
iii) altering the odours of the body; or
iv) changing its appearance; or
v) cleansing it; or
vi) maintaining it in good condition; or
vii) perfuming it; or
viii) protecting it.
“Debitterised neem seed oil” means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.
“Dermal use” means application to the skin primarily for localised effect.
“Designated solvent” means the following:
acetone
dimethylformamide
N-(N-dodecyl)-2-pyrrolidone
hydrocarbons, liquid
methanol when included in Schedule 5
methyl ethyl ketone
methyl isoamyl ketone
methyl isobutyl ketone
N-methyl-2-pyrrolidone
N-(N-octyl)-2- pyrrolidone
phenyl methyl ketone
styrene
tetrachloroethylene
1,1,1-trichloroethane
"Dispensing label” means the label attached to the immediate container of a substance for therapeutic use at the time of dispensing.
“Distributor” means a person who imports, sells or otherwise supplies a poison.
“Divided preparation” means a preparation manufactured and packed as discrete pre-measured dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.
“Dosage unit” means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.
“Drug” means a poison intended for human or animal therapeutic use.
“Essential oils” means products obtained from natural raw materials either by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation. For scheduling purposes it also means:
a) oils of equivalent composition derived through synthetic means; or
b) prepared mixtures of oils of equivalent composition comprising a mixture of synthetic and natural components.
“External” in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.
“First Group Paint” means a paint containing the specified proportion of any substance in the First Group to Part 2 Section 7 of this Standard.
“Free formaldehyde” includes all hydrated and non-hydrated formaldehyde present in aqueous solution, including methylene glycol and formaldehyde released from formaldehyde donors.
“Graphic material” means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.
“Hawking” means to sell or supply (including peddle or distribute or cause to be distributed) in a public place.
“Height” in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.
“Hemp seed oil” means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.
“Immediate container” includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.
“Immediate wrapper” means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.
“Internal use” means administration:
a) orally, except for topical effect in the mouth; or
b) for absorption and the production of a systemic effect;
i) by way of a body orifice other than the mouth; or
ii) parenterally, other than by application to unbroken skin.
“Label” means:
a) a written statement on a container of a poison; and
b) in relation to a therapeutic good, includes a display of printed information about the product:
i) on, or attached to, the good;
ii) on, or attached to, a container or primary pack in which the good is supplied; or
iii) supplied with such a container or pack.
“Main label” means, where there are two or more labels on a container or a label is divided into two or more portions:
a) the part of a label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and
b) where there are two or more labels or two or more portions of a single label – that label or portion of the label where the product name is more or most conspicuously shown; or
c) where the product name is equally conspicuous on two or more labels or portions of a label – each such label or portion.
“Manufacturer” means a person who manufactures, produces, or packs a poison.
“Measure pack” means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.
“Medicine” means any poison for therapeutic use.
Note: To be preceded by “human” or “veterinary” where restriction of the “medicine” to human or animal use is intended.
“Name and address” means the name and address, in Australia, of the manufacturer or distributor of a poison but does not include a post office, cable, telegraphic or code address. Where such manufacturer or distributor is a company incorporated in accordance with the appropriate law of any State or Territory of the Commonwealth of Australia or a firm registered under the Business Names Act of any State or Territory, the inclusion in the label of the registered name of the corporation or firm or its branch or its division and the city or town in which a registered office is situated shall be deemed to comply with the requirements.
“Non-access packaging” is packaging that complies with the requirements of Australian Standard AS4710-2001 entitled Packages for chemicals not intended for access or contact with their contents by humans, in relation to products that are not intended for human therapeutic use.
See also "Child-resistant closure" and "Child-resistant packaging”.
“Non-volatile content” in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005 entitled Paints and related materials – Methods of test – Non-volatile content by mass.
“Oromucosal use” means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.
“Paint”, without limiting the ordinary meaning, includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.
“Pesticide” means any substance or mixture of substances used or intended to be used:
a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or
b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.
“Poison” means any substance or preparation included in a Schedule to this Standard.
“Primary pack” means the pack in which a poison and its immediate container or immediate wrapper or measure pack are presented for sale or supply.
“Product sample” means a packed poison supplied directly to the consumer free of charge or a nominal charge as a mechanism to promote the sale of the product and may be small packs produced specifically for the purposes of promotion or normal commercial packs which in other circumstances a consumer would need to purchase.
“Public Place” means any place where members of the public are lawfully entitled, invited or permitted to be present in their capacity as members of the public. For example a street, road, footway, court, alley or through-fare that the public are allowed to use, in any residential premises, door to door, place to place or house to house.
“Required Advisory Statements for Medicine Labels” means the document made under subsection 3(5A) of the Therapeutic Goods Act 1989 by the Therapeutic Goods Administration.
“Restricted flow insert” means a restriction fitted, or moulded, in the neck of a container which:
a) cannot readily be removed from the container by manual force; and
b) limits the delivery of the contents to drops each of which is not more than 200 microlitres.
“Second Group Paint” means a paint containing the specified proportion of any substance in the Second Group to Part 2 Section 7 of this Standard.
“Selected container” means:
a) an injection vial having a nominal capacity of ten millilitres or less;
b) a single use syringe; or
c) any other container for substances for therapeutic use having a nominal capacity of ten millilitres or less.
“Solid” is considered to include “powder” for the purposes of scheduling.
“Therapeutic good” has the meaning defined in the Commonwealth Therapeutic Goods Act 1989.
“Therapeutic use” means use in or in connection with:
a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals;
b) influencing, inhibiting or modifying a physiological process in human beings or animals;
c) testing the susceptibility of human beings or animals to a disease or ailment;
d) influencing, controlling or preventing conception in human beings or animals;
e) testing for pregnancy in human beings or animals; or
f) the replacement or modification of parts of the anatomy in human beings or animals.
“Tinter” means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.
“Topical use” means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.
“Toy” means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of 14 years.
“Transdermal use” means application to the skin primarily for systemic effect.
“Veterinary chemical” means a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:
a) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest;
b) curing or alleviating an injury suffered by the animal;
c) modifying the physiology of the animal:
i) so as to alter its natural development, productivity, quality or reproductive capacity; or
ii) so as to make it more manageable;
d) modifying the effect of another veterinary chemical
e) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a), (b), (c) or (d); or
f) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an veterinary chemical product;
but does not include:
g) an agricultural chemical.
“Veterinary chemical product” has the meaning defined in the Agricultural and Veterinary Chemicals Code Act 1994.
“Writing” includes the visible representation or reproduction of words or figures in any form, and “to write” and “written” have corresponding meanings.
(2) Unless the contrary intention appears a reference to a substance in a Schedule or an Appendix to this Standard includes:
a) that substance prepared from natural sources or artificially; and
b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that plant or any part of that plant when packed or prepared for therapeutic use; and
c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; and
d) every alkaloid of the substance and every salt of such an alkaloid; and
e) every stereoisomer of the substance and every salt of such a stereoisomer; and
f) every recombinant form of the substance; and
g) a preparation or admixture containing any proportion of the substance,
but does not include:
h) a preparation or product included in Appendix A, or a substance and the reason for its entry in Appendix B; or
i) a substance included in Appendix G at a concentration not exceeding the concentration specified in column 2 of that Appendix in respect of that substance; or
j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; or
k) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the Standards for Active Constituents, as published by the Australian Pesticides and Veterinary Medicines Authority.
(3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a Schedule or an Appendix to this Standard in respect of a substance:
a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and
b) the expression “one per cent” means:
i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or
ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram of the substance per 100 grams of the preparation; and
iii) any expression of greater or lesser percentages shall have a corresponding meaning; and
c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.
(4) A reference to a boiling or distillation temperature in the Schedules means that temperature at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).
1.1 General requirements
(1) A person must not sell or supply a poison unless it is labelled in accordance with Part 2 Section 1 of this Standard.
(2) Any word, expression or statement required by this Standard to be written on a label or container must be written:
a) on the outside face of the label or container; and
b) in the English language; and
c) in durable characters; and
d) in a colour or colours to provide a distinct contrast to the background colour; and
e) in letters at least 1.5 millimetres in height.
(3) Section 1.1(2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 millilitres or less, or on the label of such a container if:
a) an appropriate authority approves the use of smaller letters; and
b) the letters are at least 1 millimetre in height.
(4) The label must be printed on, or securely attached to:
a) the outside of the immediate container; and
b) if the immediate container is enclosed in a primary pack, the outside of that primary pack.
1.2 Immediate wrapper
(1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in accordance with Section 1.3 of this Standard; and
(2) the immediate wrapper must be conspicuously labelled with:
a) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and
b) the approved name of the poison; and
c) a statement of the quantity or strength of the poison in accordance with Section 1.4 of this Standard.
1.3 Primary packs and immediate containers
(1) The primary pack and immediate container of a poison must be labelled as follows:
a) with the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the following table:
Schedule | Purpose | Signal words required |
2 | for any purpose | PHARMACY MEDICINE |
3 | for any purpose | PHARMACIST ONLY MEDICINE |
4 | for human use | PRESCRIPTION ONLY MEDICINE |
4 | for animal use | PRESCRIPTION ANIMAL REMEDY |
5 | for any purpose | CAUTION |
6 | for any purpose | POISON |
7 | for any purpose | DANGEROUS POISON |
8 | for any purpose | CONTROLLED DRUG |
written:
i) on the first line or lines of the main label; and
ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least half the height of the largest letter or numeral on the label but need not be larger than:
A) 6 millimetres on labels for packages having a nominal capacity of 2 litres or less; or
B) 15 millimetres on labels for packages having a nominal capacity of more than 2 litres; and
iv) if the poison:
A) is a Schedule 5 poison, with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail or a statement of the principal hazard of the poison, written on that line; or
B) is not a Schedule 5 poison, with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on that line;
b) if the poison is a Schedule 8 poison, with the cautionary statement –
POSSESSION WITHOUT AUTHORITY ILLEGAL
written:
i) on a separate line or lines immediately below the signal words required by Section1.3(1)(a); and
ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least four-tenths the height of the letters used for the signal words; and
iv) with no other statement written on the same line;
c) with the cautionary statement –
KEEP OUT OF REACH OF CHILDREN
written:
i) on a separate line or lines:
A) immediately below the signal word or words required by Section 1.3(1)(a); or
B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by Section 1.3(1)(b), on the line immediately below that statement; and
ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least four-tenths the height of the letters used for the signal word or words; and
iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line;
d) if the poison is a dry chlorinating compound containing more than 10 per cent of available chlorine, except for preparations certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, with the cautionary statement –
FIRE AND EXPLOSION HAZARD
written:
i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section 1.3(1)(c); and
ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least four-tenths the height of the letters used for the signal word or words; and
iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line;
e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary statement –
BURNS SKIN AND THROAT
written:
i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section 1.3(1)(c); and
ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least four-tenths the height of the letters used for the signal word; and
iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line of the main label;
f) if the poison is an aqueous solution of paraquat, with the cautionary statements –
CAN KILL IF SWALLOWED
DO NOT PUT IN DRINK BOTTLES
KEEP LOCKED UP
written:
i) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section1.3(1)(c); and
ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least four-tenths the height of the letters used for the signal words; and
iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same lines of the main label;
g) for any poison other than a poison for human therapeutic use labelled in accordance with the Required Advisory Statements for Medicine Labels, if safety directions are required on the label by Section 1.3(1)(n), with the cautionary statement –
READ SAFETY DIRECTIONS BEFORE OPENING
OR USING
or with the cautionary statement –
READ SAFETY DIRECTIONS
written:
i) on a separate line or lines;
A) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section (1)(c); or
B) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and
ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least four-tenths the height of the letters used for the signal word or words; and
iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line;
h) if the poison meets the criteria for a ‘flammable liquid’ in the Australian Code for the Transport of Dangerous Goods by Road and Rail, with the cautionary statement –
FLAMMABLE
written on the main label in bold-face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Code for the Transport of Dangerous Goods by Road and Rail;
i) if the poison is for the treatment of animals, with the cautionary statement –
FOR ANIMAL TREATMENT ONLY
written on the main label in bold-face sans serif capital letters of uniform thickness;
j) if the poison is a Schedule 5 poison intended for any purpose other than internal or pesticidal use, with the cautionary statement –
DO NOT SWALLOW
written in sans serif capital letters on the main label or as part of the directions for use;
k) with the approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with Section 1.4:
i) if the poison is for human therapeutic use, written in accordance with orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act, 1989; or
ii) if the poison is not for human therapeutic use, written in bold-face sans serif capital letters on the main label, unless:
A) list of approved names is required; and
B) it is impractical to include the list on the main label; and
C) an appropriate authority has authorised its inclusion on another part of the label; or
iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table the appropriate name opposite thereto in column 2 may be used as the approved name:
TABLE
Column 1 | Column 2 |
Alkaline salts | Alkaline salts |
Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules) | Aliphatic amines or aromatic amines |
Epoxy resins, liquid | Liquid epoxy resins |
Hydrocarbons, liquid | Liquid hydrocarbons |
Quaternary ammonium compounds | Quaternary ammonium compound(s) |
iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25 per cent, the approved names of those solvents may be expressed as follows:
A) where the designated solvent is a liquid hydrocarbon as “liquid hydrocarbons”; or
B) where the designated solvent is a ketone as “ketones”; or
C) in any other case as “solvents” or “other solvents”;
l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, with the following expression written immediately below the approved name or the list of declared contents –
AN ANTICHOLINESTERASE COMPOUND
i) the requirements of Section 1.3(1)(l) do not apply to:
A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or
B) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or
C) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use;
m) for any poison other than a poison for human therapeutic use labelled in accordance with Therapeutic Goods Order 69 General requirements for labels for medicines or Therapeutic Goods Order 91 Standard for labels of prescription and related medicines or Therapeutic Goods Order 92 Standard for labels of non-prescription medicines or in an agricultural or veterinary chemical product labelled in compliance with the Agricultural and Veterinary Chemicals Code Act 1994, if the poison is prepared, packed or sold for a specific purpose, with clear and adequate directions for use unless:
i) the poison is included in Schedule 4 or Schedule 8; or
ii) it is impractical to include such directions on the label and:
A) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; and
B) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; and
C) the insert is enclosed in the primary pack;
n) for any poison other than a poison for human therapeutic use labelled in accordance with the Required Advisory Statements for Medicine Labels, if use of the poison may be harmful to the user, with appropriate safety directions (see Appendix F), grouped together as a distinct section of the label and prefaced by the words –
SAFETY DIRECTIONS
written in bold-face capital letters;
o) for any poison other than a poison for human therapeutic use labelled in accordance with the Required Advisory Statements for Medicine Labels, if any warning statement or statements are required for the poison (see Appendix F), with that warning statement or those statements grouped together:
i) if safety directions are included on the label, immediately after the words “SAFETY DIRECTIONS”; or
ii) if there are no safety directions, immediately preceding the directions for use;
p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or Schedule 8 poison, with appropriate first aid instructions (see Appendix E):
i) grouped together and prefaced by the words –
FIRST AID
written in bold-face capital letters; or
ii) if a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:
A) written on each immediate container as specified in Section 1.3(1)(p)(i); and
B) replaced on the primary pack with the statement –
FIRST AID: See inner packs;
q) with the name and address of the manufacturer or distributor.
(2) For the purposes of Section 1.3(1)(a)(iii) the term “largest letter or numeral” does not include:
a) a single letter or numeral which is larger than other lettering on the label; or
b) an affix forming part of the trade name; or
c) in the case of a poison for therapeutic use, numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.
1.4 Statements of quantity, proportion or strength
(1) The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:
a) if the poison is for human therapeutic use, in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989;
b) if the poison is for a purpose or purposes other than human therapeutic use and:
i) if the poison is in a pressurised spray aerosol preparation, as the mass of the poison per stated mass of the preparation;
ii) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;
iii) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;
iv) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;
v) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
vi) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;
vii) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
viii) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;
c) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised by any bases present in the preparation) in a preparation may be expressed as the un-neutralised mass of the acid per stated mass of the preparation;
d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:
contains not more than 10 per cent of (insert name of the metal); or
contains not more than 30 per cent of (insert name of the metal); or
contains more than 30 per cent of (insert name of the metal);
e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5 per cent of the product;
f) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;
g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.
h) for the purposes of Section 1.4(1)(g) “derivative” includes alkaloid.
1.5 Exemptions
1.5.1 Selected containers and measure packs
(1) The requirements of Section 1.3 do not apply to an immediate container that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which Section 1.5.2 (1) and (2) apply) when:
a) the immediate container is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or
b) the immediate container is:
i) packed in a primary pack labelled in accordance with Section 1.3; and
ii) labelled with:
A) the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the table to Section 1.3(1)(a); and
B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with Section 1.4; and
C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
D) if the poison is for the treatment of animals, with the cautionary statement –
FOR ANIMAL TREATMENT ONLY
written in sans serif capital letters.
1.5.2 Ampoules, pre-filled syringes and injection vials
(1) The requirements of Section 1.3 do not apply to a selected container, or an ampoule (other than an ampoule to which Section 1.5.2(2) applies) when:
a) the selected container or ampoule is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or
b) the selected container or ampoule is:
i) packed in a primary pack labelled in accordance with Section 1.3; and
ii) labelled with:
A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with Section 1.4; and
B) with the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
C) if the poison is for the treatment of animals, with the cautionary statement –
FOR ANIMAL TREATMENT ONLY
written in sans serif capital letters.
(2) The requirements of Section 1.3 do not apply to a selected container that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:
a) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or
b) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is:
i) packed in a primary pack labelled in accordance with Section 1.3; and
ii) the strip is labelled in accordance with Section 1.5.2; and
iii) the ampoule is labelled with:
A) the approved name of the poison or the trade name of the product; and
B) the quantity, proportion or strength of the poison in accordance with Section 1.4.
1.5.3 Transport containers and wrappings
(1) The labelling requirements of this Standard do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.
1.5.4 Dispensary, industrial, laboratory and manufacturing poisons
(1) The labelling requirements of this Standard do not apply to a poison that:
a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and
b) is labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time.
1.5.5 Exemptions from label requirements in certain circumstances
(1) the labelling requirements of Sections 1.3 to 1.5.3 do not apply to a poison where an appropriate authority has granted a labelling exemption in whole or in part for these sections for a specified product; and
(2) the labelling exemption from an appropriate authority referred to in Section 1.5.5(1) is limited to no more than 12 months from the effective date of the decision for retail supply of the product; and
(3) for the avoidance of doubt this paragraph does not apply to exemptions issued under Section 1.3(1)(m)(ii)(B) of this Standard.
1.5.6 Dispensed medicines
(1) Unless otherwise specified by regulation:
a) The labelling requirements of this Standard do not apply to a medicine that:
i) is supplied by an authorised prescriber or other person authorised to supply and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or
ii) is supplied on and in accordance with a prescription written by an authorised prescriber and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or
iii) is prepared and supplied by a pharmacist for an individual patient and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard.
b) A person must not supply a dispensed medicine for human use containing:
i) a poison listed in column 1 of the table at Appendix L Part 2 of this Standard unless it is clearly labelled with the warning statement(s) specified in column 2 of that table; or
ii) a poison listed in Appendix K unless it is clearly labelled with a sedation warning (being statement 39, 40 or 90 as specified in Appendix F Part 1 of this Standard).
1.5.7 Gas cylinders
(1) The requirements of Sections 1.3(1)(a)(iv), 1.3(1)(c)(iv), and 1.3(1)(g)(iv) do not apply to a cylinder containing a poison that is a compressed gas.
1.5.8 Paints
(1) The requirements of Section 1.3 do not apply to:
a) paint (other than a paint for therapeutic or cosmetic use) which:
i) contains only Schedule 5 poisons; or
ii) is a First Group or Second Group paint that is labelled with:
A) the word “WARNING”, written in bold-face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and
B) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and
C) the appropriate warnings specified for the paint in Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and
D) the name and proportion of the First Group or Second Group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or
b) a tinter which contains:
i) only Schedule 5 poisons; or
ii) a poison included in the First Group or Second Group in Part 2 Section 7, provided that it is labelled with the name and proportion of that poison, and where the poison is a metal or metal salt, the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”.
1.5.9 Camphor and naphthalene
(1) The labelling requirements of Section1.1(2)(d) and Section 1.3 do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:
a) complies with Section 2.7; and
b) is sold or supplied in a primary pack labelled in accordance with Section 1.1 and Section 1.3.
1.6 Prohibitions
(1) A label used in connection with any poison must not include:
a) any reference to this Standard, or any comment on, reference to, or explanation of any expression required by this Standard that directly or by implication contradicts, qualifies or modifies such expression; or
b) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by the Government or any government authority unless required by legislation; or
c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or
d) any trade name or description that:
i) represents any single constituent of a compound preparation; or
ii) misrepresents the composition or any property or quality of the poison; or
iii) gives any false or misleading indication of origin or place of manufacture of the poison.
(2) A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure:
a) any expression required by this Standard to be written or embossed on the container or pack; or
b) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as appropriate.
2.1 Containers for poisons other than Schedule 5 poisons
(1) A person must not sell or supply a poison unless the immediate container complies with the requirements of Sections 2.1 and 2.3 to 2.7 of this Standard.
(2) If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of 2 litres or less, the container must comply with Australian Standard AS 2216-1997, entitled Packaging for poisonous substances.
(3) Notwithstanding Section 2.1(2), a poison which is in Schedule 6 and is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, entitled Packaging for poisonous substances, if:
a) the other safety factors are not diminished; and
b) the container has a restricted flow insert and a child-resistant closure.
(4) If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of more than 2 litres, the container must:
a) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled Packaging for poisonous substances; and
b) have the word “POISON”:
i) in sans serif capital letters the height of which is at least one thirty second part of the length, height or width of the container, whichever is the greatest:
A) embossed; or
B) indelibly written in a colour in distinct contrast to the background colour;
ii) on the side or shoulder of the container.
2.2 Containers for Schedule 5 poisons
(1) The container in which any Schedule 5 poison is sold or supplied must:
a) comply with the container requirements of Sections 2.1(2) or 2.1(4); or
b) be readily distinguishable from a container in which food, wine or other beverage is sold; and
i) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled Packaging for poisonous substances, excluding paragraph 1.4.3;
ii) be securely closed and, except when containing a preparation for use on one occasion only, be capable of being re-closed to prevent spillage of its contents; and
iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.
(2) Notwithstanding Section 2.2(1), the following Schedule 5 poisons namely:
a) methylated spirit(s);
b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;
c) petrol;
d) toluene; or
e) xylene,
must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less, unless the immediate container complies with the container requirements specified in Section 2.1(2).
2.3 Approved containers
(1) Notwithstanding section 2.1(2), 2.1(4) and 2.2 a poison may be packed in a container that does not comply with the tactile identification requirements of Australian Standard AS2216-1997 entitled Packaging for poisonous substances or the requirements of Section 2.1(4)(b) or Section 2.2(1)(b)(iii) if:
a) the other safety factors are not diminished;
b) the container is for a specific purpose; and
c) an appropriate authority has approved the use of the container for that purpose.
2.4 Child-resistant closures
(1) If a poison, other than a poison included in a therapeutic good packaged in a manner compliant with orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989, listed in column 1 of the following table is sold or supplied in a container having a nominal capacity specified for that poison in column 2, it must be closed with a child-resistant closure.
Column 1
Name of the poison | Column 2
Nominal capacity |
Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets. | All sizes |
Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels. | 5 litres /kilograms or less |
Alkaline salts included in Schedule 5, when packed and labelled as a food additive. | 2.5 litres or less |
Anise oil when included in Schedule 5. | 200 millilitres or less |
Basil oil when included in Schedule 5. | 200 millilitres or less |
Bay oil when included in Schedule 6. | 200 millilitres or less |
Cajuput oil when included in Schedule 6. | 200 millilitres or less |
Cassia oil when included in Schedule 5. | 200 millilitres or less |
Cineole when included in Schedule 6. | 2 litres or less |
Cinnamon bark oil when included in Schedule 5. | 200 millilitres or less |
Cinnamon leaf oil when included in Schedule 6. | 200 millilitres or less |
Clove oil when included in Schedule 6. | 200 millilitres or less |
Essential oils when included in Schedule 6 because of their natural camphor component. | 200 millilitres or less |
Ethylene glycol when included in
Schedule 6. | 5 litres or less |
Ethylene glycol when included in Schedule 5 in preparations containing more than 50 per cent of ethylene glycol. | 5 litres or less |
Eucalyptus oil when included in Schedule 6. | 2 litres or less |
Eugenol when included in Schedule 6. | 200 millilitres or less |
Fennel oil when included in Schedule 5. | 200 millilitres or less |
Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid. | 5 litres or less |
Hydrochloric acid when included in Schedule 6. | 5 litres or less |
Leptospermum scoparium oil (manuka oil) when included in Schedule 6 | 200 millilitres or less |
Marjoram oil when included in Schedule 5. | 200 millilitres or less |
Melaleuca oil (tea-tree oil) when included in Schedule 6. | 200 millilitres or less |
Methylated spirit excluding preparations or admixtures. | 5 litres or less |
Methyl salicylate and preparations containing more than 50 per cent of methyl salicylate. | 200 millilitres or less |
Nutmeg oil when included in Schedule 5. | 200 millilitres or less |
Oil of turpentine. | 5 litres or less |
Pennyroyal oil when included in Schedule 6. | 200 millilitres or less |
Potassium hydroxide as such. | 2.5 litres or less |
Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs. | 5 litres or less |
d-Pulegone when included in Schedule 6. | 200 millilitres or less |
Sage oil (Dalmatian) when included in Schedule 6. | 200 millilitres or less |
Sodium hydroxide as such. | 2.5 litres or less |
Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs. | 5 litres or less |
Thujone when included in Schedule 6. | 200 millilitres or less |
Thyme oil when included in Schedule 5. | 200 millilitres or less |
(2) The manufacturer or packer of a poison must ensure that the child-resistant closure is appropriate for the container and the poison and that it retains its child-resistant properties for the expected life of the poison.
2.5 Schedule 8 poisons
(1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.
(2) This paragraph does not apply to the supply of a Schedule 8 poison by an:
a) authorised prescriber or other authorised supplier;
b) pharmacist on the prescription of an authorised prescriber;
c) pharmacist employed at a hospital, on the written requisition of a medical practitioner, a dentist or the nurse or midwife in charge of the ward in which the Schedule 8 poison is to be used or stored; or
d) nurse or midwife on the direction in writing of an authorised prescriber.
2.6 Exemptions
(1) Section 2.1(2), Section 2.1(4) and Section 2.2 do not apply to the immediate container of a poison prepared, packed and sold:
a) for human internal or animal internal use; or
b) as a solid or semi-solid preparation for human external or animal external use; or
c) as a paint, other than a paint for therapeutic or cosmetic use; or
d) in containers having a nominal capacity of 15 millilitres or less; or
e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or
f) solely for dispensary, industrial, laboratory or manufacturing purposes.
(2) Section 2.4 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.
(3) The tactile identification or embossing required by Section 2.1(2), Section 2.1(4) and Section (2.2) of this Standard or Australian Standard AS 2216-1997 entitled Packaging for poisonous substances do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.
2.7 Camphor and naphthalene
(1) The container requirements of Section 2.1(2) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:
a) in normal use, prevents removal or ingestion of its contents; and
b) is incapable of reacting with the poison; and
c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and
d) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.
(2) A person must not sell or supply camphor or naphthalene in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.
2.8 Prohibitions
(1) A person must not sell or supply a poison in a container which has the name of another poison embossed or indelibly marked thereon.
(2) A person must not sell any poison which is for internal use or any food, drink or condiment in a container prescribed by Sections 2.1(2), 2.1(4) and Section 2.2 of this Standard.
(3) A person must not sell any poison in a container that is not readily distinguishable from a container in which food, alcohol, other beverage or condiment is sold.
3.1 General requirements
(1) A person who sells or supplies Schedule 6 poisons by way of retail sale must keep those poisons in such a way as to prevent access by children.
(2) A person who sells or supplies Schedule 7 poisons must not keep those poisons for retail sale in any areas or in any area or in any manner that allows physical access by any person unless they are:
a) the owner of the retail establishment; or
b) an employee of the owner; or
c) legally permitted to purchase the substance and are under the supervision of the owner or an employee of the owner.
(3) Controls on storage of Schedule 2, 3, 4 and 8 poisons require referral to Part 3 of this Standard and relevant legislation.
4.1 General requirements
(1) A person must not dispose of or cause to be disposed of a Schedule 5, Schedule 6 or Schedule 7 poison in any place or manner that constitutes or is likely to constitute a risk to public health or safety.
(2) Controls on disposal of Schedule 2, 3, 4 and 8 poisons require referral to relevant legislation.
5.1 General Requirements
(1) A person who sells or supplies Schedule 7 poisons must keep a record of:
a) Name and address of seller or supplier and purchaser; and
b) Date of order and supply; and
c) Approved name or trade name that identifies the poison to be supplied or sold; and
d) Quantity supplied or sold; and
e) Proof of purchaser authorisation must be recorded in jurisdictions where an authorisation is required for purchase.
(2) Records for sale or supply of Schedule 7 poisons must be kept for a minimum period of five years.
(3) Controls on record keeping for sale or supply of Schedule 2, 3, 4 and 8 poisons require referral to relevant legislation.
6.1 General Requirements for Schedule 5 and Schedule 6 Product samples
(1) A person must not sell or supply or distribute free a product sample containing a Schedule 5 or Schedule 6 poison in any manner unless the recipient has the opportunity to refuse at the time of sale or supply.
(2) A person must not sell or supply or distribute free a product sample containing a Schedule 5 or Schedule 6 poison in an unsolicited manner for example via the post / mailbox or attached to any other product.
(3) A person must not sell or supply a Schedule 5 or Schedule 6 poison product sample in a manner that does not promote disposal in accordance with section four.
6.2 Schedule 7 Poisons
(1) A person must not possess or use a Schedule 7 poison for domestic or domestic garden purposes.
(2) A person must not sell or supply:
a) a Schedule 7 poison for domestic or domestic garden purposes; or
b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell; or
c) a Schedule 7 poison for which an authorisation to purchase, possess or use is required by the appropriate authority unless the purchaser produces his or her authorisation.
(3) A person must not sell, supply or distribute free product samples containing Schedule 7 poisons.
6.3 Schedule 10 (previously Appendix C) poisons
(1) A person must not knowingly have in his or her possession or sell, supply or use a poison listed in Schedule 10 of this Standard for the purpose or purposes indicated in relation to that poison in Schedule 10.
6.4 Hawking
(1) A person must not sell by way of hawking a Schedule 7 poison.
(2) Controls on sale or supply or sale by way of hawking of Schedule 2, 3, 4 and 8 poisons require referral to Part 3 of this Standard and relevant legislation.
7.1 General Requirements
(1) A person must not manufacture, sell, supply or use a First Group Paint for application to:
a) a roof or any surface to be used for the collection or storage of potable water; or
b) furniture; or
c) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or
d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.
(2) A person must not manufacture, sell, supply or use a paint or tinter containing more than 0.1% Lead (the proportion of Lead for the purposes of this section is calculated as a percentage of the element present in the non-volatile content of the paint).
(3) A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012 entitled Safety of toys Part 3: Migration of certain elements (ISO 8124-03:2010, MOD).
(4) A person must not manufacture, sell, supply, or use a paint or tinter containing a pesticide except a fungicide, algaecide, bactericide or antifouling agent.
The First Group
The proportion of a substance for the purposes of this Group is calculated as a percentage of the element present in the non-volatile content of the paint.
Substance | Proportion |
ANTIMONY or antimony compounds other than antimony titanate pigments | more than 5 per cent |
BARIUM salts except barium sulfate or barium metaborate | more than 5 per cent |
CADMIUM or cadmium compounds | more than 0.1 per cent |
CHROMIUM as chromates of ammonia, barium, potassium sodium, strontium or zinc | more than 5 per cent |
SELENIUM or selenium compounds | more than 0.1 per cent |
The Second Group
Substance | Proportion |
DICHLOROMETHANE (methylene chloride) | more than 5 per cent by wt |
ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates | more than 10 per cent by vol |
HEXYLOXYETHANOL | more than 10 per cent by vol |
TOLUENE | more than 50 per cent by vol |
XYLENE | more than 50 per cent by vol |
(It is recommended that the States and Territories implement regulations which provide controls similar to those included in this Part of the Standard.)
3.1 General requirements
(1) A person must not include any reference to a poison included in:
a) Schedule 3 unless included in Appendix H; or
b) Schedule 4 or Schedule 8,
of this Standard in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.
(2) A person must not include any reference to a poison included in Schedule 9 or Schedule 10 (previously Appendix C) of this Standard in any advertisement.
3.2 Schedule 2 poisons
(1) A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a medical, dental or veterinary practitioner in the lawful practice of their professions, must not sell or supply a Schedule 2 poison unless licensed to do so.
(2) A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail sale unless:
a) he or she is carrying on the business of selling goods by retail; and
b) the premises from which the poison will be sold is more than 25 kilometres by the shortest practical route from the nearest pharmacy; and
c) he or she produces such evidence, as may be required, that he or she is a fit and proper person to be so licensed.
3.3 Schedule 3 poisons
(1) A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.
(2) The person who sells or supplies a Schedule 3 poison must:
a) provide adequate instructions for use, either written or verbal, at the time of supply or sale; and
b) label the container with his or her name or the name of the pharmacy and the address from which it was sold or supplied; and
c) if required by regulation, make a record of the transaction in a prescription book or other approved recording system.
3.4 Schedule 4 poisons
(1) A person, other than a medical, dental or veterinary practitioner in the ordinary course of their professions or a pharmacist dispensing a legal prescription must not sell or supply a Schedule 4 poison.
(2) Section 3.4(1) does not apply to a pharmacist who sells or supplies a Schedule 4 poison, other than a poison excepted by regulation from this provision, without a prescription if:
a) the patient is under medical treatment with the poison and continuation of medication is essential; and
b) the quantity sold or supplied does not exceed 3 days' medication; and
c) the pharmacist is satisfied that an emergency exists.
(3) Section 3.2(1), Sections 3.3(1) and (2) and Section 3.4(1) do not apply to sale by way of wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a person licensed or otherwise authorised to possess, sell or supply such poisons.
3.5 Prohibitions on sale, prescribing and possession
(1) A person must not:
a) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in Appendix D paragraphs 1, 2, 3, 4, 6 and 7 except in accordance with the provisions indicated for that poison in Appendix D; or
b) knowingly have in his or her possession a poison listed in Appendix D paragraph 5 without authority.
(1) A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way that public access to advice from a pharmacist is available if required.
(2) A person who sells or supplies Schedule 3 or Schedule 4 poisons must keep those poisons in a part of the premises to which the public does not have access.
This Schedule is intentionally blank.
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) for therapeutic use.
ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
ACONITUM spp. for therapeutic use in adults:
a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or
b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.
ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:
a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
b) in a day-night pack containing alimemazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
ALOXIPRIN.
AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.
ANTAZOLINE in eye drops.
ASPIRIN except:
a) when included in Schedule 4, 5 or 6;
b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:
i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and
ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
i) packed in blister or strip packaging or in a container with a child-resistant closure;
ii) in a primary pack of not more than 25 tablets or capsules, each containing 325 mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and
iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
i) packed in blister or strip packaging or in a container with a child-resistant closure;
ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and
iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels.
ATROPA BELLADONNA (belladonna):
a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
b) for oral use:
i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ATROPINE (excluding atropine methonitrate) for oral use:
a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
AZELAIC ACID in dermal preparations.
AZELASTINE:
a) in preparations for nasal use; or
b) in topical eye preparations containing 0.05 per cent or less of azelastine.
BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
BENZOCAINE in preparations for topical use other than eye drops:
a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide except in preparations containing 5 per cent or less of benzoyl peroxide.
BENZYDAMINE in preparations for topical use, except:
a) in preparations for dermal use;
b) in divided topical oral preparations containing 3 mg or less of benzydamine; or
c) in undivided topical oral preparations containing 0.3 per cent or less of benzydamine in a primary pack containing not more than 50 mL.
BEPHENIUM SALTS.
BIFONAZOLE in preparations for dermal use except:
a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or
b) in preparations for the treatment of tinea pedis.
BROMHEXINE.
BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
CARBETAPENTANE except in preparations containing 0.5 per cent or less of carbetapentane.
CARBOCISTEINE.
CETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
a) in a primary pack containing not more than 10 days’ supply; and
b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
CHLOPHEDIANOL.
CHLORBUTANOL for human use in topical preparations containing 5 per cent or less of chlorbutanol except in preparations containing 0.5 per cent or less of chlorbutanol.
CHLOROFORM in preparations for therapeutic use except:
a) when included in Schedule 4; or
b) in preparations containing 0.5 per cent or less of chloroform.
CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
b) in a day-night pack containing chlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
CICLOPIROX:
a) in preparations for dermal use containing 2 per cent or less of ciclopirox except in preparations for the treatment of tinea pedis; or
b) in preparations for application to the nails containing 8 per cent or less of ciclopirox.
CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.
CINNAMEDRINE.
CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
CREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.
DATURA spp. for oral use:
a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or
b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except when separately specified in these Schedules.
DATURA STRAMONIUM (stramonium) for oral use when:
a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except for smoking or burning.
DATURA TATULA (stramonium) for oral use:
a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except for smoking or burning.
DELPHINIUM STAPHISAGRIA except in preparations containing 0.2 per cent or less of Delphinium staphisagria.
DESLORATADINE in preparations for oral use.
DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
b) in a day-night pack containing dexchlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.
DIBROMOPROPAMIDINE for ophthalmic use.
DICLOFENAC when:
a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac;
b) in preparations for dermal use containing 4 per cent or less of diclofenac except in preparations for dermal use containing 2 per cent or less of diclofenac or for the treatment of solar keratosis; or
c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.
DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
DIPHENHYDRAMINE in oral preparations:
a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
b) when combined with one or more other therapeutically active substances when:
i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:
a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
DUBOISIA LEICHHARDTII for oral use:
a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
DUBOISIA MYOPOROIDES for oral use:
a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.
ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days supply.
ETAFEDRINE.
ETHER for therapeutic use except:
a) when included in Schedule 4; or
b) in preparations containing 10 per cent or less of ether.
ETHYLMORPHINE when:
a) compounded with one or more other therapeutically active substances:
i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or
ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine;
b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.
ETOFENAMATE in preparations for external use.
FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.
FELBINAC in preparations for external use.
FEXOFENADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
a) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
b) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.
FLUORIDES for human use:
a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or
b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:
i) for therapeutic use when compliant with the requirements of the Required Advisory Statements for Medicine Labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of Required Advisory Statements for Medicine Labels; or
ii) for non-therapeutic use when labelled with warnings to the following effect:
A) Do not swallow; and
B) Do not use (this product/insert name of product) in children 6 years of age or less,
except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:
A) Do not swallow; and
B) Do not use (this product/insert name of product) in children 6 years of age or less,
except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.
FLURBIPROFEN in preparations for topical oral use when:
a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit; or
b) in undivided preparations containing 0.25 per cent or less, or 10 mg or less per dose, of flurbiprofen.
FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
FOLIC ACID for human therapeutic use except:
a) when included in Schedule 4; or
b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.
FOLINIC ACID for human therapeutic use except:
a) when included in Schedule 4; or
b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.
FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
b) in other preparations containing 0.2 per cent or less of free formaldehyde.
GELSEMIUM SEMPERVIRENS.
GLUTARAL for human therapeutic use.
GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.
HEXACHLOROPHENE in preparations for human use containing 3 per cent or less of hexachlorophene except:
a) in preparations for use on infants, as specified in Schedule 4; or
b) in preparations for cosmetic use, as specified in Schedule 6; or
c) in other preparations containing 0.75 per cent or less of hexachlorophene.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:
a) for dermal use in preparations containing 0.5 per cent or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
b) for dermal use in preparations containing 1 per cent or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent:
i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and
ii) not labelled for the treatment of children under 12 years of age; or
c) for rectal use in preparations containing 0.5 per cent or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:
i) in undivided preparations in packs of 35 g or less; or
ii) in packs containing 12 or less suppositories.
HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone except:
a) in hair preparations containing 0.3 per cent or less of hydroquinone; or
b) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.
HYOSCINE (excluding hyoscine butylbromide):
a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
b) for oral use:
i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.
HYOSCYAMINE:
a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
b) for oral use:
i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.
HYOSCYAMUS NIGER for oral use:
a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:
a) in liquid preparations when sold in the manufacturer’s original pack containing 8 g or less of ibuprofen; or
b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:
i) as the only therapeutically active constituent (other than phenylephrine or when combined with an effervescent agent);
ii) packed in blister or strip packaging or in a container with a child-resistant closure;
iii) in a primary pack containing not more than 25 dosage units;
iv) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
v) not labelled for the treatment of children 6 years of age or less; and
vi) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.
INDANAZOLINE.
INDOMETACIN in preparations for external use containing 1 per cent or less of indometacin.
IODINE:
a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors),
except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.
IPRATROPIUM in preparations for nasal use.
IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use except:
a) when included in Schedule 4; or
b) when labelled with a recommended daily dose of 24 mg or less of iron:
i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or
ii) in divided preparations:
A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
B) containing 5 mg or less of iron per dosage unit.
ISOCONAZOLE for human use in dermal preparations.
ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.
KETOCONAZOLE in preparations for dermal use except:
a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
b) in preparations for the treatment of tinea pedis.
KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.
LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply.
LEVOCABASTINE in topical eye or nasal preparations.
LEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
a) in a primary pack containing not more than 5 days’ supply; and
b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LIDOCAINE in preparations for topical use other than eye drops:
a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
b) in divided preparations containing 200 mg or less of total local anaesthetic substances, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.
LITHIUM in preparations for dermal use containing 1 per cent or less of lithium except:
a) when present as an excipient at 0.25 per cent or less of lithium; or
b) in preparations containing 0.01 per cent or less of lithium.
LOBELIA INFLATA except for smoking or burning.
LOBELINE except in preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.
LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
LORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:
a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and
b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.
MEBENDAZOLE for human therapeutic use.
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.
MEPYRAMINE for dermal use.
MERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome except when included in Schedule 6.
MERCURY for external use in preparations containing 0.5 per cent or less of mercury.
METHOXAMINE in preparations for external use except in preparations containing 1 per cent or less of methoxamine.
METHOXYPHENAMINE.
METHYLEPHEDRINE.
MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.
MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.
NAPHAZOLINE.
NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.
NICLOSAMIDE for human therapeutic use.
NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.
NOSCAPINE.
NYSTATIN in dermal preparations.
OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply.
OXETACAINE (oxethazaine) in preparations for internal use.
OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.
OXYMETAZOLINE.
OXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, except in preparations for external use containing 1 per cent or less of such substances.
PAPAVERINE except when included in Schedule 4.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7days’ supply.
PARACETAMOL for therapeutic use:
a) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a primary pack containing no more than 12 dosage units per pack; or
b) in tablets or capsules enclosed in a primary pack containing not more than 100 tablets or capsules; or
c) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled ‘For dispensing only’ and ‘This pack is not to be supplied to a patient’; or
d) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules; or
e) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled ‘For dispensing only’ and ‘This pack is not to be supplied to a patient’; or
f) in other preparations except:
i) when included in Schedule 3 or 4; or
ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:
(A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules,
(B) compliant with the requirements of the Required Advisory Statements for Medicine Labels,
(C) not labelled for the treatment of children 6 years of age or less, and
(D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or
iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:
(A) packed in blister or strip packaging or in a container with a child-resistant closure,
(B) in a primary pack containing not more than 20 tablets or capsules,
(C) compliant with the requirements of the Required Advisory Statements for Medicine Labels,
(D) not labelled for the treatment of children 6 years of age or less, and
(E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin.
PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
b) in other preparations containing 0.2 per cent or less of free formaldehyde.
PHEDRAZINE.
PHENAZONE for human external use.
PHENIRAMINE:
a) in eye drops; or
b) when combined with one or more other therapeutically active substances in oral preparations when:
i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
PHENOL, or any homologue boiling below 220°C, for human therapeutic use except:
a) when included in Schedule 4; or
b) in preparations for external use containing 1 per cent or less of phenol and in preparations for external use containing 3 per cent or less of cresols and xylenols and other homologues of phenol.
PHENYLEPHRINE except:
a) when included in Schedule 4;
b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or
c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.
PHOLCODINE:
a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.
PIPERAZINE for human therapeutic use.
PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.
POTASSIUM CHLORATE for therapeutic use except in preparations containing 10 per cent or less of potassium chlorate.
PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.
PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.
PROMETHAZINE in oral preparations:
a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
b) when combined with one or more other therapeutically active substances when:
i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
PROPAMIDINE for ophthalmic use.
PYRANTEL for human therapeutic use.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.
PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply.
RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days' supply except:
a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units; or
b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.
SALICYLAMIDE except when included in Schedule 4.
SELENIUM in preparations for human therapeutic use except:
a) for topical use containing 3.5 per cent or less of selenium sulfide;
b) when included in Schedule 4; or
c) for oral use with a recommended daily dose of 150 micrograms or less.
SILVER for therapeutic use except:
a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
b) in other preparations containing 1 per cent or less of silver.
SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.
SODIUM NITRITE for therapeutic use (excluding when present as an excipient).
SQUILL except in preparations containing 1 per cent or less of squill.
SULCONAZOLE in preparations for dermal use.
TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.
TETRACAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.
TETRACHLOROETHYLENE for human therapeutic use.
TETRYZOLINE.
THIABENDAZOLE for human therapeutic use.
TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.
TRAMAZOLINE.
TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:
a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
TUAMINOHEPTANE.
TYMAZOLINE.
XYLOMETAZOLINE.
ZINC CHLORIDE for human dermal use except in preparations containing 5 per cent or less of zinc chloride.
ADRENALINE in preparations containing 1 per cent or less of adrenaline except in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.
ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.
ALIMEMAZINE:
a) in solid oral preparations except when included in Schedule 2; or
b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL,
except in preparations for the treatment of children under 2 years of age.
AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.
ASTODRIMER SODIUM except in a condom lubricant.
AZATADINE in oral preparations.
BROMPHENIRAMINE in oral preparations except:
a) when included in Schedule 2; or
b) for the treatment of children under 2 years of age.
BUCLIZINE in oral preparations.
BUTOCONAZOLE in preparations for vaginal use.
CHLORAMPHENICOL for ophthalmic use only.
CHLORBUTANOL in preparations for human use except:
a) when included in Schedule 2; or
b) in preparations containing 0.5 per cent or less of chlorbutanol.
CHLORPHENAMINE in oral preparations except:
a) when included in Schedule 2; or
b) for the treatment of children under 2 years of age.
CICLOPIROX in preparations for dermal use and for application to the nails except:
a) when included in Schedule 2; or
b) in preparations for the treatment of tinea pedis.
CIMETIDINE in a primary pack containing not more than 14 days' supply.
CLEMASTINE in preparations for oral use.
CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.
CLOTRIMAZOLE in preparations for vaginal use.
CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less.
CYPROHEPTADINE in oral preparations.
DEXCHLORPHENAMINE in oral preparations except:
a) when included in Schedule 2; or
b) for the treatment of children under 2 years of age.
DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2.
DIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances:
a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.
DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.
DIMENHYDRINATE in oral preparations except when included in Schedule 2.
DIMETHINDENE in oral preparations.
DIPHENHYDRAMINE in oral preparations except:
a) when included in Schedule 2; or
b) for the treatment of children under 2 years of age.
DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.
DITHRANOL for therapeutic use.
DOXYLAMINE in oral preparations except:
a) when included in Schedule 2; or
b) for the treatment of children under 2 years of age.
ECONAZOLE in preparations for vaginal use.
ERYTHRITYL TETRANITRATE for therapeutic use.
FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).
FLAVOXATE.
FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.
FLUORIDES for human topical use:
a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure except when included in or expressly excluded from Schedule 2; or
b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion except:
i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the Required Advisory Statements for Medicine Labels;
ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:
A) Do not swallow; and
B) Do not use [this product/name of product] in children six years of age or less; or
iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.
GLUCAGON.
GLYCERYL TRINITRATE:
a) in preparations for oral use; or
b) in preparations for rectal use.
GLYCOPYRRONIUM except when included in Schedule 4.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:
a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or
c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:
i) in undivided preparations, in packs of 35 g or less; or
ii) in packs containing 12 or less suppositories;
except when included in Schedule 2.
IBUPROFEN:
a) in divided preparations, each containing 400 mg or less of ibuprofen in a primary pack containing not more than 50 dosage units, when labelled:
i) with a recommended daily dose of 1200 mg or less of ibuprofen; and
ii) not for the treatment of children under 12 years of age; or
b) in a modified release dosage form, each containing 600 mg of ibuprofen in a primary pack containing not more than 32 dosage units, when labelled:
i) with a recommended daily dose of 1200 mg or less of ibuprofen; and
ii) not for the treatment of children under 12 years of age;
except when included in or expressly excluded from Schedule 2.
INOSITOL NICOTINATE.
ISOCONAZOLE in preparations for vaginal use.
ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.
KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.
LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2.
LEVONORGESTREL for emergency post-coital contraception.
MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.
MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.
MALATHION in preparations for human external use except in preparations containing 2 per cent or less of malathion.
MANNITYL HEXANITRATE for therapeutic use.
MEPYRAMINE in oral preparations.
METHDILAZINE in oral preparations.
METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.
MICONAZOLE for human use in topical preparations:
a) for the treatment of oral candidiasis; or
b) for vaginal use.
NALOXONE when used for the treatment of opioid overdose.
NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.
NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:
a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
b) nicotinamide.
NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.
NYSTATIN in preparations for topical use except when included in Schedule 2.
OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2.
ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.
OXICONAZOLE in preparations for vaginal use.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2.
PARACETAMOL when combined with ibuprofen in a primary pack containing 30 dosage units or less except when included in Schedule 2.
PHENIRAMINE in oral preparations except:
a) when included in Schedule 2; or
b) for the treatment of children under 2 years of age.
PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.
PROMETHAZINE in oral preparations except:
a) when included in Schedule 2; or
b) in preparations for the treatment of children under 2 years of age.
PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:
a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or
b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2.
SALBUTAMOL as the only therapeutically active substance:
a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.
SALICYLIC ACID in preparations for dermal use except in preparations containing 40 per cent or less of salicylic acid.
SANTONIN.
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.
TERBUTALINE as the only therapeutically active substance:
a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or
b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.
THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.
TIOCONAZOLE in preparations for vaginal use.
TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.
TRIPROLIDINE in oral preparations except:
a) when included in Schedule 2; or
b) for the treatment of children under 2 years of age.
ULIPRISTAL for emergency post-coital contraception.
VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.
ABACAVIR.
ABATACEPT.
ABIRATERONE ACETATE.
ABCIXIMAB.
ACAMPROSATE CALCIUM.
ACARBOSE.
ACEBUTOLOL.
ACEPROMAZINE.
ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.
ACETARSOL.
ACETAZOLAMIDE.
ACETOHEXAMIDE.
ACETYL ISOVALERYLTYLOSIN.
ACETYLCARBROMAL.
ACETYLCHOLINE.
ACETYLCYSTEINE except:
a) when included in Schedule 2; or
b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
ACETYLDIGITOXIN.
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.
ACETYLSTROPHANTHIDIN.
ACICLOVIR except in preparations containing 5 per cent or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.
ACIPIMOX.
# ACITRETIN.
ACLIDINIUM BROMIDE.
ACOKANTHERA OUABAIO.
ACOKANTHERA SCHIMPERI.
ACONITUM spp. except:
a) when included in Schedule 2;
b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or
c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.
ACRIVASTINE.
ADALIMUMAB.
ADAPALENE.
ADEFOVIR.
ADENOSINE for human therapeutic use in preparations for injection.
ADIPHENINE.
ADONIS VERNALIS.
ADRAFINIL.
ADRENALINE except:
a) when included in Schedule 3; or
b) in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.
ADRENOCORTICAL HORMONES except when separately specified in these Schedules.
AFAMELANOTIDE.
AFATINIB DIMALEATE.
AFLIBERCEPT.
AGALSIDASE.
AGLEPRISTONE.
AGOMELATINE.
ALATROFLOXACIN MESILATE.
ALBENDAZOLE except:
a) when included in Schedule 5 or 6; or
b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.
ALCLOFENAC.
ALCLOMETASONE except when included in Schedule 3.
ALCURONIUM.
ALDESLEUKIN.
ALDOSTERONE.
ALECTINIB.
# ALEFACEPT.
ALEMTUZUMAB.
ALENDRONIC ACID.
ALFACALCIDOL.
ALFUZOSIN.
ALGLUCERASE.
ALGLUCOSIDASE.
ALIMEMAZINE except when included in Schedule 2 or 3.
ALIROCUMAB.
ALISKIREN.
ALLERGENS for therapeutic use.
ALLOPURINOL.
ALLYLESTRENOL.
ALOGLIPTIN.
ALOSETRON.
ALPHA1-PROTEINASE INHIBITOR (HUMAN).
ALPHADOLONE.
ALPHAXALONE.
ALPRENOLOL.
ALPROSTADIL.
ALSEROXYLON.
ALTEPLASE.
ALTRENOGEST.
ALTRETAMINE (hexamethylmelamine).
AMANTADINE.
AMBENONIUM CHLORIDE.
# AMBRISENTAN.
AMBUCETAMIDE.
AMBUTONIUM BROMIDE.
AMCINONIDE.
AMIFOSTINE.
AMIKACIN.
AMILORIDE.
AMINOCAPROIC ACID.
AMINOGLUTETHIMIDE.
5-AMINOLEVULINIC ACID.
AMINOMETRADINE.
AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.
AMINOPHYLLINE except when included in Schedule 3.
AMINOPTERIN.
4-AMINOPYRIDINE for therapeutic use.
AMINOREX.
AMINOSALICYLIC ACID.
AMIODARONE.
AMIPHENAZOLE.
AMISOMETRADINE.
AMISULPRIDE.
AMITRIPTYLINE.
AMLODIPINE.
AMMI VISNAGA.
AMMONIUM BROMIDE for therapeutic use.
AMOBARBITAL when packed and labelled for injection.
AMODIAQUINE.
AMOROLFINE except:
a) when included in Schedule 2; or
b) in preparations for the treatment of tinea pedis.
AMOXAPINE.
AMOXICILLIN
AMPHOMYCIN.
AMPHOTERICIN B
AMPICILLIN.
AMPRENAVIR.
AMRINONE.
AMSACRINE.
AMYL NITRITE.
AMYLOCAINE.
# ANABOLIC STEROIDAL AGENTS.
ANAGRELIDE.
ANAKINRA.
ANASTROZOLE.
ANCESTIM.
ANCROD and its immunoglobulin antidote.
ANECORTAVE.
# ANDROGENIC STEROIDAL AGENTS.
# ANDROISOXAZOLE.
# ANDROSTANOLONE.
# ANDROSTENEDIOL.
# ANDROSTENEDIONE.
ANGIOTENSIN AMIDE.
ANIDULAFUNGIN.
ANISTREPLASE.
ANTAZOLINE except when included in Schedule 2.
ANTIBIOTIC SUBSTANCES except:
a) when separately specified in these Schedules; or
b) nisin.
ANTIGENS for human therapeutic use except when separately specified in this Schedule.
ANTIHISTAMINES except:
a) when included in Schedule 2 or 3; or
b) when separately specified in this Schedule.
ANTIMONY for therapeutic use except when separately specified in these Schedules.
ANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.
# AOD-9604 (CAS No. 221231-10-3).
APALUTAMIDE.
APIXABAN.
APOCYNUM spp.
APOMORPHINE.
APRACLONIDINE.
APRAMYCIN.
APREMILAST.
APREPITANT.
APRONAL.
APROTININ.
ARECOLINE.
ARIPIPRAZOLE.
ARMODAFINIL.
ARSENIC for human therapeutic use except when separately specified in these Schedules.
ARTEMETHER.
ARTICAINE.
ASENAPINE.
ASFOTASE ALFA.
ASPARAGINASE.
ASPIRIN:
a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or
b) for injection.
ASTEMIZOLE.
ASUNAPREVIR.
# ATAMESTANE.
ATAZANAVIR.
ATENOLOL.
ATEZOLIZUMAB.
ATIPAMEZOLE.
ATOMOXETINE.
ATORVASTATIN.
ATOSIBAN.
ATOVAQUONE.
ATRACURIUM BESILATE.
ATROPA BELLADONNA (belladonna) except when included in Schedule 2.
ATROPINE except when included in Schedule 2.
ATROPINE METHONITRATE.
AURANOFIN.
AUROTHIOMALATE SODIUM.
AVELUMAB.
AVILAMYCIN except:
a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or
b) in animal feeds containing 50 mg/kg or less of avilamycin activity.
AVIPTADIL.
AXITINIB.
AVOPARCIN.
AZACITIDINE.
AZACYCLONOL.
AZAPERONE.
AZAPROPAZONE.
AZARIBINE.
AZATADINE except when included in Schedule 3.
AZATHIOPRINE.
AZELAIC ACID except:
a) when included in Schedule 2; or
b) in preparations containing 1 per cent or less of azelaic acid for non-human use.
AZELASTINE except when included in Schedule 2.
AZITHROMYCIN.
AZLOCILLIN.
AZTREONAM.
BACAMPICILLIN.
BACITRACIN.
BACLOFEN.
BALSALAZIDE.
BAMBERMYCIN (flavophospholipol) except:
a) when included in Schedule 6; or
b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
BAMBUTEROL.
BAMETHAN.
BAMIPINE.
BARBITURATES except when separately specified in these Schedules.
BARICITINIB.
BASILIXIMAB.
BAZEDOXIFENE.
BECAPLERMIN.
BECLAMIDE.
BECLOMETASONE except when included in Schedule 2.
BELATACEPT.
BELIMUMAB.
BEMEGRIDE.
BENACTYZINE.
BENAZEPRIL.
BENDAMUSTINE.
BENDROFLUAZIDE.
BENETHAMINE PENICILLIN.
BENORYLATE.
BENOXAPROFEN.
BENPERIDOL.
BENRALIZUMAB.
BENSERAZIDE.
BENZATHINE PENICILLIN.
BENZILONIUM.
BENZOCAINE except:
a) when included in Schedule 2;
b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
# BENZODIAZEPINE derivatives except when separately specified in these Schedules.
BENZOYL PEROXIDE in preparations for human therapeutic use except:
a) when included in Schedule 2; or
b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.
BENZPHETAMINE.
BENZTHIAZIDE.
BENZATROPINE.
BENZYDAMINE except:
a) when included in Schedule 2;
b) in preparations for dermal use;
c) in divided topical oral preparations containing 3 mg or less of benzydamine; or
d) in undivided topical oral preparations containing 0.3 per cent or less of benzydamine in a primary pack containing not more than 50 mL.
BENZYLPENICILLIN.
BEPRIDIL.
BERACTANT.
BESIFLOXACIN.
BETAHISTINE.
BETAMETHASONE.
BETAXOLOL.
BETHANECHOL CHLORIDE.
BETHANIDINE.
BEVACIZUMAB.
BEVANTOLOL.
# BEXAROTENE.
BEZAFIBRATE.
BEZLOTOXUMAB.
BICALUTAMIDE.
BICTEGRAVIR.
BIFONAZOLE except:
a) when included in Schedule 2;
b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or
c) in preparations for dermal use for the treatment of tinea pedis.
BIMATOPROST.
BINIMETINIB.
BIPERIDEN.
BISMUTH COMPOUNDS for cosmetic use, except:
a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per or less; or
b) bismuth oxychloride.
BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.
BISOPROLOL.
BIVALIRUDIN.
BLEOMYCIN.
BLINATUMOMAB.
BOCEPREVIR.
# BOLANDIOL.
# BOLASTERONE.
# BOLAZINE.
# BOLDENONE (dehydrotestosterone).
# BOLENOL.
# BOLMANTALATE.
BORON, including boric acid and borax, for human therapeutic use except:
a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose;
b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or
c) when present as an excipient.
BORTEZOMIB.
# BOSENTAN.
BOSUTINIB.
BOTULINUM TOXINS for human use except when separately specified in these Schedules.
BRENTUXIMAB VEDOTIN.
BRETYLIUM TOSILATE.
BREXPIPRAZOLE.
BRIGATINIB.
BRIMONIDINE.
BRINZOLAMIDE.
BRIVARACETAM.
# BROMAZEPAM.
BROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules.
BROMOCRIPTINE.
BROMOFORM for therapeutic use.
BROMPHENIRAMINE except when included in Schedule 2 or 3.
BROMVALETONE.
BRUGMANSIA spp.
BUCLIZINE except when included in Schedule 3.
BUDESONIDE except when included in Schedule 2.
BUFEXAMAC except:
a) in preparations for dermal use containing 5 per cent or less of bufexamac; or
b) in suppositories.
BUMETANIDE.
BUPHENINE.
BUPIVACAINE except when included in Schedule 5.
BUPROPION.
BUSERELIN.
BUSPIRONE.
BUSULPHAN.
BUTACAINE.
BUTAMBEN except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.
BUTOCONAZOLE except when included in Schedule 3.
BUTRACONAZOLE.
BUTYLCHLORAL HYDRATE.
BUTYL NITRITE.
CABAZITAXEL.
CABERGOLINE.
CABOZANTINIB.
CADMIUM COMPOUNDS for human therapeutic use.
CALCIPOTRIOL.
CALCITONIN.
CALCITONIN SALMON.
CALCITRIOL.
CALCIUM CARBIMIDE for therapeutic use.
CALCIUM HYDROXYAPATITE in preparations for injection or implantation:
a) for tissue augmentation; or
b) for cosmetic use.
CALCIUM POLYSTYRENE SULPHONATE.
CALOTROPIS GIGANTEA.
CALOTROPIS PROCERA.
# CALUSTERONE.
CAMPHORATED OIL for therapeutic use.
CAMPHOTAMIDE.
CANAGLIFLOZIN.
CANAKINUMAB.
CANDESARTAN CILEXETIL.
CANDICIDIN.
CANINE TICK ANTI-SERUM.
CANNABIDIOL in preparations for therapeutic use where:
- cannabidiol comprises 98 per cent or more of the total cannabinoid content of the preparation; and
b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2 per cent or less of the total cannabinoid content of the preparation.
CANTHARIDIN.
CAPECITABINE.
CAPREOMYCIN.
CAPTODIAME.
CAPTOPRIL.
CAPURIDE.
CARAMIPHEN.
CARBACHOL.
CARBAMAZEPINE.
CARBARYL for human therapeutic use.
CARBAZOCHROME.
CARBENICILLIN.
CARBENOXOLONE for internal use.
CARBETOCIN.
CARBIDOPA.
CARBIMAZOLE.
CARBOCROMEN.
CARBOPLATIN.
CARBOPROST.
CARBROMAL.
CARBUTAMIDE.
CARBUTEROL.
CARFILZOMIB.
CARGLUMIC ACID (N-carbamoyl-L-glutamic acid)
CARINDACILLIN.
CARISOPRODOL.
CARMUSTINE.
CARNIDAZOLE.
CARPROFEN.
CARVEDILOL.
CASPOFUNGIN.
CATHINE.
CATUMAXOMAB.
CEFACETRILE.
CEFACLOR.
CEFADROXIL.
CEFALEXIN.
CEFALORIDINE.
CEFALOTIN.
CEFAMANDOLE.
CEFAPIRIN.
CEFAZOLIN.
CEFEPIME.
CEFETAMET.
CEFIXIME.
CEFODIZIME.
CEFONICID.
CEFOPERAZONE.
CEFOTAXIME.
CEFOTETAN.
CEFOTIAM.
CEFOVECIN for veterinary use.
CEFOXITIN.
CEFPIROME.
CEFPODOXIME.
CEFQUINOME.
CEFTAROLINE FOSAMIL.
CEFSULODIN.
CEFTAZIDIME.
CEFTIBUTEN.
CEFTIOFUR.
CEFTRIAXONE.
CEFUROXIME.
CELECOXIB.
CELIPROLOL.
CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2 per cent or less of emetine.
CEPHAELIS IPECACUANHA except in preparations containing 0.2 per cent or less of emetine.
CEPHALONIUM.
CEPHRADINE.
CERITINIB.
CERIVASTATIN.
CERLIPONASE ALFA.
CERTOLIZUMAB PEGOL.
CERULETIDE.
CETIRIZINE except
a) when included in Schedule 2; or
b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
i) in a primary pack containing not more than 10 days’ supply; and
ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
CETRORELIX.
CETUXIMAB.
CHENODEOXYCHOLIC ACID.
CHLORAL FORMAMIDE.
CHLORAL HYDRATE except in preparations for topical use containing 2 per cent or less of chloral hydrate.
CHLORALOSE except when included in Schedule 6.
CHLORAMBUCIL.
CHLORAMPHENICOL except when included in Schedule 3.
# CHLORANDROSTENOLONE.
CHLORAZANIL.
CHLORCYCLIZINE.
# CHLORDIAZEPOXIDE.
CHLORMERODRIN.
CHLORMETHIAZOLE.
CHLORMEZANONE.
CHLOROFORM for use in anaesthesia.
# 4-CHLOROMETHANDIENONE.
2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.
CHLOROQUINE.
CHLOROTHIAZIDE.
CHLOROTRIANISENE.
# CHLOROXYDIENONE.
CHLORPHENAMINE except when included in Schedule 2 or 3.
CHLORPHENTERMINE.
CHLORPROMAZINE.
CHLORPROPAMIDE.
CHLORPROTHIXENE.
CHLORQUINALDOL for human topical use.
CHLORTALIDONE
CHLORTETRACYCLINE except when included in Schedule 5.
CHLORZOXAZONE.
CHOLERA VACCINE.
CHOLIC ACID.
CHYMOPAPAIN for human therapeutic use.
CICLACILLIN.
CICLESONIDE.
CICLOPIROX except:
a) when included in Schedule 2 or 3; or
b) in preparations for the treatment of tinea pedis.
CICLOSPORIN.
CIDOFOVIR.
CILASTATIN.
CILAZAPRIL.
CILOSTAZOL.
CIMETIDINE except when included in Schedule 3.
CIMICOXIB.
CINACALCET.
CINCHOCAINE except when included in Schedule 2.
CINNARIZINE.
CINOXACIN.
CIPROFLOXACIN.
CISAPRIDE.
CISATRACURIUM BESILATE.
CISPLATIN.
CITALOPRAM.
# CJC-1295 (CAS No. 863288-34-0).
CLADRIBINE.
CLANOBUTIN.
CLARITHROMYCIN.
CLAVULANIC ACID.
CLEMASTINE except when included in Schedule 3.
CLEMIZOLE.
CLENBUTEROL.
CLEVIDIPINE.
CLIDINIUM BROMIDE.
CLINDAMYCIN.
CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use except when separately specified in this Schedule.
CLOBAZAM.
CLOBETASOL.
CLOBETASONE (clobetasone-17-butyrate) except when included in Schedule 3.
CLOCORTOLONE.
CLODRONIC ACID (includes sodium clodronate).
CLOFARABINE.
CLOFAZIMINE.
CLOFENAMIDE.
CLOFIBRATE.
# CLOMIFENE.
CLOMIPRAMINE.
CLOMOCYCLINE.
# CLONAZEPAM.
CLONIDINE.
CLOPAMIDE.
CLOPIDOGREL.
CLOPROSTENOL.
# CLORAZEPATE.
CLOREXOLONE.
CLORPRENALINE.
# CLOSTEBOL (4-chlorotestosterone).
CLOTRIMAZOLE except:
a) when included in Schedule 2, 3 or 6; or
b) in preparations for dermal use for the treatment of tinea pedis.
CLOXACILLIN.
# CLOZAPINE.
COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.
COBICISTAT.
COBIMETINIB.
CODEINE when compounded with one or more other therapeutically active substances:
a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
b) in undivided preparations containing 1 per cent or less of codeine.
CO-DERGOCRINE.
COLCHICINE.
COLCHICUM AUTUMNALE.
COLESTIPOL.
COLESTYRAMINE for human therapeutic use.
COLFOSCERIL PALMITATE for human therapeutic use.
COLISTIN.
COLLAGEN in preparations for injection or implantation:
a) for tissue augmentation; or
b) for cosmetic use.
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.
CONVALLARIA KEISKI.
CONVALLARIA MAJALIS.
COPPER COMPOUNDS for human use except:
a) when separately specified in these Schedules;
b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
c) in other preparations containing 5 per cent or less of copper compounds.
# CORIFOLLITROPIN ALFA.
CORONILLA spp.
CORTICOSTERONE.
CORTICOTROPHIN.
CORTISONE.
CO-TRIMOXAZOLE.
COUMARIN for therapeutic use (excluding when present as an excipient).
CRISABOROLE.
CRIZOTINIB.
CROFELEMER.
CUPRIMYXIN.
CURARE.
CYCLANDELATE.
CYCLIZINE except when included in Schedule 3.
CYCLOBENZAPRINE.
# CYCLOFENIL.
CYCLOHEXIMIDE.
CYCLOPENTHIAZIDE.
CYCLOPENTOLATE.
CYCLOPHOSPHAMIDE.
CYCLOPROPANE for therapeutic use.
CYCLOSERINE.
CYCLOTHIAZIDE.
CYCRIMINE.
CYMARIN.
CYPROHEPTADINE except when included in Schedule 3.
CYPROTERONE.
CYTARABINE.
DABRAFENIB MESILATE.
DABIGATRAN.
DACARBAZINE.
DACLATASVIR.
DACLIZUMAB.
DACTINOMYCIN.
DALFOPRISTIN.
DALTEPARIN (includes dalteparin sodium).
DANAPAROID (includes danaparoid sodium).
# DANAZOL.
DANTHRON for human use.
DANTROLENE.
DAPAGLIFLOZIN.
DAPOXETINE.
DAPSONE.
DAPTOMYCIN.
DARATUMUMAB.
# DARBEPOETIN.
DARIFENACIN.
DARUNAVIR.
DATURA spp. except:
a) when included in Schedule 2; or
b) when separately specified in this Schedule.
DASABUVIR.
DASATINIB.
DATURA STRAMONIUM (stramonium) except:
a) when included in Schedule 2; or
b) for smoking or burning.
DATURA TATULA (stramonium) except:
a) when included in Schedule 2; or
b) for smoking or burning.
DAUNORUBICIN.
DEANOL for therapeutic use.
DEBRISOQUINE.
DECAMETHONIUM.
DEFERASIROX.
DEFERIPRONE.
DEFLAZACORT.
DEGARELIX.
# DEHYDROCHLOROMETHYLTESTOSTERONE.
DEHYDROCORTICOSTERONE.
DELAVIRDINE MESILATE.
DEMBREXINE except when included in Schedule 5.
DEMECARIUM.
DEMECLOCYCLINE.
DENGUE VACCINE.
DENOSUMAB.
DEOXYCHOLIC ACID.
DEOXYCORTONE.
DEOXYRIBONUCLEASE except:
a) when separately specified in this Schedule; or
b) for external use.
DERACOXIB.
DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.
DESFERRIOXAMINE.
DESFLURANE.
DESIPRAMINE.
DESIRUDIN.
DESLANOSIDE.
DESLORATADINE except when included in Schedule 2.
DESLORELIN.
DESMOPRESSIN (D.D.A.V.P.).
DESOGESTREL.
DESONIDE.
DESOXYMETHASONE.
DESVENLAFAXINE.
DETOMIDINE.
DEXAMETHASONE.
DEXCHLORPHENAMINE except when included in Schedule 2 or 3.
DEXFENFLURAMINE.
DEXMEDETOMIDINE.
DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.
# DEXTROPROPOXYPHENE:
a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.
DEXTRORPHAN (excluding its stereoisomers).
DIAMTHAZOLE.
DIAVERIDINE.
# DIAZEPAM.
DIAZOXIDE.
DIBENZEPIN.
DIBOTERMIN.
DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.
DICHLORALPHENAZONE.
DICHLOROPHEN for human therapeutic use.
DICHLORPHENAMIDE.
DICLOFENAC except:
a) when included in Schedule 2 or 3; or
b) in preparations for dermal use unless:
i) for the treatment of solar keratosis; or
ii) containing more than 4 per cent of diclofenac.
DICLOXACILLIN.
DICYCLOMINE.
DIDANOSINE.
DIENESTROL.
DIENOGEST.
DIETHAZINE.
DIETHYLCARBAMAZINE for human therapeutic use.
DIETHYLPROPION.
DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.
DIFLORASONE.
DIFLOXACIN.
DIFLUCORTOLONE.
DIFLUNISAL.
DIGITALIS LANATA.
DIGITALIS PURPUREA.
DIGITOXIN.
DIGOXIN.
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).
DIHYDRALAZINE.
DIHYDROCODEINE when compounded with one or more other therapeutically active substances:
a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine,
except when included in Schedule 3.
DIHYDROERGOTOXINE.
# DIHYDROLONE.
DIHYDROSTREPTOMYCIN.
DIHYDROTACHYSTEROL.
DIIODOHYDROXYQUINOLINE (iodoquinol) except:
a) when included in Schedule 3; or
b) for human internal use.
DIISOPROPYLAMINE DICHLOROACETATE.
DILTIAZEM.
DIMENHYDRINATE except when included in Schedule 2 or 3.
DIMERCAPROL.
# DIMETHANDROSTANOLONE.
# DIMETHAZINE.
DIMETHINDENE except when included in Schedule 3.
DIMETHOTHIAZINE.
DIMETHOXANATE.
DIMETHYL FUMARATE.
DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:
a) when included in Schedule 6; or
b) in in vitro test kits; or
c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines.
DIMETRIDAZOLE.
2,4-DINITROCHLOROBENZENE for therapeutic use.
DINITROCRESOLS for therapeutic use except when separately specified in these Schedules.
DINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules.
DINITROPHENOLS for therapeutic use.
DINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.
# DINOPROST.
# DINOPROSTONE.
DIPERODON.
DIPHEMANIL except in preparations for dermal use.
DIPHENHYDRAMINE except when included in Schedule 2 or 3.
DIPHENIDOL.
DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate except when included in Schedule 3.
DIPHENYLPYRALINE.
DIPHTHERIA TOXOID.
DIPIVEFRIN.
DIPYRIDAMOLE.
DIRITHROMYCIN.
DIRLOTAPIDE.
DISOPHENOL.
DISOPYRAMIDE.
DISTIGMINE.
DISULFIRAM for therapeutic use.
DISULPHAMIDE.
DITHIAZANINE except when included in Schedule 6.
DITIOCARB.
DOBUTAMINE.
DOCETAXEL.
DOFETILIDE.
DOLASETRON.
DOLUTEGRAVIR.
DOMPERIDONE.
DONEPEZIL.
DOPAMINE.
DOPEXAMINE.
DORIPENEM.
DORNASE.
DORZOLAMIDE.
DOSULEPIN.
DOXANTRAZOLE.
DOXAPRAM.
DOXAZOSIN.
DOXEPIN.
DOXORUBICIN.
DOXYCYCLINE.
DOXYLAMINE except when included in Schedule 2 or 3.
DRONEDARONE.
DROPERIDOL.
DROSPIRENONE.
# DROSTANOLONE.
DROTRECOGIN.
DUBOISIA LEICHHARDTII except when included in Schedule 2.
DUBOISIA MYOPOROIDES except when included in Schedule 2.
DULOXETINE.
DUPILUMAB.
DURVALUMAB.
DUTASTERIDE.
DYDROGESTERONE.
ECONAZOLE except:
a) when included in Schedule 2, 3 or 6; or
b) in preparations for dermal use for the treatment of tinea pedis.
ECOTHIOPATE (includes ecothiopate iodide).
ECTYLUREA.
ECULIZUMAB.
EDETIC ACID for human therapeutic use except:
a) in preparations containing 0.25 per cent or less of edetic acid;
b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
c) in contact lens preparations.
EDOXUDINE.
EDROPHONIUM.
EFALIZUMAB.
EFAVIRENZ.
EFLORNITHINE.
ELBASVIR.
ELETRIPTAN.
ELOSULFASE ALFA.
ELOTUZUMAB.
ELTENAC.
ELTROMBOPAG.
ELUXADOLINE.
ELVITEGRAVIR.
EMEPRONIUM.
EMETINE except in preparations containing 0.2 per cent or less of emetine.
EMPAGLIFLOZIN.
EMTRICITABINE.
ENALAPRIL.
ENCORAFENIB.
# ENESTEBOL.
ENFLURANE for therapeutic use.
ENFUVIRTIDE.
# ENOBOSARM.
ENOXACIN.
ENOXAPARIN.
ENOXIMONE.
ENPROSTIL.
ENROFLOXACIN.
ENTACAPONE.
ENTECAVIR.
ENZALUTAMIDE.
EPHEDRA spp. except in preparations containing 0.001 per cent or less of ephedrine.
# EPHEDRINE.
EPICILLIN.
EPINASTINE.
EPIRUBICIN.
# EPITIOSTANOL.
EPLERENONE.
# EPOETINS.
EPOPROSTENOL.
EPROSARTAN.
EPTIFIBATIDE.
ERENUMAB.
ERGOMETRINE.
ERGOT.
ERGOTAMINE.
ERGOTOXINE.
ERIBULIN MESILATE.
ERLOTINIB.
ERTAPENEM.
ERTUGLIFLOZIN.
ERYSIMUM spp.
ERYTHROMYCIN.
# ERYTHROPOIETIN.
# ERYTHROPOIETINS except when separately specified in these Schedules.
ESCITALOPRAM.
ESMOLOL.
ESOMEPRAZOLE except when included in Schedule 2.
ESTRADIOL except when included in Schedule 5.
ESTRIOL.
ESTRAMUSTINE.
ESTROGENS except when separately specified in these Schedules.
ESTRONE.
ESTROPIPATE (piperazine estrone sulfate).
ETACRYNIC ACID.
ETANERCEPT.
ETHAMBUTOL.
ETHAMIVAN.
ETHCHLORVYNOL.
ETHER for use in anaesthesia.
ETHINAMATE.
ETHINYLESTRADIOL.
ETHIONAMIDE.
# ETHISTERONE.
ETHOGLUCID.
ETHOHEPTAZINE.
ETHOPROPAZINE.
ETHOSUXIMIDE.
ETHOTOIN.
ETHOXZOLAMIDE.
ETHYL CHLORIDE for human therapeutic use.
# ETHYLDIENOLONE.
ETHYLMORPHINE when compounded with one or more other therapeutically active substances:
a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine;
except when included in Schedule 2.
# ETHYLESTRENOL.
ETIDOCAINE.
ETIDRONIC ACID (includes etidronate disodium):
a) for internal use; or
b) in topical preparations except in preparations containing 1 per cent or less of etidronic acid.
ETILEFRIN.
ETIPROSTON.
ETODOLAC.
ETOFENAMATE except when included in Schedule 2.
ETONOGESTREL.
ETOPOSIDE.
ETORICOXIB.
ETRAVIRINE.
# ETRETINATE.
ETYNODIOL.
EVEROLIMUS.
EXEMESTANE.
EXENATIDE.
EZETIMIBE.
FAMCICLOVIR except when included in Schedule 3.
FAMOTIDINE except when included in Schedule 2.
FEBUXOSTAT.
FELBINAC except when included in Schedule 2.
FELODIPINE.
FELYPRESSIN.
FENBUFEN.
FENCAMFAMIN.
FENCLOFENAC.
FENFLURAMINE.
FENOFIBRATE.
FENOLDOPAM.
FENOPROFEN.
FENOTEROL.
FENPIPRAMIDE.
FENPIPRANE.
FENPROPOREX.
FENPROSTALENE.
FERRIC DERISOMALTOSE.
FEXOFENADINE except:
a) when included in Schedule 2; or
b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.
FIBRINOLYSIN except for external use.
FIBROBLAST GROWTH FACTORS
FIDAXOMICIN.
FILGRASTIM.
FINASTERIDE.
FINGOLIMOD.
FIROCOXIB.
FLECAINIDE.
FLEROXACIN.
FLOCTAFENINE.
FLORFENICOL.
FLUANISONE.
FLUCLOROLONE.
FLUCLOXACILLIN.
FLUCONAZOLE except when included in Schedule 3.
FLUCYTOSINE.
FLUDARABINE.
FLUDROCORTISONE.
FLUFENAMIC ACID.
FLUMAZENIL.
FLUMETASONE.
FLUMETHIAZIDE.
FLUNISOLIDE.
FLUNIXIN MEGLUMINE.
FLUOCINOLONE.
FLUOCINONIDE.
FLUOCORTIN.
FLUOCORTOLONE.
FLUORESCEIN in preparations for injection.
FLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.
FLUOROMETHOLONE.
FLUOROURACIL.
FLUOXETINE.
# FLUOXYMESTERONE.
FLUPENTIXOL.
FLUPHENAZINE.
FLUPROSTENOL.
FLURANDRENOLONE.
# FLURAZEPAM.
FLURBIPROFEN except when included in Schedule 2.
FLUROXENE for human therapeutic use.
FLUSPIRILENE.
FLUTAMIDE.
FLUTICASONE except when included in Schedule 2.
FLUVASTATIN.
FLUVOXAMINE.
FOLIC ACID in preparations for human use for injection.
FOLINIC ACID in preparations for human use for injection.
FOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule.
# FOLLISTATIN.
# FOLLITROPIN ALFA.
# FOLLITROPIN BETA.
# FOLLITROPIN DELTA.
FOMEPIZOLE.
FOMIVIRSEN.
FONDAPARINUX.
# FORMEBOLONE.
FORMESTANE.
FORMOTEROL
FOSAMPRENAVIR.
FOSAPREPITANT.
FOSCARNET.
FOSFESTROL (diethylstilbestrol diphosphate).
FOSFOMYCIN.
FOSINOPRIL.
FOSPHENYTOIN.
FOTEMUSTINE.
FRAMYCETIN.
FULVESTRANT.
FURALTADONE.
# FURAZABOL.
FURAZOLIDONE.
FUROSEMIDE (frusemide).
FUSIDIC ACID.
GABAPENTIN.
GALANTAMINE.
GALANTHUS spp.
GALLAMINE.
GALSULFASE.
GANCICLOVIR.
GANIRELIX.
GATIFLOXACIN.
GRAZOPREVIR.
GEFITINIB.
GEMCITABINE.
GEMEPROST.
GEMFIBROZIL.
GEMIFLOXACIN.
GEMTUZUMAB OZOGAMICIN.
GENTAMICIN.
GESTODENE.
GESTONORONE.
# GESTRINONE.
GHRH INJECTABLE PLASMID.
GITALIN.
GLATIRAMER ACETATE.
GLECAPREVIR.
GLIBENCLAMIDE.
GLIBORNURIDE.
GLICLAZIDE.
GLIMEPIRIDE.
GLIPIZIDE.
GLISOXEPIDE.
GLUTATHIONE for parenteral use.
# GLUTETHIMIDE.
GLYCERYL TRINITRATE except when included in Schedule 3.
GLYCOPYRRONIUM in preparations for injection.
GLYMIDINE.
GnRH VACCINE.
GOLIMUMAB.
GONADORELIN.
GONADOTROPHIC HORMONES except when separately specified in this Schedule.
GOSERELIN.
GRAMICIDIN.
GRANISETRON.
GREPAFLOXACIN.
GRISEOFULVIN.
# GROWTH HORMONE RELEASING HORMONES* (GHRHs).
# GROWTH HORMONE RELEASING PEPTIDES (GHRPs).
# GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6).
# GROWTH HORMONE SECRETAGOGUES* (GHSs).
GUAIFENESIN for human therapeutic use except:
a) when included in Schedule 2;
b) in oral liquid preparations containing 2 per cent or less of guaifenesin; or
c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.
GUANABENZ.
GUANACLINE.
GUANETHIDINE.
GUANFACINE.
GUANIDINE for therapeutic use.
GUSELKUMAB.
HACHIMYCIN.
HAEMATIN.
HAEMOPHILUS INFLUENZAE VACCINE.
HALCINONIDE.
HALOFANTRINE.
HALOFENATE.
HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.
HALOPERIDOL.
HALOTHANE for therapeutic use.
HEMEROCALLIS (Hemerocallis flava).
HEPARINS for internal use except when separately specified in this Schedule.
HEPATITIS A VACCINE.
HEPATITIS B VACCINE.
HETACILLIN.
HEXACHLOROPHENE:
a) in preparations for use on infants; or
b) in other preparations except:
i) when included in Schedule 2 or 6; or
ii) in preparations containing 0.75 per cent or less of hexachlorophene.
HEXAMETHONIUM.
# HEXARELIN.
HEXETIDINE for human internal use.
HEXOBENDINE.
HEXOCYCLIUM.
HEXOPRENALINE.
HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)
HISTAMINE for therapeutic use except in preparations containing 0.5 per cent or less of histamine.
HMG-CoA REDUCTASE INHIBITORS (including "statins") except when separately specified in these Schedules.
HOMATROPINE.
HUMAN CHORIONIC GONADATROPHIN except in pregnancy test kits.
HUMAN PAPILLOMAVIRUS VACCINE.
HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:
a) for tissue augmentation;
b) for cosmetic use; or
c) for the treatment of animals.
HYDRALAZINE.
HYDRARGAPHEN.
HYDROCHLOROTHIAZIDE.
HYDROCORTISONE:
a) for human use except when included in Schedule 2 or 3; or
b) for the treatment of animals.
HYDROCYANIC ACID for therapeutic use.
HYDROFLUMETHIAZIDE.
HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except:
a) when included in Schedule 2; or
b) in hair preparations containing 0.3 per cent or less of hydroquinone; or
c) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.
HYDROXYCARBAMIDE.
HYDROXYCHLOROQUINE.
HYDROXYEPHEDRINE.
HYDROXYPHENAMATE.
HYDROXYPROGESTERONE.
# HYDROXYSTENOZOL.
HYDROXYZINE.
HYGROMYCIN.
HYOSCINE except when included in Schedule 2.
HYOSCYAMINE except when included in Schedule 2.
HYOSCYAMUS NIGER except:
a) when included in Schedule 2; or
b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.
HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.
HYPROMELLOSE in preparations for injection.
IBAFLOXACIN for veterinary use.
IBANDRONIC ACID.
IBOGAINE.
IBRITUMOMAB.
IBRUTINIB.
IBUFENAC.
IBUPROFEN except:
a) when included in or expressly excluded from Schedule 2 or 3; or
b) in preparations for dermal use.
# IBUTAMOREN.
IBUTEROL.
IBUTILIDE.
ICATIBANT.
IDARUBICIN.
IDARUCIZUMAB
IDEBENONE.
IDOXURIDINE except in preparations containing 0.5 per cent or less of idoxuridine for dermal use.
IDURSULFASE.
IFOSFAMIDE.
ILOPROST.
IMATINIB.
IMEPITOIN.
IMIDAPRIL.
IMIGLUCERASE.
IMIPENIM.
IMIPRAMINE.
IMIQUIMOD.
IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.
INDACATEROL.
INDAPAMIDE.
INDINAVIR.
INDOMETACIN except when included in Schedule 2.
INDOPROFEN.
INDORAMIN.
INFLIXIMAB.
INFLUENZA AND CORYZA VACCINES:
a) for parenteral use; or
b) for nasal administration.
INGENOL MEBUTATE.
INOTUZUMAB OZOGAMICIN.
INSULIN DEGLUDEC.
INSULIN GLARGINE.
# INSULIN-LIKE GROWTH FACTOR I.
# INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule.
INSULINS.
INTERFERONS.
INTERLEUKINS except when separately specified in these Schedules.
IODOTHIOURACIL.
# IPAMORELIN.
IPILIMUMAB.
IPRATROPIUM except when included in Schedule 2.
IPRIFLAVONE.
IPRINDOLE.
IPRONIAZID.
IRBESARTAN.
IRINOTECAN.
IRON COMPOUNDS in injectable preparations for human use.
ISOAMINILE.
ISOAMYL NITRITE.
ISOBUTYL NITRITE.
ISOCARBOXAZID.
ISOCONAZOLE except when included in Schedule 2, 3 or 6.
ISOETARINE.
ISOFLURANE for therapeutic use.
ISOMETHEPTENE.
ISONIAZID.
ISOPRENALINE.
ISOPRINOSINE.
ISOPROPAMIDE except when included in Schedule 2.
ISOSORBIDE DINITRATE except when included in Schedule 3.
ISOSORBIDE MONONITRATE.
# ISOTRETINOIN.
ISOXICAM.
ISOXSUPRINE.
ISRADIPINE.
ITRACONAZOLE.
IVABRADINE.
IVACAFTOR.
IVERMECTIN:
a) for human use; or
b) for the treatment of mange in dogs.
IXABEPILONE.
IXAZOMIB.
IXEKIZUMAB.
JAPANESE ENCEPHALITIS VACCINE.
KANAMYCIN.
KETANSERIN except in topical veterinary preparations containing 0.5 per cent or less of ketanserin.
# KETAZOLAM.
KETOCONAZOLE except:
a) when included in Schedule 2;
b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
c) in preparations for dermal use for the treatment of tinea pedis.
KETOPROFEN except:
a) in preparations for dermal use; or
b) when included in Schedule 3.
KETOROLAC (includes ketoralac trometamol).
KETOTIFEN except when included in Schedule 2.
KHELLIN.
KITASAMYCIN except:
a) when included in Schedule 5 ; or
b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
LABETALOL.
LACIDIPINE.
LACOSAMIDE.
LAMIVUDINE.
LAMOTRIGINE.
LANADELUMAB.
LANATOSIDES.
LANREOTIDE.
LANSOPRAZOLE except when included in Schedule 2 or 3.
LANTHANUM for therapeutic use.
LAPATINIB.
LARONIDASE.
LAROPIPRANT.
LATAMOXEF.
LATANOPROST.
LAUDEXIUM.
LAUROMACROGOLS in preparations for injection except:
a) when present as an excipient; or
b) when separately specified in these Schedules.
LEAD for human therapeutic use.
LEDIPASVIR.
LEFETAMINE.
LEFLUNOMIDE.
# LENALIDOMIDE.
LENOGRASTIM.
LENVATINIB.
LEPIRUDIN.
LEPTAZOL.
LERCANIDIPINE.
LESINURAD.
LETERMOVIR.
LETROZOLE.
LEUPRORELIN.
LEVALLORPHAN.
LEVAMISOLE:
a) for human therapeutic use; or
b) in preparations for the prevention or treatment of heartworm in dogs.
LEVETIRACETAM.
LEVOBUNOLOL.
LEVOBUPIVACAINE.
LEVOCABASTINE except when included in Schedule 2.
LEVOCETIRIZINE except:
a) when included in Schedule 2; or
b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
i) in a primary pack containing not more than 5 days’ supply; and
ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LEVODOPA.
LEVOMEPROMAZINE.
LEVOMILNACIPRAN.
LEVONORGESTREL except when included in Schedule 3.
LEVOSIMENDAN.
LIDOCAINE except:
a) when included in Schedules 2 or 5;
b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances per dosage unit; or
c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.
LIDOFLAZINE.
LIFITEGRAST.
LINAGLIPTIN.
LINCOMYCIN.
LINDANE for human therapeutic use except when included in Schedule 2.
LINEZOLID.
LIOTHYRONINE.
LIPEGFILGRASTIM.
LIRAGLUTIDE.
LISINOPRIL.
LISURIDE.
LITHIUM for therapeutic use except:
a) when included in Schedule 2;
b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or
c) in preparations containing 0.01 per cent or less of lithium.
LIXISENATIDE.
LODOXAMIDE except when included in Schedule 2.
LOFEXIDINE.
LOGIPARIN for internal use.
LOMEFLOXACIN.
LOMUSTINE.
LOPERAMIDE except:
a) when included in Schedule 2; or
b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
LOPINAVIR.
# LOPRAZOLAM.
LORACARBEF.
LORATADINE except:
a) when included in Schedule 2; or
b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:
i) in a primary pack containing 10 dosage units or less; and
ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
# LORAZEPAM.
# LORMETAZEPAM.
LOSARTAN.
LOTEPREDNOL.
LOXAPINE.
LUMACAFTOR.
LUMEFANTRINE.
LUMIRACOXIB.
LURASIDONE.
# LUTEINISING HORMONE except in ovulation test kits.
LYMECYCLINE.
MACITENTAN for human use.
MAFENIDE except when included in Schedule 6.
MANDRAGORA OFFICINARUM.
MANNOMUSTINE.
MAPROTILINE.
MARAVIROC.
MARBOFLOXACIN.
MAROPITANT.
MAVACOXIB.
MAZINDOL.
MEASLES VACCINE.
MEBANAZINE.
MEBEVERINE.
MEBHYDROLIN.
# MEBOLAZINE.
MEBUTAMATE.
MECAMYLAMINE.
MECASERMIN.
MECILLINAM.
MECLOCYCLINE.
MECLOFENAMATE.
MECLOFENOXATE.
MECLOZINE except when included in Schedule 2.
# MEDAZEPAM.
MEDETOMIDINE.
MEDIGOXIN (methyldigoxin).
MEDROXYPROGESTERONE.
MEDRYSONE.
MEFENAMIC ACID except when included in Schedule 2.
MEFENOREX.
MEFLOQUINE.
MEFRUSIDE.
MEGESTROL.
MELAGATRAN.
MELANOTAN II.
MELATONIN for human use.
MELENGESTROL except when included in Schedule 6.
MELOXICAM.
MELPHALAN.
MEMANTINE.
MENINGOCOCCAL VACCINE.
MENINGOCOCCAL GROUP B VACCINE.
MENOTROPHIN.
MEPACRINE.
MEPENZOLATE.
MEPHENESIN.
MEPHENTERMINE.
MEPINDOLOL.
# MEPITIOSTANE.
MEPIVACAINE.
MEPROBAMATE.
MEPTAZINOL.
MEPYRAMINE except when included in Schedule 2 or 3.
MEQUITAZINE.
MERCAPTAMINE for human therapeutic use.
MERCAPTOMERIN.
MERCAPTOPURINE.
MERCUROCHROME except when included in Schedule 2 or 6.
MERCURY for cosmetic or therapeutic use except:
a) when separately specified in these Schedules; or
b) in a sealed device which prevents access to the mercury.
MEROPENEM.
MERSALYL.
# MESABOLONE.
MESALAZINE.
MESNA.
# MESTANOLONE (androstalone).
# MESTEROLONE.
MESTRANOL.
# METANDIENONE.
METARAMINOL.
# METENOLONE.
METERGOLINE.
METFORMIN.
METHACHOLINE.
METHACYCLINE.
METHALLENESTRIL.
# METHANDRIOL.
METHANTHELINIUM.
METHAZOLAMIDE.
METHDILAZINE except when included in Schedule 3.
# METHENOLONE.
METHICILLIN.
METHIMAZOLE.
METHISAZONE.
METHIXENE.
METHOCARBAMOL.
METHOHEXITONE.
METHOIN.
METHOTREXATE.
METHOXAMINE except:
a) when included in Schedule 2; or
b) in preparations for external use containing 1 per cent or less of methoxamine.
METHOXSALEN.
METHOXYFLURANE.
METHSUXIMIDE.
METHYCLOTHIAZIDE.
METHYL AMINOLEVULINATE.
#METHYLANDROSTANOLONE.
# METHYLCLOSTEBOL.
METHYLDOPA.
METHYLENE BLUE in preparations for injection.
METHYLERGOMETRINE.
METHYLMERCURY for therapeutic use.
METHYLNALTREXONE.
METHYLPENTYNOL.
METHYLPHENOBARBITAL.
METHYLPREDNISOLONE.
METHYLROSANILINIUM CHLORIDE for human use except when used as a dermal marker.
METHYL SALICYLATE in preparations for internal therapeutic use.
# METHYLTESTOSTERONE.
METHYLTHIOURACIL.
# METHYLTRIENOLONE.
METHYPRYLONE.
METHYSERGIDE.
METOCLOPRAMIDE except when included in Schedule 3.
METOLAZONE.
METOPROLOL.
# METRIBOLONE.
METRIFONATE (trichlorfon) for human therapeutic use.
METRONIDAZOLE.
METYRAPONE.
MEXILETINE.
MEZLOCILLIN.
MIANSERIN.
MIBEFRADIL.
# MIBOLERONE.
MICAFUNGIN.
MICONAZOLE except:
a) when included in Schedule 2, 3 or 6; or
b) in preparations for dermal use for the treatment of tinea pedis.
# MIDAZOLAM.
MIDOSTAURIN.
MIDODRINE.
MIFEPRISTONE.
MIGALASTAT.
MIGLITOL.
MIGLUSTAT.
MILBEMYCIN OXIME except when included in Schedule 5.
MILNACIPRAN.
MILRINONE.
MINOCYCLINE.
MINOXIDIL except when included in Schedule 2.
MIRABEGRON.
MIRTAZAPINE.
MISOPROSTOL.
MITOBRONITOL.
MITOMYCIN.
MITOTANE.
MITOXANTRONE.
MITRATAPIDE.
MIVACURIUM CHLORIDE.
MOCLOBEMIDE.
MODAFINIL.
MOLGRAMOSTIM.
MOLINDONE.
MOMETASONE except when included in Schedule 2.
MONENSIN except:
a) when included in Schedule 5 or 6; or
b) in animal feeds containing 360 mg/kg or less of antibiotic substances.
MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02 per cent or less of monobenzone or alkyl ethers of hydroquinone.
MONOCLONAL ANTIBODIES for therapeutic use except:
a) in diagnostic test kits; or
b) when separately specified in these Schedules.
MONOETHANOLAMINE in preparations for injection.
MONTELUKAST.
MOPERONE.
MORAZONE.
MORICIZINE.
MOTRAZEPAM.
MOTRETINIDE.
MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin except when included in Schedule 5 or 6.
MOXIFLOXACIN.
MOXONIDINE.
MUMPS VACCINE.
MUPIROCIN.
MURAGLITAZAR.
MUROMONAB.
MUSTINE (nitrogen mustard).
MYCOPHENOLIC ACID (includes mycophenolate mofetil).
NABUMETONE.
NADOLOL.
NADROPARIN.
NAFARELIN.
NAFTIDROFURYL.
NALBUPHINE.
NALIDIXIC ACID.
NALMEFENE.
NALORPHINE.
NALOXEGOL.
NALOXONE except when in Schedule 3.
NALTREXONE.
# NANDROLONE.
NAPROXEN except when included in Schedule 2 or 3.
NARASIN except:
a) when included in Schedule 6; or
b) in animal feeds containing 100 mg/kg or less of antibiotic substances.
NARATRIPTAN.
NATALIZUMAB.
NATAMYCIN except for use as a food additive.
NATEGLINIDE.
NEBACUMAB.
NEBIVOLOL.
NEDOCROMIL.
NEFAZODONE.
NEFOPAM.
NELFINAVIR (includes nelfinavir mesilate).
NEOMYCIN.
NEOSTIGMINE.
NEPAFENAC.
NERATINIB.
NERIUM OLEANDER.
NESIRITIDE.
NETILMICIN.
NETUPITANT.
NEVIRAPINE.
NIALAMIDE.
NICARDIPINE.
NICERGOLINE.
NICOFURANOSE.
NICORANDIL.
NICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal from tobacco smoking in preparations for oromucosal or transdermal use.
NICOTINIC ACID for human therapeutic use except:
a) when separately specified in these Schedules;
b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
c) nicotinamide.
NICOUMALONE.
NIFEDIPINE.
NIFENAZONE.
NIKETHAMIDE.
NILOTINIB.
NILUTAMIDE.
NIMESULIDE.
NIMODIPINE.
NIMORAZOLE.
NINTEDANIB.
NIRIDAZOLE.
NISOLDIPINE.
NITISINONE.
# NITRAZEPAM.
NITRENDIPINE.
NITRIC OXIDE for human therapeutic use.
NITROFURANTOIN.
NITROFURAZONE.
NITROUS OXIDE for therapeutic use.
NITROXOLINE.
NIVOLUMAB.
NIZATIDINE except when included in Schedule 2.
NOMEGESTROL.
NOMIFENSINE.
NORADRENALINE.
# 19-NORANDROSTENEDIOL.
# 19-NORANDROSTENEDIONE.
# NORANDROSTENOLONE.
# NORBOLETHONE.
# NORCLOSTEBOL.
NORELGESTROMIN.
# NORETHANDROLONE.
NORETHISTERONE.
NORFLOXACIN.
NORGESTREL.
NORIBOGAINE.
NORMAL HUMAN IMMUNOGLOBULIN.
# NORMETHANDRONE.
NORTRIPTYLINE.
NOVOBIOCIN.
NOXIPTYLINE.
NUSINERSEN.
NYSTATIN except when included in Schedule 2 or 3.
OBETICHOLIC ACID.
OCLACITINIB.
OCRELIZUMAB.
OCRIPLASMIN.
OCTAMYLAMINE.
OCTATROPINE.
OCTREOTIDE.
OCTYL NITRITE.
OFATUMUMAB.
OFLOXACIN.
OLANZAPINE.
OLAPARIB.
OLARATUMAB.
OLEANDOMYCIN except:
a) when included in Schedule 5; or
b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
OLEANDRIN.
OLMESARTAN.
OLODATEROL.
OLOPATADINE.
OLSALAZINE.
OMALIZUMAB.
OMBITASVIR.
OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.
OMEPRAZOLE except when included in Schedule 2 or 3.
ONDANSETRON.
OPIPRAMOL.
ORBIFLOXACIN.
ORCIPRENALINE.
ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:
a) when separately specified in these Schedules; or
b) in preparations containing 2 per cent or less of malathion for external use.
ORLISTAT except when included in Schedule 3.
ORNIDAZOLE.
ORNIPRESSIN.
ORPHENADRINE.
ORTHOPTERIN.
OSELTAMIVIR.
OSIMERTINIB.
OUABAIN.
# OVANDROTONE.
# OXABOLONE.
OXACILLIN.
OXALIPLATIN.
# OXANDROLONE.
OXAPROZIN.
# OXAZEPAM.
OXCARBAZEPINE.
OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.
OXETACAINE (oxethazaine) except when included in Schedule 2.
OXICONAZOLE except:
a) when included in Schedule 2 or 3; or
b) in preparations for the treatment of tinea pedis.
OXITROPIUM.
OXOLAMINE.
OXOLINIC ACID.
OXPRENOLOL.
OXYBUPROCAINE.
OXYBUTYNIN.
# OXYMESTERONE.
# OXYMETHOLONE.
OXYPHENBUTAZONE.
OXYPHENCYCLIMINE.
OXYPHENONIUM.
OXYTETRACYCLINE except when included in Schedule 5.
OXYTOCIN.
PACLITAXEL.
PALBOCICLIB.
PALIFERMIN.
PALIPERIDONE.
PALIVIZUMAB.
PALONOSETRON.
PAMAQUIN.
PAMIDRONIC ACID (includes pamidronate disodium)
PANCREATIC ENZYMES except:
a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or
b) when separately specified in these Schedules.
PANCURONIUM.
PANITUMUMAB.
PANOBINOSTAT.
PANTOPRAZOLE except when included in Schedule 2 or 3.
PAPAVERINE in preparations for injection.
PARACETAMOL:
a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules;
b) when combined with ibuprofen in a primary pack containing more than 30 dosage units;
c) in slow release tablets or capsules containing more than 665 mg paracetamol;
d) in non-slow release tablets or capsules containing more than 500 mg paracetamol;
e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol;
f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules except in schedule 2;
g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules except when included in Schedule 2;
h) for injection.
PARALDEHYDE.
PARAMETHADIONE.
PARAMETHASONE.
PARECOXIB.
PARICALCITOL.
PARITAPREVIR.
PAROMOMYCIN.
PAROXETINE.
PASIREOTIDE.
PATIROMER SORBITEX CALCIUM.
PAZOPANIB.
PECAZINE.
PEFLOXACIN.
PEGAPTANIB.
PEGASPARGASE.
PEGFILGRASTIM.
PEGINTERFERON.
PEGVISOMANT.
PEMBROLIZUMAB.
PEMETREXED.
PEMOLINE.
PEMPIDINE.
PENBUTOLOL.
PENCICLOVIR except in preparations containing 1 per cent or less of penciclovir for the treatment of herpes labialis in packs containing 10 g or less.
PENETHAMATE.
PENICILLAMINE.
PENTAERYTHRITYL TETRANITRATE.
PENTAGASTRIN.
PENTAMETHONIUM.
PENTAMIDINE (includes pentamidine isetionate).
PENTHIENATE.
PENTOBARBITAL when packed and labelled for injection.
PENTOLINIUM.
PENTOSAN POLYSULFATE SODIUM.
PENTOXIFYLLINE.
PERAMIVIR.
# PERAMPANEL.
PERGOLIDE.
PERHEXILINE.
PERICIAZINE.
PERINDOPRIL.
PERMETHRIN for human therapeutic use except in preparations containing 5 per cent or less of permethrin.
PERPHENAZINE.
PERTUSSIS ANTIGEN.
PERTUZUMAB.
PHENACEMIDE.
PHENACETIN for therapeutic use (excluding when present as an excipient).
PHENAGLYCODOL.
PHENAZONE except when included in Schedule 2 or 5.
PHENAZOPYRIDINE.
PHENELZINE.
PHENETICILLIN.
PHENFORMIN.
PHENGLUTARIMIDE.
PHENINDIONE.
PHENIRAMINE except when included in Schedule 2 or 3.
PHENISATIN.
PHENOBARBITAL.
PHENOL in preparations for injection.
PHENOLPHTHALEIN for human therapeutic use.
PHENOXYBENZAMINE.
PHENOXYMETHYLPENICILLIN.
PHENSUXIMIDE.
# PHENTERMINE.
PHENTHIMENTONIUM.
PHENTOLAMINE.
PHENYLBUTAZONE.
PHENYLEPHRINE:
a) in preparations for injection; or
b) in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.
PHENYLPROPANOLAMINE.
PHENYLTOLOXAMINE.
PHENYTOIN.
PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract).
PHOLCODINE:
a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
b) in undivided preparations containing 2.5 per cent or less of pholcodine,
except when included in Schedule 2.
PHOSPHODIESTERASE TYPE 5 INHIBITORS except:
a) when separately specified in these Schedules; or
b) when present as an unmodified, naturally occurring substance.
PHTHALYLSULFATHIAZOLE.
PHYSOSTIGMINE.
PIBRENTASVIR.
PICROTOXIN.
PILOCARPINE except in preparations containing 0.025 per cent or less of pilocarpine.
PIMECROLIMUS.
PIMOBENDAN.
PIMOZIDE.
PINACIDIL.
PINDOLOL.
PIOGLITAZONE.
PIPECURONIUM.
PIPEMIDIC ACID.
PIPENZOLATE.
PIPER METHYSTICUM (kava) in preparations for human use except when included on the Australian Register of Therapeutic Goods in preparations:
a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:
i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or
ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g;
and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome and/or root; or
c) in dermal preparations.
PIPERACILLIN.
PIPERIDINE.
PIPERIDOLATE.
PIPOBROMAN.
PIPOTHIAZINE.
PIPRADROL.
PIRACETAM.
PIRBUTEROL.
PIRENOXINE (catalin).
PIRENZEPINE.
PIRETANIDE.
PIRFENIDONE.
PIROXICAM except in preparations for dermal use.
PIRPROFEN.
PITAVASTATIN.
PITUITARY HORMONES except when separately specified in these Schedules.
PIVAMPICILLIN.
PIZOTIFEN.
PLICAMYCIN.
PLERIXAFOR.
PNEUMOCOCCAL VACCINE.
PODOPHYLLOTOXIN for human use:
a) internally;
b) in preparations for the treatment of anogenital warts; or
c) in other preparations except when included in Schedule 2 or 3.
PODOPHYLLUM EMODI (podophyllin) for human use:
a) internally;
b) in preparations for the treatment of anogenital warts; or
c) in other preparations except when included in Schedule 2 or 3.
PODOPHYLLUM PELTATUM (podophyllin) for human use:
a) internally;
b) in preparations for the treatment of anogenital warts; or
c) in other preparations except when included in Schedule 2 or 3.
POLIDEXIDE.
POLIOMYELITIS VACCINE.
POLYACRYLAMIDE in preparations for injection or implantation:
a) for tissue augmentation; or
b) for cosmetic use.
POLYCAPROLACTONE in preparations for injection or implantation:
a) for tissue augmentation; or
b) for cosmetic use.
POLYESTRADIOL.
POLYLACTIC ACID in preparations for injection or implantation:
a) for tissue augmentation; or
b) for cosmetic use.
POLYMYXIN.
POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules.
POLYTHIAZIDE.
POMALIDOMIDE.
PORACTANT.
POSACONAZOLE.
POTASSIUM BROMIDE for therapeutic use.
POTASSIUM CHLORIDE in oral preparations for human therapeutic use except:
a) when containing less than 550 mg of potassium chloride per dosage unit;
b) in preparations for oral rehydration therapy;
c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
d) in preparations for enteral feeding.
POTASSIUM PERCHLORATE for therapeutic use.
PRACTOLOL.
PRADOFLOXACIN.
PRALATREXATE.
PRALIDOXIME.
PRAMIPEXOLE.
PRAMOCAINE.
# PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2 (GHRP-2)).
PRAMPINE.
# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).
PRASUGREL.
PRAVASTATIN.
# PRAZEPAM.
PRAZIQUANTEL for human therapeutic use.
PRAZOSIN.
PREDNISOLONE.
PREDNISONE.
PREGABALIN.
PREGNENOLONE.
PRENALTEROL.
PRENYLAMINE.
PRILOCAINE except when included in Schedule 2.
PRIMAQUINE.
PRIMIDONE.
PROBENECID.
PROBUCOL.
PROCAINAMIDE.
PROCAINE.
PROCAINE BENZYLPENICILLIN.
PROCARBAZINE.
PROCHLORPERAZINE except when included in Schedule 3.
PROCYCLIDINE except when included in Schedule 2.
PROGESTERONE except when included in Schedule 5.
PROGESTOGENS except when separately specified in these Schedules.
PROGLUMIDE.
PROGUANIL.
PROLINTANE.
PROMAZINE.
PROMETHAZINE except when included in Schedule 2 or 3.
PROMOXOLANE.
PROPAFENONE.
PROPAMIDINE for therapeutic use except when included in Schedule 2.
PROPANIDID.
PROPANTHELINE.
PROPENTOFYLLINE.
# PROPETANDROL.
PROPIONIBACTERIUM ACNES for therapeutic use.
PROPOFOL.
PROPRANOLOL.
PROPYLHEXEDRINE.
PROPYLTHIOURACIL.
PROPYPHENAZONE.
PROQUAZONE.
PROSCILLARIDIN.
PROSTAGLANDINS except when separately specified in this Schedule.
PROSTIANOL.
PROTAMINE.
PROTHIONAMIDE.
PROTHIPENDYL.
PROTIRELIN.
PROTOVERATRINES.
PROTRIPTYLINE.
PROXYMETACAINE.
PRUCALOPRIDE.
PSEUDOEPHEDRINE except when included in Schedule 3.
PYRAZINAMIDE.
PYRIDINOLCARBAMATE.
PYRIDOSTIGMINE.
PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except:
a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.
PYRIMETHAMINE.
PYROVALERONE.
PYRVINIUM.
# QUAZEPAM.
QUETIAPINE.
QUINAGOLIDE.
QUINAPRIL.
# QUINBOLONE.
QUINETHAZONE.
QUINIDINE.
QUININE for human therapeutic use except when the maximum recommended daily dose is 50 mg or less of quinine.
QUINISOCAINE (dimethisoquin).
QUINUPRISTIN.
RABEPRAZOLE except when included in Schedule 2 or 3.
RABIES VACCINE.
RACTOPAMINE except when included in Schedule 5.
RALOXIFENE.
RALTEGRAVIR.
RALTITREXED.
RAMIPRIL.
RAMUCIRUMAB.
RANIBIZUMAB.
RANITIDINE except:
a) when included in Schedule 2;
b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units;
c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.
RANOLAZINE
RAPACURONIUM.
RASAGILINE.
RASBURICASE.
RAUWOLFIA SERPENTINA.
RAUWOLFIA VOMITORIA.
RAZOXANE.
REBOXETINE.
RED YEAST RICE for human therapeutic use.
REGORAFENIB.
REMOXIPRIDE.
REPAGLINIDE.
RESERPINE.
RESLIZUMAB.
RETAPAMULIN.
RETEPLASE.
RETIGABINE.
RIBAVIRIN.
RIBOCICLIB.
RIDAFOROLIMUS.
RIFABUTIN.
RIFAMPICIN.
RIFAMYCIN.
RIFAPENTINE.
RIFAXIMIN.
RILPIVIRINE.
RILUZOLE.
RIMEXOLONE.
RIMITEROL.
RIMONABANT.
RIOCIGUAT.
RISEDRONIC ACID.
RISPERIDONE.
RITODRINE.
RITONAVIR.
RITUXIMAB.
RIVAROXABAN.
RIVASTIGMINE.
RIZATRIPTAN.
ROBENACOXIB.
ROCURONIUM.
ROFECOXIB.
ROFLUMILAST.
ROLITETRACYCLINE.
ROMIDEPSIN.
ROMIFIDINE.
ROMIPLOSTIM.
ROMOSOZUMAB.
RONIDAZOLE.
ROPINIROLE.
ROPIVACAINE.
ROSIGLITAZONE.
ROSOXACIN.
ROSUVASTATIN.
ROTIGOTINE.
# ROXIBOLONE.
ROXITHROMYCIN.
RUBELLA VACCINE.
RUBOXISTAURIN.
RUFINAMIDE.
RUPATADINE.
RUXOLITINIB.
SACUBITRIL.
SAFINAMIDE
SALBUTAMOL except when included in Schedule 3.
SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.
SALINOMYCIN except:
a) when included in Schedule 6; or
b) in animal feeds containing 60 mg/kg or less of antibiotic substances.
SALMETEROL.
SAPROPTERIN.
SAQUINAVIR.
SARILUMAB.
SAXAGLIPTIN.
SCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.
SCOPOLIA CARNIOLICA for therapeutic use.
SEBELIPASE ALFA.
SECUKINUMAB.
# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).
SELEGILINE.
SELENIUM:
a) for human oral use with a recommended daily dose of more than 300 micrograms; or
b) for the treatment of animals except:
i) when included in Schedule 6 or 7;
ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;
iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;
iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
v) in feeds containing 1 g/tonne or less of selenium.
SERELAXIN.
SELEXIPAG.
SERMORELIN.
SERTINDOLE.
SERTRALINE.
SEVELAMER.
SEVOFLURANE.
SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.
SIBUTRAMINE.
# SILANDRONE.
SILDENAFIL.
SILICONES for intra-ocular use.
SILODOSIN.
SILTUXIMAB.
SILVER SULFADIAZINE.
SIMEPREVIR.
SIMVASTATIN.
SIROLIMUS.
SISOMICIN (sisomycin).
SITAGLIPTIN.
# SITAXENTAN.
SODIUM BROMIDE for therapeutic use.
SODIUM CELLULOSE PHOSPHATE for human internal use.
SODIUM CROMOGLYCATE except when included in Schedule 2.
SODIUM MORRHUATE in preparations for injection.
SODIUM NITROPRUSSIDE for human therapeutic use.
SODIUM PHENYLBUTYRATE.
SODIUM PHOSPHATE in preparations for oral laxative use.
SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.
SODIUM SALICYLATE in preparations for injection for the treatment of animals.
SODIUM TETRADECYLSULFATE in preparations for injection.
SODIUM ZIRCONIUM CYCLOSILICATE.
SOFOSBUVIR.
SOLASODINE.
SOLIFENACIN.
SOMATOSTATIN.
SOMATOTROPIN EQUINE.
# SOMATROPIN (human growth hormone).
SONIDEGIB.
SONTOQUINE.
SORAFENIB.
SOTALOL.
SPARFLOXACIN.
SPARTEINE.
SPECTINOMYCIN.
SPIRAMYCIN.
SPIRAPRIL.
SPIRONOLACTONE.
# STANOLONE.
# STANOZOLOL.
STAVUDINE.
# STENABOLIC (SR9009) and other synthetic REV-ERB agonists.
# STENBOLONE.
STEROID HORMONES except when separately specified in these Schedules.
STILBESTROL (diethylstilbestrol).
STIRIPENTOL.
STREPTODORNASE.
STREPTOKINASE.
STREPTOMYCIN.
STRONTIUM RANELATE.
STROPHANTHINS.
STROPHANTHUS spp.
STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.
STRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine.
STYRAMATE.
SUCCIMER.
SUGAMMADEX.
SULBACTAM.
SULCONAZOLE except when included in Schedule 2.
SULFACETAMIDE except when included in Schedule 3 or 5.
SULFADIAZINE except when included in Schedule 5.
SULFADIMETHOXINE.
SULFADIMIDINE except when included in Schedule 5.
SULFADOXINE.
SULFAFURAZOLE.
SULFAGUANIDINE.
SULFAMERAZINE except when included in Schedule 5.
SULFAMETHIZOLE.
SULFAMETHOXAZOLE.
SULFAMETHOXYDIAZINE.
SULFAMETHOXYPYRIDAZINE.
SULFAMETROLE.
SULFAMONOMETHOXINE.
SULFAMOXOLE.
SULFAPHENAZOLE.
SULFAPYRIDINE.
SULFAQUINOXALINE.
SULFASALAZINE.
SULFATHIAZOLE except when included in Schedule 5.
SULFATROXAZOLE.
SULFINPYRAZONE.
SULFOMYXIN.
SULFONAMIDES except:
a) when separately specified in this Schedule;
b) when included in Schedule 3, 5 or 6; or
c) when packed and labelled solely for use as a herbicide.
SULFONMETHANE (sulfonal) and alkyl sulfonals.
SULINDAC.
SULTAMICILLIN.
SULTHIAME.
SUMATRIPTAN.
SUNITINIB.
SUPROFEN.
SUTILAINS.
SUXAMETHONIUM.
SUXETHONIUM.
SUVOREXANT.
TACRINE.
TACROLIMUS.
TADALAFIL.
TAFENOQUINE SUCCINATE.
TAFLUPROST.
TALIGLUCERASE ALFA.
TALIMOGENE LAHERPAREPVEC.
TAMOXIFEN.
TAMSULOSIN.
TANACETUM VULGARE except in preparations containing 0.8 per cent or less of oil of tansy.
TASONERMIN.
TAZAROTENE.
TAZOBACTAM.
TB-500.
T-CELL RECEPTOR ANTIBODY.
TEDUGLUTIDE.
TEGAFUR.
TEGASEROD.
TELAPREVIR.
TELITHROMYCIN.
TEICOPLANIN.
TELBIVUDINE.
TELMISARTAN.
TELOTRISTAT ETHYL.
# TEMAZEPAM.
TEMOZOLOMIDE.
TEMSIROLIMUS.
TENECTEPLASE.
TENIPOSIDE.
TENOFOVIR.
TENOXICAM.
TEPOXALIN.
TERAZOSIN.
TERBINAFINE except:
a) when included in Schedule 2; or
b) in preparations for dermal use for the treatment of tinea pedis.
TERBUTALINE except when included in Schedule 3.
TERFENADINE.
TERIFLUNOMIDE.
# TERIPARATIDE.
TERLIPRESSIN.
TERODILINE.
TEROPTERIN.
# TESTOLACTONE.
# TESTOSTERONE except when included in Schedule 6.
TETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in animals.
TETANUS TOXOID for human use.
TETRABENAZINE.
TETRACAINE except:
a) when included in Schedule 2; or
b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.
TETRACOSACTIDE.
TETRACYCLINE except when included in Schedule 5.
TETRAETHYLAMMONIUM.
TETROXOPRIM.
TEZACAFTOR.
# THALIDOMIDE.
THENYLDIAMINE.
THEOPHYLLINE except when included in Schedule 3.
THEVETIA PERUVIANA.
THEVETIN.
THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.
THIAMBUTOSINE.
THIAZOSULFONE.
THIETHYLPERAZINE.
THIOACETAZONE.
THIOCARLIDE.
# THIOMESTERONE (tiomesterone).
THIOPENTAL.
THIOPROPAZATE.
THIOPROPERAZINE.
THIORIDAZINE.
THIOSTREPTON.
THIOTEPA.
THIOTHIXENE.
THIOURACIL.
THIOUREA for therapeutic use except in preparations containing 0.1 per cent or less of thiourea.
THYMOSIN BETA 4 (THYMOSIN β4)
THYMOXAMINE (includes thymoxamine hydrochloride).
THYROID except when separately specified in this Schedule.
THYROTROPHIN.
THYROXINE (includes thyroxine sodium).
TIAGABINE.
TIAMULIN.
# TIANEPTINE.
TIAPROFENIC ACID.
TIARAMIDE.
TIBOLONE.
TICAGRELOR.
TICARCILLIN.
TICLOPIDINE.
TIEMONIUM.
TIENILIC ACID.
TIGECYCLINE.
TIGLOIDINE.
TILDIPIROSIN.
TILETAMINE.
TILMANOCEPT
TILMICOSIN.
TILUDRONIC ACID (includes disodium tiludronate).
TIMOLOL.
TINIDAZOLE.
TINZAPARIN (includes tinzaparin sodium).
TIOCONAZOLE except:
a) when included in Schedule 2 or 3; or
b) in preparations for dermal use for the treatment of tinea pedis.
TIOGUANINE.
TIOTROPIUM.
TIPEPIDINE.
TIPIRACIL.
TIPRANAVIR.
TIRILAZAD.
TIROFIBAN.
TOBRAMYCIN.
TOCAINIDE.
TOCERANIB.
TOCILIZUMAB.
TOFACITINIB.
TOLAZAMIDE.
TOLAZOLINE.
TOLBUTAMIDE.
TOLCAPONE.
TOLFENAMIC ACID.
TOLMETIN.
TOLONIUM.
TOLPROPAMINE.
TOLRESTAT.
TOLTERODINE.
TOLVAPTAN.
TOPIRAMATE.
TOPOTECAN.
TORASEMIDE.
TOREMIFENE.
TOXOIDS for human parenteral use except when separately specified in these Schedules.
TRAMADOL.
TRANDOLAPRIL.
TRAMETINIB DIMETHYL SULFOXIDE.
TRANEXAMIC ACID except in preparations containing 3 per cent or less of cetyl tranexamate hydrochloride for dermal cosmetic use.
TRANYLCYPROMINE.
TRASTUZUMAB.
TRASTUZUMAB EMTANSINE.
TRAVOPROST.
TRAZODONE.
# TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5.
TREOSULPHAN.
TREPROSTINIL.
# TRESTOLONE.
TRETAMINE.
# TRETINOIN.
TRIACETYLOLEANDOMYCIN.
TRIAMCINOLONE except when included in Schedule 2 or 3.
TRIAMTERENE.
TRIAZIQUONE.
# TRIAZOLAM.
TRICHLORMETHIAZIDE.
TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.
TRICHLOROETHYLENE for therapeutic use.
TRICLOFOS.
TRICYCLAMOL.
TRIDIHEXETHYL.
TRIFLUOPERAZINE.
TRIFLUPERIDOL.
TRIFLUPROMAZINE.
TRIFLURIDINE.
TRIHEXYPHENIDYL
TRILOSTANE.
TRIMETAPHAN.
TRIMETHOPRIM.
TRIMIPRAMINE.
TRIMUSTINE.
TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.
TRIOXYSALEN.
TRIPELENNAMINE.
TRIPLE ANTIGEN VACCINE.
TRIPROLIDINE except when included in Schedule 2 or 3.
TRIPTORELIN.
TROGLITAZONE.
TROLAMINE when in preparations for tattoo removal.
TROMETAMOL in preparations for injection except in preparations containing 3 per cent or less of trometamol.
TROPICAMIDE.
TROPISETRON.
TROVAFLOXACIN.
TROXIDONE.
TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.
TUBERCULIN.
TUBOCURARINE.
TULATHROMYCIN.
TULOBUTEROL.
TYLOSIN.
TYPHOID VACCINE.
ULIPRISTAL except when included in Schedule 3.
UMECLIDINIUM.
UNOPROSTONE.
URACIL.
URAPIDIL.
URETHANE (excluding its derivatives) for therapeutic use.
# UROFOLLITROPIN.
UROKINASE.
URSODEOXYCHOLIC ACID.
USTEKINUMAB.
VACCINES for human therapeutic use except when separately specified in this Schedule.
VACCINES – PLASMID DNA for animal use except when separately specified in these Schedules.
VACCINES, veterinary live virus except:
a) poultry vaccines;
b) pigeon pox vaccine; or
c) scabby mouth vaccine.
VACCINIA VIRUS VACCINE.
VALACICLOVIR.
VALDECOXIB.
VALGANCICLOVIR.
VALNOCTAMIDE.
VALPROIC ACID.
VALSARTAN.
VANCOMYCIN.
VANDETANIB.
VARDENAFIL.
VARENICLINE.
VARICELLA VACCINE.
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.
VASOPRESSIN.
VECURONIUM.
VEDAPROFEN.
VEDOLIZUMAB.
VELAGLUCERASE ALFA.
VELPATASVIR.
VEMURAFENIB.
VENETOCLAX.
VENLAFAXINE.
VERAPAMIL.
VERATRUM spp. except when separately specified in this Schedule.
VERNAKALANT.
VERTEPORFIN.
VIDARABINE.
VIGABATRIN.
VILANTEROL.
VILDAGLIPTIN.
VILOXAZINE.
VINBLASTINE.
VINCAMINE.
VINCRISTINE.
VINDESINE.
VINFLUNINE.
VINORELBINE.
VINYL ETHER for therapeutic use.
VIRGINIAMYCIN except when included in Schedule 5.
VISMODEGIB.
VISNADINE.
VITAMIN A for human therapeutic or cosmetic use except:
a) in preparations for topical use containing 1 per cent or less of Vitamin A;
b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or
c) in preparations for parenteral nutrition replacement.
VITAMIN D for human internal therapeutic use except:
a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or
b) when included in Schedule 3.
VORAPAXAR.
VORICONAZOLE.
VORINOSTAT.
VORTIOXETINE.
VOXILAPREVIR.
WARFARIN for therapeutic use.
XAMOTEROL.
XANTHINOL NICOTINATE.
XIMELAGATRAN.
XIPAMIDE.
XYLAZINE.
YOHIMBINE.
ZAFIRLUKAST.
ZALCITABINE.
ZALEPLON.
ZANAMIVIR.
ZERANOL except when included in Schedule 6.
ZIDOVUDINE.
ZILPATEROL.
ZIMELDINE.
ZINC COMPOUNDS for human internal use except:
a) in preparations with a recommended daily dose of 25 mg or less of zinc; or
b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.
ZIPRASIDONE.
ZOLAZEPAM.
ZOLEDRONIC ACID.
ZOLMITRIPTAN.
ZOLPIDEM.
ZONISAMIDE.
ZOPICLONE.
ZOXAZOLAMINE.
ZUCLOPENTHIXOL.
ABAMECTIN
a) in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin; or
b) in gel formulations containing 0.05 per cent or less of abamectin in applicators containing 50 mg or less of abamectin.
ABSCISIC ACID.
ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH3COOH) except:
a) when included in Schedule 2 or 6; or
b) for therapeutic use.
ACETONE except in preparations containing 25 per cent or less of designated solvents.
ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5 per cent or less of acriflavinium chloride.
AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit
a) for the treatment and prevention of flea infestations and control of ticks in dogs; or
b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxime.
AKLOMIDE.
ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole except in intraruminal implants each containing 3.85 g or less of albendazole.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:
a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5;
b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;
c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:
i) in food additive preparations for domestic use; or
ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5,
except when separately specified in these Schedules.
ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxylated fatty alkylamine polymer except in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.
ALLETHRIN in preparations containing 10 per cent or less of allethrin except:
a) in insecticidal mats; or
b) in other preparations containing 1 per cent or less of allethrin.
ALLOXYDIM.
ALPHA-CYPERMETHRIN:
a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or
b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.
AMETRYN.
AMINES for use as curing agents for epoxy resins except when separately specified in these Schedules.
AMINOACRIDINE in preparations for veterinary use containing 2.5 per cent or less of aminoacridine.
AMINOPYRALID in preparations containing 22 per cent or less of aminopyralid.
AMITROLE.
AMINOCYCLOPYRACHLOR.
AMISULBROM
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia except:
a) in preparations for human internal therapeutic use;
b) in preparations for inhalation when absorbed in an inert solid material; or
c) in preparations containing 0.5 per cent or less of free ammonia.
AMMONIUM THIOCYANATE except in preparations containing 10 per cent or less of ammonium thiocyanate.
ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when separately specified in these Schedules.
ANISE OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 50 per cent or less of anise oil.
ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.
ATRAZINE.
AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.
AZOXYSTROBIN.
BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.
BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.
BASIL OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 5 per cent or less of methyl chavicol.
BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL or less of Beauveria bassiana.
BENALAXYL.
BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.
BENTAZONE.
BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride except in preparations containing 5 per cent or less of benzalkonium chloride.
BENZOFENAP.
BENZOYL PEROXIDE except:
a) when included in Schedule 2 or 4; or
b) in preparations containing 5 per cent or less of benzoyl peroxide.
BERGAMOT OIL except:
a) when steam distilled or rectified;
b) in preparations for internal use;
c) in preparations containing 0.4 per cent or less of bergamot oil;
d) in soaps or bath or shower gels that are washed off the skin;
e) in medicines for human therapeutic use when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
BETACYFLUTHRIN:
a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or
b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.
BICYCLOPYRONE in preparations containing 20 per cent or less of bicyclopyrone.
BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3 per cent or less of total bifluorides.
BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin except in preparations containing 1 per cent or less of bioallethrin.
BIORESMETHRIN except in preparations containing 10 per cent or less of bioresmethrin.
BISPYRIBAC except in preparations containing 10 per cent or less of bispyribac.
BIXAFEN.
BORIC ACID (excluding its salts) and BORAX except:
a) when included in Schedule 4;
b) in preparations, other than insect baits, containing 1 per cent or less of boron; or
c) in hand cleaning preparations.
BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF3).
BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.
BUPIVACAINE in aqueous gel preparations containing 0.5 per cent or less of bupivacaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.
BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.
BUTHIDAZOLE.
BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.
BUTRALIN.
BUTROXYDIM.
n-BUTYL ALCOHOL in preparations containing 10 per cent or less of n-butyl alcohol except:
a) in preparations containing 5 per cent or less of n-butyl alcohol; or
b) in preparations for cosmetic or therapeutic use other than spray form.
CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor except:
a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
c) in rosemary oil, sage oil (Spanish), or lavandin oils; or
d) in preparations containing 2.5 per cent or less of camphor.
CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide except in preparations containing 9 per cent or less of carbamide peroxide.
CARBARYL:
a) in preparations containing 10 per cent or less of carbaryl except when included in Schedule 4; or
b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.
CASSIA OIL except:
a) in food additives;
b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or
c) in other preparations containing 2 per cent or less of cassia oil.
CHLORFENAC.
CHLORFENAPYR. in preparations containing 0.5 per cent or less of chlorfenapyr.
CHLORFENSON.
CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine except:
a) in preparations containing 1 per cent or less of chlorhexidine; or
b) when in solid preparations.
CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, except:
a) when separately specified in these Schedules;
b) sodium hypochlorite preparations with a pH of less than 11.5;
c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
d) liquid preparations containing less than 2 per cent of available chlorine; or
e) other preparations containing 4 per cent or less of available chlorine.
CHLORNIDINE.
CHLOROCRESOL except in preparations containing 3 per cent or less of chlorocresol.
CHLORPROPHAM.
CHLORPYRIFOS:
a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;
b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or
c) in other preparations containing 5 per cent or less of chlorpyrifos,
except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.
CHLORSULFURON.
CHLORTETRACYCLINE in preparations:
a) for topical application to animals for ocular use only; or
b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
CHLORTHAL-DIMETHYL.
CINMETHYLIN.
CINNAMON BARK OIL except:
a) in food additives; or
b) in preparations containing 2 per cent or less of cinnamon bark oil.
CLETHODIM.
CLIMBAZOLE in preparations containing 40 per cent or less of climbazole except:
a) in leave-on hair, face and foot cosmetic preparations containing 0.5 per cent or less of climbazole; or
b) in other preparations (that are not leave-on cosmetic preparations) containing 2 per cent or less of climbazole.
CLOFENTEZINE.
CLOPYRALID.
CLOQUINTOCET.
CLORSULON.
CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin except in gel preparations dispensed in sealed cartridges containing 1 per cent or less of clothianidin.
CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except in preparations containing 25 per cent or less of clove oil.
COPPER ACETATE in preparations containing 20 per cent or less of copper acetate except in preparations containing 5 per cent or less of copper acetate.
COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper except in preparations containing 1 per cent or less of copper.
COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide except in preparations containing 12.5 per cent or less of copper hydroxide.
COPPER OXIDES in preparations containing 25 per cent or less of copper oxides except:
a) in preparations for internal use;
b) in marine paints; or
c) in other preparations containing 5 per cent or less of copper oxides.
COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride except in preparations containing 12.5 per cent or less of copper oxychloride.
COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate except:
a) in preparations for internal use; or
b) in other preparations containing 5 per cent or less of copper sulfate.
COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.
4-CPA.
CYANATRYN.
CYANOACRYLATE ESTERS in contact adhesives except:
a) when labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or
b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:
i) labelled with the approved name or trade name of the poison, the quantity and the warning:
Can cause eye injury. Instantly bonds skin; and
ii) enclosed in a primary pack labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.
CYANTRANILIPROLE.
CYANURIC ACID (excluding its salts and derivatives).
CYAZOFAMID.
CYCLOHEXANONE PEROXIDE.
CYCLOPROTHRIN except in preparations containing 10 per cent or less of cycloprothrin.
CYCLOXYDIM.
CYFLUFENAMID.
CYFLUTHRIN:
a) in wettable powders containing 10 per cent or less of cyfluthrin;
b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or
c) in emulsions containing 5 per cent or less of cyfluthrin.
CYHALOFOP-BUTYL.
CYMIAZOLE.
CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.
CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.
CYPROCONAZOLE except in preparations containing 10 per cent or less of cyproconazole.
CYPRODINIL.
CYTHIOATE for the treatment of animals:
a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or
b) in undivided preparations containing 5 per cent or less of cythioate.
2,4-D in preparations containing 20 per cent or less of 2,4-D.
DAMINOZIDE.
2,4-DB.
DECOQUINATE:
DELTAMETHRIN:
a) when impregnated in plastic resin strip material containing 4 per cent or less of deltamethrin;
b) in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;
c) in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 g or less of the formulation;
d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or
e) in other preparations containing 0.5 per cent or less of deltamethrin,
except:
a) in factory prepared mosquito nets containing 1 per cent or less deltamethrin; or
b) in preparations containing 0.1 per cent or less of deltamethrin.
DEMBREXINE in oral preparations for the treatment of animals.
2,4-DES.
DIAFENTHIURON.
N,N-DIALLYLDICHLOROACETAMIDE except in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.
DIAZINON in dust preparations containing 2 per cent or less of diazinon.
DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.
DICHLONE.
p-DICHLOROBENZENE.
DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, except in:
a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
b) liquid preparations containing less than 2 per cent of available chlorine; or
c) other preparations containing 4 per cent or less of available chlorine.
DICHLOROMETHANE (methylene chloride) except:
a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;
b) in other preparations in pressurised spray packs; or
c) in paints and tinters containing 5 per cent or less of dichloromethane.
DICHLOROPHEN for the treatment of animals.
DICHLORVOS:
a) when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;
b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or
c) in pressurised spray packs containing 10 grams or less of dichlorvos.
DICLOBUTRAZOL.
DICLORAN.
DICOFOL.
DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine except in preparations containing 5 per cent or less of diethanolamine.
DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:
a) in paints or paint tinters;
b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or
c) in other preparations containing 2.5 per cent or less of diethylene glycol.
DIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.
DIETHYLTOLUAMIDE (DEET) except:
a) in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:
WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or
c) in preparations other than for human use containing 20 per cent or less of diethyltoluamide.
DIFENOCONAZOLE.
DIFLUBENZURON.
DIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.
DIMETHIRIMOL.
DIMETHOMORPH except in preparations containing 10 per cent or less of dimethomorph.
DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.
DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide except in silicone rubber mastic containing 2 per cent or less of dimethylformamide.
3,7-DIMETHYL-2,6-OCTADIENAL and its isomers in cosmetic and household cleaning preparations except in preparations containing 5 per cent or less of 3,7-dimethyl-2,6,-octadienal isomers.
DINICONAZOLE.
DINOTEFURAN except in preparations containing 1 per cent or less of dinotefuran.
DI-n-PROPYL ISOCINCHOMERONATE except in preparations containing 25 per cent or less of di-n-propyl isocinchomeronate.
DIPHENAMID.
DIRECT RED 254 in preparations containing 30 per cent or less of Direct Red 254 calculated as free acid.
DITHIOPYR.
N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.
DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.
EMAMECTIN in preparations containing 2 per cent or less of emamectin.
EMODEPSIDE in preparations:
a) containing 2.5 per cent or less of emodepside for the external treatment of animals; or
b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.
EPOXICONAZOLE.
EPOXY RESINS, LIQUID.
EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.
ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin except in pressurised spray packs containing 1 per cent or less of esbiothrin.
ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.
ESTRADIOL in implant preparations for growth promotion in animals.
1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N-METHYLMETHANAMINE.
ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.
ETHOFUMESATE.
ETHOXYQUIN except in preparations containing 10 per cent or less of ethoxyquin.
ETHOXYSULFURON.
ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:
a) in paints or paint tinters;
b) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or
c) in other preparations containing 2.5 per cent or less of ethylene glycol.
ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.
ETRIDIAZOLE.
EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25 per cent or less of eugenol.
EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora) , except in preparations containing 40 per cent or less of extract of lemon eucalyptus.
FENARIMOL.
FENBENDAZOLE for the treatment of animals.
FENBUCONAZOLE.
FENCHLORAZOLE-ETHYL.
FENNEL OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Medicines Advisory Statements Specification;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 5 per cent or less of methyl chavicol.
FENOPROP.
FENOXAPROP-ETHYL.
FENOXAPROP-p-ETHYL.
FENPYRAZAMINE except in preparations containing 40 per cent or less of fenpyrazamine
FENSON.
FENTHION:
a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or
b) in preparations containing 10 per cent or less of fenthion.
FIPRONIL in preparations containing 10 per cent or less of fipronil except in preparations containing 0.05 per cent or less of fipronil.
FLAMPROP-METHYL.
FLAMPROP-M-METHYL.
FLAZASULFURON.
FLORASULAM.
FLUAZURON.
FLUBENDAZOLE for the treatment of animals.
FLUBENDIAMIDE.
FLUCHLORALIN.
FLUDIOXONIL except in preparations containing 10 per cent or less of fludioxonil.
FLUMETHRIN:
a) when impregnated in plastic resin strip material containing 3 per cent or less of flumethrin; or
b) in oil based preparations containing 1 per cent or less of flumethrin.
FLUMICLORAC PENTYL.
FLUOPYRAM except in preparations containing 50 per cent or less of fluopyram.
FLUORIDES in preparations containing 3 per cent or less of fluoride ion except:
a) in preparations for human use; or
b) in preparations containing 15 mg/kg or less of fluoride ion.
FLURALANER.
FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.
FLUXAPYROXAD.
FORAMSULFURON.
FORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5 per cent or less of formic acid.
FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.
FURALAXYL.
FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.
GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.
GLUFOSINATE-AMMONIUM.
GLUTARAL in preparations containing 5 per cent or less of glutaral except:
a) when included in Schedule 2; or
b) in preparations containing 0.5 per cent or less of glutaral when labelled with the statements:
IRRITANT; and
Avoid contact with eyes.
GLYPHOSATE.
HALOSULFURON-METHYL.
HEXACONAZOLE except in preparations containing 5 per cent or less of hexaconazole.
HEXAZINONE in preparations containing 25 per cent or less of hexazinone.
HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.
HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), except:
a) toluene and xylene when included in Schedule 6;
b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;
c) food grade and pharmaceutical grade white mineral oils;
d) in solid or semi-solid preparations;
e) in preparations containing 25 per cent or less of designated solvents;
f) in preparations packed in pressurised spray packs;
g) in adhesives packed in containers each containing 50 grams or less of adhesive;
h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or
i) in other preparations when packed in containers with a capacity of 2 mL or less.
HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) except:
a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or
b) for therapeutic use.
HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.
HYDROGEN PEROXIDE (excluding its salts and derivatives):
a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide except in hair dyes containing 6 per cent or less of hydrogen peroxide; or
b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide except in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H2SiF6).
2-HYDROXYETHYL METHACRYLATE except when included in dental restorative preparations for therapeutic use or in nail preparations when labelled “Avoid contact with skin”.
2-HYDROXYPROPYL METHACRYLATE in nail preparations except when labelled 'avoid contact with skin'.
IMAZALIL.
IMAZAMOX except in preparations containing 25 per cent or less of imazamox.
IMAZAPIC except in preparations containing 25 per cent or less of imazapic.
IMAZAPYR except in preparations containing 25 per cent or less of imazapyr.
IMAZETHAPYR except in preparations containing 25 per cent or less of imazethapyr.
IMIDACLOPRID in preparations containing 20 per cent or less of imidacloprid except in preparations containing 5 per cent or less of imidacloprid.
IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin except in preparations containing 10 per cent or less of imiprothrin.
INDOXACARB (includes the R and S enantiomers) in preparations containing 1 per cent or less of indoxacarb.
3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) ) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate except:
a) in aqueous preparations not for cosmetic use containing 10 per cent or less 3-iodo-2-propynyl butyl carbamate; or
b) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.
IODOSULFURON-METHYL-SODIUM.
IPCONAZOLE in preparations containing 2 per cent or less of ipconazole.
IRON COMPOUNDS:
a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):
i) in preparations for injection containing 20 per cent or less of iron except in preparations containing 0.1 per cent or less of iron; or
ii) in other preparations containing 4 per cent or less of iron except:
A) in liquid or gel preparations containing 0.1 per cent or less of iron; or
B) in animal feeds or feed premixes; or
b) in garden preparations except in preparations containing 4 per cent or less of iron.
ISOEUGENOL in preparations not intended for skin contact containing 25 per cent or less of isoeugenol except in preparations containing 10 per cent or less of isoeugenol.
ISOPHORONE.
ISOXABEN.
ISOXAFLUTOLE.
IVERMECTIN for use in animals:
a) in preparations for the prophylaxis of heartworm in cats and dogs;
b) in intraruminal implants containing 160 mg or less of ivermectin;
c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or
d) in other preparations containing 2 per cent or less of ivermectin.
KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.
LAMBDA-CYHALOTHRIN:
a) in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or
b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.
LASIODIPLODIA PSEUDOTHEOBROMAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
LEAD COMPOUNDS in preparations for use as hair cosmetics.
LEMON OIL except:
a) when steam distilled or rectified;
b) in preparations for internal use;
c) in preparations containing 0.05 per cent or less of lemon oil;
d) in soaps or bath or shower gels that are washed off the skin;
e) in medicines for human therapeutic use, when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
LEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations containing 5 per cent or less of 3,7-dimethyl-2,6-octadienal.
LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals except:
a) when included in Schedule 4; or
b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.
LIDOCAINE in aqueous gel preparations containing 4.5 per cent or less of lidocaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.
LIME OIL except:
a) when steam distilled or rectified;
b) in preparations for internal use;
c) in preparations containing 0.5 per cent or less of lime oil;
d) in soaps or bath or shower gels that are washed off the skin;
e) in medicines for human therapeutic use, when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
LINDANE in preparations containing 10 per cent or less of lindane except when included in Schedule 2 or 4.
LOTILANER.
LUFENURON except:
a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or
b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.
MACROPHOMINA PHASEOLINA except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.
MAGNESIUM CHLORATE except in preparations containing 10 per cent or less of magnesium chlorate.
MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.
MALATHION in preparations containing 10 per cent or less of malathion except:
a) for human therapeutic use; or
b) in dust preparations containing 2 per cent or less of malathion.
MANCOZEB.
MANDESTROBIN except in preparations containing 25 per cent or less of mandestrobin.
MANDIPROPAMID.
MARJORAM OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 50 per cent or less of marjoram oil.
MCPA:
a) in preparations containing 25 per cent or less of MCPA (acid); or
b) in preparations containing 50 per cent or less of the salts and esters of MCPA.
MCPB.
MEBENDAZOLE for the treatment of animals:
a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or
b) in undivided preparations containing 25 per cent or less of mebendazole.
MECLOFENAMIC ACID for the treatment of animals.
MECOPROP in preparations containing 2 per cent or less of mecoprop.
MEFENPYR-DIETHYL.
MEFENTRIFLUCONAZOLE except in preparations containing 7.5 per cent or less of mefentrifluconazole.
MEPIQUAT.
MERCAPTAMINE in cosmetic preparations containing 6 per cent or less of mercaptamine except in preparations containing 1 per cent or less of mercaptamine.
MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20 per cent or less of mercaptoacetic acid or its salts (as mercapturic acid), except in preparations containing 5 per cent or less of mercaptoacetic acid or its salts (as mercapturic acid)
MESOTRIONE.
METAFLUMIZONE.
METALAXYL in preparations containing 35 per cent or less of metalaxyl.
METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.
METAZACHLOR.
METHABENZTHIAZURON.
METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol except in preparations containing 2 per cent or less of methanol.
METHENAMINE in cosmetic preparations, except in preparations containing 0.15 per cent or less of methenamine.
METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.
METHOXYCHLOR.
METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except:
a) when included in preparations or admixtures; or
b) when packed in containers having a capacity of more than 5 litres.
METHYLATED SPIRIT(S) when packed and labelled as a 'biofuel' suitable for use in 'spirit burners'
METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.
METHYL ETHYL KETONE except in preparations containing 25 per cent or less of designated solvents.
METHYL ETHYL KETONE PEROXIDE.
METHYL ISOAMYL KETONE except in preparations containing 25 per cent or less of designated solvents.
METHYL ISOBUTYL KETONE except in preparations containing 25 per cent or less of designated solvents.
N-METHYL-2-PYRROLIDONE:
a) when packed in single use containers having a capacity of 2 mL or less; or
b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.
METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate except:
a) in preparations for therapeutic use; or
b) in preparations containing 5 per cent or less of methyl salicylate.
2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.
METIRAM.
METOFLUTHRIN:
a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or
b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin.
METOLACHLOR.
METRAFENONE in preparations containing 50 per cent or less of metrafenone.
MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.
MILBEMYCIN OXIME
a) for the prophylaxis of heartworm in dogs and cats; or
b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit.
MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.
MONEPANTEL.
MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of monoethanolamine except:
a) when included in Schedule 4; or
b) in preparations containing 5 per cent or less of monoethanolamine.
MORANTEL in preparations containing 25 per cent or less of morantel except in preparations containing 10 per cent or less of morantel.
MOXIDECTIN:
a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;
b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or
c) for internal use for the treatment of animals:
i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or
ii) in other preparations containing 2 per cent or less of moxidectin.
MYCLOBUTANIL.
NAA except in preparations containing 25 per cent or less of NAA.
NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.
NAPTALAM.
NEOSCYTALIDIUM NOVAEHOLLANDIAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.
NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO3) except in preparations containing 0.5 per cent or less of nitric acid.
NITROSCANATE for the treatment of animals.
NONANOIC ACID except in preparations containing 10 per cent or less of nonanoic acid.
NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 except:
a) when labelled with the statements:
IRRITANT; and
Avoid contact with eyes;
b) in preparations containing 12.5 per cent or less of nonoxinol 9; or
c) in preparations for human use.
NORBORMIDE.
NUTMEG OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 50 per cent or less of nutmeg oil.
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10 per cent or less of N-octyl bicycloheptene dicarboximide.
N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of:
a) N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or
b) N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.
OLEANDOMYCIN in animal feed premixes for growth promotion.
OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.
ORANGE OIL (BITTER) except:
a) when steam distilled or rectified;
b) in preparations for internal use;
c) in preparations containing 1.4 per cent or less of orange oil (bitter);
d) in soaps or bath or shower gels that are washed off the skin;
e) in medicines for human therapeutic use, when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
OXADIARGYL.
OXADIXYL.
OXANTEL EMBONATE for the treatment of animals.
OXFENDAZOLE for the treatment of animals.
OXIBENDAZOLE for the treatment of animals.
OXYCARBOXIN.
OXYTETRACYCLINE in preparations:
a) for topical application to animals for ocular use only; or
b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
OXYTHIOQUINOX.
PACLOBUTRAZOL.
PENCONAZOLE.
PENDIMETHALIN.
PENFLUFEN.
PENTHIOPYRAD except in preparations containing 20 per cent or less of penthiopyrad.
PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.
PERMETHRIN (excluding preparations for human therapeutic use):
a) in preparations containing 25 per cent or less of permethrin; or
b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,
except in preparations containing 2 per cent or less of permethrin.
PETROL except preparations containing 25 per cent or less of petrol.
PHENAZONE for the external treatment of animals.
PHENISOPHAM.
PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, except in preparations containing 1 per cent or less of phenol and in preparations containing 3 per cent or less of cresols and xylenols and other homologues of phenol.
PHENYL METHYL KETONE except in preparations containing 25 per cent or less of designated solvents.
o-PHENYLPHENOL except in preparations containing 5 per cent or less of o-phenylphenol.
PHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10 per cent or less of phosphonic acid (H3PO3).
PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H3PO4) except:
a) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);
b) in solid or semi-solid preparations; or
c) in professional dental kits.
o-PHTHALALDEHYDE in preparations containing 1 per cent or less of o-phthalaldehyde.
PICARIDIN except in preparations containing 20 per cent or less of picaridin.
PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.
PINOXADEN in preparations containing 10 per cent or less of pinoxaden.
PIPERAZINE for animal use.
PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.
POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts except in preparations containing 1 per cent or less of polixetonium salts.
POLYETHANOXY (15) TALLOW AMINE.
POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS.
POTASSIUM CHLORATE except:
a) when included in Schedule 2; or
b) in preparations containing 10 per cent or less of potassium chlorate.
POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:
a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.
POTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10 per cent or less of potassium metabisulphite.
POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite except:
a) in preparations containing 0.5 per cent or less of potassium nitrite;
b) when present as an excipient in preparations for therapeutic use; or
c) in aerosols.
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:
a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or
b) liquid or semi-solid preparations, the pH of which is less than 2.5.
POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.
PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin except in insecticidal mats containing 1 per cent or less of prallethrin.
PROFOXYDIM except in preparations containing 20 per cent or less of profoxydim.
PROGESTERONE:
a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or
b) in implant preparations for growth promotion in cattle.
PROHEXADIONE CALCIUM.
PROMETRYN.
PROPAMOCARB.
PROPANIL.
PROPAQUIZAFOP.
PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.
PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, except:
a) in preparations containing 30 per cent or less of propionic acid; or
b) for therapeutic use.
PROPOXUR:
a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;
b) in dust preparations containing 3 per cent or less of propoxur;
c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;
d) in pressurised spray packs containing 2 per cent or less of propoxur; or
e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.
n-PROPYL ALCOHOL in preparations containing 10 per cent or less of n-propyl alcohol except:
a) in preparations containing 5 per cent or less of n-propyl alcohol; or
b) in preparations for cosmetic or therapeutic use other than in spray form.
PROPYZAMIDE.
PROTHIOCONAZOLE-DESCHLORO except in preparations containing 0.5 per cent or less of prothioconazole-deschloro.
PROTHIOCONAZOLE-TRIAZOLIDINETHIONE except in preparations containing 0.5 per cent or less of prothioconazole-triazolidinethione.
PYMETROZINE.
PYRACLOSTROBIN.
PYRAFLUFEN-ETHYL.
PYRASULFOTOLE.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:
a) in preparations for human therapeutic use; or
b) in preparations containing 10 per cent or less of such substances.
PYRIDABEN in preparations containing 25 per cent or less of pyridaben.
PYRIFENOX.
PYRITHIOBAC SODIUM.
PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint except in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.
PYRIOFENONE in preparations containing 30 per cent or less of pyriofenone.
QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds except:
a) when separately specified in these Schedules;
b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.
QUINCLORAC.
QUININE in preparations for veterinary use containing 1 per cent or less of quinine.
QUINTOZENE.
QUIZALOFOP-p-ETHYL in aqueous preparations containing 40 per cent or less of
quizalofop-p-ethyl.
RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.
RESMETHRIN in preparations containing 10 per cent or less of resmethrin.
RIMSULFURON.
ROBENIDINE except in preparations containing 20 per cent or less of robenidine.
ROSIN when packaged for use as a soldering flux or in flux-cored solder.
SAFLUFENACIL in water dispersible granule preparations.
SALICYLANILIDE.
SAROLANER for the treatment, prevention and control of fleas and ticks in dogs in oral divided preparations each containing 120 mg or less of sarolaner per dosage unit.
SEDAXANE.
SELAMECTIN except in preparations containing 12 per cent or less of selamectin.
SETHOXYDIM.
SIDURON.
SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion except:
a) barium silicofluoride when separately specified in this Schedule; or
b) in preparations containing 15 mg/kg or less of fluoride ion.
SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin except in preparations containing 1 per cent or less of sinbioallethrin.
SODIUM CHLORATE except in preparations containing 10 per cent or less of sodium chlorate.
SODIUM DIACETATE except in preparations containing 60 per cent or less of sodium diacetate.
SODIUM DODECYLBENZENE SULFONATE except in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.
SODIUM HYDROGEN SULFATE except in preparations containing 10 per cent or less of sodium hydrogen sulfate.
SODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10 per cent or less of sodium hydrosulfite.
SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:
a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.
SODIUM LAURETH-6 CARBOXYLATE except in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.
SODIUM METABISULPHITE when packed for domestic use except in preparations containing 10 per cent or less of sodium metabisulphite.
SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite except:
a) in preparations containing 0.5 per cent or less of sodium nitrite;
b) when present as an excipient in preparations for therapeutic use; or
c) in aerosols.
SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate except in preparations containing 15 per cent or less of sodium percarbonate.
SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10 per cent or less of sodium polystyrene sulphonate.
SODIUM STANNATE except in preparations for cosmetic use containing 1 per cent or less of sodium stannate.
SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.
SPINETORAM.
SPINOSAD except in aqueous suspensions containing 25 per cent or less of spinosad.
STAR ANISE OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 50 per cent or less of star anise oil.
STYRENE (excluding its derivatives).
SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H3NO3S).
SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFOMETURON-METHYL.
SULFOXAFLOR in preparations containing 25 per cent or less of sulfoxaflor.
SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.
2,3,6-TBA.
TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10 per cent or less of TDE.
TEBUCONAZOLE.
TEBUFENOZIDE.
TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.
TEMEPHOS:
a) in liquid preparations containing 10 per cent or less of temephos;
b) in powders containing 2 per cent or less of temephos; or
c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.
TEPRALOXYDIM.
TERBUTRYN.
TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene except:
a) when included in Schedule 2;
b) in preparations for the treatment of animals; or
c) when absorbed into an inert solid.
TETRACHLORVINPHOS except in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.
TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.
TETRACYCLINE in preparations:
a) for topical application to animals for ocular use only; or
b) containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
TETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs.
THIABENDAZOLE:
a) for the treatment of animals; or
b) when packed and labelled for use as a fungicide except in preparations containing 50 per cent or less of thiabendazole.
THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.
THIAZOPYR.
THIFENSULFURON.
THIOBENCARB.
THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.
THIOPHANATE-METHYL in preparations containing 25 per cent or less of thiophanate-methyl.
THYME OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 50 per cent or less of thyme oil.
TIOCARBAZIL.
TOLCLOFOS-METHYL.
TOLTRAZURIL.
TOPRAMEZONE
TRALKOXYDIM.
TRENBOLONE in implant preparations for growth promotion in animals.
TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.
TRIADIMENOL.
TRI-ALLATE.
TRIBENURON-METHYL.
TRICHLOROACETIC ACID, alkali salts of.
1,1,1-TRICHLOROETHANE except:
a) in preparations packed in pressurised spray packs;
b) in preparations containing 25 per cent or less of designated solvents;
c) in preparations, other than writing correction fluids or thinners for writing correction fluidsin containers having a capacity of 50 mL or less; or
d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:
i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and
ii) the expression:
WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;
written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.
TRIDIPHANE.
TRIETAZINE.
TRIFLOXYSTROBIN.
TRIFLUMIZOLE.
TRIFLUMURON.
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing 30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:
Avoid contact with eyes and skin; and
Wash hands after handling.
TRINEXAPAC-ETHYL except:
a) when packed in a sealed water-soluble measure pack; or
b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.
3,6,9-TRIOXAUNDECANEDIOIC ACID except in preparations containing 5 per cent or less of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.
TRITICONAZOLE.
TROLAMINE (excluding its salts and derivatives) except:
a) when in Schedule 4;or
b) in preparations containing 5 per cent or less of trolamine.
TURPENTINE OIL except in preparations containing 25 per cent or less of turpentine oil.
VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.
VERNOLATE.
WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.
ZINEB.
ABAMECTIN:
a) in preparations for pesticidal use containing 4 per cent or less of abamectin except when included in Schedule 5; or
b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.
ACEPHATE.
ACETAMIPRID except in preparations containing 1 per cent or less of acetamiprid.
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) except when included in Schedule 2.
ACETIC ANHYDRIDE excluding its derivatives.
ACIFLUORFEN.
ACINITRAZOLE except in preparations containing 20 per cent or less of acinitrazole.
ALBENDAZOLE for the treatment of animals except:
a) when included in Schedule 5; or
b) in intraruminal implants each containing 3.85 g or less of albendazole.
ALDRIN.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:
a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.
ALKOXYLATED FATTY ALKYLAMINE POLYMER except:
a) when included in Schedule 5; or
b) in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.
ALLETHRIN except:
a) when included in Schedule 5;
b) in insecticidal mats containing 20 per cent or less of allethrin; or
c) in other preparations containing 1 per cent or less of allethrin.
ALLYL ESTERS (excluding derivatives) being:
ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9)
ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5)
ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8)
ALLYL HEXANOATE (CAS No. 123-68-2)
ALLYL ISOVALERATE (CAS No. 2835-39-4)
ALLYL NONANOATE (CAS No. 7493-72-3)
ALLYL OCTANOATE (CAS No. 4230-97-1)
ALLYL PHENYLACETATE (CAS No. 1797-74-6)
ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9)
in preparations containing 0.1 per cent or less of free allyl alcohol by weight of allyl ester except in preparations containing 5 per cent or less of allyl esters with 0.1 per cent or less of free allyl alcohol by weight of allyl esters.
ALPHA-CYPERMETHRIN:
a) in aqueous preparations containing 30 per cent or less of alpha-cypermethrin; or
b) in other preparations containing 10 per cent or less of alpha-cypermethrin,
except when included in Schedule 5.
AMICARBAZONE.
AMIDITHION.
AMIDOPROPYL BETAINES except:
a) in cosmetic wash-off preparations containing 30 per cent or less of amidopropyl betaines and, if containing more than 5 per cent of amidopropyl betaines when labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER;
b) in cosmetic leave-on preparations containing 1.5 per cent or less of amidopropyl betaines; or
c) in other preparations containing 30 per cent or less of amidopropyl betaines and, if containing more than 5 per cent of amidopropyl betaines, when labelled with warnings to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER
2-AMINO-6-CHLORO-4-NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, except:
a) in preparations containing 2 per cent or less of 2-amino-6-chloro-4-nitrophenol when applied directly to the hair, or containing 2 per cent or less of 2-amino-6-chloro-4-nitrophenol after mixing and when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN; and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
b) in eyelash and eyebrow tinting products containing 1.5 per cent or less of 2-amino-6-chloro-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5mm in height.
4-AMINO-m-CRESOL in hair dyes and eyebrow/eyelash colouring preparations except:
a) in hair dye preparations containing 1.5 per cent or less of 4-amino-m-cresol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5mm in height; or
b) in eyelash and eyebrow tinting products containing 1.5 per cent or less of 4-amino-m-cresol after mixing for use when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5mm in height.
2-AMINO-5-ETHYLPHENOL in hair dye preparations except in preparations containing 1 per cent or less of 2-amino-5-ethylphenol when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN; and
WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes and eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
4-AMINO-2-HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products except:
a) in hair dye preparations containing 1.5 per cent or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5mm in height; or
b) in eyelash and eyebrow tinting products containing 1.5 per cent or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5mm in height.
AMINOCARB in preparations containing 25 per cent or less of aminocarb.
AMINOETHOXYVINYLGLYCINE except in preparations containing 15 per cent or less of aminoethoxyvinylglycine.
1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.
4-AMINO-3-NITROPHENOL except:
a) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1 per cent or less of 4-amino-3-nitrophenol when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1 per cent or less of 4-amino-3-nitrophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL (including its salts) except:
a) in non-oxidative hair dye preparations containing 2.5 per cent or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations containing 1.25 per cent or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
m-AMINOPHENOL except when used in hair dye and eyebrow/eyelash preparations at a concentration of 1.2 per cent or less of m-aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
p- AMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1 per cent or less of p-aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
AMINOPYRALID except when included in Schedule 5.
AMITRAZ.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:
a) when included in Schedule 5;
b) in preparations for human internal therapeutic use;
c) in preparations for inhalation when absorbed in an inert solid material; or
d) in preparations containing 0.5 per cent or less of ammonia.
AMMONIUM COCOYL ISETHIONATE, except in cosmetic rinse-off preparations containing 30 per cent or less of ammonium cocoyl isethionate and, if containing more than 5 per cent of ammonium cocoyl isethionate, when labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER
AMMONIUM PERSULFATE in hair preparations.
ANILINE (excluding its salts and derivatives) except in preparations containing 1 per cent or less of aniline.
ANTIMONY COMPOUNDS except:
a) when included in Schedule 4;
b) antimony chloride in polishes;
c) antimony titanate pigments in paint; or
d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.
ARSENIC:
a) in ant poisons containing 0.4 per cent or less of arsenic;
b) in animal feed premixes containing 4 per cent or less of arsenic; or
c) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4,
except when separately specified in this Schedule.
ASPIRIN for the treatment of animals except when included in Schedule 4 or 5.
AZACONAZOLE except in preparations containing 1 per cent or less of azaconazole.
AZADIRACHTA INDICA (Neem) including its extracts and derivatives except:
a) when included in Schedule 5;
b) in preparations for human internal use;
c) debitterised neem seed oil;
d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.
AZAMETHIPHOS.
AZOBENZENE.
BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.
BARIUM SALTS except:
a) when included in Schedule 5;
b) barium sulfate; or
c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.
BASIC BLUE 26 (CAS No. 2580-56-5) except when used as a colourant in cosmetics not intended to be in contact with mucous membranes.
BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) except:
a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or
b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN;
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
BASIC RED 76 (CAS No. 68391-30-0) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 2 per cent or less of Basic Red 76 and 0.001 per cent or less of free o-anisidine.
BAY OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of bay oil.
BEAUVERIA BASSIANA except when included in Schedule 5.
BENDIOCARB:
a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;
b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;
c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or
d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,
except when included in Schedule 5.
BENQUINOX.
BENSULIDE.
BENZALKONIUM CHLORIDE except:
a) when included in Schedule 5; or
b) in preparations containing 5 per cent or less of benzalkonium chloride.
1,2-BENZENEDIOL.
BENZOVINDIFLUPYR
6-BENZYLADENINE except in preparations containing 2 per cent or less of 6-benzyladenine.
BERYLLIUM.
BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin except when included in Schedule 5.
BETA-CYPERMETHRIN.
BHC (excluding lindane).
BICYCLOPYRONE except when included in Schedule 5.
BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin except in preparations containing 0.5 per cent or less of bifenthrin.
BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3 per cent or less of total bifluorides except when included in Schedule 5.
BIOALLETHRIN except:
(a) when included in Schedule 5; or
(b) in preparations containing 1 per cent or less of bioallethrin.
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE (including its salts) except when in hair dye preparations containing 1.2 per cent or less of 1,3-bis(2,4-diaminophenoxy)propane after mixing when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER except in rinse-off cosmetic products containing 1 per cent or less of bis-isobutyl PEG/PPG-20/35/amodimeticone copolymer when labelled with a warning to the following effect:
IF IN EYES, WASH OUT IMMEDIATELY WITH WATER.
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE except in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE except in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.
BITHIONOL for the treatment of animals.
BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF3) except when included in Schedule 5.
BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.
BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.
BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.
BROMOFORM except when included in Schedule 4.
BROMOPHOS.
BROMOPHOS-ETHYL.
BROMOXYNIL.
BROMUCONAZOLE except when included in Schedule 5.
BROTIANIDE.
BUNAMIDINE.
BUTACARB.
BUTOXYCARBOXIM except when included in Schedule 5.
2-BUTOXYETHANOL and its ACETATES except:
a) in plant growth regulator preparations containing 20 per cent or less of such substances; or
b) in other preparations containing 10 per cent or less of such substances.
2-BUTOXY-2’-THIOCYANODIETHYL ETHER.
n-BUTYL ALCOHOL except:
a) when included in Schedule 5;
b) in preparations containing 5 per cent or less of n-butyl alcohol; or
c) in preparations for cosmetic or therapeutic use other than in spray form.
BUTYRIC ACID in preparations for use as insect lures.
CACODYLIC ACID:
a) in animal feed premixes containing 4 per cent or less of arsenic; or
b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.
CADMIUM COMPOUNDS except:
a) when included in Schedule 4; or
b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.
CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.
CAJUPUT OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
e) in preparations containing 25 per cent or less of cajuput oil; or
f) in oils containing 25 per cent or less of cajuput oil.
CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.
CAMBENDAZOLE.
CAMPHOR except:
a) when included in Schedule 4 or 5;
b) when enclosed in an inhaler device which prevents ingestion of its contents;
c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;
d) in liquid preparations containing 2.5 per cent or less of camphor;
e) in essential oils when the camphor is present as a natural component of the oil:
i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.
CAPTAN.
CARBARYL except when included in Schedule 4 or 5.
CARBON DISULFIDE.
CARBAMIDE PEROXIDE except:
a) when included in Schedule 5; or
b) in other preparations containing 9 per cent or less of carbamide peroxide.
CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use except in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.
CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.
CHLORDANE.
CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr except when included in Schedule 5.
CHLORFENETHOL.
CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine except:
a) when included in Schedule 5;
b) in preparations containing 1 per cent or less of chlorhexidine; or
c) when in solid preparations.
CHLORINATING COMPOUNDS except:
a) when included in Schedule 5;
b) when separately specified in these Schedules;
c) sodium hypochlorite preparations with a pH of less than 11.5;
d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
e) in liquid preparations containing less than 2 per cent of available chlorine; or
f) in other preparations containing 4 per cent or less of available chlorine.
CHLORMEQUAT.
CHLOROACETAMIDE
a) in preparations for cosmetic use; or
b) in preparations for topical therapeutic use; or
c) in other preparations containing more than 0.3 per cent of chloroacetamide.
2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL except:
a) in non-oxidative hair dye preparations containing 3 per cent or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations containing 1.5 per cent or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
CHLOROFORM except:
a) when included in Schedule 2 or 4; or
b) in preparations containing 10 per cent or less of chloroform.
ALPHA-CHLOROHYDRIN.
CHLOROPHACINONE.
(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) except in preparations containing 5 per cent or less of (E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.
CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.
CHLOROTHALONIL except in water-based paint containing 0.5 per cent or less of chlorothalonil.
2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE.
CHLORPYRIFOS except:
a) when included in Schedule 5; or
b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.
CHLORPYRIFOS-METHYL.
CHLORTHIAMID.
CHROMATES (including dichromates) except in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.
CHROMIUM TRIOXIDE (excluding its salts and derivatives).
CHRYSOIDINE BASE except when in Schedule 10.
CINEOLE except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
e) in preparations containing 25 per cent or less of cineole;
f) in oils containing 25 per cent or less of cineole; or
g) in rosemary oil or camphor oil (white).
CINNAMON LEAF OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of cinnamon leaf oil.
CLIMBAZOLE except:
a) when included in Schedule 5; or
b) in leave-on hair, face and foot cosmetic preparations containing 0.5 per cent or less of climbazole; or
c) in other preparations (that are not leave-on cosmetic preparations) containing 2 per cent or less of climbazole.
CLODINAFOP-PROPARGYL.
CLOMAZONE.
CLOSANTEL.
CLOTHIANIDIN except
a) When included in Schedule 5; or
b) When in gel preparations dispensed in sealed cartridges containing 1 per cent or less of clothianidin.
CLOTRIMAZOLE for the external treatment of animals.
CLOVE OIL except:
a) when included in Schedule 5;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
f) in preparations containing 25 per cent or less of clove oil.
N-COCO-1,3-DIAMINOPROPANE.
COCOYL GLYCINATE in cosmetic preparations except:
a) in leave-on preparations containing 5 per cent or less of cocoyl glycinate; or
b) in wash-off preparations containing 30 per cent or less of cocoyl glycinate and, when containing more than 5 per cent of cocoyl glycinate labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER.
COPPER ACETATE except:
a) when included in Schedule 5; or
b) in preparations containing 5 per cent or less of copper acetate.
COPPER COMPOUNDS except:
a) when separately specified in these Schedules;
b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;
c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;
d) in feed additives containing 1 per cent or less of copper; or
e) in other preparations containing 5 per cent or less of copper compounds.
COPPER HYDROXIDE except:
a) when included in Schedule 5; or
b) in preparations containing 12.5 per cent or less of copper hydroxide.
COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.
COPPER OXIDES except:
a) when included in Schedule 5;
b) in preparations for internal use;
c) in marine paints; or
d) in other preparations containing 5 per cent or less of copper oxides.
COPPER OXYCHLORIDE except:
a) when included in Schedule 5; or
b) in preparations containing 12.5 per cent of less of copper oxychloride.
COPPER SULFATE except:
a) when included in Schedule 5;
b) in preparations for internal use; or
c) in other preparations containing 5 per cent or less of copper sulfate.
COUMAPHOS:
a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or
b) in other preparations containing 5 per cent or less of coumaphos.
COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl except when included in Schedule 5.
CREOSOTE derived from wood other than beechwood except:
a) when included in Schedule 2;
b) in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or
c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.
CROTOXYPHOS.
CRUFOMATE.
CYANAMIDE.
CYANAZINE.
CYCLANILIDE.
N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.
CYFLUTHRIN except:
a) when included in Schedule 5; or
b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.
CYOMETRINIL.
CYPERMETHRIN except when included in Schedule 5.
CYPHENOTHRIN except when included in Schedule 5.
CYTHIOATE except when included in Schedule 5.
2,4-D except when included in Schedule 5.
DAZOMET.
DELTAMETHRIN:
a) in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;
b) in wettable granular preparations containing 25 per cent or less of deltamethrin;
c) in water-dispersible tablets each containing 500 mg or less of deltamethrin;
d) in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or
e) in other preparations containing 3 per cent or less of deltamethrin,
except:
a) when included in Schedule 5;
b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
c) in preparations containing 0.1 per cent or less of deltamethrin.
DERQUANTEL.
1-DEOXY-1-(METHYLAMINO)-d-GLUCITOL N-COCO ACYL DERIVATIVES except:
a) in cosmetic rinse-off preparations containing 8 per cent or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl derivatives when labelled with the following statement:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or
b) in household cleaning preparations, other than those intended to be sprayed, containing 10 per cent or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl derivatives when labelled with the following statement:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER.
2,4-DIAMINOPHENOXYETHANOL except when used in hair dye and eyebrow/eyelash preparations at concentrations of 2 per cent or less of 2,4-diaminophenoxyethanol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
DIAZINON except when included in Schedule 5.
DICAMBA (including its salts and derivatives) except when included in Schedule 5.
DICHLOBENIL.
DICHLOFENTHION.
DICHLOFLUANID.
o-DICHLOROBENZENE.
DICHLOROETHYL ETHER.
DICHLOROISOCYANURIC ACID except:
a) when included in Schedule 5;
b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
c) in liquid preparations containing less than 2 per cent of available chlorine; or
d) in other preparations containing 4 per cent or less of available chlorine.
4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.
DICHLOROPHEN except:
a) when included in Schedule 4 or 5; or
b) in fabrics other than when:
i) for human therapeutic use; or
ii) as part of a registered pesticidal product.
1,2-DICHLOROPROPANE.
2,4-DICHLORPROP (including the R and S enantiomers).
DICHLORVOS in preparations containing 50 per cent or less of dichlorvos except when included in Schedule 5.
DICLOFOP-METHYL.
DICYCLANIL except in preparations containing 6.5 per cent or less of dicyclanil.
DIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1 per cent or less of didecyldimethylammonium salts labelled with the statement:
Avoid contact with eyes.
DIELDRIN.
DIETHANOLAMINE (excluding its salts and derivatives) except:
a) when included in Schedule 5; or
b) in preparations containing 5 per cent or less of diethanolamine.
DIETHYLENE GLYCOL (excluding its salts and derivatives) except:
a) when included in Schedule 5;
b) in paints or paint tinters;
c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or
d) in other preparations containing 2.5 per cent or less of diethylene glycol.
DIETHYLENE GLYCOL MONOMETHYL ETHER.
DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.
DIFENZOQUAT.
DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.
5,6-DIHYDROXYINDOLINE.
DIMETHENAMID-P.
DIMETHIPIN.
DIMETHOATE.
2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 0.25 per cent or less of 2,6-dimethoxy-3,5-pyridinediamine after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
DIMETHYLACETAMIDE except when included in Schedule 5.
DIMETHYLFORMAMIDE except:
a) when included in Schedule 5; or
b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.
4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL except:
a) in leave-on cosmetic preparations containing 0.1 per cent or less of 4,4-dimethyl-1-cyclohexene-1-propanal;
b) in rinse-off cosmetic preparations containing 0.5 per cent or less of 4,4-dimethyl-1-cyclohexene-1-propanal; or
c) in other preparations containing 1 per cent or less of 4,4-dimethyl-1-cyclohexene-1-propanal.
3,7-DIMETHYL-2,6-OCTADIEN-1-OL and its isomers except in products containing 5 per cent or less 3,7-dimethyl-2,6-octadien-1-ol and its isomers.
DIMETHYL SULFOXIDE (excluding dimethyl sulfone):
a) when not for therapeutic use; or
b) in cosmetic preparations; or
c) for the treatment of animals:
i) when combined with no other therapeutic substance(s);
ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl salicylate as the only other therapeutic substances; or
iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide; or
d) in other preparations except when containing 10 per cent or less of dimethyl sulfoxide.
DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds except:
a) when included in Schedule 4; or
b) when separately specified in this Schedule.
DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds except:
a) when included in Schedule 4; or
b) when separately specified in this Schedule.
DIOXACARB.
DIOXANE.
DIPHACINONE.
DIQUAT in preparations containing 20 per cent or less of diquat.
DIRECT RED 254 except when included in Schedule 5.
DISPERSE YELLOW 3 except when in Schedule 10.
DISULFIRAM except when included in Schedule 4.
DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.
DITHIANON.
DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.
DIUREDOSAN.
N-(N-DODECYL)-2-PYRROLIDONE except:
a) when included in Schedule 5; or
b) in preparations containing 25 per cent or less of designated solvents.
DODINE.
DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.
DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.
ECONAZOLE for the external treatment of animals.
EMAMECTIN in preparations containing 5 per cent or less of emamectin except when included in Schedule 5.
EMODEPSIDE for the treatment of animals except when included in Schedule 5.
ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.
ENDOTHAL in preparations containing 20 per cent or less of endothal.
EPRINOMECTIN for internal use in preparations containing 5 per cent or less of eprinomectin except when included in Schedule 5.
EPTC.
ESBIOTHRIN except:
a) when included in Schedule 5; or
b) in pressurised spray packs containing 1 per cent or less of esbiothrin.
ESFENVALERATE except when included in Schedule 5.
ETHEPHON (excluding its salts and derivatives).
ETHER except:
a) when included in Schedule 2, 4 or 5; or
b) in preparations containing 10 per cent or less of ether.
ETHIOFENCARB.
ETHOATE-METHYL.
ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.
ETHYL BROMIDE.
ETHYLENE CHLOROHYDRIN.
ETHYLENE DICHLORIDE.
ETHYLENE GLYCOL (excluding its salts and derivatives) except:
a) when included in Schedule 5;
b) in paints or paint tinters;
c) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or
d) in other preparations containing 2.5 per cent or less of ethylene glycol.
ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, except:
a) when separately specified in these Schedules; or
b) in preparations containing 10 per cent or less of such substances.
ETHYL FORMATE when packed and labelled for use as a fumigant.
ETHYLHEXANEDIOL except in preparations containing 5 per cent or less of ethylhexanediol.
2-ETHYLHEXANOIC ACID and its alkyl esters except in preparations containing 5 per cent or less calculated as 2-ethylhexanoic acid.
ETRIMFOS.
EUCALYPTUS OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of eucalyptus oil.
EUGENOL except:
a) when included in Schedule 5;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
f) in preparations containing 25 per cent or less of eugenol.
FAMPHUR in preparations containing 20 per cent or less of famphur.
FEBANTEL except:
a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or
b) in undivided preparations containing 10 per cent or less of febantel.
FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.
FENAZAFLOR.
FENBUTATIN OXIDE.
FENCHLORPHOS.
FENITROTHION.
FENOXACRIM in preparations for the treatment of carpets during manufacture.
FENPYROXIMATE.
FENTHION in preparations containing 60 per cent or less of fenthion except when included in Schedule 5.
FENVALERATE.
FIPRONIL except:
a) when included in Schedule 5; or
b) in preparations containing 0.05 per cent or less of fipronil.
FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.
FLONICAMID.
FLUAZIFOP-BUTYL.
FLUAZIFOP-p-BUTYL.
FLUAZINAM.
FLUCOFURON in preparations for the treatment of carpets during manufacture.
FLUENSULFONE.
FLUMETHRIN except when included in Schedule 5.
FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.
FLUORIDES except:
a) when included in Schedule 5;
b) in preparations for human use; or
c) in preparations containing 15 mg/kg or less of fluoride ion.
FLUPROPANATE.
FLUPYRADIFURONE.
FLUQUINCONAZOLE.
FLUSILAZOL.
FLUTRIAFOL except in fertilisers containing 0.5 per cent or less of flutriafol.
FLUVALINATE except when included in Schedule 5.
FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde except:
a) for human therapeutic use;
b) in oral hygiene preparations;
c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:
PROTECT CUTICLES WITH GREASE OR OIL;
e) in all other cosmetic preparations; or
f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.
FORMOTHION.
FOSPIRATE except when included in Schedule 5.
FUMAGILLIN.
FURFURAL except in preparations containing 0.1 per cent or less of furfural.
GLUTARAL except:
a) when included in Schedule 2 or 5; or
b) in preparations containing 0.5 per cent or less of glutaral when labelled with the statements:
IRRITANT; and
Avoid contact with eyes.
GLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with directions for use that include the statement:
Wear protective gloves when using. Keep out of eyes.
GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical except:
a) in cosmetic preparations for salon use only, when labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time;
b) in preparations containing 5 per cent or less of glycolic acid; or
c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.
GUANIDINE except:
a) when included in Schedule 4; or
b) in preparations containing 1 per cent or less of guanidine.
GUAZATINE.
HALOXON.
HALOXYFOP.
HC VIOLET 1 except:
a) in non-oxidative hair dye preparations containing 0.28 per cent or less of HC Violet 1 after mixing when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations containing 0.25 per cent or less of HC Violet 1 after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
HEPTACHLOR.
HEXACHLOROPHENE:
a) in preparations for the treatment of animals; or
b) for cosmetic use.
HEXAZINONE except when included in Schedule 5.
HEXYLOXYETHANOL except in preparations containing 10 per cent or less of hexyloxyethanol.
HYDRAMETHYLNON except when included in Schedule 5.
HYDRAZINE.
HYDROCHLORIC ACID (excluding its salts and derivatives) except:
a) when included in Schedule 5;
b) in preparations for therapeutic use; or
c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).
HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride except when included in Schedule 5.
HYDROGEN PEROXIDE (excluding its salts and derivatives) except:
a) when included in Schedule 5;
b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or
c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.
HYDROQUINONE except:
a) when included in Schedule 2 or 4; or
b) in preparations containing 10 per cent or less of hydroquinone.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H2SiF6) except when included in Schedule 5.
HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE (including its salts) except in oxidative hair dye preparations containing 1.5 per cent or less of hydroxyethyl-3,4-methylenedioxyaniline after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
IMIDACLOPRID except:
a) when included in Schedule 5; or
b) in preparations containing 5 per cent or less of imidacloprid.
IMIDOCARB.
IMINOCTADINE TRIALBESILATE.
IMIPROTHRIN except:
a) when included in Schedule 5; or
b) in preparations containing 10 per cent or less of imiprothrin.
INDAZIFLAM.
INDOXACARB (includes the R and S enantiomers) except when included in Schedule 5.
IODINE (excluding its salts, derivatives and iodophors) except:
a) when included in Schedule 2; or
b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.
IODOPHORS except in preparations containing 1.5 per cent or less of available iodine.
3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) except:
a) when included in Schedule 5;
b) in aqueous preparations not for cosmetic use containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or
c) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.
IOXYNIL.
IPCONAZOLE except when included in Schedule 5.
IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals except:
a) when included in Schedule 5;
b) in liquid or gel preparations containing 0.1 per cent or less of iron; or
c) in animal feeds or feed premixes.
ISOCONAZOLE for the external treatment of animals.
ISOCYANATES, free organic, boiling below 300° C, except in:
a) viscous polyurethane adhesives; or
b) viscous polyurethane sealants;
containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.
ISOEUGENOL except:
a) when included in Schedule 5; or
b) in preparations not intended for skin contact containing 10 per cent or less of isoeugenol; or
c) in preparations intended for skin contact containing 0.02 per cent or less of isoeugenol.
ISOPYRAZAM.
LAMBDA-CYHALOTHRIN:
a) in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or
b) in emulsifiable granule formulations containing 25 per cent or less lambda-cyhalothrin; or
c) in other preparations containing 1.6 per cent or less of lambda-cyhalothrin
except when included in Schedule 5.
LASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.
LAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) except:
a) in leave-on preparations containing 1.5 per cent or less of laureth carboxylic acids;
b) in wash-off preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or
c) in other preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with warnings to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
LAURYL ISOQUINOLINIUM BROMIDE.
LAURYL SULFATE SALTS (excluding their derivatives) except:
a) in wash-off preparations containing 30 per cent or less of lauryl sulfates and, if containing more than 5 per cent of lauryl sulfates, when labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER;
b) in leave-on preparations containing 1.5 per cent or less of lauryl sulfates;
c) in toothpaste and oral hygiene preparations containing 5 per cent or less of lauryl sulfates;
d) in other preparations for animal use containing 2 per cent or less of lauryl sulfates; or
e) in other preparations containing 30 per cent or less of lauryl sulfates and, if containing more than 5 per cent of lauryl sulfates, when labelled with warnings to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
LEAD COMPOUNDS except:
a) when included in Schedule 4 or 5;
b) in paints, tinters, inks or ink additives;
c) in preparations for cosmetic use containing 100 mg/kg or less of lead;
d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or
e) in ceramic glazes when labelled with the warning statement:
CAUTION – Harmful if swallowed. Do not use on surfaces which contact food or drink.
written in letters not less than 1.5 mm in height.
LEPTOSPERMUM SCOPARIUM OIL (manuka oil) except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings;
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of Leptospermum scoparium oil.
LEVAMISOLE for the treatment of animals except:
a) when included in Schedule 4 or 5; or
b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.
LINDANE except when included in Schedule 2, 4 or 5.
MAFENIDE when packed and labelled for the treatment of ornamental fish only.
MALATHION except:
a) when included in Schedule 5;
b) for human therapeutic use; or
c) in dust preparations containing 2 per cent or less of malathion.
MCPA except when included in Schedule 5.
MEBENDAZOLE for the treatment of animals except when included in Schedule 5.
MECOPROP except when included in Schedule 5.
MECOPROP-P.
MEFLUIDIDE.
MELALEUCA OIL (tea tree oil) except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of melaleuca oil.
MELENGESTROL ACETATE when used as an animal feed additive.
MENAZON.
MERCAPTAMINE for cosmetic use except:
a) when included in Schedule 5; or
b) in preparations containing 1 per cent or less of mercaptamine.
MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations except:
a) when included in Schedule 5
b) in preparations containing 5 per cent or less of mercaptoacetic acid or its salts (as mercapturic acid).
2-MERCAPTOETHANOL in preparations for use as insect lures.
MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.
MERCUROCHROME for the treatment of animals, in preparations for topical use.
METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.
METALAXYL except when included in Schedule 5.
METALDEHYDE except when included in Schedule 5.
METHACRIFOS in preparations containing 60 per cent or less of methacrifos.
METHAM.
METAMITRON.
METHANOL (excluding its derivatives) except:
a) when included in Schedule 5; or
b) in preparations containing 2 per cent or less of methanol.
METHIOCARB in preparations containing 20 per cent or less of methiocarb except when included in Schedule 5.
METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.
2-METHOXY-5-NITROPHENOL.
METHYLCHLOROISOTHIAZOLINONE except:
a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015 per cent or less of methylchloroisothiazolinone and methylisothiazolinone in total; or
b) in other preparations that are not intended for direct application to the skin containing 0.1 per cent or less of methylchloroisothiazolinone and methylisothiazolinone in total.
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.
METHYLDIBROMO GLUTARONITRILE except when in Schedule 10.
METHYLENE BISTHIOCYANATE except in preparations containing 1 per cent or less of methylene bisthiocyanate.
METHYLEUGENOL except in preparations containing 1 per cent or less of methyleugenol.
METHYL ETHYL KETONE OXIME except:
a) in viscous silicone adhesives or viscous silicone sealants containing 2.5 per cent or less of methyl ethyl ketone oxime; or
b) in other preparations conting 1 per cent or less of methyl ethyl ketone oxime.
p-METHYLAMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1 per cent or less of p-methylaminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
METHYL ISOTHIOCYANATE.
METHYL METHACRYLATE (excluding its derivatives) except:
a) for cosmetic use; or
b) in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.
METHYL NEODECANAMIDE except in liquid preparations containing 2 per cent or less of methyl neodecanamide.
METHYLISOTHIAZOLINONE except:
a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.01 per cent or less of methylisothiazolinone; or
b) in other preparations that are not intended for direct application to the skin containing 0.1 per cent or less of methylisothiazolinone
METHYLNORBORNYLPYRIDINE.
N-METHYL-2-PYRROLIDONE except:
a) when included in Schedule 5; or
b) in preparations containing 25 per cent or less of designated solvents.
2-METHYLRESORCINOL except:
a) in non-oxidative hair dye preparations containing 1.8 per cent or less of 2‑methylresorcinol when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations containing 1.8 per cent or less of 2-methylresorcinol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letter not less than 1.5 mm in height.
METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548-62-9) and the following TRIARYLMETHANE DYES:
- Acid Violet 49 (CAS No. 1694-09-3),
- Ethyl Violet (CAS No. 2390-59-2),
- Basic Blue 7 (CAS No. 2390-60-5),
- Methylium, 4-(dimethylamino)phenylbis4-(ethylamino)-3-methylphenyl-, acetate (CAS No. 72102-55-7),
except when included in Schedule 4 or Schedule 10.
METHYL SALICYLATE except:
a) when included in Schedule 5;
b) in preparations for therapeutic use; or
c) in preparations containing 5 per cent or less of methyl salicylate.
METOFLUTHRIN except when included in Schedule 5.
METOSULAM.
METRAFENONE except when included in Schedule 5.
METRIBUZIN.
MICONAZOLE for the external treatment of animals.
MILBEMECTIN except when included in Schedule 5.
MOMFLUOROTHRIN.
MONENSIN:
a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or
b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.
MONOETHANOLAMINE (excluding its salts and derivatives) except:
a) when included in Schedule 4 or 5; or
b) in preparations containing 5 per cent or less of monoethanolamine.
MORANTEL except:
a) when included in Schedule 5; or
b) in preparations containing 10 per cent or less of morantel.
MOXIDECTIN:
a) in preparations for external use containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or
b) in preparations for external use containing 2 per cent or less of moxidectin for the treatment of animals; or
c) in preparations for internal use containing 10 per cent or less of moxidectin for the treatment of sheep or cattle,
except when included in Schedule 5.
MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.
NALED except when included in Schedule 5.
NAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons as an impurity.
1,5-NAPHTHALENEDIOL except:
a) in non-oxidative hair dye preparations containing 1 per cent or less of 1,5-naphthalenediol when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations containing 1 per cent or less of 1,5-naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
2,7-NAPHTHALENEDIOL except:
a) in non-oxidative hair dye preparations containing 1 per cent or less of 2,7-naphthalenediol when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations containing 1 per cent or less of 2,7-naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
1-NAPHTHOL except in hair dye preparations containing 1 per cent or less of 1-naphthol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.
NARASIN in animal feed premixes containing 12 per cent or less of narasin.
NETOBIMIN for the treatment of animals except when included in Schedule 5.
NICKEL SULFATE.
NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.
NIMIDANE in preparations containing 25 per cent or less of nimidane.
NITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram.
NITRIC ACID (excluding its salts and derivatives) except:
a) when included in Schedule 5; or
b) in preparations containing 0.5 per cent or less of nitric acid (HNO3).
NITROBENZENE except:
a) in solid or semi-solid polishes;
b) in soaps containing 1 per cent or less of nitrobenzene; or
c) in other preparations containing 0.1 per cent or less of nitrobenzene.
3-NITRO-p-HYDROXYETHYLAMINOPHENOL except
a) in non-oxidative hair dye preparations containing 1.85 per cent or less of 3-nitro-p-hydroxyethylaminophenol after mixing when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations containing 3 per cent or less of 3-nitro-p-hydroxyethylaminophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
NITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules.
NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides except when included in Schedule 4.
NITROXYNIL.
NONOXINOL 9 except:
a) when included in Schedule 5;
b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:
IRRITANT; and
Avoid contact with eyes;
c) in preparations containing 12.5 per cent or less of nonoxinol 9; or
d) in preparations for human use.
1-OCTEN-3-OL except in preparations containing 5 per cent or less of 1-octen-3-ol.
OCTHILINONE except in paints, jointing compounds and sealants containing 1 per cent or less of octhilinone calculated on the non-volatile content.
N-(N-OCTYL)-2-PYRROLIDONE except:
a) when included in Schedule 5; or
b) in preparations containing 25 per cent or less of designated solvents.
OLAQUINDOX except in preparations containing 10 per cent or less of olaquindox.
N-OLEYL-1,3-DIAMINOPROPANE.
OMETHOATE in preparations containing 30 per cent or less of omethoate except when included in Schedule 5.
OXADIAZON.
OXALIC ACID except
a) in dental care preparations, including mouthwashes, containing 3 per cent or less of soluble salts of oxalic acid; or
b) its insoluble salts.
OXYCLOZANIDE.
PAECILOMYCES LILACINUS STRAIN 251.
PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde except:
a) for human therapeutic use;
b) in oral hygiene preparations;
c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:
PROTECT CUTICLES WITH GREASE OR OIL;
e) in all other cosmetic preparations; or
f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.
PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.
PARBENDAZOLE.
PEBULATE.
PENNYROYAL OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
c) in preparations containing 4 per cent or less of d-pulegone.
PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.
PERACETIC ACID except when included in Schedule 5.
PERFLUIDONE.
PERMANGANATES except potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.
PERMETHRIN except:
a) when included in Schedule 4 or 5;
b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or
c) in preparations containing 2 per cent or less of permethrin.
2-PHENOXYETHANOL except:
a) in cosmetic preparations containing 1 per cent or less of 2-phenoxyethanol; or
b) in other preparations containing 15 per cent or less of 2-phenoxyethanol.
PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, except:
a) when separately specified in these Schedules; or
b) in preparations containing 1 per cent or less of phenols, and in preparations containing 3 per cent or less of cresols and xylenols and other homologues of phenol.
PHENOTHIAZINE (excluding its derivatives) except in preparations containing 10 per cent or less of phenothiazine.
PHENOXYMETHYL OXIRANE.
†PHENYLENEDIAMINES including alkylated, arylated and nitro derivatives not elsewhere specified in these Schedules:
a) in preparations packed and labelled for photographic purposes;
b) in preparations packed and labelled for testing water except tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”;
c) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
PHOSALONE.
PHOSMET.
PHOSPHORIC ACID (excluding its salts and derivatives) except:
a) when included in Schedule 5;
b) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);
c) in solid or semi-solid preparations; or
d) in professional dental kits.
PHOXIM.
o-PHTHALALDEHYDE except when included in Schedule 5.
PINDONE.
PINE OILs when packed and labelled as a herbicide except when included in Schedule 5.
PINOXADEN except when included in Schedule 5.
PIPEROPHOS.
PIRIMICARB except when included in Schedule 5.
PIRIMIPHOS-ETHYL.
PIRIMIPHOS-METHYL.
POLIHEXANIDE except:
a) in preparations containing 5 per cent or less of polihexanide; or
b) when packed and labelled for therapeutic use.
POLIXETONIUM SALTS except:
a) when included in Schedule 5; or
b) in preparations containing 1 per cent or less of polixetonium salts.
POTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.
POTASSIUM BROMATE except in preparations containing 0.5 per cent or less of potassium bromate.
POTASSIUM CYANATE.
POTASSIUM HYDROXIDE (excluding its salts and derivatives) except:
a) when included in Schedule 5 or Schedule 10;
b) in preparations containing 5 per cent or less of potassium hydroxide being:
i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.
POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite except:
a) when included in Schedule 5;
b) in preparations containing 0.5 per cent or less of potassium nitrite;
c) when present as an excipient in preparations for therapeutic use; or
d) in aerosols containing 2 per cent or less of potassium nitrite.
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT except:
a) when included in Schedule 5;
b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or
c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:
i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or
ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.
POTASSIUM PERSULFATE in hair preparations.
PRALLETHRIN (cis:trans=20:80) except:
a) when included in Schedule 5; or
b) in insecticidal mats containing 1 per cent or less of prallethrin.
PROCHLORAZ.
PROFENOFOS.
PROMACYL.
PROPACHLOR.
PROPARGITE.
PROPETAMPHOS.
PROPICONAZOLE except when included in Schedule 5.
PROPINEB.
PROPIONIC ACID (excluding its salts and derivatives) except:
a) when included in Schedule 5;
b) in preparations containing 30 per cent or less of propionic acid; or
c) for therapeutic use.
PROPOXUR except when included in Schedule 5.
n-PROPYL ALCOHOL except:
a) when included in Schedule 5;
b) in preparations containing 5 per cent or less of n-propyl alcohol; or
c) in preparations for cosmetic or therapeutic use other than in spray form.
PROQUINAZID.
PROSULFOCARB.
PROSULFURON.
PROTHIOFOS.
d-PULEGONE except in preparations containing 4 per cent or less of d- pulegone.
PYRACLOFOS.
PYRAZOPHOS.
PYRIDABEN except when included in Schedule 5.
PYRIDALYL.
PYRIDATE.
PYRIPROLE.
PYRITHIONE COPPER.
PYRITHIONE ZINC except:
a) when included in Schedule 2 or 5;
b) for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels;
c) in semi-solid hair preparations for animal use;
d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”;
e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or
f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.
PYRIOFENONE except when included in Schedule 5.
PYROXASULFONE.
PYROXSULAM.
QUATERNARY AMMONIUM COMPOUNDS except:
a) when separately specified in these Schedules;
b) when included in Schedule 5;
c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.
QUININE in cosmetic preparations except:
a) in rinse-off hair preparations containing 0.5 per cent or less of quinine calculated as free base; or
b) in leave-on hair preparations containing 0.2 per cent or less of quinine calculated as free base.
QUINOLINE and its salts (excluding other derivatives).
QUIZALOFOP ETHYL.
QUIZALOFOP-p-ETHYL except when included in Schedule 5.
QUIZALOFOP-p-TEFURYL.
RESMETHRIN except when included in Schedule 5.
RESORCINOL except:
a) in preparations for human therapeutic use; or
b) in oxidative hair dye preparations containing 1.25 per cent or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
c) in oxidative eyelash and eyebrow dye preparations containing 1.25 per cent or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING - This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height; or
d) in hair lotions/shampoo products containing 0.5 per cent or less of resorcinol when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals.
written in letters not less than 1.5 mm in height.
ROTENONE except in solid or semi-solid preparations containing 2 per cent or less of rotenone.
SAFROLE except:
a) for internal use; or
b) in other preparations containing 1 per cent or less of safrole.
SAGE OIL (Dalmatian) except:
a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;
b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
c) in preparations containing 4 per cent or less of thujone.
SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.
SAROLANER except when included in Schedule 5.
SASSAFRAS OIL except:
a) for internal use; or
b) in other preparations containing 1 per cent or less of safrole.
SELENIUM:
a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:
i) for the blueing of gun barrels;
ii) for photographic purposes; or
iii) for the colouring of lead or lead alloys;
b) in coated granules containing 1 per cent or less of selenium for application to pasture except in fertilisers containing 200 g/tonne or less of selenium; or
c) for the treatment of animals:
i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;
ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;
iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or
iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.
SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.
SILICOFLUORIDES except:
a) when included in Schedule 5; or
b) in preparations containing 15 mg/kg or less of fluoride ion.
SILVER NITRATE except:
a) when included in or expressly excluded from Schedule 2; or
b) in preparations containing 1 per cent or less of silver.
SINBIOALLETHRIN except:
a) when included in Schedule 5; or
b) in preparations containing 1 per cent or less of sinbioallethrin.
SODIUM ALUMINATE (excluding its salts and derivatives) except:
a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
b) in liquid preparations, the pH of which is 11.5 or less.
SODIUM BROMATE except in preparations containing 0.5 per cent or less of sodium bromate.
SODIUM HYDROXIDE (excluding its salts and derivatives) except:
a) when included in Schedule 5 or Schedule 10;
b) in preparations containing 5 per cent or less of sodium hydroxide being:
i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.
SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite except:
a) when included in Schedule 2 or 5;
b) in preparations containing 0.5 per cent or less of sodium nitrite;
c) when present as an excipient in preparations for therapeutic use; or
d) in aerosols containing 2 per cent or less of sodium nitrite.
SODIUM PERCARBONATE (CAS No. 15630-89-4) except:
a) when included in Schedule 5; or
b) in preparations containing 15 per cent or less of sodium percarbonate.
SODIUM PERSULFATE:
a) in hair preparations; or
b) in products for the treatment of water for swimming pools and spas.
SODIUM SULFIDE in preparations for use as insect lures.
SPIROTETRAMAT.
SPIROXAMINE.
SULCOFURON in preparations for the treatment of carpets during manufacture.
SULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.
SULFLURAMID.
SULFOXAFLOR except when included in Schedule 5.
SULFURIC ACID (excluding its salts and derivatives) except:
a) in fire extinguishers; or
b) in preparations containing 0.5 per cent or less of sulfuric acid (H2SO4).
SULFURYL FLUORIDE.
SULPROFOS.
2,4,5-T.
N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.
TAR ACIDS distilling within the range 230-290°C inclusive.
TCMTB (2-[thiocyanomethylthio]benzothiazole).
TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) except when included in Schedule 5.
TEBUFENPYRAD.
TEBUTHIURON.
TEMEPHOS except when in Schedule 5.
TERBUTHYLAZINE except in preparations containing 5 per cent or less of terbuthylazine.
TERPENES, CHLORINATED.
TESTOSTERONE in implant preparations for use in animals.
TETRACHLOROETHYLENE except:
a) when included in Schedule 2 or 5;
b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or
c) in preparations for the treatment of animals.
TETRACONAZOLE except when included in Schedule 5.
TETRADIFON.
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2’,6,6’-tetraisopropyl-diphenyl-carbodiimide.
TETRAMISOLE in preparations for the treatment of animals.
THIACLOPRID.
THIAMETHOXAM except when included in Schedule 5.
THIAZAFLURON.
THIODICARB except when included in Schedule 5.
THIOMETON.
THIOPHANATE-METHYL except when included in Schedule 5.
THIOUREA AND ALKYL THIOUREAS except:
a) when separately specified in these Schedules; or
b) for therapeutic use.
THIRAM except in paint containing 0.5 per cent or less of thiram.
THUJONE except in preparations containing 4 per cent or less of thujone.
THYMOL when packed and labelled for the control of Varroa mites in bee hives.
TOLUENE (excluding its derivatives) except in preparations containing 50 per cent or less of toluene or toluene and xylene.
TOLUENEDIAMINE not elsewhere specified in these Schedules:
a) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and
WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
c) in nail polish preparations containing 2,5-toluenediamine except when labelled ‘avoid contact with skin’
TOLYLFLUANID.
TRANSFLUTHRIN except:
a) in preparations containing 1 per cent or less of transfluthrin; or
b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.
TRIADIMEFON except:
a) when included in Schedule 5; or
b) in fertilisers containing 5 g/kg or less of triadimefon.
TRICHLORFON except metrifonate included in Schedule 4.
TRICHLOROACETIC ACID except:
a) when included in Schedule 4 or 5; or
b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.
TRICHLOROETHYLENE except when included in Schedule 4.
TRICHLOROPHENOL.
TRICLABENDAZOLE except in preparations containing 20 per cent or less of triclabendazole.
TRICLOPYR.
TRICLOSAN in cosmetic preparations for human use containing more than 0.3 per cent of triclosan.
TRIDEMORPH.
TRIETHYL PHOSPHATE.
TRIFLUOROMETHANESULFONIC ACID.
TRINITROPHENOL (excluding its derivatives) except:
(a) in preparations for human therapeutic use; or
(b) in preparations containing 5 per cent or less of trinitrophenol.
TRISODIUM NITRILOTRIACETATE except in preparations containing 20 per cent or less of trisodium nitrilotriacetate.
VAMIDOTHION.
VINYL ACETATE MONOMER (excluding its derivatives) except:
a) in preparations for therapeutic use; or
b) in cosmetic preparations containing 0.01 per cent or less of vinyl acetate as residual monomer in a polymer; or
c) in other preparations containing 1 per cent or less of vinyl acetate.
WARFARIN except when included in Schedule 4 or 5.
XYLENE (excluding its derivatives) except in preparations containing 50 per cent or less of xylene or xylene and toluene.
ZERANOL in ear implants for use as a growth promotant in steer cattle.
ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.
ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.
ZINC CHLORIDE except:
a) when included in Schedule 2; or
b) in preparations containing 5 per cent or less of zinc chloride.
ZINC para-PHENOLSULFONATE except in preparations containing 5 per cent or less of zinc para-phenolsulfonate.
ZINC LACTATE in toothpaste except in toothpaste preparations containing 2.5 per cent or less of zinc lactate and labelled with the statement :
Not recommended for children under twelve years of age.
ZINC SULFATE except:
a) when included in or expressly excluded from Schedule 4; or
b) in other preparations containing 5 per cent or less of zinc sulfate.
ZIRAM in granular preparations.
ABAMECTIN except when included in Schedule 5 or 6.
ACIBENZOLAR-S-METHYL.
ACRIFLAVINIUM CHLORIDE for veterinary use except when in Schedule 5.
ACROLEIN.
ACRYLONITRILE.
ALACHLOR.
ALDICARB.
ALDOXYCARB.
ALLYL ALCOHOL except:
a) in preparations containing 5 per cent or less of allyl esters with 0.1 per cent or less of free allyl alcohol by weight of allyl ester; or
b) when separately specified in these Schedules.
ALPHA-CYPERMETHRIN except when included in Schedule 5 or 6.
AMINOACRIDINE for veterinary use except when included in Schedule 5.
AMINOCARB except when included in Schedule 6.
4-AMINOPROPIOPHENONE.
4-AMINOPYRIDINE except when included in Schedule 4.
AMITON.
ARPRINOCID.
ARSENIC except:
a) when separately specified in this Schedule;
b) when included in Schedule 4 or 6;
c) as selenium arsenide in photocopier drums;
d) as 10,10’-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;
e) as 10,10’-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:
i) in contact with food stuffs, animal feeds or potable water;
ii) of clothing and footwear in contact with the skin;
iii) used as infant wear; or
iv) intended for use as packaging materials;
f) in animal feeds containing 75 g/tonne or less of arsenic; or
g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.
AZAFENIDIN.
AZINPHOS-ETHYL.
AZINPHOS-METHYL.
AZOCYCLOTIN.
AZO DYES that are derivatives by diazotisation of any of the following substances:
p-aminoazobenzene (CAS No. 60-09-3)
o-aminoazotoluene (CAS No. 97-56-3)
o-anisidine (CAS No. 90-04-0)
p-chloroaniline (CAS No. 106-47-8)
4-chloro-o-toluidine (CAS No. 95-69-2)
6-methoxy-m-toluidine (p-cresidine) (CAS No. 120-71-8)
2-naphthylamine (CAS No. 91-59-8)
5-nitro-o-toluidine (CAS No. 99-55-8)
2,4-toluenediamine (CAS No. 95-80-7)
o-toluidine (CAS No. 95-53-4)
2,4,5-trimethylaniline (CAS No. 137-17-7)
except for BASIC RED 76 (CAS No. 68391-30-0) when included in Schedule 6.
BENDIOCARB except when included in Schedule 5 or 6.
BENOMYL except in paints containing 0.5 per cent or less of benomyl.
BENZENE (excluding its derivatives) except:
a) preparations containing 15 mL/L or less of benzene; or
b) petrol containing 50 mL/L or less of benzene.
BENZIDINE-BASED AZO DYES being:
2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[N-(4-chlorophenyl)-3-oxobutanamide]
(CAS No. 94249-03-3)
Acid Red 85 (Acid Fast Red A)
1,3-Naphthalenedisulfonic acid, 7-hydroxy-8-[[4'-[[4-[[(4-methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-, disodium salt
(CAS No. 3567-65-5)
C.I Acid Black 29
(CAS No. 12217-14-0)
C.I. Direct Orange 1
(CAS No. 54579-28-1)
Direct Black 38
2,7-Naphthalenedisulfonic acid, 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)-, disodium salt
(CAS No. 1937-37-7)
Direct Blue 2
2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-4-hydroxy-, trisodium salt
(CAS No. 2429-73-4)
Direct Blue 6
2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-hydroxy-, tetrasodium salt
(CAS No. 2602-46-2)
Direct Brown 2
5-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxy- benzoic acid disodium salt
(CAS No. 2429-82-5)
Direct Brown 95
Cuprate(2-), [5-[[4'-[[2,6-dihydroxy-3-[(2-hydroxy-5-sulfophenyl)azo]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxybenzoato(4-)]-, disodium salt
(CAS No. 16071-86-6)
Direct Green 1
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-6-(phenylazo)-, disodium salt
(CAS No. 3626-28-6)
Direct Green 6
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-3-[(4-nitrophenyl)azo]-, disodium salt
(CAS No. 4335-09-5)
Direct Red 28 (Congo Red)
1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-, disodium salt
(CAS No. 573-58-0)
Direct Red 37
1,3-Naphthalenedisulfonic acid, 8-[[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-7-hydroxy-, disodium salt
(CAS No. 3530-19-6)
BENZIDINE-CONGENER (3,3’-disubstituted) AZO DYES.
BETACYFLUTHRIN except when included in Schedule 5 or 6.
BIFENTHRIN except:
(a) when included in Schedule 6; or
(b) in preparations containing 0.5 per cent or less of bifenthrin.
BIFLUORIDES (including ammonium, potassium and sodium salts) except when included in Schedule 5 or 6.
BORON TRIFLUORIDE except when included in Schedule 5 or 6.
BRODIFACOUM except when included in Schedule 6.
BROMADIOLONE except when included in Schedule 6.
BROMETHALIN except when included in Schedule 6.
BROMINE (excluding its salts and derivatives).
BRUCINE except in alcohol containing 0.02 per cent or less of brucine as a denaturant.
CACODYLIC ACID except:
a) when included in Schedule 6; or
b) in animal feeds containing 75 g/tonne or less of arsenic.
CADUSAFOS except when included in Schedule 6.
CALCIFEROL for use as a rodenticide except when included in Schedule 6.
CAPTAFOL.
CARBADOX.
CARBENDAZIM except in paints, jointing compounds and sealants containing 0.1 per cent or less of carbendazim.
CARBOFURAN.
CARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.
CARBONYL SULFIDE when packed and labelled for use as a fumigant.
CARBOPHENOTHION.
CARBOSULFAN.
CHLORDECONE.
CHLORDIMEFORM.
CHLORFENAPYR except when included in Schedule 5 or 6.
CHLORFENVINPHOS.
CHLORINE (excluding its salts and derivatives).
CHLORHEXIDINE except:
a) when included in Schedule 5 or 6;
b) in preparations containing 1 per cent or less of chlorhexidine; or
c) in solid preparations.
CHLOROMETHIURON.
5-CHLORO-3-METHYL-4-NITROPYRAZOLE.
4-CHLORO-o-TOLUIDINE.
CHLOROPICRIN except when included in Schedule 6.
CHLORTHIOPHOS.
COLECALCIFEROL for use as a rodenticide.
COUMAPHOS except when included in Schedule 6.
COUMATETRALYL except when included in Schedule 5 or 6.
CREOSOTE derived from coal.
CREOSOTE derived from beechwood.
CYANIDES, metallic except:
a) ferricyanides;
b) ferrocyanides; or
c) when separately specified in these Schedules.
CYANOGEN.
CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.
CYHEXATIN.
DELTAMETHRIN except:
a) when included in Schedule 5 or 6; or
b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
c) in preparations containing 0.1 per cent or less of deltamethrin.
DEMETON.
DEMETON-O-METHYL.
DEMETON-S-METHYL.
DIALIFOS.
4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).
1,2-DIBROMO-3-CHLOROPROPANE.
1,3-DICHLOROPROPENE except in biocidal preparations containing 0.3 per cent or less of 1,3-dichloropropene.
DICHLORVOS except when included in Schedule 5 or 6.
DICROTOPHOS.
DIFENACOUM except when included in Schedule 6.
DIFETHIALONE except when included in Schedule 6.
DIMEFOX.
4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).
DIMETHYL SULFATE.
DIMETILAN.
DINITROCRESOLS except when included in Schedule 4 or 6.
DINITROPHENOLS except when included in Schedule 4, 6 or 10.
DINOCAP.
DINOSEB.
DIQUAT except when included in Schedule 6.
DISULFOTON except when included in Schedule 6.
DORAMECTIN except when included in Schedule 5 or 6.
DSMA except when included in Schedule 6.
EMAMECTIN except when included in Schedule 5 or 6.
ENDOSULFAN except when included in Schedule 6.
ENDOTHAL except when included in Schedule 6.
ENDRIN.
EPICHLOROHYDRIN.
EPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use.
EPRINOMECTIN except when included in Schedule 5 or 6.
ETACONAZOLE.
ETHION.
ETHOPROPHOS except when included in Schedule 6.
2-ETHOXYETHANOL and its acetates except in preparations containing 0.5 per cent or less of 2-ethoxyethanol.
ETHYLENE DIBROMIDE.
ETHYLENE OXIDE.
FAMPHUR except when included in Schedule 6.
FENAMIPHOS except when included in Schedule 6.
FENOXACRIM except:
a) when included in Schedule 6; or
b) in treated carpets.
FENSULFOTHION.
FENTHION except when included in Schedule 5 or 6.
FENTHION-ETHYL.
FLOCOUMAFEN except when included in Schedule 6.
FLUCOFURON except:
a) when included in Schedule 6; or
b) in treated carpets.
FLUCYTHRINATE.
FLUMIOXAZIN except when included in Schedule 6.
FLUOROACETAMIDE.
FLUOROACETIC ACID.
FOLPET.
FORMETANATE.
FOSTHIAZATE.
FURATHIOCARB except when included in Schedule 5.
GAMMA-CYHALOTHRIN except when included in Schedule 5.
HALOFUGINONE except when included in Schedule 4.
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.
HCB.
HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C except:
a) when in solid polymers;
b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or
c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.
HYDROCYANIC ACID except:
a) when included in Schedule 4; or
b) its salts and derivatives other than cyanides separately specified in this Schedule.
HYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.
HYDROGEN SULFIDE.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.
IODOMETHANE.
ISOCARBOPHOS.
ISOFENPHOS.
ISOPROTURON.
IVERMECTIN except when included in Schedule 4 or 5.
LAMBDA-CYHALOTHRIN except when included in Schedule 5 or 6.
LEPTOPHOS.
LITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.
MADURAMICIN except:
a) when included in Schedule 5; or
b) in animal feeds containing 5 mg/kg or less of antibiotic substances.
MALACHITE GREEN for veterinary use except when included in Schedule 5.
MAZIDOX.
MECARBAM.
2-METHOXYETHANOL and its acetates except in preparations containing 0.5 per cent or les of 2-methoxyethanol.
MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.
MERCURY except:
a) when separately specified in this Schedule;
b) when included in Schedule 2, 4 or 6;
c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;
d) mercury (metallic) in scientific instruments;
e) dental amalgams; or
f) in a sealed device, for therapeutic use, which prevents access to the mercury.
METHACRIFOS except when included in Schedule 6.
METHAMIDOPHOS.
METHAPYRILENE.
METHAZOLE.
METHIDATHION.
METHIOCARB except when included in Schedule 5 or 6.
METHOMYL except when included in Schedule 6.
METHOXYETHYLMERCURIC ACETATE.
METHOXYETHYLMERCURIC CHLORIDE.
METHYL BROMIDE.
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL except:
a) when included in Schedule 6;
b) when used in laboratory analysis; or
c) when packed for industrial use in containers with a nominal capacity of 100 L or more.
4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA).
METHYLENE BLUE for veterinary use except when included in Schedules 4 or 5.
MEVINPHOS.
MIPAFOX.
MIREX.
MOLINATE.
MONOCROTOPHOS.
MOXIDECTIN except when included in Schedule 4, 5 or 6.
MSMA except when included in Schedule 6.
NAPHTHALOPHOS except when included in Schedule 6.
NICOTINE except:
a) when included in Schedule 6;
b) in preparations for human therapeutic use; or
c) in tobacco prepared and packed for smoking.
NIMIDANE except when included in Schedule 6.
NITROFEN.
NITROPRUSSIDES except when included in Schedule 4 or 6.
2-NITROTOLUENE.
OMETHOATE except when included in Schedule 5 or 6.
OXAMYL.
OXYDEMETON METHYL.
PARAQUAT.
PARATHION.
PARATHION-METHYL except when included in Schedule 6.
PENTACHLOROPHENOL except when included in Schedule 6.
PHENYLMERCURIC ACETATE except in preparations containing 0.01 per cent or less of mercury as a preservative.
PHORATE.
PHOSFOLAN.
PHOSPHIDES, METALLIC.
PHOSPHINE.
PHOSPHORUS, YELLOW (excluding its salts and derivatives).
POTASSIUM NITRITE except:
a) when included in Schedule 5 or 6;
b) in preparations containing 0.5 per cent or less of potassium nitrite;
c) when present as an excipient in preparations for therapeutic use; or
d) in aerosols containing 2 per cent or less of potassium nitrite.
PROCYMIDONE.
PROPYLENE OXIDE.
PYRINURON.
QUININE for veterinary use except when included in Schedule 5.
SAFLUFENACIL except when included in Schedule 5.
SCHRADAN.
SELENIUM except:
a) when included in Schedule 6;
b) as selenium arsenide in photocopier drums;
c) in preparations for therapeutic use other than:
i) drench concentrates containing 2.5 per cent or less of selenium; or
ii) pour-on preparations containing 0.5 per cent or less of selenium;
d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or
e) in fertilisers containing 200 g/tonne or less of selenium.
SEMDURAMICIN except:
a) when included in Schedule 6; or
b) in animal feeds containing 25 mg/kg or less of antibiotic substances.
SODIUM NITRITE except:
a) when included in Schedule 2, 5 or 6;
b) in preparations containing 0.5 per cent or less of sodium nitrite;
c) when present as an excipient in preparations for therapeutic use; or
d) in aerosols containing 2 per cent or less of sodium nitrite.
STRYCHNINE except when included in Schedule 4.
SULCOFURON except:
a) when included in Schedule 6; or
b) in treated carpets.
SULFENTRAZONE.
SULFOTEP.
TEFLUTHRIN except when included in Schedule 5.
TEPP.
TERBUFOS.
TETRACHLOROETHANE.
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE except when included in Schedule 6.
THALLIUM.
THIOFANOX.
TIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl except:
a) when separately specified in this Schedule;
b) in plastics;
c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or
d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.
o-TOLIDINE except in solid-state diagnostic therapeutic reagents.
TRIAMIPHOS.
TRIAZBUTIL.
TRIBUFOS (S,S,S-tributylphosphorotrithioate).
VINCLOZOLIN.
VINYL CHLORIDE.
ZETA-CYPERMETHRIN except when included in Schedule 6.
ZIRAM except when included in Schedule 6.
ACETYLDIHYDROCODEINE.
ACETYLMETHADOL.
ACETYLMORPHINES.
ALFENTANIL.
ALPHACETYLMETHADOL.
ALPHAPRODINE.
# ALPRAZOLAM.
AMFETAMINE.
AMOBARBITAL except when included in Schedule 4.
ANILERIDINE.
BENZYLMORPHINE.
BEZITRAMIDE.
BUPRENORPHINE.
BUTOBARBITAL.
BUTORPHANOL.
# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:
a) cultivated or produced, or in products manufactured[1], in accordance with the Narcotic Drugs Act 1967; and/or
b) for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
d) in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
except when:
i) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
ii) separately specified in the NABIXIMOLS entry in this Schedule; or
iii) captured by the CANNABIDIOL entry in Schedule 4.
CARFENTANYL.
COCAINE.
CODEINE except when included in Schedule 4.
CODEINE-N-OXIDE.
CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).
4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).
CYCLOBARBITAL.
DEXAMFETAMINE.
DEXTROMORAMIDE.
DEXTROPROPOXYPHENE except when included in Schedule 4.
DIFENOXIN except when included in Schedule 4.
DIHYDROCODEINE except when included in Schedule 3 or 4.
DIHYDROMORPHINE.
DIPHENOXYLATE except when included in Schedule 3 or 4.
DIPIPANONE.
# DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.
DROTEBANOL.
ETHYLAMFETAMINE.
ETHYLMORPHINE except when included in Schedule 2 or 4.
FENTANYL.
# FLUNITRAZEPAM.
HYDROCODONE.
HYDROMORPHINOL.
HYDROMORPHONE.
KETAMINE.
LEVAMFETAMINE.
LEVOMETHAMFETAMINE.
LEVOMORAMIDE.
LEVORPHANOL (excluding its stereoisomers).
LISDEXAMFETAMINE.
METHADONE.
METAMFETAMINE.
METHYLDIHYDROMORPHINE.
METHYLPHENIDATE.
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).
MORPHINE.
MORPHINE METHOBROMIDE.
MORPHINE-N-OXIDE.
NABILONE.
# NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use.
NORCODEINE.
NORMETHADONE.
OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.
OXYCODONE.
OXYMORPHONE.
PENTAZOCINE.
PENTOBARBITAL except when included in Schedule 4.
PETHIDINE.
PHENDIMETRAZINE.
PHENMETRAZINE.
PHENOPERIDINE.
4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).
PHOLCODINE except when included in Schedule 2 or 4.
PIRITRAMIDE.
PROPIRAM.
RACEMORAMIDE.
REMIFENTANIL.
SECBUTOBARBITAL.
SECOBARBITAL.
# SODIUM OXYBATE for human therapeutic use.
SUFENTANIL.
TAPENTADOL.
# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:
a) included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
c) in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
except when:
i) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
ii) separately specified in the NABIXIMOLS entry in this Schedule; or
iii) captured by the CANNABIDIOL entry in Schedule 4.
THEBACON.
THEBAINE.
TILIDINE.
ACETORPHINE.
ACETYL-ALPHA-METHYLFENTANYL.
ALKOXYAMFETAMINES and substituted alkoxyamfetamines except when separately specified in these Schedules.
ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules.
ALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines except when separately specified in these Schedules.
ALLYLPRODINE.
ALPHAMEPRODINE.
ALPHA-METHYLFENTANYL.
ALPHA-METHYLTHIOFENTANYL.
ALPHAMETHADOL.
ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).
5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans except when separately specified in these Schedules.
BENZETHIDINE.
BENZOYLINDOLES except when separately specified in these Schedules.
BENZYLPIPERAZINE *(BZP).
BETACETYLMETHADOL.
BETA-HYDROXYFENTANYL.
BETA-HYDROXY-3-METHYLFENTANYL.
BETAMEPRODINE.
BETAMETHADOL.
BETAPRODINE.
1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE *(Bromo-Dragonfly).
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).
BUFOTENINE.
CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except:
a) when separately specified in these Schedules; or
b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or
c) when in hemp seed oil for purposes other than internal human use containing 50 mg/kg or less of cannabinoids, including 20 mg/kg or less of tetrahydrocannabinols, when labelled with either of the following warning statements:
i) Not for internal use; or
ii) Not to be taken.
CATHINONES except when separately specified in these Schedules.
CLONAZOLAM.
CLONITAZENE.
COCA LEAF.
CODOXIME.
4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE.
CYCLOHEXYLPHENOLS except
a) when separately specified in these Schedules; or
b) in preparations containing 0.5 per cent or less of cyclohexylphenols.
DESCHLOROETIZOLAM.
DESOMORPHINE.
N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES except when separately specified in these Schedules.
N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when separately specified in these Schedules.
DIAMPROMIDE.
DIBENZOPYRANS except when separately specified in these Schedules.
3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZAMIDE (U-47700).
3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921).
DICLAZEPAM.
DIETHYLTHIAMBUTENE.
N,N-DIETHYLTRYPTAMINE *(DET).
DIMENOXADOL.
DIMEPHEPTANOL.
2,5-DIMETHOXYAMFETAMINE *(DMA).
2,5-DIMETHOXY-4-BROMOAMFETAMINE *(DOB).
2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE *(DOET).
2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).
2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).
2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DMHP).
N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA).
N,N-DIMETHYLAMFETAMINE (Dimetamfetamine).
DIMETHYLTHIAMBUTENE.
N,N-DIMETHYLTRYPTAMINE *(DMT).
DIOXAPHETYL BUTYRATE.
ECGONINE.
N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA).
ETHYLMETHYLTHIAMBUTENE.
ETICYCLIDINE *(PCE).
ETONITAZENE.
ETORPHINE.
ETOXERIDINE.
FENETYLLINE.
4-FLUORO-N-METHYLAMFETAMINE.
FLUBROMAZEPAM.
FLUBROMAZOLAM.
1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE *(AM-694).
FURETHIDINE.
HARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use:
a) containing 0.1 per cent or less of harmala alkaloids; or
b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.
HEROIN.
3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).
4-HYDROXYBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)).
2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue).
2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL *(CP 47,497).
HYDROXYPETHIDINE.
ISOMETHADONE.
KETOBEMIDONE.
LEVOMETHORPHAN (excluding its stereoisomers).
LEVOPHENACYLMORPHAN.
LYSERGIC ACID.
LYSERGIDE.
MECLONAZEPAM.
MECLOQUALONE.
METAZOCINE.
METHAQUALONE.
METHCATHINONE.
5-METHOXY- α –METHYLTRYPTAMINE *(5-MeO-AMT).
5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE *(MMDA).
4-METHOXY- α –METHYLPHENYLETHYLAMINE *(PMA).
2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE *(JWH-250).
METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE *(SALVINORIN A).
4-METHYLAMINOREX.
METHYLDESORPHINE.
3,4-METHYLENEDIOXYAMFETAMINE *(MDA).
3,4-METHYLENEDIOXYPYROVALERONE *(MDPV).
3-METHYLFENTANYL.
4-METHYLMETHCATHINONE *(MEPHEDRONE).
N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N-HYDROXY MDA).
N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).
2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).
METHYLONE *(MDMC).
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).
4-METHYLTHIOAMFETAMINE.
3-METHYLTHIOFENTANYL.
METOPON.
MITRAGYNA SPECIOSA.
MITRAGYNINE.
MORPHERIDINE.
(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE *(JWH-200).
MUSCIMOL.
MYROPHINE.
NAPHTHOYLINDOLES except when separately specified in these Schedules.
NAPHTHYLMETHYLINDOLES except when separately specified in these Schedules.
NAPHTHOYLPYRROLES except when separately specified in these Schedules.
NAPHTHYLMETHYLINDENES except when separately specified in these Schedules.
NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE *(JWH-073).
NICOCODINE.
NICODICODINE.
NICOMORPHINE.
NIFOXIPAM.
NORACYMETHADOL.
NORLEVORPHANOL.
NORMORPHINE.
NORPIPANONE.
PARA-FLUOROFENTANYL.
1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. *(JWH-122).
1-PENTYL-3-(1-NAPHTHOYL)INDOLE *(JWH-018).
PHENADOXONE.
PHENAMPROMIDE.
PHENAZOCINE.
PHENCYCLIDINE *(PCP).
PHENIBUT.
N-PHENETHYL-4-PIPERIDONE.
PHENOMORPHAN.
PHENYLACETYLINDOLES except when separately specified in these Schedules.
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).
PIMINODINE.
PROHEPTAZINE.
PROPERIDINE.
PSILOCYBINE.
PYRAZOLAM.
RACEMETHORPHAN.
RACEMORPHAN.
ROLICYCLIDINE *(PHP or PCPY).
SALVIA DIVINORUM.
SYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.
TENOCYCLIDINE *(TCP).
TETRAHYDROCANNABINOLS and their alkyl homologues, except:
a) when included in Schedule 4 or Schedule 8; or
b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or
c) in hemp seed oil for purposes other than internal human use containing 50 mg/kg or less of total cannabinoids, including 20 mg/kg or less of tetrahydrocannabinols, when labelled with either of the following warning statements:
i) Not for internal use; or
ii) Not to be taken.
THIOFENTANYL.
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).
TRIMEPERIDINE.
3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE *(TMA).
3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine except:
a) methoxyphenamine; or
b) when separately specified in this Schedule.
1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.
SUBSTANCES OF SUCH DANGER TO HEALTH AS TO WARRANT PROHIBITION OF SALE, SUPPLY AND USE
ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.
ACORUS CALAMUS (calamus) for human therapeutic use.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:
a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;
b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
c) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.
ALKYLAMINES WITH STIMULANT PROPERTIES except when separately specified in these schedules.
ALLYLISOPROPYLACETYLUREA for therapeutic use.
AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.
AMYGDALIN for therapeutic use.
ANCHUSA OFFICINALIS for therapeutic use.
o-ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001 per cent or less of o-anisidine.
ARISTOLOCHIA spp. for therapeutic use.
ARISTOLOCHIC ACID(S) for human therapeutic use.
ASARUM spp. containing aristolochic acid(s) for human therapeutic use.
AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except ‘debitterised neem seed oil’
BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.
1,2-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).
1,3-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).
BITHIONOL for human therapeutic use.
BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.
BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.
BUCLOSAMIDE for therapeutic use.
BUNIODYL SODIUM for therapeutic use.
1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.
BUTYL BENZYL PHTHALATE for cosmetic use.
CACALIA spp. for therapeutic use.
CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.
CARDARINE.
CHRYSOIDINE BASE in preparations for use in hair dyes.
CINCHOPHEN and its derivatives for therapeutic use.
CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use except or when being used solely for experimental purposes in humans and where such use:
a) is in accordance with:
i) an approval granted under paragraph 19(1)(b) of the Therapeutic Goods Act 1989, including any conditions specified in the notice of approval; and
ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Therapeutic Goods Act 1989; and
iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Therapeutic Goods Act 1989; or
b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990.
COAL TAR for cosmetic use other than in therapeutic goods.
CONIUM MACULATUM (coniine) for therapeutic use.
COTARNINE for therapeutic use.
CROTALARIA spp. for therapeutic use.
CROTON TIGLIUM for therapeutic use.
CYNOGLOSSUM spp. for therapeutic use.
DIBUTYLPHTHALATE for cosmetic use.
DICOPHANE (DDT) for therapeutic use.
DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of diethylene glycol.
DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.
DIETHYLHEXYL PHTHALATE for cosmetic use.
DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5 per cent or less of diethylphthalate.
5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.
DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.
DIISOBUTYL PHTHALATE for cosmetic use.
1,3-DIMETHYLAMYLAMINE (DMAA).
1,3-DIMETHYLBUTYLAMINE (DMBA) except when separately specified in these schedules.
1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette).
1,5-DIMETHYLHEXYLAMINE (DMHA) except when separately specified in these schedules.
DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5 per cent or less of dimethylphthalate.
DI(METHYLOXYETHYL) PHTHALATE for cosmetic use.
2,4-DINITROPHENOL for human use.
DISPERSE YELLOW 3 for use in hair dyes.
DULCIN for therapeutic use.
ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of ethylene glycol.
EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.
FARFUGIUM JAPONICUM for therapeutic use.
FORMALDEHYDE (excluding its derivatives):
a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.
GAMMA BUTYROLACTONE (excluding its derivatives) in non-polymerised form in preparations for domestic and cosmetic use.
HELIOTROPIUM spp. for therapeutic use.
HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.
JUNIPERUS SABINE [savin(e)] for therapeutic use.
LEAD COMPOUNDS in paints, tinters, inks or ink additives except in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.
LIGULARIA DENTATA for therapeutic use.
MELIA AZEDARACH including its extracts and derivatives.
METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use..
METHYL METHACRYLATE for cosmetic use except in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer .
METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548-62-9) and the following TRIARYLMETHANE DYES – for use in hair dyes:
- Acid Violet 49 (CAS No. 1694-09-3),
- Ethyl Violet (CAS No. 2390-59-2),
- Basic Blue 7 (CAS No. 2390-60-5),
- Basic Blue 26 (CI 44045) (CAS No. 2580-56-5).
OXYPHENISATIN for therapeutic use.
PARAFORMALDEHYDE (excluding its derivatives):
a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.
PETASITES spp. for therapeutic use.
PHENYLENEDIAMINES, including alkylated, arylated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows except when included in Schedule 6.
POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.
PTERIDIUM spp. for therapeutic use.
PULMONARIA spp. for therapeutic use.
SAFROLE for internal therapeutic use except in preparations containing 0.1 per cent or less of safrole.
SENECIO spp. for therapeutic use.
SILICONES for injection or implantation except when included in Schedule 4.
SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.
SYMPHYTUM spp. (Comfrey) in preparations for human or animal use except when in Schedule 5.
2,4-TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.
TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows except when included in Schedule 6.
o-TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001 per cent or less of o-toluidine.
1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.
TRICHODESMA AFRICANA for therapeutic use.
TRIPARANOL for therapeutic use.
TUSSILAGO FARFARA for therapeutic use.
This Standard does not apply to a poison in any of the following products:
ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.
BACTERIAL CULTURE MEDIA containing antibiotics.
CERAMICS.
CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4-2003 Safety of toys entitled Part 4: Experimental sets for chemistry and related activities.
COPPER COMPOUNDS in paints.
DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders.
ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.
ELECTRONIC COMPONENTS.
ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.
EXPLOSIVES.
FOOD except:
a) food additives before incorporation into food; or
b) when used as a means of administering a poison for therapeutic use.
FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.
GLASS (including CRYSTAL WARE).
GLAZED POTTERY.
HUMAN BLOOD PRODUCTS including:
a) whole blood;
b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and
c) the following plasma-derived therapeutic proteins; and their equivalent recombinant alternatives:
i) albumin;
ii) anticoagulation complex;
iii) C1 esterase inhibitors;
iv) clotting factors;
v) fibrinogen;
vi) protein C;
vii) prothrombin complex concentrate (PCC) ; and
viii) thrombin.
IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.
INTRAOCULAR VISCOELASTIC PRODUCTS.
LUBRICANTS except soluble oils and solvent-deposited lubricating agents.
MATCHES.
MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.
MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, except:
a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;
b) medical devices which include anticoagulants;
c) artificial tears;
d) urinary catheters; or
e) intra-articular fluids.
MOTOR, HEATING or FURNACE FUELS except:
a) when the contrary intention appears in any Schedule;
b) when containing methanol;
c) toy or hobby fuels; or
d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.
NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.
PAPER except:
a) when prepared for pesticidal use; or
b) when containing a poison included in Schedule 8 or 9.
PHOTOGRAPHIC PAPER or FILM.
PIGMENTS when immobilised in a polymer.
PORCELAIN.
PRINTING INKS or INK ADDITIVES except:
a) when containing a pesticide; or
b) preparations containing more than 0.1 per cent of lead calculated on the non-volatile content of the ink or ink additive.
RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.
RADIOISOTOPES for therapeutic use.
SEEDS treated with seed protectants.
SINGLE-USE TUBES for the estimation of alcohol content of breath.
TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.
TIMBER or WALLBOARD.
VITREOUS ENAMELS.
WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.
(This Appendix should be read in conjunction with Appendix A.)
INTRODUCTION
Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.
Listing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.
Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:
- the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;
- the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or
- the public access was limited such that scheduling was inappropriate or unnecessary.
The list was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.
Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.
Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.
PART 1 – REASONS FOR ENTRY
a | Low Toxicity. |
b | Use pattern restricts hazard. |
c | Presentation/packaging restricts hazard. |
d | Industrial use only. |
PART 2 – AREAS OF USE
1. | Agriculture |
| 1.1 | Herbicide |
| 1.2 | Insecticide |
| | 1.2.1 | Insecticide for codling moth |
| | 1.2.2 | Termiticide |
| 1.3 | Fungicide |
| | 1.3.1 | On seed fungicide |
| 1.4 | Bird Repellent |
| 1.5 | Fertiliser |
| 1.6 | Plant Growth Regulator |
| 1.7 | Insect Pheromone |
| 1.8 | Mushroom Bactericide |
| 1.9 | Acaricide |
| 1.10 | Biological control agent |
| 1.11 | Adjuvant in agricultural products |
2 | Veterinary |
| 2.1 | For animal use |
| 2.2 | Treatment of mastitis in cows |
| 2.3 | Coccidiostat |
| 2.4 | Feed additive |
| 2.5 | Antiseptic |
| 2.6 | Scabicide |
| 2.7 | Anthelmintic |
| 2.8 | Vitamin/Mineral |
| 2.9 | Growth Promotant |
| 2.10 | Ectoparasiticide |
3 | Domestic |
| 3.1 | Aromatherapy |
| 3.2 | Food additive |
| 3.3 | Cosmetic |
| 3.4 | Human use |
| 3.5 | Miticide |
4. | Industrial |
| 4.1 | Water treatment |
| 4.2 | Biological control agent |
5. | Environmental |
| 5.1 | Mosquito control |
6. | Human therapeutic use |
| 6.1 | Diagnostic agent |
| 6.2 | Medical device |
| 6.3 | Antiseptic |
| 6.4 | Sunscreen |
| 6.5 | External use |
| 6.6 | Laxative |
| 6.7 | Antiseborrheic |
| 6.8 | Cytoprotective |
| 6.9 | Vitamin/Mineral |
| 6.10 | Eye Drops |
7. | General |
| 7.1 | Any use |
| 7.2 | Excipient |
| 7.3 | Synergist |
| 7.4 | Flux |
| 7.5 | Pesticide |
| 7.6 | Insect repellent |
| 7.7 | Solvent |
| 7.8 | Disinfectant |
| 7.9 | Preservative |
| 7.10 | Antioxidant |
| 7.11 | Resin activator/accelerant |
| 7.12 | Sweetener artificial |
| 7.13 | Food additive |
PART 3 – Substances considered not to require control by scheduling
SUBSTANCE | DATE OF ENTRY | REASON FOR LISTING | AREA OF USE |
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE | Feb 2005 | b | 1.7 |
AFIDOPYROPEN | Jun 2018 | b | 1.2 |
AGROBACTERIUM RADIOBACTER | Nov 1989 | b | 1 |
ALCOHOL, DEHYDRATED | Aug 2000 | b | 6 |
ALUM | May 1997 | a | 7.1 |
ALUMINIUM AMMONIUM SULFATE | May 1997 | a | 7.1 |
ALUMINIUM POTASSIUM SULFATE | May 1997 | a | 7.1 |
ALUMINIUM SILICATE | Nov 1974 | a | 7.1 |
ALUMINIUM tris (ETHYLPHOSPHONATE) | Aug 1986 | a | 1 |
AMETOCTRADIN | May 2012 | a | 1.3 |
AMMONIUM PHOSPHATE | Nov 1974 | a | 7.1 |
AMMONIUM THIOSULPHATE | Nov 1974 | a | 7.1 |
AMPROLIUM | Jun 1969 | a | 2.3 |
AMYL ACETATE | Nov 1974 | a | 7.1 |
α -AMYLASE derived from Aspergillus niger | Feb 2005 | a | 2.4 |
AMYL CINNAMALDEHYDE | Feb 2017 | a, b | 3.3 |
ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT | Jun 2004 | a | 2.1 |
ASPARTIC ACID | - | a | 6 |
ASULAM | May 1986 | a | 1 |
AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941) | Oct 2017 | a | 1.3 |
AZIMSULFURON | Jun 2003 | a | 1.1 |
BACILLUS AMYLOLIQUEFACIENS | Jun 2018 | a | 1.3 |
BACILLUS SPHAERICUS, STRAIN 2362 | Feb 2003 | a | 5.1 |
BACILLUS THURINGIENSIS | May 1992 | a | 5.1 |
(excluding endotoxin) | Jun 2003 | a | 2.10 |
BACILLUS TOYOI | Aug 1980 | a | 2.9 |
BACULOVIRUS CYDIA POMONELLA | Jun 2006 | a | 1.2 |
BENFLURALIN | - | a | 1.1 |
BENSULFURON-METHYL | Aug 1987 | a | 1 |
BENTONITE | Jun 2002 | a | 7.1 |
BENZYL BENZOATE | Aug 1989 | a | 1.2 |
BETAINE HYDROCHLORIDE | Nov 1974 | a | 7.1 |
BIFENAZATE | Oct 2002 | a | 1.9 |
BISMUTH SUBNITRATE | Nov 1999 | b,c | 2.1 |
BISTRIFLURON | Feb 2014 | a | 1.2.2 |
BIURET | Nov 1974 | a | 2.4 |
BLAD (banda de Lupinus albus doce) | Feb 2016 | a | 1.3 |
BOSCALID | June 2003 | a | 1.3 |
BOVINE SOMATOTROPHIN | May 1992 | a | 2 |
BROMACIL | Aug 1987 | a | 1 |
BROMOPROPYLATE | Nov 1994 | a | 1 |
BUPIRIMATE | Nov 1990 | a | 1 |
BUTAFENACIL | May 2000 | a | 1 |
BUTOXYPOLYPROPYLENE GLYCOL | Nov 1974 | a | 7.7 |
n-BUTYL BUTYRATE | - | a | 7.1 |
n-BUTYL LACTATE | - | a | 7.1 |
CARBETAMIDE | Aug 1991 | a | 1 |
CARBOXIN | Aug 1987 | a | 1 |
CARFENTRAZONE-ETHYL | Aug 1998 | a | 1 |
CELLULASE derived from Aspergillus niger | Feb 2005 | a | 2.4 |
CETYL ALCOHOL | Nov 1974 | a | 7.1 |
CHAMOMILE OIL | Feb 2000 | a | 3.1 |
CHINA CLAY | Sep 2008 | a | 1.2 |
CHLORANTRANILIPROLE | Sep 2008 | a | 1.2 |
CHLORFLUAZURON | Oct 2005 | a | 1.2.2 |
CHLORFLURENOL | Feb 1974 | a | 1.6 |
CHLORIDAZON | May 1988 | a | 1 |
CHLOROXYLENOLS | Feb 1975 | a | 7.8 |
CITRONELLA OIL | Feb 2000 | a | 7.1 |
CLARY SAGE OIL | Feb 2000 | a | 7.1 |
CLITORIA TERNATEA EXTRACT | Feb 2016 | a | 1.2 |
CLOPIDOL | Nov 1974 | d | 2.3 |
COBALT NAPHTHENATE | - | d | 7.1 |
CROSPOVIDONE | Aug 1996 | a | 2 |
CULICINOMYCES CLAVOSPORUS | Nov 1982 | a | 5.1 |
CYCLAMIC ACID | Nov 1971 | a | 7.1 |
CYCLANILIPROLE | Oct 2016 | a | 1.2 |
CYCLOHEXANE | Nov 1974 | a | 7.7 |
CYCLOHEXANOL ACETATE | - | a | 7.7 |
CYPRINID HERPESVIRUS-3 | Oct 2018 | a | 1.10 |
CYROMAZINE | Nov 1980 | a | 2 |
DICLAZURIL | Nov 2001 | a | 2.3 |
DIETHYL CARBONATE | - | a | 7.1 |
DIFLUFENICAN | Feb 1987 | a | 1 |
DIKEGULAC-SODIUM | Mar 1980 | a | 1.6 |
DIMETHYL ETHER | Nov 1988 | d | 4 |
DIMETICONE | - | a | 7.1 |
DIPHENYLAMINE | Feb 1988 | a | 1 |
DIPROPYLENE GLYCOL MONOMETHYL ETHER | Nov 1987 | a | 4 |
DIURON | Nov 1987 | a | 1 |
DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) | Feb 1970 | a | 7.1 |
2,2-DPA | Nov 1989 | a | 1 |
DROMETRIZOLE TRISILOXANE | Oct 2003 | a | 6.4 |
DUDDINGTONIA FLAGRANS, STRAIN IAH 1297 | Feb 2018 | a | 2.7 |
EPSIPRANTEL | Nov 1991 | a | 2 |
ETHAMETSULFURON-METHYL | Nov 2000 | a | 1.1 |
ETHOPABATE | Jun 1969 | d | 2.3 |
ETHYL ACETATE | Nov 1974 | a | 7.1 |
ETHYL ALCOHOL | Nov 1974 | a | 7.1 |
ETHYLBUTYLACETYL AMINOPROPRIONATE | Aug 2000 | a | 3.4 |
ETHYL BUTYRATE | - | a | 7.1 |
ETHYL LACTATE | - | a | 7.1 |
ETOFENPROX | Jun 2018 | a | 1.2 |
ETOXAZOLE | Oct 2003 | a | 1.2 |
EUBACTERIUM sp. strain DSM11798 | Sep 2013 | a | 2.4 |
FENFURAM | May 1977 | a | 1.3.1 |
FENHEXAMID | Feb 1999 | a | 1 |
FENOXYCARB | Feb 1988 | a | 1 |
FLORPYRAUXIFEN-BENZYL | Feb 2018 | a | 1, 1.1 |
FLUFENOXURON | Feb 1997 | a | 1 |
FLUMETSULAM | Feb 1992 | a | 1 |
FLUOMETURON | Aug 1989 | a | 1 |
FLUOPICOLIDE | Oct 2016 | a | 1.3 |
FLUTOLANIL | Nov 2001 | a | 1.3 |
FLUROXYPYR | May 1986 | a, c | 1 |
FORCHLORFENURON | Feb 2005 | a | 1.6 |
FULLERS EARTH | Nov 1974 | a | 7.1 |
FUNGAL PROTEASE derived from Aspergillus niger | Feb 2005 | a | 2.4 |
GERANIUM OIL | Feb 2000 | a | 7.1 |
GIBBERELLIC ACID | Nov 1974 | a | 1.6 |
α-GLUCANASE derived from Aspergillus niger | Feb 2005 | a | 2.4 |
HALAUXIFEN METHYL | Oct 2014 | a | 1, 1.1 |
HEXAFLURON | Nov 1988 | a | 1 |
HEXYL ACETATE | - | a | 7.7 |
HEXYL CINNAMALDEHYDE | Feb 2017 | a, b | 3.3 |
HEXYTHIAZOX | Feb 1988 | a | 1 |
HUMAN OSTEOGENIC PROTEIN-1 (OP-1) | Aug 2001 | b | 6.2 |
HYDROPRENE | Feb 1988 | a | 1 |
HYDROXYPROPYL CELLULOSE | Nov 1982 | a | 7.1 |
ICODEXTRIN | Nov 2000 | b | 6 |
INDOLE-3-ACETIC ACID | Feb 1985 | b | 1.6 |
ISOPRENE ALCOHOL | - | a | 7.1 |
IPRODIONE | Feb 1997 | a | 1 |
ISETHIONATE, as mixed ammonium and ethanolamine salts of 2-hydroxyethanesulfonic acid | Jun 2016 | a, b | 1.11 |
ISOFETAMID | Feb 2018 | a | 1.3 |
ISOSTEARYL ALCOHOL ETHOXYLATE | Nov 1999 | a | 5.1 |
KAOLIN | Nov 1974 | a | 7.1 |
KRESOXIM-METHYL | Aug 1999 | a | 1 |
KUNZEA OIL | Feb 2000 | a | 7.1 |
LAURIC ACID | Oct 2005 | a | 7.1 |
LAURYL ALCOHOL (1-DODECANOL) | Nov 1974 | a | 7.1 |
LAVANDIN OIL | Feb 2000 | a | 7.1 |
LAVENDER OIL | Feb 2000 | a | 7.1 |
LEAD METALLIC | - | a | 7.1 |
LEPIDOPTEROUS SEX PHEROMONES | Nov 1990 | a | 1 |
LIMONENE (DIPENTENE) | Jun 2002 | a | 7.1 |
LINOLEIC ACID | Oct 2005 | a | 7.1 |
LINSEED FATTY ACIDS | Aug 1990 | a | 2.1 |
LINURON | Feb 1990 | a | 1 |
LIQUORICE, DEGLYCYRRHISINISED | May 1999 | a | 7.1 |
MALEIC HYDRAZIDE | Nov 1992 | a | 1 |
MANGANESE DIOXIDE | May 1999 | b | 1 |
MEGASPHAERA ELSDENII strain 41125 | Sep 2013 | a | 2.4 |
MESOSULFURON-METHYL | Feb 2002 | a | 1.1 |
METARHIZIUM ANISOPLIAE | Feb 2000 | b | 4.2 |
METARHIZIUM ANISOPLIAE | Jun 2003 | a | 1.10 |
METHOPRENE | Aug 1987 | a | 1 |
METHOXYFENOZIDE | Nov 2000 | a | 1 |
METHYL ACETATE | - | a | 7.7 |
METHYL BENZOQUATE | Nov 1974 | d | 2.3 |
1-METHYLCYCLOPROPENE | Jun 2003 | a | 1.6 |
METHYL p-HYDROXYBENZOATE | Nov 1974 | a | 7.9 |
METSULFURONMETHYL | Nov 1985 | a | 1.1 |
MYRISTIC ACID | Oct 2005 | a | 7.1 |
NAPROPAMIDE | Aug 1987 | a | 1 |
NAPTHYL ACETAMIDE | Nov 1974 | a | 1.6 |
NEROLI OIL | Feb 2000 | a | 7.1 |
NICARBAZIN | Jun 1969 | d | 2.3 |
NISIN | Jun 2003 | a | 3.2 |
NORFLURAZON | Nov 1983 | a | 1.1 |
NOVALURON | Nov 2000 | a | 1 |
NUCLEAR POLYHEDROSIS VIRUS of Helicoverpa armigera occlusion bodies | Feb 2004 | a | 1.2 |
OCTYL ALCOHOLS | Nov 1974 | a | 7.1 |
OLEIC ACID | Oct 2005 | a | 7.1 |
ORANGE OIL, SWEET | Aug 2000 | a | 7.1 |
OXABETRINIL | Feb 1987 | a | 1 |
OXATHIAPIPROLIN | Jun 2016 | a | 1.3 |
OXYFLUORFEN | May 2001 | a | 1 |
PALMAROSA OIL | Feb 2000 | a | 7.1 |
PALMITIC ACID | Oct 2005 | a | 7.1 |
PATCHOULI OIL | Feb 2000 | a | 7.1 |
PECTINASE derived from Aspergillus niger | Feb 2005 | a | 2.4 |
PEGBOVIGRASTIM | Jun 2017 | a | 2.1 |
PENCYCURON | Aug 1994 | a | 1 |
PENTADECANOIC ACID | Oct 2005 | a | 7.1 |
PEPPERMINT OIL | Feb 2000 | a | 7.1 |
PHENMEDIPHAM | May 1989 | a | 1.1 |
d-PHENOTHRIN | Feb 1982 | a | 7.5, 1.2 |
PHYTASE | Feb 1996 | a | 2.4 |
PICLORAM | Aug 1987 | a | 1 |
PICOLINAFEN | May 2000 | a | 1 |
PIMELIC ACID | Oct 2005 | a | 7.1 |
PIPERONYL BUTOXIDE | Aug 1991 | a | 7.5 |
POLOXALENE | Nov 1974 | a | 7.1 |
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC) | Nov 1997 | a | 4.1 |
POLYHEDROSIS VIRUS of Helico zea occlusion bodies | Nov 1996 | a | 1 |
POLY (GNRF) OVALBUMIN | Feb 1990 | a | 2 |
POLYSORBATE 20 | May 2001 | a | 1 |
PORCINE SOMATOTROPHIN | Nov 1991 | c | 2 |
POTASSIUM SORBATE | Oct 2004 | a | 1.3 |
POTASSIUM BICARBONATE | Jun 2004 | a | 1 |
PROPYL ACETATES | - | a | 7.1 |
PROPYLENE GLYCOL | Nov 1974 | a | 7.1 |
2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER | Nov 1987 | a | 4 |
PROTHIOCONAZOLE | June 2005 | a | 1.3.1 |
PSEUDOMONAS FLUORESCENS | May 1985 | a | 1.8 |
PYDIFLUMETOFEN | Feb 2018 | a | 1.3 |
PYRIMETHANIL | Feb 1996 | a | 1 |
PYRIPROXYFEN | Aug 1994 | a | 1 |
QUASSIA | Nov 1974 | d | 6, 2.1 |
QUINOXYFEN | Nov 2001 | a | 1.3 |
ROSEMARY OIL | Feb 2000 | a | 7.1 |
SAGE OIL (Spanish) | Feb 2000 | a | 7.1 |
SANDALWOOD OIL | Feb 2000 | a | 7.1 |
SEAWEED & UNFRACTIONED SEAWEED EXTRACTS | Feb 1985 | d | 1.5 |
SILVER OXIDE | Jun 2018 | b | 7.14 |
SIMAZINE | Nov 1987 | a | 1.1 |
SODIUM BICARBONATE | Jun 2004 | a | 1 |
SODIUM PROPIONATE | Oct 2004 | a | 1.3 |
STERIC ACID | Oct 2005 | a | 7.1 |
STREPTOMYCES LYDICUS WYEC 108 | Oct 2016 | a | 1.3 |
SUCRALFATE | Aug 1982 | a | 6.8 |
SULESOMAB | Jun 2002 | b | 6.1 |
SULFOSULFURON | Feb 1998 | a | 1 |
SULPHATED POLYSACCHARIDES | - | a | 7.1 |
TANNIC ACID | Dec 1965 | a | 7.1 |
TANNIC ACID/BENZYL ALCOHOL PRODUCT | Nov 1993 | a | 7.1 |
TERBACIL | Aug 1987 | a | 1 |
THAUMATIN | Nov 1990 | a | 3.2 |
THIDIAZURON | Nov 1989 | a | 1 |
TRIASULFURON | Feb 1988 | a | 1 |
TRICHODERMA HARZIANUM | May 1996 | a | 1 |
(Z)-9-TRICOSENE | Aug 1991 | a | 1 |
TRIETHYLENE GLYCOL | Nov 1974 | a | 7.1 |
TRIFLOXYSULFURON | Feb 2002 | a | 1.1 |
TRIFLURALIN | Aug 1990 | a | 1 |
TRIFORINE | Aug 1987 | a | 1 |
ULOCLADIUM OUDEMANSII | Oct 2003 | a | 1.10 |
UREA | Nov 1974 | a | 7.1 |
13C-UREA | May 2001 | a | 6.1 |
VETIVER OIL | Feb 2000 | a | 7.1 |
VINYL ETHER | Nov 1987 | b | 6 |
VITAMIN K | Jul 1963 | a | 6.9, 2.8 |
XANTHOPHYLL (lutein) | Nov 1974 | a | 7.1 |
XYLANASE derived from Aspergillus niger | Feb 2005 | a | 2.4 |
YLANG YLANG OIL | Feb 2000 | a | 7.1 |
ZINC NAPHTHENATE | - | a | 1.3 |
This Appendix is intentionally blank
(The following controls apply to the substances listed only when included in Schedule 4 or Schedule 8.)
1. | Poisons available only from or on the prescription or order of an authorised medical practitioner. |
| CANNABIS for human use. |
| CLOMIFENE for human use. |
| CLOZAPINE for human use. |
| CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use. |
| CYCLOFENIL for human use. |
| DINOPROST for human use. |
| DINOPROSTONE for human use. |
| FOLLITROPIN ALFA (recombinant human follicle-stimulating hormone) for human use. |
| FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use. |
| FOLLITROPIN DELTA (recombinant human follicle-stimulating hormone) for human use. |
| LUTEINISING HORMONE for human use. |
| NABIXIMOLS. |
| SODIUM OXYBATE for human use. |
| TETRAHYDROCANNABINOLS for human use. |
| TERIPARATIDE for human use. |
| UROFOLLITROPIN (human follicle-stimulating hormone) for human use. |
2. | Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age: |
| (1) | ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and |
| (2) | if the drug is - |
| | (a) | acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or |
| | (b) | bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment. |
| ACITRETIN for human use. |
| BEXAROTENE for human use. |
| ETRETINATE for human use. |
| ISOTRETINOIN for human oral use. |
| THALIDOMIDE for human use. |
3. | Poisons available only from or on the prescription or order of a medical practitioner authorised or approved by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the Therapeutic Goods Act 1989. |
| DRONABINOL (delta-9-tetrahydrocannabinol). |
4. | Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age: |
| (a) | ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and |
| (b) | advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment. |
| LENALIDOMIDE. |
| POMALIDOMIDE. |
| RIOCIGUAT for human use. |
| TRETINOIN for human oral use. |
5. | Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription). |
| ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4. |
| ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4. |
| AOD-9604 (CAS No. 221231-10-3). |
| BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8. |
| CJC-1295 (CAS No. 863288-34-0). |
| DARBEPOETIN. |
| DEXTROPROPOXYPHENE. |
| EPHEDRINE. |
| EPOETINS. |
| ERYTHROPOIETIN. |
| ERYTHROPOIETINS except when separately specified in this Appendix. |
| FIBROBLAST GROWTH FACTORS. |
| FOLLISTATIN. |
| GLUTETHIMIDE. |
| GROWTH HORMONE RELEASING HORMONES (GHRHs) including those separately specified in Schedule 4. |
| GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately specified in Schedule 4. |
| GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6). |
| GROWTH HORMONE SECRETAGOGUES including those separately specified in Schedule 4. |
| HEXARELIN. |
| IBUTAMOREN |
| INSULIN-LIKE GROWTH FACTORS. |
| IPAMORELIN. |
| PERAMPANEL for human use. |
| PHENTERMINE. |
| PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)). |
| SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4. |
| SOMATROPIN (human growth hormone). |
| STENABOLIC (SR9009) and other synthetic REV-ERB agonists. |
| TB-500. |
| THYMOSIN BETA 4 (THYMOSIN β4). |
| TIANEPTINE |
6. | Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age: |
| (a) | ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and |
| (b) | advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment. |
| AMBRISENTAN for human use. |
| BOSENTAN for human use. |
| ENZALUTAMIDE for human use. |
| MACITENTAN for human use. |
| SITAXENTAN for human use. |
7. | Poisons available only from or on the prescription or order of a dermatologist. |
| ALEFACEPT for human use. |
(other than agricultural and veterinary chemicals including pesticides registered by the Australian Pesticides and Veterinary Medicines Authority and medicines for human use when compliant with the requirements of the Required Advisory Statements for Medicine Labels. Labelling is not required at concentrations below scheduled levels (see the Introduction to this Appendix.))
INTRODUCTION
Directions for First Aid Attention
Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this Appendix may be varied provided that the intent is not changed.
The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.
These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.
Modified First Aid Instruction on Primary Pack
Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:
a) each immediate container must be labelled with first aid instructions appropriate for its contents; and
b) the primary pack must be labelled with the statement:
FIRST AID: See inner packs.
Exempt Preparations
This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the Schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:
1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. calls must be logged and submitted for incorporation into the official collection of poisoning data.
PART 1 – STANDARD STATEMENTS
To be grouped together and prefaced with the words “FIRST AID” (see Part 2 Section 1.3(1)(p) of this Standard).
Basic
A | For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once). |
Z | First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
General
G1 | Urgent hospital treatment is likely to be needed. (Note - the words ‘at once’ to be added to instruction A). |
G2 | If swallowed, give activated charcoal if instructed. (Note - the words ‘at once’ to be added to instruction A). |
G3 | If swallowed, do NOT induce vomiting. |
G4 | Immediately give a glass of water. |
G5 | Avoid giving milk or oils. |
G6 | If sprayed in mouth, rinse mouth with water. |
Eyes
E1 | If in eyes wash out immediately with water. |
E2 | If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes. |
Respiratory system
R1 | If inhaled, remove from contaminated area. Apply artificial respiration if not breathing. |
R2 | If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area. |
Skin
S1 | If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. |
S2 | If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
S3 | If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
S4 | If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
S5 | If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766). |
Special Purpose
SP1 | If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed. |
PART 2 – FIRST AID INSTRUCTIONS
Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the Introduction to this Appendix).
POISON | STANDARD STATEMENTS |
ACETIC ACID | A,G3,E2,S1 |
ACETIC ANHYDRIDE | A,G3,E2,S1 |
ACETONE | A,G3 |
ACROLEIN | A,G1,G2,G3,E2,R2,S2 |
ALKALINE SALTS | A,G3,E2,S1 |
AMIDOPROPYL BETAINES | |
- in cosmetic wash-off preparations when included in Schedule 6
| E1 |
- in other preparations when included in Schedule 6
| E1, S1 |
AMINES for use as curing agents | A,G3,E1,S1 |
2-AMINO-6-CHLORO-4-NITROPHENOL | A, E1 |
4-AMINO-m-CRESOL | A, E1 |
2-AMINO-5-ETHYLPHENOL | A |
4-AMINO-2-HYDROXYTOLUENE | A, E1 |
4-AMINO-3-NITROPHENOL | A |
2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL | E1 |
m-AMINOPHENOL | A, S1 |
p-AMINOPHENOL | A, S1 |
4-AMINOPYRIDINE | A,G1,G2,E1,S1 |
AMMONIA | |
| A |
| A,G3,E1,R1,S1 |
AMMONIUM COCOYL ISETHIONATE | E1 |
AMMONIUM PERSULFATE | A,G3,E2 |
AMMONIUM THIOCYANATE | A |
ANHYDRIDES, organic acid, for use as curing agents for epoxy resins | A,G3,E1,S1 |
ANILINE | A,E2,R1,S1 |
ANISE OIL | A,G3 |
ANITMONY CHLORIDE | A,E2,S2 |
ANTIMONY COMPOUNDS, except antimony chloride | A |
AZADIRACHTA INDICA (neem) including its extracts and derivatives when included in Schedule 6. | A,E1 |
BARIUM SALTS, except barium sulfate | A |
BASIC RED 76 | A |
BASIL OIL | A,G3 |
BAY OIL | A,G3 |
BENZALKONIUM CHLORIDE | |
- when included in Schedule 5
| A,G3,E2 |
- when included in Schedule 6
| A,G3,E2,S1 |
BENZENE | A,G3,E1,R1,S1 |
1,2-BENZENEDIOL (Catechol) | A, E1, S1 |
BENZOYL PEROXIDE | |
| A,E2,S1 |
- above 10 per cent up to 20 per cent
| A,E1 |
| A |
BERGAMOT OIL | A,G3 |
BIFLUORIDES (including ammonium, potassium and sodium salts) | |
- when included in Schedule 5
| A |
- when included in Schedule 6 or 7
| A,G3,E2,S5 |
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE | E1, S1 |
BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER | A, E1 |
BORAX | A |
BORIC ACID | A |
BORON TRIFLUORIDE | |
- when included in Schedule 5
| A |
- when included in Schedule 6 or 7
| A,G3,E2,S5 |
BROMOFORM | A,G3,E2,R1,S2 |
BRUCINE | A,G1,G2,G3,R2 |
2-BUTOXYETHANOL and its acetates | A,E2,S1 |
n-BUTYL ALCOHOL | A, E1, S1 |
CADMIUM COMPOUNDS | A |
CAJUPUT OIL | A,G3 |
CAMPHOR | A,G1,G3,G5 |
CARBAMIDE PEROXIDE | |
- more than 9 per cent up to 60 per cent
| A,G3,E2,S1 |
| A,G1,G3,G4,E2,S1 |
CARBON DISULFIDE | A,G3,E2,R1,S2 |
CARBON TETRACHLORIDE | A,G3,E1,R1,S1 |
CASSIA OIL | A,G3 |
CARBON DISULFIDE | A,G3,E2,R1,S2 |
CARBON TETRACHLORIDE | A,G3,E1,R1,S1 |
CASSIA OIL | A,G3 |
CHLORINATING COMPOUNDS, except when separately specified, containing | |
- above 4 per cent and below 10 per cent of available chlorine
| A,G3,E1,S1 |
- 10 per cent or more of available chlorine
| A,G3,E2,S1 |
CHLORIDE (gas) | A,E1,R1 |
CHLOROACETAMIDE | A |
CHLOROCRESOL | A,G3,E2,S2 |
2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL | A, S1 |
CHLOROFORM | A,G3,E1,R1,S1 |
CHROMATES | A,G3,E2,S1 |
CHROMIUM TRIOXIDE | A,G3,E2,S1 |
CHRYSOIDINE BASE | A, S1,E1 |
CINEOLE | A,G1,G3 |
CINNAMON BARK OIL | A,G3 |
CINNAMON LEAF OIL | A,G3 |
CLIMBAZOLE | A |
CLOVE OIL | A,G1,G3,E2 |
COCOYL GLYCINATE | E1 |
COPPER SULFATE | A,G3,E2,S1 |
CREOSOTE | A,G3,E2,S1 |
CRESOLS | A,G3,E2,S3 |
CRESOLS in pressurised spray packs | A,G6,E1,S1 |
CYANIDES | A,G1,E1,R2 |
CYANOACRYLIC ACID ESTERS | A |
CYANURIC ACID | A |
CYCLOHEXANONE PEROXIDE | A,G3,E2,S1 |
CYCTEAMINE | E1 |
1-DEOXY-1-(METHYLAMINO)-d-GLUCITOL N-COCO ACYL DERIVATIVES | E1 |
2,4-DIAMINOPHENOXYETHANOL | A, E2, S1 |
o-DICHLOROBENZENE | A,G3,E1,S1 |
para-DICHLOROBENZENE (PDB) | A |
DICHLOROETHYL ETHER | A,G3,E1,R1,S1 |
DICHLOROISOCYANURATES | A,G3,E1,S1 |
DICHLOROMETHANE (methylene chloride) | A,G3,G5,E1,R1,S1 |
- in pressurised spray packs
| A,G6,S1 |
DICHROMATES | A,G1,G3,E2,S1 |
DIDECYLDIMETHYLAMMONIUM SALTS | A,G3 |
DIESEL (distillate) | A,G3 |
DIETHANOLAMINE | |
- when included in Schedule 5
| A,G3 |
- when included in Schedule 6
| A,G3,E2,S1 |
DIETHYLENE GLYCOL MONOBUTYL ETHER | A, E1, S1 |
5,6-DIHYDROXYINDOLINE | E1 |
DIMETHYLFORMAMIDE | |
| A |
| A,E1,R1,S1 |
4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL | A,E2 |
3,7-DIMETHYL-2,6-OCTADIEN-1-OL | A, E1, S1 |
DIMETHYL SULFOXIDE | A,G3,E1,S1 |
DINITROCRESOLS | A,G1,E1,S1 |
DINITROPHENOLS | A,G1,E1,S1 |
DIOXANE | A,G3,E1,R1,S1 |
DISPERSE YELLOW 3 | A, S1 |
DISTILLATE | A,G3 |
N-(N-DODECYL)-2-PYRROLIDONE | |
- when included in Schedule 5
| A,G3,E1 |
- when included in Schedule 6
| A,G3,E2,S1 |
EPOXY RESINS liquid | A,G3,E2,S1 |
Essential oils containing CAMPHOR as natural component unless otherwise specified. | A,G3 |
ETHER | A,G3,E1,R1 |
ETHYL BROMIDE | A,E2,S1,R1 |
ETHYLENE GLYCOL | A |
ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except when separately specified | A,G3,E2,S1 |
ETHYLENE OXIDE | A,E2,R1 |
ETHYLHEXANEDIOL | A, E2 |
2-ETHYLHEXANOIC ACID | A |
EUCALYPTUS OIL | A,G1,G3 |
EUGENOL | A,G1,G3,E2 |
FENNEL OIL | A, G3 |
FLUORIDES except when separately specified | |
- when included in Schedule 5
| A |
- when included in Schedule 6
| A,G1,G3,E2,S1 |
FORMALDEHYDE (see also paraformaldehyde) | A,G3,E2,R1,S1 |
FORMIC ACID | A,G3,E2,S1 |
FURFURAL | A,E1,S1 |
GLUTARAL | |
| A,G3,E1 |
| A,G3,E2,S1 |
GLYCOLIC ACID | A,G3,E2 |
GUANIDINE when included in Schedule 6 | A,G3,E2,S1 |
GLYCOLIC ACID | A,G3,E2 |
GUANIDINE when included in Schedule 6 | A,G3,E2,S1 |
HC VIOLET 1 | E1 |
HEXACHLOROPHENE when included in Schedule 6 | A |
HEXYLOXYETHANOL | A,G3,E2,S1 |
HYDRAZINE | A,G1,G3,E2,R1,S1 |
HYDROCARBONS, liquid | A,G3 |
HYDROCHLORIC ACID | A,G3,E2,S1 |
- when included in Schedule 5
| A,G3 |
HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid | |
- when included in Schedule 5
| A |
- when included in Schedule 6 or 7
| A,G3,E2,S5 |
HYDROGEN PEROXIDE | |
- more than 3 per cent up to 20 per cent
| A,G3,E2,S1 |
| A,G1,G3,G4,E2,S1 |
HYDROQUINONE | |
- when included in Schedule 2
| A |
- when included in Schedule 4 or 6
| A,G2,G3,E2,R2,S1 |
HYDROSILICOFLUORIC ACID | |
- when included in Schedule 5
| A |
- when included in Schedule 6 or 7
| A,G3,E2,S5 |
2-HYDROXYETHYL METHACRYLATE | A, E1, S1 |
HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE | E1, S1 |
IODINE (excluding salts, derivatives and iodophors) | |
- 2.5 per cent or more for human external use
| A,E2 |
- 2.5 per cent or more for other uses
| A,E2,S1 |
| A |
IODOPHORS | A |
ISOCYANATES, free organic | A,E2,S1 |
ISOEUGENOL | A, E1, S1 |
ISOPHORONE | A,G3,E2,S1 |
KEROSENE | A,G3 |
LAURETH CARBOXYLIC ACIDS | |
- leave-on or wash-off preparations above 5 per cent
| E1 |
- other preparations above 5 per cent
| E1,S1 |
LAURYL ISOQUINOLINIUM BROMIDE | A,E1 |
LEAD COMPOUNDS | |
| A |
| A,S1 |
LEMON OIL | A,G3 |
LEPTOSPERMUM SCOPARIUM OIL (manuka oil) | A,G1,G3 |
LIME OIL | A,G3 |
MAGNESIUM CHLORATE | A |
MALATHION at 20 per cent or less | A |
MARJORAM OIL | A,G3 |
MELALEUCA OIL | A,G1,G3 |
MERCAPTOACETIC ACID | A, E1 |
MERCURIC CHLORIDE | |
- for external therapeutic use
| A |
| A,G1,G3,E2,R2,S1 |
MERCURIC IODIDE | A,G1,G3,E2,R2,S1 |
MERCURIC NIRATE | A,G1,G3,E2,R2,S1 |
MERCURIC OXIDE | A,G1,G3 |
MERCURIC POTASSIUM IODIDE | A,G1,G3,E2,R2,S1 |
MERCURIC THIOCYANATE | A,G1,G3,E2,R2,S1 |
MERCUROCHROME | A |
MERCUROUS CHLORIDE | A |
MERCURY metallic | A |
MERCURY, organic compounds | A,S1 |
- in preparations for human external use
| A |
METALDEHYDE | A,E1,S1 |
METHANOL | |
| A,G3 |
| A |
METHYLATED SPIRIT(S) | A,G3 |
METHYLATED SPIRIT(S) when packed and labelled as a 'biofuel' suitable for use in 'spirit burners'. | A,G3 |
METHYL ETHYL KETONE | A,G3 |
METHYL ETHYL KETONE OXIME | A,E1,S1 |
METHYL ETHYL KETONE PEROXIDE | A,G3,E2,S1 |
METHYLEUGENOL | A |
METHYL ISOAMYL KETONE | A,G3 |
METHYL ISOBUTYL KETONE | A,G3 |
N-METHYL-2-PYRROLIDONE | |
- when included in Schedule 5
| A,G3,E1 |
- when included in Schedule 6
| A,G3,E2 |
2-METHYLRESORCINOL | A, E1 |
METHYL SALICYLATE LIQUID when included in Schedule 5 or 6 | A,G3,E1 |
MONOETHANOLAMINE | |
- when included in Schedule 5
| A,G3,E1 |
- when included in Schedule 6
| A,G3,E2,S1 |
1,5-NAPHTHALENEDIOL | A,E1,S1 |
2,7-NAPHTHALENEDIOL | A,E1,S1 |
NAPHTHALENE | A,G1,G3 |
1-NAPHTHOL | A,E1,S1 |
NITRIC ACID | A,G3,E2,S1 |
NITROBENZENE | A,G3,E1,S1 |
3-NITRO-p-HYDROXYETHYLAMINOPHENOL | E1 |
NITROPHENOL | A,G3,E2,S1 |
NITROPRUSSIDES | |
| A,G6,R1 |
| A,G3 |
NONOXINOL 9 | A,E2 |
NUTMEG OIL | A,G3 |
OCTHILINONE | A,G3,E2,S1 |
N-(N-OCTYL)-2-PYRROLIDONE | |
- when included in Schedule 5
| A,G3,E1 |
- when included in Schedule 6
| A,G3,E2 |
ORANGE OIL (bitter) | A,G3 |
OXALIC ACID | A,G3,E2,S1 |
PARAFORMALDEHYDE | A,G3,E2,R1,S1 |
PENNYROYAL OIL | A,G3 |
PERACETIC ACID | |
- when included in Schedule 5
| A,G3,E1,S1 |
- when included in Schedule 6
| A,G3,E2,S1 |
PETROL | A,G3,R1 |
2-PHENOXYETHANOL | A, E1 |
PHENOL when included in Schedule 6 | A, E1 |
PHENOLS | |
| A,G3,E2,S3 |
| A,G3,E2,S4 |
PHENOLS in pressurised spray packs | A,E1 |
PHENOXYMETHYL OXIRANE | A, E1 |
PHENYLENEDIAMINES including alkylated, arylated and nitro derivatives | |
| A,E1 |
- in preparations other than hair dyes.
| A,G1,G3,E1,S1 |
PHENYL METHYL KETONE as such, or in preparations of similar viscosity | A,G3,E1 |
N,N-BIS(PHENYLMETHYLENE)-BICYCLO -(2.2.1)HEPTANE-2,5-DIMETHANAMINE | A,E2,S1 |
N,N-BIS(PHENYLMETHYLENE)-BICYCLO- (2.2.1)HEPTANE-2,6-DIMETHANAMINE | A,E2,S1 |
o-PHENYLPHENOL | A,G3,E2,S1 |
- in pressurised spray packs
| A,G6,E2,S1 |
PHOSPHONIC ACID | A,G3,E2,S1 |
- neutralised to pH 6 (approx)
| A |
| A,E2,S1 |
PHOSPHORIC ACID | A,G3,E2,S1 |
PHOSPHORUS, yellow | A,G1,G3,E2,R2,S2 |
o-PHTHALALDEHYDE | |
- when included in Schedule 5
| A,E1 |
- when included in Schedule 6
| A,G3,E2,S1 |
PICRIC ACID | A,G1,G3,E2,R1,S1 |
POLIHEXANIDE | E1 |
POLYETHANOXY (15) TALLOW AMINE | A,E2,S1 |
POLY(OXY-1,2-ETHANEDIYL), Α - [2-[(2-HYDROXYETHYL)AMINO]-2- OXOETHYL]- Α -HYDROXY-,MONO-C13-15 -ALKYL ETHERS | A,E1 |
POTASSIUM BROMATE | A |
POTASSIUM CHLORATE | A |
POTASSIUM CYANATE | A,E1,S1 |
POTASSIUM HYDROXIDE | A,G3,E2,S1 |
POTASSIUM METABISULPHITE | A |
POTASSIUM NITRITE | |
- when included in Schedule 7
| A,G1,G3 |
- when included in Schedule 5 or 6
| A,G3 |
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT | |
- when included in Schedule 5
| A,G3,E1 |
- when included in Schedule 6
| A,G3,E2,S1 |
POTASSIUM PERSULFATE | A,G3,E2 |
POTASSIUM SULFIDE | A,G3,E2,S1 |
PROPIONIC ACID | A,G3,E1,S1 |
n-PROPYL ALCOHOL | A, E1 |
d-PULEGONE | A,G3 |
PYRITHIONE ZINC | A,E1 |
QUATERNARY AMMONIUM COMPOUNDS except when separately specified | |
| A,G3,E2 |
| A,E2 |
- in pressurised spray packs
| A,E2,G6 |
QUINOLINE | A, E1, S1 |
RESORCINOL | A, E2, S1 |
SAFROLE | A,G1,G3 |
SAGE OIL (Dalmatian) | A,G3 |
SASSAFRAS OIL | A,G1,G3 |
SELENIUM COMPOUNDS | A,G1,E1,S1 |
SILICOFLUORIDES | |
- when included in Schedule 5
| A |
- when included in Schedule 6
| A,G1,G3,E2,S1 |
SILVER SALTS | A,E2 |
SODIUM ALUMINATE | A,G3,E2,S1 |
SODIUM BROMATE | A,G1 |
SODIUM CHLORATE | A |
SODIUM DIACETATE | A,G3,E2,S1 |
SODIUM DICHLOROISOCYANURATE | A,G3,E1,S1 |
SODIUM DODECYLBENZENE SULFONATE | A,G3,E2,S1 |
SODIUM HYDROGEN SULFATE | A,G3,E1,S1 |
SODIUMHYDROSULFITE | A,G3,E2,S1 |
SODIUM HYDROXIDE | A,G3,E2,S1 |
SODIUM LAURETH-6 CABOXYLATE | A |
LAURYL SULFATE SALTS | |
- leave-on or wash-off preparations above 5 per cent
| E1 |
- other preparations above 5 per cent
| E1,S1 |
SODIUM METABISULPHITE | A, G3 |
SODIUM NITRITE | |
- when included in Schedule 7
| A,G1,G3 |
- when included in Schedule 5 or 6
| A,G3 |
SODIUM PERCARBONATE | |
- when included in Schedule 5
| A,G3,S1 |
- when included in Schedule 6
| A,G3,E2,S1 |
SODIUM PERSULFATE | A,G3,E2 |
SODIUM STANNATE | A,E1 |
SODIUM SULFIDE | A,G3,E2,S1 |
SODIUM TRICHLOROACETATE | A |
STRYCHNINE | A,G1,G2,G3,R2 |
STYRENE | A,G3,S1,E1 |
SULCOFURON | A |
SULFAMIC ACID | A,G3,E2,S1 |
SULFURIC ACID | A,G3,E2,S1 |
TERPENES, chlorinated | A,G3 |
TETRACHLOROETHANE | A,G3,E1,R1,S1 |
TETRACHLOROETHYLENE | A,G3,E2,R1,S1 |
THIOUREA | A |
THUJONE | A,G3 |
THYME OIL | A,G3 |
o-TOLIDINE | A |
TOLUENE | |
| A,G3,E1,R1,S1 |
| A,G3 |
- in pressurised spray packs
| A |
TOLUENEDIAMINES | |
| A,E1 |
| A,G1,G3,E1,S1 |
TRICHLOROACETIC ACID | A,G3,E2,S1 |
TRICHLOROACETIC ACID ALKALI SALTS | A |
1,1,1-TRICHLOROETHANE | A,G3,E1,R1,S1 |
TRICHLOROETHYLENE | A,G3,E1,R1,S1 |
TRICHLOROISOCYANURIC ACID | A,G3,E1,S1 |
TRIETHYL PHOSPHATE | A,E1 |
TRIFLUOROMETHANESULFONIC ACID | A,G3,E2 |
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE | A,E1,S1 |
TROLAMINE | A,G3,E1,S1 |
TURPENTINE (mineral) | A,G3 |
TURPENTINE OIL (vegetable) | A,G3,E2 |
VINYL ACETATE MONOMER | A, R1 |
WHITE SPIRIT | A,G3 |
XYLENE | |
| A,G3,E1,R1,S1 |
| A,G3 |
- in pressurised spray packs
| A,G6,E1,S1 |
XYLENOLS | |
- in pressurised spray packs
| A,E1 |
ZINC CHLORIDE | A,G3,E2,S1 |
| |
ZINC SULFATE | A,G3,E2,S1 |
(other than agricultural and veterinary chemicals including pesticides registered by the Australian Pesticides and Veterinary Medicines Authority and medicines for human use when compliant with the requirements of the Required Advisory Statements for Medicine Labels. (where more than one statement or direction is required, they may be combined to form simple sentences where appropriate.))
INTRODUCTION
Warning Statements and Safety Directions
It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.
Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.
The wording of warning statements and safety directions specified in this Appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:
1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. calls must be logged and submitted for incorporation into the official collection of poisoning data.
PART 1 – WARNING STATEMENTS
1. | Highly corrosive. |
2. | Corrosive. |
3. | Corrosive liquid. |
4. | Strongly alkaline. |
5. | Irritant. |
6. | May cause cancer. |
7. | WARNING – Causes birth defects. |
8. | WARNING – May be fatal to children. |
9. | Can be fatal to children if sucked or swallowed. |
10. | May produce severe burns. |
11. | WARNING – Vapour may be harmful. |
12. | Vapour is harmful to health on prolonged exposure. |
13. | May be fatal if inhaled, swallowed or absorbed through skin. |
14. | Dust will irritate and burn eyes, nose and skin. |
15. | Liquid will cause burns. |
16. | Forms dangerous gas near radiators or naked flames. |
17. | Contact with eyes even for short periods can cause blindness. |
18. | Product will irritate the eyes, nose, throat and skin. |
19. | WARNING – Skin contact may be dangerous. Take every precaution to avoid contact – wash off after spillage and after use. |
20. | May give off dangerous gas if mixed with other products. |
21. | WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye. |
22. | Highly reactive oxidising chlorine compound. |
23. | May cause fire or explosion. |
24. | For external washing only. Rinse skin thoroughly after use. |
25. | Do not use on broken skin. Wash hands thoroughly after use. |
26. | (Powder) (and) (concentrated solutions) are dangerous if swallowed. |
27. | Not for therapeutic use. |
28. | (Over) (Repeated) exposure may cause sensitisation. |
29. | If congestion persists, consult your doctor or pharmacist. |
30. | WARNING – Do not use on face or on anal or genital areas. |
31. | WARNING – Do not use on face or on anal or genital areas except on doctor’s advice. |
32. | This preparation should be part of an overall treatment plan regularly assessed with your doctor. |
33. | Do not take for periods longer than four weeks except on medical advice. |
34. | WARNING – This medication may be dangerous when used in large amounts or for a long time (period). |
35. | CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful. or CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful. |
36. | For use under medical supervision only. |
37. | Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever. |
38. | CAUTION – Do not use for children under 2 years unless a doctor has told you to. |
39. | This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol. |
40. | This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery. |
41. | Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice. |
42. | WARNING – Overuse may stain the skin or mouth. |
43. | Use of this product is not necessary in areas supplied with fluoridated water. |
44. | WARNING – May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time. |
45. | WARNING – If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice. |
46. | WARNING – Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance). |
47. | WARNING – This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed. |
48. | WARNING – This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed. |
49. | WARNING – Do not mix with other medication except on veterinarian’s advice. |
50. | Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning. |
51. | Irritant to skin, eyes, mucous membranes and upper respiratory tract. |
52. | Breathing vapour or spray mist is harmful and may cause an asthma-like reaction. |
53. | CAUTION – (Name of substance) should not be used by pregnant women. |
54. | Seek medical advice before first course of treatment. |
55. | Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light. |
56. | WARNING – Can cause elevated blood pressure and interact adversely with other medication. |
57. | Not to be applied to infants under 12 months of age unless on doctor’s advice. |
58. | Highly reactive oxidising bromine and chlorine compound. |
59. | May cause allergy. |
60. | Do not mix with detergents or other chemicals. |
61. | WARNING - Can react with other medicines. Ask your doctor or pharmacist before taking. |
62. | Do not use if pregnant. |
63. | See a doctor if you are pregnant or diabetic. |
64. | See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days. |
65. | If getting better, keep using for (Insert number of days as per approved Product Information ) days. |
66. | See a doctor if problem returns. |
67. | Do not use if pregnant or likely to become pregnant. |
68. | If symptoms persist beyond 5 days consult a doctor (or) (dentist). |
69. | If symptoms recur within two weeks of completing the course, consult a doctor. |
70. | Use only under medical supervision if you are taking other medicines. |
71. | Do not use during the last three months of pregnancy. |
72. | Do not use in the eyes. |
73. | Do not use for acne. |
74. | Do not use under waterproof bandages unless a doctor has told you to. |
75. | Do not use for more than 7 days unless a doctor has told you to. |
76. | Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment. |
77. | WARNING - May cause birth defects. |
78. | Attacks skin and eyes. |
79. | Will irritate eyes. |
80. | WARNING: Do not attempt to refill burner while it is in use or still warm; it could lead to serious burn injury |
81. | (Intentionally blank) |
82. | (Intentionally blank) |
83. | This paint is dangerous to health, even when dry. For industrial use only. Do not use on toys or furniture. Do not use on, in or around the home. |
84. | Breathing the vapour is dangerous. Provide adequate ventilation during application. Do not use in the presence of a naked flame. Do not smoke. |
85. | This paint contains lead and is dangerous to health, even when dry. For industrial use only. Do not use on toys or furniture. Do not use for painting any building or fixed structure. Do not use where contact with food or drinking water is possible. |
86. | This tinter contains lead. Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water. |
87. | (Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor. |
88. | This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye. |
89. | Application to skin may increase sensitivity to sunlight. |
90. | This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol. |
91. | CAUTION – Total iodine intake may exceed recommended level when taking this preparation. |
92. | WARNING – Contains iodine - do not take when pregnant except on physician’s advice. |
93. | Causes severe burns, which are not likely to be immediately painful or visible. |
94. | WARNING – Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children. |
95. | CAUTION – Do not use for children under 12 years unless a doctor has told you to. |
96. | CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor. |
97. | Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor. |
98. | Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor. |
99. | If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage. |
100. | Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist. |
101. | Don’t use [this product/name of the product]: If you have a stomach ulcer. In the last 3 months of pregnancy. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.] If you are allergic to (name of substance) or anti-inflammatory medicines. |
102. | Unless a doctor has told you to, don’t use [this product/name of the product]: For more than a few days at a time. With other medicines containing aspirin or other anti-inflammatory medicines. If you have asthma. In children under 12 years of age. In children 12-16 years of age with or recovering from chicken pox, influenza or fever. If you are pregnant. |
103. | See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.] |
104. | Unless a doctor has told you to, don’t use [this product/name of the product]: For more than a few days at a time. With other medicines containing (name of substance) or other anti-inflammatory medicines. If you have asthma. If you are pregnant. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.] |
105. | Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less. |
106. | Contains formaldehyde. |
107. | Not recommended for children under twelve years of age. |
108. | Breathing of solder fumes is harmful and may cause asthma or sensitisation. |
109. | See your healthcare provider if you consider that you may be at risk of a Sexually Transmitted Infection (STI). |
110. | See a doctor if you plan to become pregnant, or are breastfeeding or plan to breastfeed. |
PART 2 - SAFETY DIRECTIONS - GENERAL
To be grouped together and prefaced with the words “SAFETY DIRECTIONS” (see Part 2, Section 1.3(1)(n) to this Standard).
1. | Avoid contact with eyes. |
2. | Attacks eyes - protect eyes when using. |
3. | Wear eye protection when mixing or using. |
4. | Avoid contact with skin. |
5. | Wear protective gloves when mixing or using. |
6. | Wash hands after use. |
7. | Wash hands thoroughly after use. |
8. | Avoid breathing dust (or) vapour (or) spray mist. |
9. | Use only in well ventilated area. |
10. | Ensure adequate ventilation when using. |
11. | No smoking. |
12. | Do not allow product to come into contact with other chemicals, especially acids. |
13. | Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene. |
14. | Do not allow to get damp. |
15. | Store under cover in a dry, clean, cool, well ventilated place away from sunlight. |
16. | Store and transport in an upright container. |
17. | Do not mix with other chemicals. |
18. | Do not mix with different types of chlorinating chemicals. |
19. | Use clean containers for dispensing. |
20. | Mix with water only. |
21. | Do not add water to product - add product to water, but in case of fire drench with water. |
22. | In case of spillage flush with large quantities of water. |
23. | Keep away from heat, sparks and naked flames. |
24. | Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes. |
25. | Avoid contact with food. |
26. | Avoid contact with clothing. |
27. | Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed. |
28. | Do not mix with hot water. |
29. | Obtain a supply of calcium gluconate gel. |
30. | (Intentionally blank.) |
31. | Do not use on broken skin. |
32. | Do not use under occlusive dressing. |
33. | Mix strictly according to instructions. |
34. | May cause fire if it comes into contact with other chemicals, paper or other flammable materials. |
35. | Wash gloves thoroughly, immediately after use. |
36. | Protect cuticles with grease or oil. |
37. | Avoid breathing solder fumes. |
PART 3 - POISONS (other than agricultural and veterinary chemicals) TO BE LABELLED WITH WARNING STATEMENTS OR SAFETY DIRECTIONS
(Where more than one statement or direction is required, they may be combined to form simple sentences where appropriate.)
POISON | WARNING STATEMENTS | SAFETY DIRECTION |
ACETIC ACID in concentrations of 80 per cent 2 or more except when in Schedule 2. | 2 | 1,4,8 |
ACETIC ANHYDRIDE | 2 | 1,4,8 |
ACETONE in concentrations greater than 75 per cent. | | 1,4,8 |
ACITRETIN | | 7,62,76 |
ADAPALENE for topical use. | 62,77 | |
ALCLOMETASONE when included in Schedule 3. | 38,72,73,74,75 | |
ALKALINE SALTS | 4 | 1,4 |
AMBRISENTAN | 7,62,76 | |
AMINES used as curing agents for epoxy resins. | | 1,3,4,5,8 |
2-AMINO-6-CHLORO-4-NITROPHENOL | 28 | |
4-AMINO-m-CRESOL | 28 | |
2-AMINO-5-ETHYLPHENOL | 21 | |
4-AMINO-2-HYDROXYTOLUENE | 28 | |
4-AMINO-3-NITROPHENOL | 28 | |
2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL | 28 | |
m-AMINOPHENOL | 28 | 4, 8 |
p-AMINOPHENOL | 28 | |
AMMONIA/AMMONIUM HYDROXIDE in concentrations greater than 20 per cent ammonia except in smelling salts. | 4 | 1,4,8 |
AMMONIUM PERSULFATE | 5,21,25 | 1,5,23,33,34 |
ANHYDRIDES, organic acid, for use as curing agents for epoxy resins. | | 1,3,4,5,8 |
ANILINE | 13 | 1,4,8 |
ANTIHISTAMINES not separately specified in this Appendix except: | 39 or 40 | |
a) dermal, ocular, parenteral and paediatric preparations; | | |
b) oral preparations of astemizole, azelastine, desloratadine, fexofenadine, loratadine, terfenadine or cetirizine; | | |
c) nasal preparations of azelastine; or | | |
d) preparations for the treatment of animals | | |
AROMATIC EXTRACT OILS | | 1,3,4,5,6 |
ASPIRIN | | |
a) for inhibition of platelet aggregation. | 36 | |
b) in sustained release preparations containing 650 mg or more of aspirin. | 36 | |
c) in other preparations. | 101,102,103 | |
ASTEMIZOLE | 61 | |
ASTODRIMER SODIUM | 63,64,69,75,109,110 | |
AZADIRACHTA INDICA including its extracts and derivatives when included in Schedule 6 | 67 | |
AZOCYCLOTIN | 48 | |
BASIC RED 76 | | 5 |
BENOMYL | 46 | |
BENZENE | 12 | 1,4,9 |
1,2-BENZENEDIOL (Catechol) | 51,59 | 1,4,8 |
BENZOYL PEROXIDE when included in Schedule 2. | 55 | |
BENZOYL PEROXIDE when included in Schedule 5. | | 1,4,8 |
BERGAMOT OIL | 89 | |
BERYLLIUM | | 1,4,8 |
BEXAROTENE | | |
a) for human use. | 7,62,76 | |
b) for topical use. | 62,77 | |
BIFLUORIDES (including ammonium, potassium and sodium salts) | | |
a) when included in Schedule 5. | 1,4 | |
b) when included in Schedule 6 or 7. | 1,17,93 | 1,3,4,5,8,29,35 |
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE | 28, 79 | 1 |
BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER | | 1 |
BITHIONOL for the treatment of animals. | | 1,4,8 |
BORON TRIFLUORIDE (including mixtures that generate boron trifluoride) | | |
a) when included in Schedule 5. | 2 | 1,4 |
b) when included in Schedule 6 or 7. | 1,17,93 | 1,3,4,5,8,29,35 |
BOSENTAN | 7,62,76 | |
BROMOFORM | 1,4,8 | |
2-BUTOXY-2’-THIOCYANODIETHYL ETHER | | 1,4,8 |
2-BUTOXYETHANOL and its acetates | | 1,4,8 |
n-BUTYL ALCOHOL | 5 | 2, 4, 8 |
CAMPHOR | | |
a) in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents. | 9 | |
b) in other forms. | 9 | 1 |
CARBAMIDE PEROXIDE | | |
a) more than 9 per cent up to 30 per cent. | 5 | 1 |
b) more than 30 per cent up to 60 per cent. | 5 | 2 |
c) more than 60 per cent. | 2 | 2,4 |
CARBON DISULFIDE | 12 | 1,4,8,9,23 |
CARBON TETRACHLORIDE | 12 | 1,4,8,9 |
CASSIA OIL | | 4 |
CHLORINATING COMPOUNDS | | |
a) in household cleaning or bleaching preparations. | 20 | |
b) in preparations containing less than 10 per cent of available chlorine. | 11 | 1,4,10 |
c) in liquid preparations containing 10 per cent or more of available chlorine. | 3,18 | 1,4,6,8,10, 15,16, 17,18, 19,20,22,26 |
d) in dry preparations containing 10 per cent or more of available chlorine. | 10,18,22,23 | 1,4,8,12,13, 14,15,16,17, 18, 19,20,21, 22,26 |
e) in dry preparations containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail. | 10,18,22 | 1,4,8,12,13, 14,15,16,17, 18,19,20,21, 22,26 |
f) in compressed block or tablets containing 10 per cent or more of available chlorine except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid. | 10,22,23 | 12,13,14,15, 17,18,19,21 |
g) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid. | 10,22 | 12,13,14,15, 17,18,19,21 |
CHLOROACETAMIDE | 28 | 4 |
2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL | 28 | 4 |
CHLOROFORM when included in Schedule 6 | | 1,4,8 |
alpha-CHLOROHYDRIN | 13,51 | 1,4,8,9 |
CHROMATES (including dichromates) of alkali metals or ammonia | | 1,4,8 |
CHROMIUM TRIOXIDE | 2,14,15,23 | 1,4,8,13 |
CIMETIDINE when included in Schedule 3 | 70,96 | |
CINNAMON BARK OIL | | 4 |
CLOBETASONE when included in Schedule 3. | 72,73,74,75,95 | |
CLOTRIMAZOLE in vaginal preparations when included in Schedule 3. | 54,63,64,66 | |
CLOVE OIL | | 1 |
CYANIDES when included in Schedule 7. | 13 | 4,8 |
CYANURIC ACID | | 1,4,8 |
CYCLOHEXANONE PEROXIDE | | 1,4,8 |
CYCTEAMINE | | 1 |
1-DEOXY-1-(METHYLAMINO)-d-GLUCITOL N-COCO ACYL DERIVATIVES | 79 | 1 |
4,4-DIAMINODIPHENYLMETHANE (methylene dianiline) | | 1,4,8 |
2,4-DIAMINOPHENOXYETHANOL | 28, 79 | 1, 4 |
o-DICHLOROBENZENE | | 1,4,8 |
para-DICHLOROBENZENE | | 1,4 |
DICHLOROETHYLENE | | 1,4,8 |
DICHLOEOETHYL ETHER | | 1,4,8 |
DICHLOROISOCYANURATES | | |
a) in household cleaning or bleaching preparations. | 20 | |
b) in preparations containing less than 10 per cent of available chlorine. | 11 | 1,4,10 |
c) in liquid preparations containing 10 per cent or more of available chlorine. | 3,18 | 1,4,6,8,10, 15,16,17,18, 19,20,22,26 |
d) in dry preparations containing 10 per cent or more of available chlorine. | 10,18,22,23 | 1,4,8,12,13,14, 15,16,17,18,19, 20,21,22,26 |
e) in dry preparations containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail. | 10,18,22 | 1,4,8,12,13,14, 15,16,17,18,19, 20,21,22,26 |
f) in anti-bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate. | 60 | |
g) in other compressed blocks or tablets containing 10 per cent or more of available chlorine except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only. | 10,22,23 | 12,13,14,15, 17,18,19,21 |
h) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail except in preparations containing 21 g less of sodium dichloroisocyanurate for use in toilet cisterns only. | 10,22 | 12,13,14,15,17, 18,19,21 |
i) in other compressed blocks or tablets containing 10 per cent or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only: | | |
i) during storage | 10,22,23 | 12,13,14,15,17, 18,21 |
ii) during use | 5 | 1,4,7,12 |
j) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only. | | |
i) during storage | 10,22 | 12,13,14,15,17, 18,21 |
ii) during use | 5 | 1,4,7,12 |
DICHLOROMETHANE (methylene chloride) | | |
a) in paint or lacquer removers. | 12,16 | 1,4,8,11 |
b) other than in paint or lacquer removers | | 1,4,8,25 |
DICLOFENAC | 101,104 | |
DIENESTROL | 67 | |
DIETHANOLAMINE when included in Schedule 5. | 5 | 1,4 |
DIETHANOLAMINE when included in Schedule 6. | 2,11,18 | 1,4,8 |
DIETHYLTOLUAMIDE for human use. | 44 | |
DIETHYLENE GLYCOL MONOBUTYL ETHER | 5 | 1, 4, 8, 9 |
5,6-DIHYDROXYINDOLINE | 21,28 | |
2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE | 28 | |
DIMETHYLFORMAMIDE | | 1,4,8 |
4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL | 5,28 | 1,2 |
3,7-DIMETHYL-2,6-OCTADIEN-1-OL | 5 | 1, 4 |
DIMETHYL SULFATE | 2 | 1,4,8 |
DIMETHYL SULFOXIDE | | |
a) when not packed and labelled for therapeutic use. | 27 | 1,4,5,8 |
b) when packed and labelled for the treatment of animals. | 49 | 1,4,5,8 |
DINITROCRESOLS (and their homologues) except when for therapeutic use. | | 1,4,8 |
DINITROPHENOLS (and their homologues) except when for therapeutic use. | | 1,4,8 |
DINOCAP | 47 | |
DIOXANE | | 1,4,8 |
DIPHENOXYLATE when included in Schedule 3. | 39 or 40,41 | |
DISPERSE YELLOW 3 | 28 | 4 |
ECONAZOLE in vaginal preparations when included in Schedule 3. | 54,63,64,66 | |
ENZALUTAMIDE. | 7, 67,87 | |
EPHEDRINE in nasal preparations for topical use. | 29 | |
EPICHLOROHYDRIN | 2 | 1,4,8 |
EPOXY RESINS, liquid. | | 1,3,4,5,8 |
ETHER when included in Schedule 5 or 6. | | 1,4,8 |
2-ETHOXYETHANOL | 77 | 1,4,8 |
ETHOXYETHYLMERCURIC CHLORIDE | | 1,4 |
ETHYL BROMIDE | | 1,4,8 |
ETHYLENE CHLOROHYDRIN | | 1,4,8 |
ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates except when separately specified. | | 1,4,8 |
ETHYLENE OXIDE | | 1,4,8 |
ETHYLHEXANEDIOL | 79 | 1 |
2-ETHYLHEXANOIC ACID | 53 | |
ETHYLMERCURIC CHLORIDE | | 1,4 |
ETHYL METHACRYLATE | 28 | 4,9,23 |
ETRETINATE | 7,62,76 | |
EUGENOL | | 1 |
FAMOTIDINE when included in Schedule 2. | 96 | |
FENTEROL in metered aerosols. | 32 | |
FLUCONAZOLE in oral preparations when included in Schedule 3. | 64 | |
FLUORIDES (including silicofluorides) when included in Schedule 5 or 6 except when separately specified. | | 1,4 |
FORMALDEHYDE | | |
a) in nail hardener cosmetics. | 106 | 1,4,8,36 |
b) in other preparations. | 106 | 1,4,8 |
FORMIC ACID | | 1,4,8 |
FURFURAL | 5 | 1,4 |
Glazing preparations containing LEAD COMPOUNDS. | 50 | |
GLUTARAL except when in Schedule 2 | | |
a) 25 per cent or less. | 5,59 | 1,4,5 |
b) more than 25 per cent. | 3,59 | 1,4,5,8 |
GLYCOLIC ACID | 79 | 1,5,6,31 |
HC VIOLET 1 | 28 | |
HEXACHLOROPHENE in preparations for skin cleansing purposes containing 3 per cent or less of hexachlorophene. | 24 | |
HEXYLOXYETHANOL | 2 | 1,4,8 |
HYDRAZINE | | 1,4,8 |
HYDROCLORIC ACID | | |
a) 30 per cent or less of HCl. | | 1,4 |
b) more than 30 per cent of HCl. | | 1,4,8 |
HYDROCORTISONE | | |
a) for dermal use when included in Schedule 2 or 3. | 38,72,73,74,75 | |
b) for topical rectal use when included in Schedule 2 or 3. | 38,75 | |
HYDROCYANIC ACID when included in Schedule 7. | 13 | 4,8 |
HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid) | | |
a) when included in Schedule 5. | 2 | 1,4 |
b) when included in Schedule 6 or 7. | 1,17,93 | 1,3,4,5,8,29,35 |
HYDROGEN PEROXIDE | | |
a) more than 3 per cent up to 10 per cent. | 5 | 1 |
b) more than 10 per cent up to 20 per cent. | 5 | 2 |
c) more than 20 per cent. | 2 | 2,4 |
HYDROQUINONE | | |
a) when in Schedule 2. | 45 | |
b) except when in Schedule 2 or 4. | | 1,4 |
HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid) | | |
a) when included in Schedule 5. | 2 | 1,4 |
b) when included in Schedule 6 or 7. | 1,17,93 | 1,3,4,5,8,29,35 |
2-HYDROXYETHYL METHACRYLATE | 28 | 4 |
HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE | 28 | |
IBUPROFEN | 101,104 | |
IODINE | | |
a) more than 20 per cent. | | 1,4,8 |
b) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose. | 91,92 | |
IPRATROPIUM BROMIDE in metered aerosols. | 32 | |
ISOCYANATES (free organic) | | |
a) when in paint. | 28,52 | 1,5,8,10,27 |
b) other than in paint. | 28,52 | 1,4,8 |
ISOEUGENOL | 19, 28, 79 | 1, 4 |
ISOPRENALINE in metered aerosols | 32 | |
ISOTRETINOIN | | |
a) for human oral use. | 7,62,76 | |
b) for topical use. | 62,77 | |
LEAD COMPOUNDS | | |
a) in hair cosmetics. | 25 | |
b) when in Schedule 6. | | 1,4,8 |
LEFLUNOMIDE | 7,62,87 | |
LEMON OIL | 89 | |
LENALIDOMIDE | 7,62,76 | |
LEVOCABASTINE | | |
a) in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine. | 62 | |
b) in other preparations. | 62 and either 39 or 40 | |
LIME OIL | 89 | |
LOPERAMIDE when in Schedule 2. | 41 | |
MAGNESIUM CHLORATE | | 1,4 |
MEFENAMIC ACID | 101,104 | |
MERCAPTOACETIC ACID | 5, 28 | 1, 31 |
MERCURIC THIOCYANATE | | 1,4 |
METACRESOLSULPHONIC ACID and formaldehyde condensation product for the treatment of animals. | | 1,4 |
METHANOL except in methylated spirit. | | 1,4,8 |
METHOXAMINE in nasal preparations for topical use. | 29 | |
2-METHOXYETHANOL | 77 | 1,4,8 |
METHYLATED SPIRIT(S) when packed and labelled as a 'biofuel' suitable for use in 'spirit burners'. | 80 | |
p-METHYLAMINOPHENOL | 28 | |
METHYL CHLORIDE | | 1,4,8 |
METHYL ETHYL KETONE | 5 | 1,4,8 |
METHYL ETHYL KETONE OXIME | 5,28 | 1,4 |
METHYL ETHYL KETONE PEROXIDE | 2 | 2,3,4,6 |
METHYL ISOAMYL KETONE | | 1,4,8 |
METHYL ISOBUTYL KETONE | | 1,4,8 |
METHYL ISOTHIOCYANATE | 5,12 | 1,4,8 |
METHYL METHACRYLATE | 28 | 4,9,23 |
METHYLCHLOROISOTHIAZOLINONE | 28 | |
METHYLDIBROMO GLUTARONITRILE | 28 | 1,4,7 |
METHYLENE BISTHIOCYANATE | | 1,4 |
METHYLEUGENOL | | 1,6 |
METHYLISOTHIAZOLINONE | 28 | |
METHYLNORBORNYLPYRIDINE | 59 | |
2-METHYLRESORCINOL | | 1 |
1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3-N,N-DIETHYLAMINOBENZENE | | 1,4,8 |
MICONAZOLE in vaginal preparations when included in Schedule 3. | 54,63,64,66 | |
MISOPROSTOL | 53 | |
MONOETHANOLAMINE when included in Schedule 5. | 5 | 1,4 |
MONOETHANOLAMINE when included in Schedule 6. | 2,11,18 | 1,4,8 |
NAPHAZOLINE in nasal preparations for topical use. | 29 | |
NAPHTHALENE | | |
a) in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents. | 9,105 | |
b) in other forms. | 9,105 | 1 |
1,5-NAPHTHALENEDIOL | 28 | 1 |
2,7-NAPHTHALENEDIOL | 28 | 1,3 |
1-NAPHTHOL | 28 | 1 |
NAPROXEN | 101,104 | |
NICOTINE except when in tobacco | | 1,4 |
NITRIC ACID | | |
a) 75 per cent or less HNO3. | 2 | 1,4 |
b) more than 75 per cent HNO3. | 2 | 1,4,8 |
NITROBENZENE | | 1,4,8 |
3-NITRO-p-HYDROXYETHYLAMINOPHENOL | 28 | |
NITROPHENOLS | | 1,4 |
NITROPRUSSIDES in aerosols. | 84 | 8 |
NIZATIDINE when included in Schedule 2. | 96 | |
NORADRENALINE in metered aerosols. | 32 | |
NYSTATIN in vaginal preparations when included in Schedule 3. | 54,63,64,65,66 | |
ORANGE OIL (bitter) | 89 | |
ORCIPRENALINE in metered aerosols. | 32 | |
OXALATES, metallic | | 4,8 |
OXALIC ACID | 2 | 4,8 |
OXYMETAZOLINE in nasal preparations for topical use. | 29 | |
OXYQUINOLINE (including salts and derivatives) when prepared for internal use. | 33 | |
PAINT | | |
a) First Group paints. | 83 | |
b) Second Group paints. | 84 | |
PARACETAMOL | 97 and/or 98,99,100 | |
PENTACHLOROPHENOL | | 1,4,8 |
PERACETIC ACID | 2 | 1,4,8 |
PERMANGANATES | 2 | 24 |
2-PHENOXYETHANOL | 5 | 1 |
PHENOL and any other homologue of phenol. | | 1,4 |
PHENOL when included in Schedule 6 | 3, 51 | 2, 4, 8 |
PHENOLS | | 5 |
PHENOXYMETHYL OXIRANE | 12, 28, 51 | 1, 3, 4, 5, 7, 8, 9 |
PHENYLENEDIAMINES including both alkylated, arylated and nitro derivative | | |
a) in hair dyes. | 21 | |
b) in preparations other than hair dyes. | 28 | 1,4,8 |
PHENYLEPHRINE in nasal preparations for topical use. | 29 | |
POMALIDOMIDE. | 7, 62, 76 | |
N,N-BIS(PHENYLMETHYLENE)-BICYCLO- (2.2.1)HEPTANE-2,5-DIMETHANAMINE | 5,28 | 1,4,5,10 |
o-PHENYLPHENOL except when in antiseptics. | | 1,4 |
PHENYLPROPANOLAMINE | 56 | |
PHENYTOIN in pastes for the treatment of horses. | 9 | |
PHOSPHONIC ACID | | 1,4 |
PHOSPHORUS (yellow) | 2 | 1,4 |
o-PHTHALADEHYDE | | |
a) when included in Schedule 5. | 51,52,59 | 1,4,5,8,10 |
b) when included in Schedule 6. | 51,52,59 | 2,4,5,8,10 |
PICRIC ACID (more than 20 per cent). | | 1,4 |
PODOPHYLLIN | | |
a) in preparations specifically for use on anal or genital area. | 36 | |
b) in other liquid preparations when included in Schedule 2 or Schedule 3. | 31 | |
c) in other solid or semi-solid preparations when included in Schedule 2. | 30 | |
PODOPHYLLOTOXIN | | |
a) in preparations specifically for use on anal or genital area. | 36 | |
b) in other liquid preparations when included in Schedule 2 or Schedule 3. | 31 | |
c) in other solid or semi-solid preparations when included in Schedule 2. | 30 | |
POLIHEXANIDE | | 1,4,8 |
POLYETHANOXY (15) TALLOW AMINE | | 1,4 |
POLY(OXY-1,2-ETHANEDIYL), Α -[2-[(2-HYDROXYETHYL)AMINO] -2-OXOETHYL]- Α -HYDROXY-,MONO-C13-15 -ALKYL ETHERS | 5,88 | 1,5 |
POTASSIUM HYDROXIDE | | |
a) in preparations containing 0.5 per cent or less of potassium hydroxide. | 5 | 1,4,6 |
b) in solid preparations containing more than 0.5 per cent of potassium hydroxide. | 2,10,78 | 3,5,28 |
c) in liquid preparations containing more than 0.5 per cent of potassium hydroxide. | 2,10,78 | 3,5 |
POTASSIUM PERSULFATE | 5,21,25 | 1,5,23,33,34 |
POTASSIUM SULFIDE | 2 | 1,4 |
PROPIONIC ACID when in Schedule 6. | 2 | 1,4 |
n-PROPYL ALCOHOL | 5 | 1, 9 |
QUININE | 28 | |
QUINOLINE | 79 | 1, 4 |
RANITIDINE when included in Schedule 2. | 96 | |
RESORCINOL | 19,28,79 | 1,3,4 |
ROSIN | 108 | 37 |
SAFROLE | | |
a) in preparations for therapeutic use. | | 1 |
b) other than for therapeutic use. | | 1,4 |
SALBUTAMOL in metered aerosols or in dry powder formulations. | 32 | |
SALICYLAMIDE | 34 or 35 | |
SASSAFRAS OIL | | |
a) in preparations for therapeutic use. | | 1 |
b) other than for therapeutic use. | | 1,4 |
SELENIUM COMPOUNDS except when for therapeutic use (human or animal). | | 1,4,8 |
SLIVER in smoking deterrents. | 42 | |
SITAXENTAN | 7,62,76 | |
SODIUM ALUMINATE | 2 | 1,4 |
SODIUM CHLORATE | | 1,4 |
SODIUM DODECYLBENZENE SULFONATE | 79 | 1 |
SODIUM FLUORIDE in preparations for human ingestion when in Schedule 2. | 43 | |
SODIUM HYDROGEN SULFATE | | 1,4,8 |
SODIUM HYDROSULFITE (more than 50 per cent). | 5,26 | 1,4,8 |
SODIUM HYDROXIDE | | |
a) in preparations containing 0.5 per cent or less of sodium hydroxide. | 5 | 1,4,6 |
b) in solid preparations containing more than 0.5 per cent of sodium hydroxide. | 2,10,78 | 3,5,28 |
c) in liquid preparations containing more than 0.5 per cent of sodium hydroxide. | 2,10,78 | 3,5 |
SODIUM LAURETH-6 CARBOXYLATE | 79 | 1 |
SODIUM METABISULPHITE (more than 50 per cent) | 5,26 | 1,4 |
SODIUM NITRITE in pickling or curing salts | 94 | |
SODIUM PERSULFATE | 5,21,25 | 1,5,23,33,34 |
SODIUM SULFIDE | 2 | 1,4 |
STYRENE | | 1,4,8 |
SULFAMIC ACID | 2 | 1,4 |
SULFURIC ACID | 2 | 1,4 |
SYMPHYTUM SPP. (Comfrey) when included in Schedule 5. | | 31,32 |
TAZAROTENE for topical use. | 77,62 | |
TERBUTALINE in metered aerosols or in dry powder formulations. | 32 | |
TERFENADINE | | 61 |
TERIFLUNOMIDE. | 7,62,87 | |
TERPENES, chlorinated | | 1,4,8 |
TETRACHLOROETHANE | 12 | 8 |
TETRACHLOROETHYLENE when in Schedule 5 or 6. | 12,16 | 1,4,8,11 |
TETRYZOLINE in nasal preparations for topical use. | 29 | |
THALIDOMIDE | 7,62,76 | |
THIOUREA | | 1,4 |
TOLUENE | | 1,4,8 |
TOLUENEDIAMINES | | |
a) in hair dyes. | 21 | |
b) in preparations other than hair dyes. | | 1,4,8 |
TRAMAZOLINE in nasal preparations for topical use. | 29 | |
TRETINOIN | | |
a) for human oral use. | 7,62,76 | |
b) for topical use. | 62,77 | |
TRIAMCINOLONE when in topical preparations for the treatment of mouth ulcers. | 64 or 68 | |
TRICHLOROACETIC ACID except when for therapeutic use. | 2 | 1,4 |
1,1,1-TRICHLOROETHANE | | 8,9 |
TRICHLOROETHYLENE except when for therapeutic use. | 12 | 1,4,5,8,9 |
TRICHLOROPHENOL | | 1,4,8 |
TRIETHYL PHOSPHATE | | 1,4,8 |
TRIFLUOROMETHANESULFONIC ACID | | |
a) more than 10 per cent. | 1,17 | 1,4,8 |
b) 10 per cent or less. | | 1,4,8 |
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE | | 1,4,6 |
3,6,9-TRIOXAUNDECANEDIOIC ACID | 5 | 1 |
TROLAMINE | 5 | 1,4 |
TYMAZOLINE in nasal preparations for topical use. | 29 | |
VINCLOZOLIN | 46 | |
VINYL ACETATE MONOMER | 11 | 8, 9 |
XYLENE | | 1,4,8 |
XYLOMETAZOLINE in nasal preparations for topical use. | 29 | |
ZINC CHLORIDE | | 1,4 |
ZINC LACTATE | 107 | |
ZINC SULFATE when in Schedule 6. | | 1,4 |
The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.
Column 1 Poison | Column 2 Concentration (quantity per litre or kilogram) |
ACETYLCHOLINE | 1 mg |
ALDOSTERONE | 10 micrograms |
ANTIMONY COMPOUNDS | 1 mg |
APOMORPHINE | 1 mg |
ARSENIC | 1 mg |
ATROPA BELLADONNA (belladonna) | 300 micrograms |
ATROPINE | 300 micrograms |
CANTHARIDIN | 10 micrograms |
CHLORINE | 5 mg |
CROTON TIGLIUM (croton oil) | 1 mg |
DIOXANE | 100 mg |
EPIDERMAL GROWTH FACTOR | 2 mg |
ERYSIMUM spp. | 1 mg |
ESTRADIOL | 10 micrograms |
ESTRONE | 100 micrograms |
FOLLICLE-STIMULATING HORMONE | 100 micrograms |
GELSEMIUM SEMPERVIRENS | 1 mg |
GLUCAGON | 100 micrograms |
GLYCERYL TRINITRATE | 100 micrograms |
GROWTH HORMONE | 10 micrograms |
HALOPERIDOL | 1 mg |
HYDROCYANIC ACID | 1 microgram |
HYOSCINE | 300 micrograms |
HYOSCYAMINE | 300 micrograms |
HYOSCYAMUS NIGER | 300 micrograms |
HYPOTHALAMIC RELEASING FACTORS | 10 micrograms |
INDOMETACIN | 1 mg |
MERCURY | 1 mg |
METHYLMERCURY | 300 micrograms |
NAPHTHALENE | 1 mg |
NERIUM OLEANDER | 1 mg |
OXYTOCIN | 1 microgram |
PHOSPHORUS | 1 mg |
PODOPHYLLUM RESIN (podophyllin) | 1 mg |
PROGESTERONE | 1 mg |
PROPRANOLOL | 1 mg |
SELENIUM | 100 micrograms |
STROPHANTHUS spp. | 1 mg |
STRYCHNINE | 1 mg |
TESTOSTERONE | 1 mg |
THYROXINE | 10 micrograms |
ADRENALINE. |
ASTODRIMER SODIUM for the treatment and relief of bacterial vaginosis. |
BUTOCONAZOLE. |
CICLOPIROX. |
CLOBETASONE. |
CLOTRIMAZOLE. |
DICLOFENAC. |
DIMENHYDRINATE for the prevention and relief of motion sickness. |
DIPHENOXYLATE. |
ECONAZOLE. |
ESOMEPRAZOLE. |
FAMCICLOVIR. |
FLUCONAZOLE. |
FLUORIDES. |
GLUCAGON. |
HYDROCORTISONE. |
IBUPROFEN. |
ISOCONAZOLE. |
KETOPROFEN. |
LANSOPRAZOLE. |
LEVONORGESTREL. |
MICONAZOLE. |
NALOXONE. |
NAPROXEN |
NYSTATIN. |
OMEPRAZOLE. |
OXICONAZOLE. |
PANTOPRAZOLE. |
PARACETAMOL. |
PODOPHYLLOTOXIN. |
PODOPHYLLUM EMODI (podophyllin). |
PODOPHYLLUM PELTATUM (podophyllin). |
RABEPRAZOLE. |
SALICYLIC ACID. |
TIOCONAZOLE. |
TRIAMCINOLONE. |
ULIPRISTAL for emergency post-coital contraception. |
VITAMIN D. |
This Appendix is intentionally blank
PART 1 – AUTHORISATION CONSIDERATIONS FOR AVAILABILITY AND USE
All poisons included in this Appendix are not to be available except to authorised or licensed persons.
The use of a poison may be restricted for a particular purpose. Controls recommended for the Schedule 7 poisons listed in the table below may be implemented through poisons controls or other State or Territory legislation.
Authorisation considerations
a | Poisons marked with ‘a’ are restricted to analytical or research purposes only. |
p | Poisons marked with ‘p’ have been identified as representing a significant risk to public health. Additional restrictions on their possession and use must be applied through an authorisation or licensing process which includes a case by case assessment of risks to public health. |
PART 2
A poison listed in this Appendix is to be available in accordance with the authorisations considerations specified beside it in the “Authorisation Considerations” column.
POISONS | AUTHORISATION
CONSIDERATIONS |
ABAMECTIN | |
ACIBENZOLAR-S-METHYL | |
ACROLEIN | |
ACRYLONITRILE | |
ALACHLOR | a |
ALLYL ALCOHOL | |
4-AMINOPROPIOPHENONE | p |
4-AMINOPYRIDINE | |
ARPRINOCID | a |
ARSENIC | p |
AZOCYCLOTIN | a |
BENZENE | |
BIFLUORIDE | |
BORON TRIFLUORIDE | |
BRODIFACOUM | |
BROMADIOLONE | |
BROMINE | |
BRUCINE | |
CALCIFEROL | |
CAPTAFOL | a |
CARBADOX | |
CARBON TETRACHLORIDE | |
CARBONYL SULFIDE | |
CHLORDECONE | a |
CHLORDIMEFORM | a |
CHLORINE | |
CHLOROMETHIURON | a |
CHLOROPICRIN | |
4-CHLORO-o-TOLUIDINE | a |
COLECALCIFEROL | |
COUMATETRALYL | |
CYANOGEN | |
CYHEXATIN | a |
4,4-DIAMINODIPHENYLMETHANE | |
1,2-DIBROMO-3-CHLOROPROPANE | a |
1,3-DICHLOROPROPENE | |
DIFENACOUM | |
4-DIMETHYLAMINOAZOBENZENE | a |
DINITROCRESOLS | a |
DINITROPHENOLS | a |
DINOSEB | a |
EPICHLOROHYDRIN | |
EPIDERMAL GROWTH FACTOR | |
ETACONAZOLE | a |
ETHYLENE DIBROMIDE | a |
ETHYLENE OXIDE | |
FLUOROACETAMIDE | p |
FLUOROACETIC ACID | p |
FOLPET | |
HALOFUGINONE | |
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS | a |
HCB | a |
HYDROCYANIC ACID AND CYANIDES | p |
HYDROFLUORIC ACID | |
HYDROSILICOFLUORIC ACID | |
IODOMETHANE | |
MADURAMICIN | |
MERCURY | |
METHACRIFOS | |
METHOXYETHYLMERCURIC ACETATE | a |
METHOXYETHYLMERCURIC CHLORIDE | |
METHYL BROMIDE | |
4,4’-METHYLENEBIS[2-CHLOROANILINE] | |
MIREX | a |
MOLINATE | |
NICOTINE | |
NITROFEN | a |
PHENYLMERCURIC ACETATE | |
PHOSPHIDE, metallic | |
PHOSPHINE | |
PROPYLENE OXIDE | |
PYRINURON | a |
STRYCHNINE | p |
SULCOFURON | a |
TETRACHLOROETHANE | |
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE | |
THALLIUM | p |
o-TOLIDINE | |
VINYL CHLORIDE | |
(see Part 2, Section 1.5.6)
ALIMEMAZINE |
ALPRAZOLAM |
AMISULPRIDE |
AMITRIPTYLINE |
AMOBARBITAL |
ARIPIPRAZOLE |
ASENAPINE |
AZATADINE |
BACLOFEN |
BENZATROPINE |
BREXPIPRAZOLE |
BRIVARACETAM |
BROMAZEPAM |
BROMPHENIRAMINE |
BUCLIZINE |
BUPRENORPHINE |
BUTOBARBITAL |
CANNABIS except cannabidiol when included in Schedule 4 |
CETIRIZINE |
CHLORAL HYDRATE |
CHLORDIAZEPOXIDE |
CHLORMETHIAZOLE |
CHLORPHENAMINE |
CHLORPROMAZINE |
CLEMASTINE |
CLOMIPRAMINE |
CLONAZEPAM |
CLONIDINE |
CLORAZEPATE |
CLOZAPINE |
CODEINE. |
CYCLIZINE |
CYCLOBARBITAL |
CYCLOSERINE |
CYPROHEPTADINE |
DANTROLENE |
DESIPRAMINE |
DEXCHLORPHENAMINE |
DEXTROMORAMIDE |
DEXTROPROPOXYPHENE |
DIAZEPAM |
DIFENOXIN |
DIHYDROCODEINE |
DIMENHYDRINATE |
DIMETHINDENE |
DIPHENHYDRAMINE |
DIPHENOXYLATE |
DIPHENYLPYRALINE |
DOSULEPIN |
DOXEPIN |
DOXYLAMINE |
DRONABINOL (delta-9-TETRAHYDROCANNABINOL) |
DROPERIDOL |
DULOXETINE |
ETHYLMORPHINE |
FENFLURAMINE |
FLUNITRAZEPAM |
FLUPENTIXOL |
FLUPHENAZINE |
FLURAZEPAM |
GABAPENTIN |
GEMCITABINE |
GLUTETHIMIDE |
GUANFACINE |
HALOPERIDOL |
HYDROCODONE |
HYDROMORPHONE |
HYDROXYZINE |
IMIPRAMINE |
LAMOTRIGINE |
LEVETIRACETAM |
LEVOCABASTINE |
LEVOCETIRIZINE |
LORAZEPAM |
LURASIDONE. |
MAZINDOL |
MEBHYDROLIN |
MECLOZINE |
MEDAZEPAM |
MEPROBAMATE |
MEPYRAMINE |
MERCAPTAMINE |
METHADONE |
METHDILAZINE |
METHOCARBAMOL |
METHYLPHENOBARBITAL |
MIANSERIN |
MIRTAZAPINE |
MORPHINE |
NABIXIMOLS . |
NALBUPHINE |
NITRAZEPAM |
NORMETHADONE |
NORTRIPTYLINE |
OLANZAPINE |
OPIUM in any form except the alkaloids noscapine and papaverine. |
OXAZEPAM |
OXYCODONE |
PALIPERIDONE |
PAPAVERETUM |
PENTAZOCINE |
PENTOBARBITAL |
PERAMPANEL |
PERICIAZINE |
PERPHENAZINE |
PETHIDINE |
PHENELZINE |
PHENIRAMINE |
PHENOBARBITAL |
PHENOPERIDINE |
PHENYLTOLOXAMINE |
PHOLCODINE |
PIMOZIDE |
PIZOTIFEN |
PRAZEPAM |
PREGABALIN |
PROCHLORPERAZINE |
PROMAZINE |
PROMETHAZINE |
PROTRIPTYLINE |
QUETIAPINE |
RETIGABINE |
RISPERIDONE |
ROTIGOTINE |
RUFINAMIDE |
RUPATADINE |
SAFINAMIDE |
SECBUTOBARBITAL |
SECOBARBITAL |
SODIUM OXYBATE |
STIRIPENTOL |
SUVOREXANT |
TAPENTADOL |
TEMAZEPAM |
TETRAHYDROCANNABINOLS except cannabidiol when included in Schedule 4 |
THENYLDIAMINE |
THIETHYLPERAZINE |
THIOPROPAZATE |
THIORIDAZINE |
THIOTHIXENE |
TRAMADOL |
TRANYLCYPROMINE |
TRIFLUOPERAZINE |
TRIMIPRAMINE |
TRIPROLIDINE |
ZIPRASIDONE |
ZOLPIDEM |
ZONISAMIDE |
ZOPICLONE |
PART 1 – GENERAL REQUIREMENTS FOR DISPENSING LABELS
(see Part 2, Controls on Medicines and Poisons Section 1.5.6(1)(a))
(1) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 millimetres in height.
(2) All symbols, numbers and words on a label must be in durable characters.
(3) The label on a container of a substance for therapeutic use must contain the following details:
a) the name, address and telephone number of the dispenser supplying the substance;
b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);
c) adequate directions for use;
d) the strength and form of the substance;
e) the total quantity of the goods in the container;
f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;
g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;
h) if the substance is a medicine, the name of the person for whom it was dispensed; and
i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.
(4) The label on a container of a medicine or veterinary chemical that is supplied on prescription must also include:
a) the prescription reference number;
b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and
c) the directions for use set out in the prescription.
PART 2 - ADDITIONAL LABELLING REQUIREMENTS FOR CERTAIN HUMAN MEDICINES
(see Part 2, Controls on Medicines and Poisons Section 1.5.6(1)(a))
Medicines required to be labelled with certain warning statements A substance listed in Column 1 of the following table must be labelled with the warning statement in Appendix F, Part 1, as specified opposite in Column 2.
Column 1 Substance | Column 2 Warning statement |
ACITRETIN: | |
(i) for oral use. | 7,62 and 76 |
(ii) for topical use. | 62 and 77 |
ADAPALENE: | |
(i) for oral use. | 7, 62 and 76 |
(ii) for topical use. | 62 and 77 |
AMBRISENTAN. | 7, 62 and 76 |
BEXAROTENE: | |
(i) for oral use. | 7, 62 and 76 |
(ii) for topical use. | 62 and 77 |
BOSENTAN. | 7, 62 and 76 |
DIENESTROL. | 67 |
ETRETINATE: | |
(i) for oral use. | 7, 62 and 76 |
(ii) for topical use. | 62 and 77 |
ENZALUTAMIDE | 7, 67 and 87 |
FINGOLIMOD. | 76 |
ISOTRETINOIN: | |
(i) for oral use. | 7, 62 and 76 |
(ii) for topical use. | 62 and 77 |
LEFLUNOMIDE. | 7, 62 and 87 |
LENALIDOMIDE: | |
(i) for oral use. | 7, 62 and 76 |
(ii) for topical use. | 62 and 77 |
LEVOCABASTINE. | 62 |
MACITENTAN. | 7, 62 and 76 |
MISOPROSTOL. | 53 |
POMALIDOMIDE. | 7,62 and 76 |
RIOCIGUAT. | 7, 62 and 76 |
RUFINAMIDE. | 62, 76, 77 |
SAFINAMIDE | 62, 76, 77 |
SITAXENTAN. | 7, 62 and 76 |
TERIFLUOMIDE. | 7, 62 and 87 |
THALIDOMIDE: | |
(i) for oral use. | 7, 62 and 76 |
(ii) for topical use. | 62 and 77 |
TRETINOIN: | |
(i) for oral use. | 7, 62 and 76 |
(ii) for topical use. | 62 and 77 |
A
ABACAVIR
Schedule 4
ABAMECTIN
Schedule 7
Schedule 6
Schedule 5
Appendix J, Part 2
ABATACEPT
Schedule 4
ABCIXIMAB
Schedule 4
ABIRATERONE ACETATE
Schedule 4
ABRUS PRECATORIUS
cross reference: JEQUIRITY
Schedule 10
ABSCISIC ACID
Schedule 5
ACAMPROSATE CALCIUM
Schedule 4
ACARBOSE
Schedule 4
ACEBUTOLOL
Schedule 4
ACEPHATE
Schedule 6
ACEPROMAZINE
Schedule 4
ACETAMIPRID
Schedule 6
ACETANILIDE
cross reference: ALKYL ACETANILIDES
Schedule 4
ACETARSOL
Schedule 4
ACETAZOLAMIDE
Schedule 4
ACETIC ACID
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
ACETIC ANHYDRIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ACETOHEXAMIDE
Schedule 4
ACETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Part 1 – Interpretation
ACETORPHINE
Schedule 9
ACETYL-ALPHA-METHYLFENTANYL
Schedule 9
ACETYLCARBROMAL
Schedule 4
ACETYLCHOLINE
Schedule 4
Appendix G
ACETYLCYSTEINE
Schedule 4
Schedule 2
ACETYLDIGITOXIN
Schedule 4
ACETYLDIHYDROCODEINE
Schedule 8
ACETYL ISOVALERYLTYLOSIN
Schedule 4
ACETYLMETHADOL
Schedule 8
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE
Schedule 4
ACETYLMORPHINES
Schedule 8
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE
Appendix B, Part 3
ACETYLSTROPHANTHIDIN
Schedule 4
ACIBENZOLAR-S-METHYL
Schedule 7
Appendix J, Part 2
ACICLOVIR
Schedule 4
ACIFLUORFEN
Schedule 6
ACINITRAZOLE
Schedule 6
ACIPIMOX
Schedule 4
ACITRETIN
Schedule 4
Appendix D, Item 2
Appendix F, Part 3
Appendix L, Part 2
ACLIDINIUM BROMIDE
Schedule 4
ACOKANTHERA OUABAIO
Schedule 4
ACOKANTHERA SCHIMPERI
Schedule 4
ACONITUM spp.
Schedule 4
Schedule 2
ACORUS CALAMUS
cross reference: CALAMUS
Schedule 10
ACRIFLAVINE
cross reference: ACRIFLAVINIUM CHLORIDE
ACRIFLAVINUM CHLORIDE
Schedule 7
Schedule 5
ACRIVASTINE
Schedule 4
ACROLEIN
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
ACRYLONITRILE
Schedule 7
Appendix J, Part 2
ADALIMUMAB
Schedule 4
ADAPALENE
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
ADEFOVIR
Schedule 4
ADENOSINE
Schedule 4
ADIPHENINE
Schedule 4
ADONIS VERNALIS
Schedule 4
ADRAFINIL
Schedule 4
ADRENALINE
Schedule 4
Schedule 3
Appendix H
ADRENOCORTICAL HORMONES
Schedule 4
AFAMELANOTIDE
cross reference: MELANOCYTE STIMULATING HORMONE
Schedule 4
AFATINIB DIMALEATE
Schedule 4
AFIDOPYROPEN
Appendix B, Part 3
AFLIBERCEPT
Schedule 4
AFOXOLANER
Schedule 5
AGALSIDASE
Schedule 4
AGLEPRISTONE
Schedule 4
AGOMELATINE
Schedule 4
AGROBACTERIUM RADIOBACTER
Appendix B, Part 3
AKLOMIDE
Schedule 5
ALACHLOR
Schedule 7
Appendix J, Part 2
ALATROFLOXACIN MESILATE
cross reference: ALATROFLOXACIN MESYLATE
Schedule 4
ALBENDAZOLE
Schedule 6
Schedule 5
Schedule 4
ALCLOFENAC
Schedule 4
ALCLOMETASONE
Schedule 4
Schedule 3
Appendix F, Part 3
ALCOHOL, DEHYDRATED
Appendix B, Part 3
ALCURONIUM
Schedule 4
ALDESLEUKIN
Schedule 4
ALDICARB
Schedule 7
ALDOSTERONE
Schedule 4
Appendix G
ALDOXYCARB
Schedule 7
ALDRIN
Schedule 6
ALECTINIB
Schedule 4
ALEFACEPT
Schedule 4
Appendix D, Item 7
ALEMTUZUMAB
Schedule 4
ALENDRONIC ACID
Schedule 4
ALFACALCIDOL
Schedule 4
ALFENTANIL
Schedule 8
ALFUZOSIN
Schedule 4
ALGICIDES
Appendix A
ALGLUCERASE
Schedule 4
ALGLUCOSIDASE
Schedule 4
ALIMEMAZINE
cross reference: TRIMEPRAZINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
ALIROCUMAB
Schedule 4
ALISKIREN
Schedule 4
ALKALINE SALTS
cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE, POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS, SODIUM SILICATE(S)
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
ALKOXYAMFETAMINES
cross reference: ALKOXYAMPHETAMINES
Schedule 9
ALKOXYLATED FATTY ALKYLAMINE POLYMER
Schedule 6
Schedule 5
ALKOXYPHENYLETHYLAMINES
Schedule 9
ALKYLAMINES WITH STIMULANT PROPERTIES
cross reference: 1,3-dimethylbutylamine, DMBA, octodrine, 1-aminoisoheptane, DMHA, 1,5-dimethylhexylamine, 4‑methylhexane-2-amine, 1,3-dimethylamylamine, DMAA, 4-amino-2-methylpentane citrate (AMP citrate)
Schedule 10
ALKYLTHIOAMFETAMINES
cross reference: ALKYLTHIOAMPHETAMINES
Schedule 9
ALLERGENS
Schedule 4
ALLETHRIN
Schedule 6
Schedule 5
ALLOPURINOL
Schedule 4
ALLOXYDIM
Schedule 5
ALLYL ALCOHOL
Schedule 7
Appendix J, Part 2
ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9)
Schedule 6
ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5)
Schedule 6
ALLYL ESTERS (excluding derivatives)
Schedule 6
ALLYLESTRENOL
cross reference: ALLYLOESTRENOL
Schedule 4
ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8)
Schedule 6
ALLYL HEXANOATE (CAS No. 123-68-2)
Schedule 6
ALLYLISOPROPYLACETYLUREA
Schedule 10
ALLYL ISOVALERATE (CAS No. 2835-39-4)
Schedule 6
ALLYL NONANOATE (CAS No. 7493-72-3)
Schedule 6
ALLYL OCTANOATE (CAS No. 4230-97-1)
Schedule 6
ALLYLOESTRENOL
cross reference: ALLYLESTRENOL
ALLYL PHENYLACETATE (CAS No. 1797-74-6)
Schedule 6
ALLYLPRODINE
Schedule 10
ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9)
Schedule 6
ALOGLIPTIN
Schedule 4
ALOSETRON
Schedule 4
ALOXIPRIN
Schedule 2
ALPHACETYLMETHADOL
Schedule 8
ALPHA-CHLOROHYDRIN
Schedule 6
Appendix F, Part 3
ALPHA-CYPERMETHRIN
Schedule 7
Schedule 6
Schedule 5
ALPHADOLONE
Schedule 4
ALPHAMEPRODINE
Schedule 9
ALPHAMETHADOL
Schedule 9
ALPHA-METHYLFENTANYL
Schedule 9
ALPHA-METHYLTHIOFENTANYL
Schedule 9
ALPHAPRODINE
Schedule 8
ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).
Schedule 9
ALPHA1-PROTEINASE INHIBITOR (HUMAN)
Schedule 4
ALPHAXALONE
Schedule 4
ALPRAZOLAM
Schedule 8
Appendix D, Item 5 (Benzodiazepine group entry)
Appendix K
ALPRENOLOL
Schedule 4
ALPROSTADIL
Schedule 4
ALSEROXYLON
Schedule 4
ALTEPLASE
Schedule 4
ALTRENOGEST
Schedule 4
ALTRETAMINE
cross reference: HEXAMETHYLMELAMINE
Schedule 4
ALUM
Appendix B, Part 3
ALUMINIUM AMMONIUM SULFATE
Appendix B, Part 3
ALUMINIUM POTASSIUM SULFATE
Appendix B, Part 3
ALUMINIUM SILICATE
Appendix B, Part 3
ALUMINIUM tris (ETHYLPHOSPHONATE)
Appendix B, Part 3
AMANTADINE
Schedule 4
AMBENONIUM CHLORIDE
Schedule 4
AMBRISENTAN
Schedule 4
Appendix D, Item 6
Appendix F, Part 3
Appendix L, Part 2
AMBUCETAMIDE
Schedule 4
AMBUTONIUM BROMIDE
Schedule 4
AMCINONIDE
Schedule 4
AMETOCTRADIN
Appendix B, Part 3
AMETRYN
Schedule 5
AMICARBAZONE
Schedule 6
AMIDITHION
Schedule 6
AMIDOPROPYL BETAINES
Schedule 6
Appendix E, Part 2
AMIFOSTINE
Schedule 4
AMIKACIN
Schedule 4
AMILORIDE
Schedule 4
AMINACRINE
cross reference: AMINOACRIDINE
AMINES
cross reference: CURING AGENTS FOR EPOXY RESINS
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
AMINOACRIDINE
cross reference: AMINACRINE
Schedule 7
Schedule 5
AMINOCAPROIC ACID
Schedule 4
AMINOCARB
Schedule 7
Schedule 6
2-AMINO-6-CHLORO-4-NITROPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
4-AMINO-m-CRESOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
5-AMINO-o-CRESOL
cross reference: 4-AMINO-2-HYDROXYTOLUENE
AMINOCYCLOPYRACHLOR
Schedule 5
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE
cross reference: DOM, STP
Schedule 9
AMINOETHOXYVINYLGLYCINE
Schedule 6
2-AMINO-5-ETHYLPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMINOGLUTETHIMIDE
Schedule 4
4-AMINO-2-HYDROXYTOLUENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
5-AMINOLEVULINIC ACID
Schedule 4
1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE
Schedule 6
2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL
cross reference: HC VIOLET 1
AMINOMETRADINE
Schedule 4
4-AMINO-3-NITROPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL
cross reference: HC RED 13
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMINOPHENAZONE
cross reference: AMIDOPYRINE
Schedule 10
Schedule 4
m-AMINOPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
p-AMINOPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMINOPHYLLINE
Schedule 4
Schedule 3
4-AMINOPROPIOPHENONE
cross reference: PARA-AMINOPROPIOPHENONE (PAPP)
Schedule 7
Appendix J, Part 2
5-(2-AMINOPROPYL)INDAN
Schedule 9
AMINOPTERIN
Schedule 4
AMINOPYRALID
Schedule 6
Schedule 5
4-AMINOPYRIDINE
cross reference: FAMPRIDINE
Schedule 7
Schedule 4
Appendix E, Part 2
Appendix J, Part 2
AMINOREX
Schedule 4
AMINOSALICYLIC ACID
Schedule 4
AMIODARONE
Schedule 4
AMIPHENAZOLE
Schedule 4
AMISOMETRADINE
Schedule 4
AMISULBROM
Schedule 5
AMISULPRIDE
Schedule 4
Appendix K
AMITON
Schedule 7
AMITRAZ
Schedule 6
AMITRIPTYLINE
Schedule 4
Appendix K
AMITROLE
Schedule 5
AMLODIPINE
Schedule 4
AMMI VISNAGA
Schedule 4
AMMONIA
cross reference: AMMONIUM HYDROXIDE, CHROMATES
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
AMMONIUM BROMIDE
Schedule 4
AMMONIUM COCOYL ISETHIONATE
Schedule 6
Appendix E, Part 2
AMMONIUM PERSULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMMONIUM PHOSPHATE
Appendix B, Part 3
AMMONIUM THIOCYANATE
Schedule 5
Appendix E, Part 2
AMMONIUM THIOSULPHATE
Appendix B, Part 3
AMOBARBITAL
Schedule 8
Schedule 4
Appendix K
AMODIAQUINE
Schedule 4
AMOROLFINE
Schedule 4
Schedule 3
AMOXAPINE
Schedule 4
AMOXICILLIN
Schedule 4
AMOXYCILLIN
cross reference: AMOXICILLIN
AMFETAMINE
cross reference: AMPHETAMINE
Schedule 8
AMPHOMYCIN
Schedule 4
AMPHOTERICIN
cross reference: AMPHOTERICIN B
AMPHOTERICIN B
Schedule 4
AMPICILLIN
Schedule 4
AMPRENAVIR
Schedule 4
AMPROLIUM
Appendix B, Part 3
AMRINONE
Schedule 4
AMSACRINE
Schedule 4
AMYGDALIN 2
Schedule 10
AMYL ACETATE
Appendix B, Part 3
AMYL NITRITE
Schedule 4
α-AMYLASE derived from Aspergillus niger
Appendix B, Part 3
AMYL CINNAMALDEHYDE
Appendix B, Part 3
AMYLOBARBITAL
cross reference: AMOBARBITAL
AMYLOBARBITONE
cross reference: AMOBARBITAL
AMYLOCAINE
Schedule 4
ANABOLIC STEROIDAL AGENTS
cross reference: ANDROSTERONE, STEROIDAL AGENTS
Schedule 4
Appendix D, Item 5
ANAGRELIDE
Schedule 4
ANAKINRA
Schedule 4
ANASTROZOLE
Schedule 4
ANCESTIM
Schedule 4
ANCHUSA OFFICINALIS
Schedule 10
ANCROD
Schedule 4
ANDROGENIC STEROIDAL AGENTS
cross reference: STEROIDAL AGENTS
Schedule 4
Appendix D, Item 5
ANDROISOXAZOLE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ANDROSTANOLONE
Schedule 4
ANDROSTENEDIOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ANDROSTENEDIONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ANDROSTENEDIONE ALBUMEN
Appendix B, Part 3
ANECORTAVE
Schedule 4
ANGIOTENSIN AMIDE
Schedule 4
ANHYDRIDES, ORGANIC ACID
cross reference: CURING AGENTS FOR EPOXY RESINS
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
ANIDULAFUNGIN
Schedule 4
ANILERIDINE
Schedule 8
ANILINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ANISE OIL
Schedule 5
Appendix E, Part 2, Part 4
o-ANISIDINE
Schedule 10
ANISTREPLASE
Schedule 4
ANTAZOLINE
Schedule 4
Schedule 2
ANTIBIOTIC SUBSTANCES
cross reference: NISIN
Schedule 4
ANTIGENS
Schedule 4
ANTIHISTAMINES
cross reference: ASTEMIZOLE, AZELASTINE, DESLORATADINE, FEXOFENADINE, LORATADINE, TERFENADINE, CETIRIZINE
Schedule 4
Appendix F, Part 3
ANTIMONY
cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY TITANATE
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix G
ANTISERA
cross reference: IMMUNOSERA
Schedule 4
AOD-9604 (CAS No. 221231-10-3)
Schedule 4
Appendix D, Item 5
APALUTAMIDE
Schedule 4
APIXABAN
Schedule 4
APOCYNUM spp.
Schedule 4
APOMORPHINE
Schedule 4
Appendix G
APRACLONIDINE
Schedule 4
APRAMYCIN
Schedule 4
APREMILAST
Schedule 4
APREPITANT
Schedule 4
APRONAL
Schedule 4
APROTININ
Schedule 4
ARBUTIN
cross reference: HYDROQUINONE
ARECOLINE
Schedule 4
ARIPIPRAZOLE
Schedule 4
Appendix K
ARISTOLOCHIA spp.
Schedule 10
ARISTOLOCHIC ACID(S)
cross reference: ASARUM spp, BRAGANTIA
Schedule 10
ARPRINOCID
Schedule 7
Appendix J, Part 2
ARMODAFINIL
Schedule 4
ARSENIC
cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS, COPPER-CHROME-ARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE
Schedule 7
Schedule 6
Schedule 4
Appendix G
Appendix J, Part 2
ARTEMETHER
Schedule 4
ARTICAINE
Schedule 4
ASARUM spp
Schedule 10
ASENAPINE
Schedule 4
Appendix K
ASFOTASE ALFA
Schedule 4
ASPARAGINASE
Schedule 4
ASPARTIC ACID
Appendix B, Part 3
ASPIRIN
cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix F, Part 3
ASTEMIZOLE
Schedule 4
Appendix F, Part 3
ASTODRIMER SODIUM
Schedule 3
Appendix F, Part 3
Appendix H
ASULAM
Appendix B, Part 3
ASUNAPREVIR
Schedule 4
ATAMESTANE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ATAZANAVIR
Schedule 4
ATENOLOL
Schedule 4
ATEZOLIZUMAB
Schedule 4
ATIPAMEZOLE
Schedule 4
ATOMOXETINE
Schedule 4
ATORVASTATIN
Schedule 4
ATOSIBAN
Schedule 4
ATOVAQUONE
Schedule 4
ATRACURIUM BESILATE
cross reference: ATRACURIUM BESYLATE
Schedule 4
ATRAZINE
Schedule 5
ATROPA BELLADONNA
cross reference: BELLADONNA
Schedule 4
Schedule 2
Appendix G
ATROPINE
Schedule 4
Schedule 2
Appendix G
ATROPINE METHONITRATE
Schedule 4
AURANOFIN
Schedule 4
AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941)
Appendix B
AUROTHIOMALATE SODIUM
Schedule 4
AVELUMAB
Schedule 4
AVILAMYCIN
Schedule 4
AVIPTADIL
Schedule 4
AVOPARCIN
Schedule 4
AXITINIB
Schedule 4
AZACITIDINE
Schedule 4
AZACONAZOLE
Schedule 6
AZACYCLONOL
Schedule 4
AZADIRACHTA INDICA
cross reference: DEBITTERISED NEEM SEED OIL, NEEM
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AZADIRACHTA INDICA EXTRACTS
Schedule 5
AZAFENIDIN
Schedule 7
AZAMETHIPHOS
Schedule 6
AZAPERONE
Schedule 4
AZAPROPAZONE
Schedule 4
AZARIBINE
Schedule 4
AZATADINE
Appendix K
AZATADINE
Schedule 4
Schedule 3
AZATHIOPRINE
Schedule 4
AZELAIC ACID
Schedule 4
Schedule 2
AZELASTINE
Schedule 4
Schedule 2
AZIMSULFURON
Appendix B, Part 3
AZINPHOS-ETHYL
Schedule 7
AZINPHOS-METHYL
Schedule 7
AZITHROMYCIN
Schedule 4
AZLOCILLIN
Schedule 4
AZOBENZENE
Schedule 6
AZOCYCLOTIN
Schedule 7
Appendix F, Part 3
Appendix J, Part 2
AZO DYES (derivatives by diazotisation)
Schedule 7
AZOXYSTROBIN
Schedule 5
AZTREONAM
Schedule 4
B
BACAMPICILLIN
Schedule 4
BACILLUS AMYLOLIQUEFACIENS
cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN MBI 600
Appendix B, Part 3
BACILLUS SPHAERICUS, STRAIN 2362
Appendix B, Part 3
BACILLUS SUBTILIS, STRAIN QST 713
cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713
BACILLUS THURINGIENSIS
cross reference: ENDOTOXIN
Appendix B, Part 3
BACILLUS THURINGIENSIS DELTA ENDOTOXIN
Schedule 5
BACILLUS TOYOI
Appendix B, Part 3
BACITRACIN
Schedule 4
BACLOFEN
Schedule 4
Appendix K
BACTERIAL CULTURE MEDIA
cross reference: ANTIBIOTIC SUBSTANCES
Appendix A
BACTERIOCIDES
Appendix A
BACULOVIRUS CYDIA POMONELLA
Appendix B, Part 3
BALSALAZIDE
Schedule 4
BAMBERMYCIN
cross reference: FLAVOPHOSPHOLIPOL
Schedule 6
Schedule 4
BAMBUTEROL
Schedule 4
BAMETHAN
Schedule 4
BAMIPINE
Schedule 4
BARBITURATES
Schedule 4
BARICITINIB
Schedule 4
BARIUM SALTS
cross reference: BARIUM METABORATE, BARIUM SULFATE
Schedule 6
Appendix E, Part 2
BARIUM SILICOFLUORIDE
Schedule 5
BASIC BLUE 26
Schedule 10
Schedule 6
BASIC ORANGE 31
Cross reference: 2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM, CHLORIDE
Schedule 10
Schedule 6
BASIC RED 76 (CAS No. 68391-30-0)
cross reference: [7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0)
Schedule 7
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BASIL OIL
cross reference: METHYL CHAVICOL
Schedule 5
Appendix E, Part 2
BASILIXIMAB
Schedule 4
BATTERIES
Appendix A
BAY OIL
Schedule 6
Appendix E, Part 2
BAZEDOXIFENE
Schedule 4
BEAUVERIA BASSIANA
Schedule 6
Schedule 5
BECAPLERMIN
Schedule 4
BECLAMIDE
Schedule 4
BECLOMETASONE
cross reference: BECLOMETHASONE
Schedule 4
Schedule 2
BECLOMETHASONE
cross reference: BECLOMETASONE
BELATACEPT
Schedule 4
BELIMUMAB
Schedule 4
BEMEGRIDE
Schedule 4
BENACTYZINE
Schedule 4
BENALAXYL
Schedule 5
BENAZEPRIL
Schedule 4
BENDAMUSTINE
Schedule 4
BENDIOCARB
cross reference: DENATONIUM BENZOATE
Schedule 7
Schedule 6
Schedule 5
BENDROFLUAZIDE
Schedule 4
BENETHAMINE PENICILLIN
Schedule 4
BENFLURALIN
Appendix B, Part 3
BENOMYL
Schedule 7
Appendix F, Part 3
BENORYLATE
Schedule 4
BENOXAPROFEN
Schedule 4
BENPERIDOL
Schedule 4
BENQUINOX
Schedule 6
BENRALIZUMAB
Schedule 4
BENSERAZIDE
Schedule 4
BENSULFURON-METHYL
Appendix B, Part 3
BENSULIDE
Schedule 6
BENTAZONE
Schedule 5
BENTONITE
Appendix B, Part 3
BENZALKONIUM CHLORIDE
Schedule 6
Schedule 5
Appendix E, Part 2
BENZATHINE PENICILLIN
Schedule 4
BENZENE
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
1,2-BENZENEDIAMINE
Schedule 10
1,3-BENZENEDIAMINE
Schedule 10
1,2-BENZENEDIOL
cross reference: CATECHOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BENZETHIDINE
Schedule 9
BENZHEXOL
cross reference: TRIHEXYPHENIDYL
BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES
Schedule 7
BENZIDINE-BASED AZO DYES
Schedule 7
BENZILONIUM
Schedule 4
BENZOCAINE
Schedule 4
Schedule 2
BENZODIAZEPINE DERIVATIVES
Schedule 4
Appendix D, Item 5
BENZOFENAP
Schedule 5
BENZOVINDIFLUPYR
Schedule 6
BENZOYL PEROXIDE
Schedule 5
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
BENZOYLINDOLES
Schedule 9
BENZPHETAMINE
Schedule 4
BENZTHIAZIDE
Schedule 4
BENZATROPINE
cross reference: BENZITROPINE
Schedule 4
Appendix K
BENZYDAMINE
Schedule 2
Schedule 4
BENZYL BENZOATE
Appendix B, Part 3
BENZYLMORPHINE
Schedule 8
BENZYLPENICILLIN
Schedule 4
BENZYLPIPERAZINE
cross reference: BZP
Schedule 9
BEPHENIUM SALTS
Schedule 2
BEPRIDIL
Schedule 4
BERACTANT
Schedule 4
BERGAMOT OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
BERYLLIUM
Schedule 6
Appendix F, Part 3
BESIFLOXACIN
Schedule 4
BETACETYLMETHADOL
Schedule 9
BETACYFLUTHRIN
Schedule 7
Schedule 6
Schedule 5
BETA-CYPERMETHRIN
Schedule 6
BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID
cross reference: PHENIBUT
BETAHISTINE
Schedule 4
BETA-HYDROXY-3-METHYLFENTANYL
Schedule 9
BETA-HYDROXYFENTANYL
Schedule 9
BETAINE HYDROCHLORIDE
Appendix B, Part 3
BETAMEPRODINE
Schedule 9
BETAMETHADOL
Schedule 9
BETAMETHASONE
Schedule 4
1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3
Appendix F, Part 3
BETAPRODINE
Schedule 9
BETAXOLOL
Schedule 4
BETHANECHOL CHLORIDE
Schedule 4
BETHANIDINE
Schedule 4
BEVACIZUMAB
Schedule 4
BEVANTOLOL
Schedule 4
BEXAROTENE
Schedule 4
Appendix D, Item 2
Appendix F, Part 3
Appendix L, Part 2
BEZAFIBRATE
Schedule 4
BEZITRAMIDE
Schedule 8
BEZLOTOXUMAB
Schedule 4
BHC
Schedule 6
BICALUTAMIDE
Schedule 4
BICTEGRAVIR
Schedule 4
BICYCLOPYRONE
Schedule 6
Schedule 5
BIFENAZATE
Appendix B, Part 3
BIFENTHRIN
Schedule 7
Schedule 6
BIFLUORIDES
cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS, SODIUM SALTS
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix J
BIFONAZOLE
Schedule 4
Schedule 2
BIMATOPROST
Schedule 4
BINIMETINIB
Schedule 4
BIOALLETHRIN
Schedule 6
Schedule 5
BIORESMETHRIN
Schedule 5
BIPERIDEN
Schedule 4
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BISMUTH COMPOUNDS
cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH OXYCHLORIDE, BISMUTH SUBIODIDE
Schedule 4
BISMUTH SUBNITRATE
Appendix B, Part 3
BISOPROLOL
Schedule 4
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE
cross reference: N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
cross reference: N,N-bIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BISPYRIBAC
Schedule 5
BISTRIFLURON
Appendix B, Part 3
BITHIONOL
Schedule 10
Schedule 6
Appendix F, Part 3
BIURET
Appendix B, Part 3
BIVALIRUDIN
Schedule 4
BIXAFEN
Schedule 5
BLAD (banda de Lupinus albus doce)
Appendix B, Part 3
BLEOMYCIN
Schedule 4
BLINATUMOMAB
Schedule 4
BOCEPREVIR
Schedule 4
BOLANDIOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
BOLASTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
BOLAZINE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
BOLDENONE
cross reference: DEHYDROTESTOSTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
BOLENOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
BOLMANTALATE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
BORAGO OFFICINALIS
cross reference: BORAGE
Schedule 10
BORIC ACID
cross reference: BORAX
Schedule 4
Schedule 5
Appendix E, Part 2
BORON
cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS
Schedule 4
BORON TRIFLUORIDE
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
BORTEZOMIB
Schedule 4
BOSCALID
Appendix B, Part 3
BOSENTAN
Schedule 4
Appendix D, Item 6
Appendix F, Part 3
Appendix L, Part 2
BOSUTINIB
Schedule 4
BOTULINUM TOXINS
Schedule 4
BOVINE SOMATOTROPHIN
Appendix B, Part 3
BRAGANTIA spp
Schedule 10
BRENTUXIMAB VEDOTIN
Schedule 4
BRETYLIUM TOSILATE
Schedule 4
BRETYLIUM TOSYLATE
cross reference: BRETYLIUM TOSILATE
BREXPIPRAZOLE
Schedule 4
Appendix K
BRIGATINIB
Schedule 4
BRIMONIDINE
Schedule 4
BRINZOLAMIDE
Schedule 4
BRIVARACETAM
Schedule 4
Appendix K
BRODIFACOUM
Schedule 7
Schedule 6
Appendix J, Part 2
BROMACIL
Appendix B, Part 3
BROMADIOLONE
Appendix J, Part 2
BROMADIOLONE
Schedule 7
Schedule 6
BROMAZEPAM
Schedule 4
Appendix D, Item 5 (benzodiazepine derivatives)
Appendix K
BROMETHALIN
Schedule 6
Schedule 7
BROMHEXINE
Schedule 2
BROMIDES
Schedule 4
BROMINE
Schedule 7
Appendix J, Part 2
1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE
cross reference: BROMO-DRAGONFLY
Schedule 9
BROMOCRIPTINE
Schedule 4
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE
cross reference: BDMPEA
Schedule 9
BROMOFORM
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
BROMOPHOS
Schedule 6
BROMOPHOS-ETHYL
Schedule 6
BROMOPROPYLATE
Appendix B, Part 3
BROMOXYNIL
Schedule 6
BROMPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
BROMUCONAZOLE
Schedule 5
Schedule 6
BROMVALETONE
Schedule 4
BROTIANIDE
Schedule 6
BRUCINE
Schedule 7
Appendix E, Part 2
Appendix J, Part 2
BRUGMANSIA spp.
Schedule 4
BUCLIZINE
Appendix K
BUCLIZINE
Schedule 4
Schedule 3
BUCLOSAMIDE
Schedule 10
BUDESONIDE
Schedule 4
Schedule 2
BUFEXAMAC
Schedule 4
BUFOTENINE
Schedule 9
BUMETANIDE
Schedule 4
BUNAMIDINE
Schedule 6
BUNIODYL SODIUM
Schedule 10
BUPHENINE
Schedule 4
BUPIRIMATE
Appendix B, Part 3
BUPIVACAINE
Schedule 5
Schedule 4
BUPRENORPHINE
Schedule 8
Appendix K
BUPROFEZIN
Schedule 5
BUPROPION
cross reference: AMFEBUTAMONE
Schedule 4
BUSERELIN
Schedule 4
BUSPIRONE
Schedule 4
BUSULPHAN
Schedule 4
BUTACAINE
Schedule 4
BUTACARB
Schedule 6
BUTAFENACIL
Appendix B, Part 3
BUTAMBEN
cross reference: BUTYL AMINOBENZOATE
Schedule 4
1,4-BUTANEDIOL
Schedule 10
BUTHIDAZOLE
Schedule 5
BUTOBARBITAL
Schedule 8
Appendix K
BUTOBARBITONE
cross reference: BUTOBARBITAL
BUTOCONAZOLE
Schedule 4
Schedule 3
Appendix H
BUTORPHANOL
Schedule 8
BUTOXYCARBOXIM
Schedule 6
Schedule 5
2-BUTOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BUTOXYPOLYPROPYLENE GLYCOL
Appendix B, Part 3
2-BUTOXY-2’-THIOCYANODIETHYL ETHER
Schedule 6
Appendix F, Part 3
BUTRACONAZOLE
Schedule 4
BUTRALIN
Schedule 5
BUTROXYDIM
Schedule 5
n-BUTYL ALCOHOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
BUTYL AMINOBENZOATE
cross reference BUTAMBEN
BUTYL BENZYL PHTHALATE
Schedule 10
n-BUTYL BUTYRATE
Appendix B, Part 3
n-BUTYL LACTATE
Appendix B, Part 3
BUTYL NITRITE
Schedule 4
BUTYLCHLORAL HYDRATE
Schedule 4
BUTYRIC ACID
Schedule 6
C
CABAZITAXEL
Schedule 4
CABERGOLINE
Schedule 4
CABOZANTINIB
Schedule 4
CACALIA spp.
Schedule 10
CACODYLIC ACID
Schedule 7
Schedule 6
CADMIUM COMPOUNDS
cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM NITRATE
Schedule 6
Schedule 4
Appendix E, Part 2
CADUSAFOS
Schedule 7
Schedule 6
CAJUPUT OIL
Schedule 6
Appendix E, Part 2
CALCIFEROL
Schedule 7
Schedule 6
Appendix J, Part 2
CALCIPOTRIOL
Schedule 4
CALCITONIN SALMON
Schedule 4
CALCITRIOL
Schedule 4
CALCIUM CARBIMIDE
Schedule 4
CALCIUM HYDROXYLAPATITE
Schedule 4
CALCIUM POLYSTYRENE SULPHONATE
Schedule 4
CALOTROPIS GIGANTEA
Schedule 4
CALOTROPIS PROCERA
Schedule 4
CALUSTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
CAMBENDAZOLE
Schedule 6
CAMPHOR
cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CAMPHORATED OIL
Schedule 4
CAMPHOTAMIDE
Schedule 4
CANAGLIFLOZIN
Schedule 4
CANAKINUMAB
Schedule 4
CANDESARTAN CILEXETIL
Schedule 4
CANDICIDIN
Schedule 4
CANINE TICK ANTI-SERUM
Schedule 4
CANNABICHROMENE
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
CANNABIDIOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
Schedule 4
CANNABIDIOLIC ACID
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
CANNABIDIVAROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
CANNABIGEROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
CANNABINOIDS
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
CANNABINOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
CANNABIS
cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS
Schedule 9
Schedule 8
Appendix D, Item 1
Appendix K
CANTHARIDIN
Schedule 4
Appendix G
CAPECITABINE
Schedule 4
CAPREOMYCIN
Schedule 4
CAPTAFOL
Schedule 7
Appendix J, Part 2
CAPTAN
Schedule 6
CAPTODIAME
Schedule 4
CAPTOPRIL
Schedule 4
CAPURIDE
Schedule 4
CARAMIPHEN
Schedule 4
CARBACHOL
Schedule 4
CARBADOX
Schedule 7
Appendix J, Part 2
CARBAMAZEPINE
Schedule 4
CARBAMIDE PEROXIDE
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CARBARYL
Schedule 6
Schedule 5
Schedule 4
CARBAZOCHROME
Schedule 4
CARBENDAZIM
Schedule 7
CARBENICILLIN
Schedule 4
CARBENOXOLONE
Schedule 4
CARBETAMIDE
Appendix B, Part 3
CARBETAPENTANE
Schedule 2
CARBETOCIN
Schedule 4
CARBIDOPA
Schedule 4
CARBIMAZOLE
Schedule 4
CARBOCISTEINE
Schedule 2
CARBOCROMEN
Schedule 4
CARBOFURAN
Schedule 7
CARBON DISULFIDE
Schedule 6
Appendix E, Part 2
CARBON TETRACHLORIDE
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
CARBONYL SULFIDE
Schedule 7
Appendix J, Part 2
CARBOPHENOTHION
Schedule 7
CARBOPLATIN
Schedule 4
CARBOPROST
Schedule 4
CARBOSULFAN
Schedule 7
CARBOXIN
Appendix B, Part 3
CARBROMAL
Schedule 4
CARBUTAMIDE
Schedule 4
CARBUTEROL
Schedule 4
CARDARINE
Schedule 10
CARFENTANYL
Schedule 8
CARFENTRAZONE-ETHYL
Appendix B, Part 3
CARFILZOMIB.
Schedule 4
CARGLUMIC ACID
Schedule 4
CARINDACILLIN
Schedule 4
CARISOPRODOL
Schedule 4
CARMUSTINE
Schedule 4
CARNIDAZOLE
Schedule 4
CARPROFEN
Schedule 4
CARVEDILOL
Schedule 4
CASPOFUNGIN
Schedule 4
CASSIA OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CASTOR OIL, MONOMALEATE
Schedule 6
CATHINE
Schedule 4
CATHINONES
cross reference: SYNTHETIC CATHINONES
Schedule 9
CATUMAXOMAB
Schedule 4
CEFACETRILE
cross reference: CEPHACETRILE
Schedule 4
CEFACLOR
Schedule 4
CEFADROXIL
Schedule 4
CEFALEXIN
cross reference: CEPHALEXIN
Schedule 4
CEFALORIDINE
cross reference: CEPHALORIDINE
Schedule 4
CEFALOTIN
cross reference: CEPHALOTHIN, CEFALOTHIN
Schedule 4
CEFAMANDOLE
cross reference: CEPHAMANDOLE
Schedule 4
CEFAPIRIN
cross reference: CEPHAPIRIN
Schedule 4
CEFAZOLIN
cross reference: CEPHAZOLIN
Schedule 4
CEFEPIME
Schedule 4
CEFETAMET
Schedule 4
CEFIXIME
Schedule 4
CEFODIZIME
Schedule 4
CEFONICID
Schedule 4
CEFOPERAZONE
Schedule 4
CEFOTAXIME
Schedule 4
CEFOTETAN
Schedule 4
CEFOTIAM
Schedule 4
CEFOVECIN
Schedule 4
CEFOXITIN
Schedule 4
CEFPIROME
Schedule 4
CEFPODOXIME
Schedule 4
CEFQUINOME
Schedule 4
CEFSULODIN
Schedule 4
CEFTAROLINE FOSAMIL
Schedule 4
CEFTAZIDIME
Schedule 4
CEFTIBUTEN
Schedule 4
CEFTIOFUR
Schedule 4
CEFTRIAXONE
Schedule 4
CEFUROXIME
Schedule 4
CELECOXIB
Schedule 4
CELIPROLOL
Schedule 4
CELLULASE derived from Aspergillus niger
Appendix B, Part 3
CEPHAELIS ACUMINATA
cross reference: IPECACUANHA
Schedule 4
CEPHAELIS IPECACUANHA
cross reference: IPECACUANHA
Schedule 4
CEPHALEXIN
cross reference: CEFALEXIN
CEPHALONIUM
Schedule 4
CEPHALOTHIN
cross reference: CEFALOTIN
CEPHRADINE
Schedule 4
CERAMICS
Appendix A
CERITINIB
Schedule 4
CERIVASTATIN
Schedule 4
CERLIPONASE ALFA
Schedule 4
CERTOLIZUMAB PEGOL
Schedule 4
CERULETIDE
Schedule 4
CETIRIZINE
Schedule 4
Schedule 2
Appendix K
CETRORELIX
Schedule 4
CETUXIMAB
Schedule 4
CETYL ALCOHOL
Appendix B, Part 3
CHAMOMILE OIL
Appendix B, Part 3
CHEMISTRY SETS
Appendix A
CHENODEOXYCHOLIC ACID
Schedule 4
CHINA CLAY
Appendix B, Part 3
CHLOPHEDIANOL
Schedule 2
CHLORAL FORMAMIDE
Schedule 4
CHLORAL HYDRATE
Schedule 4
Appendix K
CHLORALOSE
cross reference: ALPHA-CHLORALOSE
Schedule 6
Schedule 4
CHLORAMBUCIL
Schedule 4
CHLORAMPHENICOL
Schedule 4
Schedule 3
CHLORANDROSTENOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
CHLORANTRANILIPROLE
Appendix B, Part 3
CHLORAZANIL
Schedule 4
CHLORBUTANOL
Schedule 3
Schedule 2
CHLORBUTOL
cross reference: CHLOROBUTANOL
CHLORCYCLIZINE
Schedule 4
CHLORDANE
Schedule 6
CHLORDECONE
Schedule 7
Appendix J, Part 2
CHLORDIAZEPOXIDE
Schedule 4
Appendix D, Item 5 (benzodiazepine derivative)
Appendix K
CHLORDIMEFORM
Schedule 7
Appendix J, Part 2
CHLORFENAC
Schedule 5
CHLORFENAPYR
Schedule 7
Schedule 6
Schedule 5
CHLORFENETHOL
Schedule 6
CHLORFENSON
Schedule 5
CHLORFENVINPHOS
Schedule 7
CHLORFLUAZURON
Appendix B, Part 3
CHLORFLURENOL
Appendix B, Part 3
CHLORHEXIDINE
Schedule 7
Schedule 6
Schedule 5
CHLORIDAZON
Appendix B, Part 3
CHLORIDE
Appendix E, Part 2
CHLORINATING COMPOUNDS
cross reference: BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN, TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE, DICHLOROETHYL ETHER, SODIUM HYPOCHLORITE
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
CHLORINE
cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, DICHLOROISOCYANURIC ACID
Schedule 7
Appendix G
Appendix J, Part 2
CHLORMEQUAT
Schedule 6
CHLORMERODRIN
Schedule 4
CHLORMETHIAZOLE
Schedule 4
Appendix K
CHLORMEZANONE
Schedule 4
CHLORNIDINE
Schedule 5
CHLOROACETAMIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHLOROCRESOL
Schedule 5
Appendix E, Part 2
2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHLOROFORM
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
4-CHLOROMETHANDIENONE
Schedule 4
Appendix D, Item D (Anabolic and/or androgenic steroidal agents)
CHLOROMETHIURON
Schedule 7
Appendix J, Part 2
5-CHLORO-3-METHYL-4-NITROPYRAZOLE
Schedule 7
2-CHLORO-5-NITRO-N-HYDROXYETHYL-p-PHENYLENEDIAMINE
cross reference: PHENYLENEDIAMINES
CHLOROPHACINONE
Schedule 6
2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE
Schedule 4
CHLOROPICRIN
Schedule 7
Schedule 6
CHLOROPICRIN
Appendix J, Part 2
CHLOROQUINE
Schedule 4
CHLOROTHALONIL
Schedule 6
CHLOROTHIAZIDE
Schedule 4
4-CHLORO-o-TOLUIDINE
Schedule 7
Appendix J, Part 2
CHLOROTRIANISENE
Schedule 4
2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE
Schedule 6
CHLOROXYDIENONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
CHLOROXYLENOLS
Appendix B, Part 3
CHLORPHENAMINE
cross reference: CHLORPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
CHLORPHENIRAMINE
cross reference: CHLORPHENAMINE
CHLORPHENTERMINE
Schedule 4
CHLORPROMAZINE
Schedule 4
Appendix K
CHLORPROPAMIDE
Schedule 4
CHLORPROPHAM
Schedule 5
CHLORPROTHIXENE
Schedule 4
CHLORPYRIFOS
Schedule 6
Schedule 5
CHLORPYRIFOS-METHYL
Schedule 6
CHLORQUINALDOL
Schedule 4
CHLORSULFURON
Schedule 5
CHLORTALIDONE
Schedule 4
CHLORTETRACYCLINE
Schedule 5
Schedule 4
CHLORTHAL-DIMETHYL
Schedule 5
CHLORTHALIDONE
cross reference: CHLORTALIDONE
CHLORTHIAMID
Schedule 6
CHLORTHIOPHOS
Schedule 7
CHLORZOXAZONE
Schedule 4
CHOLECALCIFEROL
cross reference: COLECALCIFEROL
Schedule 7
Appendix J, Part 2
CHOLERA VACCINE
Schedule 4
CHOLESTYRAMINE
cross reference: COLESTYRAMINE
CHOLIC ACID
Schedule 4
CHROMATES
cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM, COPPER-CHROME-ARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC CHROMATE SODIUM CHROMATE, STRONTIUM CHROMATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHROMIUM TRIOXIDE
cross reference: CHROMIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHRYSOIDINE BASE
Schedule 6
Schedule 10
Appendix E, Part 2
CHYMOPAPAIN
Schedule 4
CICLACILLIN
Schedule 4
CICLESONIDE
Schedule 4
CICLOPIROX
Schedule 4
Schedule 3
Schedule 2
Appendix H
CICLOSPORIN
Schedule 4
CIDOFOVIR
Schedule 4
CILASTATIN
Schedule 4
CILAZAPRIL
Schedule 4
CILOSTAZOL
Schedule 4
CIMETIDINE
Schedule 4
Schedule 3
Appendix F, Part 3
CIMICOXIB
Schedule 4
CINACALCET
Schedule 4
CINCHOCAINE
Schedule 4
Schedule 2
CINCHOPHEN
Schedule 10
CINEOLE
cross reference: CAMPHOR OIL (white), ROSEMARY OIL
Schedule 7
Appendix E, Part 2
CINMETHYLIN
Schedule 5
CINNAMEDRINE
Schedule 2
CINNAMON BARK OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CINNAMON LEAF OIL
Schedule 6
Appendix E, Part 2
CINNARIZINE
Schedule 4
CINOXACIN
Schedule 4
CIPROFLOXACIN
Schedule 4
CISAPRIDE
Schedule 4
CISATRACURIUM BESILATE
cross reference: CISATRACURIUM BESYLATE
Schedule 4
CISPLATIN
Schedule 4
CITALOPRAM
Schedule 4
CITRONELLA OIL
Appendix B, Part 3
CJC-1295 (CAS No. 863288-34-0)
Schedule 4
Appendix D, Item 5
CLADRIBINE
Schedule 4
CLANOBUTIN
Schedule 4
CLARITHROMYCIN
Schedule 4
CLARY SAGE OIL
Appendix B, Part 3
CLAVULANIC ACID
Schedule 4
CLEMASTINE
Schedule 4
Schedule 3
Appendix K
CLEMIZOLE
Schedule 4
CLENBUTEROL
Schedule 4
CLETHODIM
Schedule 5
CLEVIDIPINE
Schedule 4
CLIDINIUM BROMIDE
Schedule 4
CLIMBAZOLE
Schedule 6
Schedule 5
Appendix E, Part 2
CLINDAMYCIN
Schedule 4
CLIOQUINOL
cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL
Schedule 10
Schedule 4
CLITORIA TERNATEA EXTRACT
Appendix B, Part 3
CLOBAZAM
Schedule 4
CLOBETASOL
Schedule 4
CLOBETASONE
Schedule 4
Schedule 3
Appendix F, Part 3
Appendix H
CLOCORTOLONE
Schedule 4
CLODINAFOP-PROPARGYL
Schedule 6
CLODRONIC ACID
cross reference: SODIUM CLODRONATE
Schedule 4
CLOFARABINE
Schedule 4
CLOFAZIMINE
Schedule 4
CLOFENAMIDE
Schedule 4
CLOFENTEZINE
Schedule 5
CLOFIBRATE
Schedule 4
CLOMAZONE
Schedule 6
CLOMIFENE
cross reference: CLOMIPHENE
Schedule 4
Appendix D, Item 1
CLOMIPHENE
cross reference: CLOMIFENE
CLOMIPRAMINE
Schedule 4
Appendix K
CLOMOCYCLINE
Schedule 4
CLONAZEPAM
Schedule 4
Appendix D, Item 5 (benzodiazepine derivatives)
Appendix K
CLONAZOLAM
Schedule 9
CLONIDINE
Schedule 4
Appendix K
CLONITAZENE
Schedule 9
CLOPAMIDE
Schedule 4
CLOPIDOGREL
Schedule 4
CLOPIDOL
Appendix B, Part 3
CLOPROSTENOL
Schedule 4
CLOPYRALID
Schedule 5
CLOQUINTOCET
Schedule 5
CLORAZEPATE
Schedule 4
Appendix D, Item 5 (benzodiazepine derivatives)
Appendix K
CLOREXOLONE
Schedule 4
CLORPRENALINE
Schedule 4
CLORSULON
Schedule 5
CLOSANTEL
Schedule 6
CLOSTEBOL
cross reference: 4-CHLOROTESTOSTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
CLOTHIANIDIN
Schedule 6
Schedule 5
CLOTRIMAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
CLOVE OIL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CLOXACILLIN
Schedule 4
CLOZAPINE
Schedule 4
Appendix D, Item 1
Appendix K
COAL TAR
Schedule 10
COBALT
cross reference: DICOBALT EDETATE
Schedule 4
COBALT NAPHTHENATE
Appendix B, Part 3
COBICISTAT
Schedule 4
COBIMETINIB
Schedule 4
COCA LEAF
Schedule 9
COCAINE
Schedule 8
N-COCO-1,3-DIAMINOPROPANE
Schedule 6
COCOYL GLYCINATE
Schedule 6
Appendix E, Part 2
COCOYL METHYL GLUCAMAIDE
cross reference: 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES
CODEINE
Schedule 8
Schedule 4
Appendix K
CODEINE-N-OXIDE
Schedule 8
CO-DERGOCRINE
Schedule 4
CODOXIME
Schedule 9
COLASPASE
cross reference: ASPARAGINASE
COLCHICINE
Schedule 4
COLCHICUM AUTUMNALE
Schedule 4
COLECALCIFEROL
cross reference: CHOLECALCIFEROL
Schedule 7
Appendix J, Part 2
COLESTIPOL
Schedule 4
COLESTYRAMINE
Schedule 4
COLFOSCERIL PALMITATE
Schedule 4
COLISTIN
Schedule 4
COLLAGEN
Schedule 4
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Schedule 4
CONCENTRATE OF POPPY STRAW
Schedule 8
CONIUM MACULATUM
cross reference: CONIINE
Schedule 10
CONVALLARIA KEISKI
Schedule 4
CONVALLARIA MAJALIS
Schedule 4
COPPER ACETATE
Schedule 6
Schedule 5
COPPER COMPOUNDS
cross reference: COPPER
Schedule 6
Schedule 5
Schedule 4
Appendix A
COPPER HYDROXIDE
Schedule 6
Schedule 5
COPPER NITRATE
cross reference: COPPER CHLORIDE
Schedule 6
COPPER OXIDES
Schedule 6
Schedule 5
COPPER OXYCHLORIDE
Schedule 6
Schedule 5
COPPER SULFATE
Schedule 6
Schedule 5
Appendix E, Part 2
CORIFOLLITROPIN ALFA
cross reference: FOLLICLE STIMULANT, RECOMBINANT
Schedule 4
Appendix D, Item 1
CORONILLA spp.
Schedule 4
CORTICOSTERONE
Schedule 4
CORTICOTROPHIN
Schedule 4
CORTISONE
Schedule 4
COTARNINE
Schedule 10
CO-TRIMOXAZOLE
Schedule 4
COUMAPHOS
Schedule 7
Schedule 6
COUMARIN
Schedule 4
COUMATETRALYL
Schedule 7
Schedule 6
Schedule 5,
Appendix J, Part 2
4-CPA
Schedule 5
CREOSOTE
cross reference: BEECHWOOD, PHENOL, WOOD
Schedule 7
Schedule 6
Schedule 2
Appendix E, Part 2
CRESOLS
Appendix E, Part 2
CRISABOROLE
Schedule 4
CRIZOTINIB
Schedule 4
CROFELEMER
Schedule 4
CROSPOVIDONE
Appendix B, Part 3
CROTALARIA spp.
Schedule 10
CROTON TIGLIUM
cross reference: CROTON OIL
Schedule 10
Appendix G
CROTOXYPHOS
Schedule 6
CRUFOMATE
Schedule 6
CRYSTAL VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET
CULICINOMYCES CLAVOSPORUS
Appendix B, Part 3
CUPRIMYXIN
Schedule 4
CURARE
Schedule 4
13C-UREA
Appendix B, Part 3
CYANAMIDE
Schedule 6
CYANATRYN
Schedule 5
CYANAZINE
Schedule 6
CYANIDES
cross reference: FERRICYANIDES, FERROCYANIDES
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
CYANOACRYLATE ESTERS
Schedule 5
CYANOACRYLIC ACID ESTERS
Appendix E, Part 2
4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE
cross reference: METHADONE INTERMEDIATE
Schedule 9
CYANOGEN
cross reference: ETHANEDINITRILE, OXALONITRILE
Schedule 7
Appendix J, Part 2
4-CYANO-1-METHYL-4-PHENYLPIPERIDINE
cross reference: PETHIDINE INTERMEDIATE A
Schedule 8
CYANTRANILIPROLE
Schedule 5
CYANURIC ACID
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CYAZOFAMID
Schedule 5
CYCLAMIC ACID
Appendix B, Part 3
CYCLANDELATE
Schedule 4
CYCLANILIDE
Schedule 6
CYCLANILIPROLE
Appendix B
CYCLIZINE
Schedule 4
Schedule 3
Appendix K
CYCLOBARBITAL
Schedule 8
Appendix K
CYCLOBARBITONE
cross reference: CYCLOBARBITAL
CYCLOBENZAPRINE
Schedule 4
CYCLOFENIL
Schedule 4
Appendix D, Item 1
CYCLOHEXANE
Appendix B, Part 3
CYCLOHEXANOL ACETATE
Appendix B, Part 3
CYCLOHEXANONE PEROXIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CYCLOHEXIMIDE
Schedule 4
N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM
cross reference: K-HDO
Schedule 6
CYCLOHEXYLPHENOLS
Schedule 9
CYCLOPENTHIAZIDE
Schedule 4
CYCLOPENTOLATE
Schedule 4
CYCLOPHOSPHAMIDE
Schedule 4
CYCLOPROPANE
Schedule 4
CYCLOPROTHRIN
Schedule 5
CYCLOSERINE
Schedule 4
Appendix J, Part 2
CYCLOSPORIN
cross reference: CICLOSPORIN
CYCLOTHIAZIDE
Schedule 4
CYCLOXYDIM
Schedule 5
CYCRIMINE
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
CYFLUFENAMID
Schedule 5
CYFLUTHRIN
Schedule 6
Schedule 5
CYHALOFOP-BUTYL
Schedule 5
CYHALOTHRIN
Schedule 7
CYHEXATIN
Schedule 7
CYMARIN
Schedule 4
CYMIAZOLE
Schedule 5
CYNOGLOSSUM spp.
Schedule 10
CYOMETRINIL
Schedule 6
CYPERMETHRIN
cross reference: ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN, ZETA-CYPERMETHRIN
Schedule 6
Schedule 5
CYPHENOTHRIN
Schedule 6
Schedule 5
CYPRINID HERPESVIRUS-3
Appendix B, Part 3
CYPROCONAZOLE
Schedule 5
CYPRODINIL
Schedule 5
CYPROHEPTADINE
Schedule 4
Schedule 3
Appendix K
CYPROTERONE
Schedule 4
CYROMAZINE
Appendix B, Part 3
CYSTEAMINE
cross reference: MERCAPTAMINE
CYTARABINE
Schedule 4
CYTHIOATE
Schedule 6
Schedule 5
D
2,4-D
Schedule 6
Schedule 5
DABIGATRAN
Schedule 4
DABRAFENIB MESILATE
Schedule 4
DACARBAZINE
Schedule 4
DACLATASVIR
Schedule 4
DACLIZUMAB
Schedule 4
DACTINOMYCIN
Schedule 4
DALFOPRISTIN
Schedule 4
DALTEPARIN
Schedule 4
DAMINOZIDE
Schedule 5
DANAPAROID
Schedule 4
DANAZOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
DANTHRON
Schedule 4
DANTROLENE
Schedule 4
Appendix K
DAPAGLIFLOZIN
Schedule 4
DAPOXETINE
Schedule 4
DAPSONE
Schedule 4
DAPTOMYCIN
Schedule 4
DARATUMUMAB
Schedule 4
DARBEPOETIN
Schedule 4
Appendix D, Item 5
DARIFENACIN
Schedule 4
DARUNAVIR
Schedule 4
DASABUVIR
Schedule 4
DASATINIB
Schedule 4
DATURA spp.
Schedule 4
Schedule 2
DATURA STRAMONIUM
cross reference: STRAMONIUM
Schedule 4
Schedule 2
DATURA TATULA
cross reference: STRAMONIUM
Schedule 4
Schedule 2
DAUNORUBICIN
Schedule 4
DAZOMET
Schedule 6
2,4-DB
Schedule 5
DEANOL
cross reference: 2-(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA
Schedule 4
DEBRISOQUINE
Schedule 4
DECAMETHONIUM
Schedule 4
DECOQUINATE
Schedule 5
DEFERASIROX
Schedule 4
DEFERIPRONE
Schedule 4
DEFLAZACORT
Schedule 4
DEGARELIX
Schedule 4
DEHYDROCHLOROMETHYLTESTOSTERONE
cross reference: CHLOROMESTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
DEHYDROCORTICOSTERONE
Schedule 4
DELAVIRDINE
cross reference: DELAVIRDINE MESILATE
DELAVIRDINE MESILATE
Schedule 4
DELPHINIUM STAPHISAGRIA
cross reference: STAPHISAGRIA
Schedule 2
DELTAMETHRIN
Schedule 7
Schedule 6
Schedule 5
DEMBREXINE
Schedule 5
Schedule 4
DEMECARIUM
Schedule 4
DEMECLOCYCLINE
Schedule 4
DEMETON
Schedule 7
DEMETON-O-METHYL
Schedule 7
DEMETON-S-METHYL
Schedule 7
DENGUE VACCINE
cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1,2,3 & 4)
Schedule 4
DENOSUMAB
Schedule 4
DEOXYCHOLIC ACID
Schedule 4
DEOXYCORTONE
Schedule 4
1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES
cross reference: COCOYL METHYL GLUCAMAIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DEOXYRIBONUCLEASE
Schedule 4
DERACOXIB
Schedule 4
DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT
Schedule 4
DERQUANTEL
Schedule 6
2,4-DES
Schedule 5
DESCHLOROETIZOLAM
Schedule 9
DESFERRIOXAMINE
Schedule 4
DESFLURANE
Schedule 4
DESIPRAMINE
Schedule 4
Appendix K
DESIRUDIN
Schedule 4
DESLANOSIDE
Schedule 4
DESLORATADINE
Schedule 4
Schedule 2
DESLORELIN
Schedule 4
DESMOPRESSIN
cross reference: D.D.A.V.P.
Schedule 4
DESOGESTREL
Schedule 4
DESOMORPHINE
Schedule 9
DESONIDE
Schedule 4
DESOXYMETHASONE
Schedule 4
DESVENLAFAXINE
Schedule 4
DETOMIDINE
Schedule 4
DEXAMETHASONE
Schedule 4
DEXAMFETAMINE
cross reference: DEXAMPHETAMINE
Schedule 8
DEXCHLORPHENAMINE
cross reference: DEXCHLORPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
DEXCHLORPHENIRAMINE
cross reference: DEXCHLORPHENAMINE
DEXFENFLURAMINE
Schedule 4
DEXMEDETOMIDINE
Schedule 4
DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES
Appendix A
DEXTROMETHORPHAN
Schedule 4
Schedule 2
DEXTROMORAMIDE
cross reference: MORAMIDE
Schedule 8
Appendix K
DEXTROPROPOXYPHENE
Schedule 8
Schedule 4
Appendix D, Item 5
Appendix K
DEXTRORPHAN
Schedule 4
N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES
cross reference: 3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZAMIDE *(U-47700)
Schedule 9
N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES
Cross reference: 3,4-DICHLORO-N-{[1-(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH‑7921)
Schedule 9
4,4-DIAMINODIPHENYLMETHANE
cross reference: METHYLENE DIANILINE
Schedule 7
Appendix F, Part 3
Appendix J, Part 2
2,4-DIAMINO-5-METHYLPHENETOLE
cross reference: PHENYLENEDIAMINES
2,4-DIAMINOPHENOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DIAFENTHIURON
Schedule 5
DIALIFOS
Schedule 7
N,N-DIALLYLDICHLOROACETAMIDE
Schedule 5
DIAMPROMIDE
Schedule 9
DIAMTHAZOLE
Schedule 4
DIAVERIDINE
Schedule 4
DIAZEPAM
Schedule 4
Appendix D, Item 5 (benzodiazepine derivatives)
Appendix K
DIAZINON
Schedule 6
Schedule 5,
DIAZOXIDE
Schedule 4
DIBENZEPIN
Schedule 4
DIBENZOPYRANS
Schedule 9
DIBOTERMIN
Schedule 4
1,2-DIBROMO-3-CHLOROPROPANE
Schedule 7
Appendix J, Part 2
DIBROMOPROPAMIDINE
Schedule 4
Schedule 2
DIBUTYLPHTHALATE
Schedule 10
DICAMBA
Schedule 6
Schedule 5
DICLAZEPAM
Schedule 9
DICHLOBENIL
Schedule 6
DICHLOEOETHYL ETHER
Appendix F, Part 3
DICHLOFENTHION
Schedule 6
DICHLOFLUANID
Schedule 6
DICHLONE
Schedule 5
DICHLORALPHENAZONE
Schedule 4
DICHLOROBENZENE
Schedule 6
Schedule 5
Appendix E, Part 2
3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZAMIDE (U-47700)
cross reference: N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES
Schedule 9
DICHLOROETHYL ETHER
Schedule 6
Appendix E, Part 2
DICHLOROETHYLENE
Appendix F, Part 3
DICHLOROISOCYANURIC ACID
cross reference: CHLORINE, CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
DICHLOROMETHANE
cross reference: METHYLENE CHLORIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
3,4-DICHLORO-N-{[1-DIMETHYLAMINO)CYCLOHEXYL]METHYL}
BENZAMIDE
cross reference: AH-7921
Schedule 9
4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE
Schedule 6
DICHLOROPHEN
Schedule 6
Schedule 5
Schedule 4
2,4-DICHLORPROP
Schedule 6
1,2-DICHLOROPROPANE
Schedule 6
1,3-DICHLOROPROPENE
Schedule 7
Appendix J, Part 2
DICHLORPHENAMIDE
Schedule 4
DICHLORVOS
Schedule 7
Schedule 6
Schedule 5
DICHROMATES
Appendix E, Part 2
DICLAZURIL
Appendix B, Part 3
DICLOBUTRAZOL
Schedule 5
DICLOFENAC
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
DICLOFOP-METHYL
Schedule 6
DICLORAN
Schedule 5
DICLOXACILLIN
Schedule 4
DICOFOL
Schedule 5
DICOPHANE
cross reference: DDT
Schedule 10
DICROTOPHOS
Schedule 7
DICYCLANIL
Schedule 6
DICYCLOMINE
Schedule 4
DIDANOSINE
Schedule 4
DIDECYLDIMETHYLAMMONIUM SALTS
Schedule 6
DIELDRIN
Schedule 6
DIENESTROL
Schedule 4
Appendix F, Part 3
Appendix L
DIENOGEST
Schedule 4
DIESEL
Appendix E, Part 2
DIETHANOLAMINE
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
DIETHAZINE
Schedule 4
DIETHYL CARBONATE
Appendix B, Part 3
DIETHYLCARBAMAZINE
Schedule 4
DIETHYLENE GLYCOL
cross reference: DENATONIUM BENZOATE
Schedule 10
Schedule 6
Schedule 5
DIETHYLENE GLYCOL MONOBUTYL ETHER
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
DIETHYLENE GLYCOL MONOMETHYL ETHER
Schedule 10
Schedule 6
DIETHYLHEXYL PHTHALATE
Schedule 10
DIETHYLPHTHALATE
Schedule 10
DIETHYLPROPION
Schedule 4
DIETHYLTHIAMBUTENE
Schedule 9
DIETHYLTOLUAMIDE (DEET)
Schedule 5
Appendix F, Part 3
N,N-DIETHYLTRYPTAMINE
cross reference: DET
Schedule 9
DIFENACOUM
Schedule 7
Schedule 6
Appendix J, Part 2
DIFENOCONAZOLE
Schedule 5
DIFENOXIN
Schedule 8
Schedule 4
Appendix K
DIFENZOQUAT
Schedule 6
DIFETHIALONE
Schedule 7
Schedule 6
DIFLORASONE
Schedule 4
DIFLOXACIN
Schedule 4
DIFLUBENZURON
Schedule 5
DIFLUCORTOLONE
Schedule 4
DIFLUFENICAN
Appendix B, Part 3
DIFLUNISAL
Schedule 4
DIGITALIS LANATA
Schedule 4
DIGITALIS PURPUREA
Schedule 4
DIGITOXIN
Schedule 4
DIGOXIN
Schedule 4
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab)
Schedule 4
DIHYDRALAZINE
Schedule 4
DIHYDROCODEINE
Schedule 8
Schedule 4
Schedule 3
Appendix K
DIHYDROERGOTOXINE
Schedule 4
DIHYDROLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
DIHYDROMORPHINE
Schedule 8
DIHYDROSTREPTOMYCIN
Schedule 4
DIHYDROTACHYSTEROL
Schedule 4
5,6-DIHYDROXYINDOLINE
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DIIODOHYDROXYQUINOLINE
cross reference: IODOQUINOL
Schedule 10
Schedule 4
Schedule 3
DI-IODOHYDROXYQUINOLINE
cross reference: DIIODOHYDROXYQUINOLINE
DIISOBUTYL PHTHALATE
Schedule 10
DIISOPROPYLAMINE DICHLOROACETATE
Schedule 4
DIKEGULAC-SODIUM
Appendix B, Part 3
DILTIAZEM
Schedule 4
DIMEFOX
Schedule 7
DIMENHYDRINATE
Schedule 4
Schedule 3
Schedule 2
Appendix H
Appendix K
DIMENOXADOL
Schedule 9
DIMEPHEPTANOL
Schedule 9
DIMERCAPROL
Schedule 4
DIMETHANDROSTANOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
DIMETHAZINE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
DIMETHENAMID-P
Schedule 6
DIMETHICODIETHYLBENZALMALONATE
cross reference: POLYSILICONE-15
Schedule 5
DIMETHICONE
cross reference: DIMETICONE
DIMETHINDENE
Schedule 4
Appendix K
DIMETHIPIN
Schedule 6
1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette)
cross reference: Amber musk
Schedule 10
DI(METHYLOXYETHYL) PHTHALATE
Schedule 10
DIMETHIRIMOL
Schedule 5
DIMETHOATE
Schedule 6
DIMETHOMORPH
Schedule 5
DIMETHOTHIAZINE
Schedule 4
DIMETHOXANATE
Schedule 4
2,5-DIMETHOXYAMFETAMINE
cross reference: 2,5-DIMETHOXYAMPHETAMINE, DMA
Schedule 9
2,5-DIMETHOXY-4-BROMOAMFETAMINE
cross reference: 2,5-DIMETHOXY-4-BROMOAMPHETAMINE, DOB
Schedule 9
2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE
cross reference: 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE, DOET
Schedule 9
2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE
cross reference: 2C-T-2
Schedule 9
2,5-DIMETHOXY-4-IODOPHENETHYLAMINE
cross reference: 2C-I
Schedule 9
2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE
cross reference: 2C-T-7
Schedule 9
2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE
Schedule 6
Appendix F, Part 3
DIMETHYLACETAMIDE
Schedule 6
Schedule 5
N,N-DIMETHYLAMFETAMINE
cross reference: N,N-DIMETHYLAMPHETAMINE, DIMETAMFETAMINE
Schedule 9
4-DIMETHYLAMINOAZOBENZENE
cross reference: MOCA, N,N-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE
Schedule 7
Appendix J, Part 2
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE
cross reference: PSILOCINE, PSILOTSIN
Schedule 9
1,3-DIMETHYLAMYLAMINE
cross reference: 4-METHYLHEXANE-2-AMINE, DMAA
Schedule 10
1,3-DIMETHYLBUTYLAMINE (DMBA)
cross reference: octodrine, 1-aminoisoheptane, DMHA, 1,5-dimethylhexylamine, 4‑methylhexane-2-amine, 1,3-dimethylamylamine, DMAA, 4-amino-2-methylpentane Citrate (AMP Citrate)
Schedule 10
4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DIMETHYL ETHER
Appendix B, Part 3
1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette)
cross reference: Amber musk
Schedule 10
DIMETHYLFORMAMIDE
cross reference: DESIGNATED SOLVENT
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Part 1 - Interpretation
DIMETHYL FUMARATE
Schedule 4
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN
cross reference: DMHP
Schedule 9
1,5-DIMETHYLHEXYLAMINE (DMHA)
cross reference: 1,3-dimethylbutylamine, DMBA, octodrine, 1-aminoisoheptane, DMHA, 4‑methylhexane-2-amine, 1,3-dimethylamylamine, DMAA, 4-amino-2-methylpentane Citrate (AMP Citrate)
Schedule 10
N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE
cross reference: 3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE, MDMA
Schedule 9
3,7-DIMETHYL-2,6-OCTADIENAL
cross reference: CITRAL, NERAL, GERANIAL
Schedule 5
3,7-DIMETHYL-2,6-OCTADIEN-1-OL
cross reference: GERANIOL, NEROL, CITROL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DIMETHYLPHTHALATE
Schedule 10
DIMETHYL SULFATE
Schedule 7
Appendix F, Part 3
DIMETHYL SULFOXIDE
cross reference: COPPER SALICYLATE, METHYL SALICYLATE
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
DIMETHYLTHIAMBUTENE
Schedule 9
N,N-DIMETHYLTRYPTAMINE
cross reference: DMT
Schedule 9
DIMETICONE
cross reference: DIMETHICONE
Appendix B, Part 3
DIMETILAN
Schedule 7
DIMETRIDAZOLE
Schedule 4
DINICONAZOLE
Schedule 5
2,4-DINITROCHLOROBENZENE
Schedule 4
DINITROCRESOLS
Schedule 7
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix J, Part 2
DINITRONAPHTHOLS
Schedule 4
DINITROPHENOLS
Schedule 10
Schedule 7
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
DINITROTHYMOLS
Schedule 4
DINOCAP
Schedule 7
Appendix F, Part 3
DINOPROST
Schedule 4
Appendix D, Item 1
DINOPROSTONE
Schedule 4
Appendix D, Item 1
DINOSEB
Schedule 7
Appendix J, Part 2
DINOTEFURAN
Schedule 5
DI-n-PROPYL ISOCINCHOMERONATE (previoiusly di-N propyl isocinchomeronate)
Schedule 5
DIOXACARB
Schedule 6
DIOXANE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
Appendix G
DIOXAPHETYL BUTYRATE
Schedule 9
DIPERODON
Schedule 4
DIPHACINONE
Schedule 6
DIPHEMANIL
Schedule 4
DIPHENAMID
Schedule 5
DIPHENHYDRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
DIPHENIDOL
Schedule 4
DIPHENOXYLATE
Schedule 8
Schedule 4
Schedule 3
Appendix F, Part 3
Appendix H
Appendix K
DIPHENYLAMINE
Appendix B, Part 3
DIPHENYLPYRALINE
Schedule 4
Appendix K
DIPHTHERIA TOXOID
Schedule 4
DIPIPANONE
Schedule 8
DIPIVEFRIN
Schedule 4
DIPROPYLENE GLYCOL
Appendix B, Part 3
DIPYRIDAMOLE
Schedule 4
DIQUAT
Schedule 7
Schedule 6
DIRECT RED 254
cross reference: 2-NAPHTHALENESULFONIC ACID, 7-AMINO-4-HYDROXY-3-[[p-[(p-SULFOPHENYL)AZO]PHENYL]AZO]-, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE-2-SULFONIC ACID, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE-2-SULFONIC ACID BIS(TRIETHANOLAMINE) SALT, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE-2-SULFONIC ACID DISODIUM SALT
Schedule 5
Schedule 6
DIRITHROMYCIN
Schedule 4
DIRLOTAPIDE
Schedule 4
DISOPHENOL
Schedule 4
DISOPYRAMIDE
Schedule 4
DISPERSE YELLOW 3
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DISTIGMINE
Schedule 4
DISTILLATE
Appendix E, Part 2
DISULFIRAM
Schedule 6
Schedule 4
DISULFOTON
Schedule 7
Schedule 6
DISULPHAMIDE
Schedule 4
DITHIANON
Schedule 6
DITHIAZANINE
Schedule 6
Schedule 4
DITHIOPYR
Schedule 5
DITHRANOL
Schedule 3
DITIOCARB
Schedule 4
DIUREDOSAN
Schedule 6
DIURON
Appendix B, Part 3
DOBUTAMINE
Schedule 4
DOCETAXEL
Schedule 4
DOCUSATE SODIUM
cross reference: DIOCTYL SODIUM SULFOSUCCINATE
Appendix B, Part 3
N-(N-DODECYL)-2-PYRROLIDONE
cross reference: DESIGNATED SOLVENT, N-(N-OCTYL)-2-PYRROLIDONE, N-METHYL-2-PYRROLIDONE
Schedule 6
Schedule 5
Appendix E, Part 2
Part 1 - Interpretation
DODINE
Schedule 6
DOFETILIDE
Schedule 4
DOLASETRON
Schedule 4
DOLUTEGRAVIR
Schedule 4
DOMPERIDONE
Schedule 4
DONEPEZIL
Schedule 4
DOPAMINE
Schedule 4
DOPEXAMINE
Schedule 4
DORAMECTIN
Schedule 7
Schedule 6
Schedule 5
DORIPENEM
Schedule 4
DORNASE
Schedule 4
DORZOLAMIDE
Schedule 4
DOSULEPIN
cross reference: DOTHIEPIN.
Schedule 4
Appendix K
DOTHIEPIN
cross reference: DOSULEPIN
DOXANTRAZOLE
Schedule 4
DOXAPRAM
Schedule 4
DOXAZOSIN
Schedule 4
DOXEPIN
Schedule 4
Appendix K
DOXORUBICIN
Schedule 4
DOXYCYCLINE
Schedule 4
DOXYLAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
2,2-DPA
cross reference: SODIUM 2,2-DICHLOROPROPIONATE
Appendix B, Part 3
DROMETRIZOLE TRISILOXANE
Appendix B, Part 3
DRONABINOL
cross reference: DELTA-9-TETRAHYDROCANNABINOL, NABIXIMOLS
Schedule 8
Appendix D, Item 3
Appendix K
DRONEDARONE
Schedule 4
DROPERIDOL
Schedule 4
Appendix K
DROSPIRENONE
Schedule 4
DROSTANOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
DROTEBANOL
Schedule 8
DROTRECOGIN
Schedule 4
DSMA
Schedule 7
Schedule 6
DUBOISIA LEICHHARDTII
Schedule 4
Schedule 2
DUBOISIA MYOPOROIDES
Schedule 4
Schedule 2
DUDDINGTONIA FLAGRANS, STRAIN IAH 1297
Appendix B, Part 3
DULCIN
Schedule 10
DULOXETINE
Schedule 4
Appendix K
DUPILUMAB
Schedule 4
DURVALUMAB
Schedule 4
DUTASTERIDE
Schedule 4
DYDROGESTERONE
Schedule 4
E
(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL
cross reference: UNICONAZOLE-P
Schedule 6
ECGONINE
Schedule 9
ECONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
ECOTHIOPATE
cross reference: ECOTHIOPATE IODIDE
Schedule 4
ECTYLUREA
Schedule 4
ECULIZUMAB
Schedule 4
EDETIC ACID
cross reference: DICOBALT EDETATE
Schedule 4
EDOXUDINE
Schedule 4
EDROPHONIUM
Schedule 4
EFALIZUMAB
Schedule 4
EFAVIRENZ
Schedule 4
EFLORNITHINE
Schedule 4
EFORMOTEROL
cross reference: FORMOTEROL
ELBASVIR
Schedule 4
ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS
Appendix A
ELECTRONIC COMPONENTS
Appendix A
ELETRIPTAN
Schedule 4
ELOSULFASE ALFA
Schedule 4
ELOTUZUMAB
Schedule 4
ELTENAC
Schedule 4
ELTROMBOPAG
Schedule 4
ELUXADOLINE
Schedule 4
ELVITEGRAVIR
Schedule 4
EMAMECTIN
Schedule 7
Schedule 6
Schedule 5
EMEPRONIUM
Schedule 4
EMETINE
cross reference: CEPHAELIS ACUMINATA
Schedule 4
EMODEPSIDE
Schedule 6
Schedule 5
EMPAGLIFLOZIN
Schedule 4
EMTRICITABINE
Schedule 4
ENALAPRIL
Schedule 4
ENCORAFENIB
Schedule 4
ENDOSULFAN
Schedule 7
Schedule 6
ENDOTHAL
Schedule 7
Schedule 6
ENDRIN
Schedule 7
ENESTEBOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ENFLURANE
Schedule 4
ENFUVIRTIDE
Schedule 4
ENHANCING AGENTS
cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS, ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING
Appendix A
ENOBOSARM
Schedule 4
Appendix D, Item 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS)
ENOXACIN
Schedule 4
ENOXAPARIN
Schedule 4
ENOXIMONE
Schedule 4
ENPROSTIL
Schedule 4
ENROFLOXACIN
Schedule 4
ENTACAPONE
Schedule 4
ENTECAVIR
Schedule 4
ENZALUTAMIDE
Schedule 4
Appendix D, Item 6
Appendix F, Part 3
Appendix L, Part 2
EPHEDRA spp.
Schedule 4
EPHEDRINE
cross reference: EPHEDRA
Schedule 4
Appendix D, Item 5
Appendix F, Part 3
EPICHLOROHYDRIN
Schedule 7
Appendix F, Part 3
Appendix J, Part 2
EPICILLIN
Schedule 4
EPIDERMAL GROWTH FACTOR
cross reference: SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1
Schedule 7
Appendix G
Appendix J, Part 2
EPINASTINE
Schedule 4
EPINEPHRINE
cross reference: ADRENALINE
EPIRUBICIN
Schedule 4
EPITIOSTANOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
EPLERENONE
Schedule 4
EPOETINS
cross reference: METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Schedule 4
Appendix D, Item 5
EPOPROSTENOL
Schedule 4
EPOXICONAZOLE
Schedule 5
EPOXY RESINS, LIQUID
cross reference: RESINS
Schedule 5
Appendix E, Part 2,
Appendix F, Part 3
EPRINOMECTIN
Schedule 7
Schedule 6
Schedule 5
EPROSARTAN
Schedule 4
EPSIPRANTEL
Appendix B, Part 3
EPTC
Schedule 6
EPTIFIBATIDE
Schedule 4
EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
cross reference: IMMUNOGLOBULINSERGOMETRINE
Schedule 4
ERENUMAB
Schedule 4
ERGOT
Schedule 4
ERGOTAMINE
Schedule 4
ERGOTOXINE
Schedule 4
ERIBULIN MESILATE
cross reference: ERIBULIN MESYLATE
Schedule 4
ERLOTINIB
Schedule 4
ERTAPENEM
Schedule 4
ERTUGLIFLOZIN
Schedule 4
ERYSIMUM spp.
Schedule 4
Appendix G
ERYTHRITYL TETRANITRATE
Schedule 3
ERYTHROMYCIN
Schedule 4
ERYTHROPOIETIN
Schedule 4
Appendix D, Item 5
ERYTHROPOIETINS
Schedule 4
Appendix D, Item 5
ESBIOTHRIN
Schedule 6
Schedule 5
ESCITALOPRAM
Schedule 4
ESFENVALERATE
Schedule 6
Schedule 5
ESMOLOL
Schedule 4
ESOMEPRAZOLE
Schedule 4
Schedule 2
Appendix H
ESTRADIOL
Schedule 5
Schedule 4
Appendix G
ESTRAMUSTINE
Schedule 4
ESTRIOL
Schedule 4
ESTROGENS
Schedule 4
ESTRONE
Schedule 4
Appendix G
ESTROPIPATE
cross reference: PIPERAZINE ESTRONE SULFATE
Schedule 4
ETACONAZOLE
Schedule 7
Appendix J, Part 2
ETACRYNIC ACID
Schedule 4
ETAFEDRINE
Schedule 2
ETANERCEPT
Schedule 4
ETHACRYNIC ACID
cross reference: ETACRYNIC ACID
ETHAMBUTOL
Schedule 4
ETHAMETSULFURON-METHYL
Appendix B, Part 3
ETHAMIVAN
Schedule 4
1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE
cross reference: N-METHYLMETHANAMINE
Schedule 5
ETHANOL
cross reference: ETHYL ALCOHOL
ETHANOLAMINE
cross reference: MONOETHANOLAMINE
ETHCHLORVYNOL
Schedule 4
ETHEPHON
Schedule 6
ETHER
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
ETHINAMATE
Schedule 4
ETHINYLESTRADIOL
Schedule 4
ETHINYLOESTRADIOL
cross reference: ETHINYLESTRADIOL
ETHIOFENCARB
Schedule 6
ETHION
Schedule 7
ETHIONAMIDE
Schedule 4
ETHISTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ETHOATE-METHYL
Schedule 6
ETHOFUMESATE
Schedule 5
ETHOGLUCID
Schedule 4
ETHOHEPTAZINE
Schedule 4
ETHOPABATE
Appendix B, Part 3
ETHOPROPAZINE
Schedule 4
ETHOPROPHOS
cross reference: LINSEED OIL
Schedule 7
Schedule 6
ETHOSUXIMIDE
Schedule 4
ETHOTOIN
Schedule 4
2-ETHOXYETHANOL
Schedule 7
Appendix F, Part 3
ETHOXYETHYLMERCURIC CHLORIDE
Appendix F, Part 3
ETHOXYQUIN
Schedule 5
ETHOXYSULFURON
Schedule 5
ETHOXZOLAMIDE
Schedule 4
ETHYL ACETATE
Appendix B, Part 3
ETHYL ALCOHOL
Appendix B, Part 3
ETHYL BROMIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ETHYL BUTYRATE
Appendix B, Part 3
ETHYL CHLORIDE
Schedule 4
ETHYL FORMATE
Schedule 6
ETHYL LACTATE
Appendix B, Part 3
ETHYL METHACRYLATE
Schedule 5
Appendix F, Part 3
ETHYLAMFETAMINE
cross reference: ETHYLAMPHETAMINE
Schedule 8
ETHYLBUTYLACETYL-
Appendix B, Part 3
ETHYLDIENOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ETHYLENE CHLOROHYDRIN
Schedule 6
Appendix F, Part 3
ETHYLENE DIBROMIDE
Schedule 7
Appendix J, Part 2
ETHYLENE DICHLORIDE
Schedule 6
ETHYLENE GLYCOL
cross reference: DENATONIUM BENZOATE
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
ETHYLENE GLYCOL MONOALKYL ETHERS
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ETHYLENE OXIDE
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
ETHYLESTRENOL
cross reference: ETHYLOESTRENOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ETHYLHEXANEDIOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2-ETHYLHEXANOIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ETHYLMERCURIC CHLORIDE
Appendix F, Part 3
N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE
cross reference: N-ETHYL MDA
Schedule 9
ETHYLMETHYLTHIAMBUTENE
Schedule 9
ETHYLMORPHINE
Schedule 8
Schedule 4
Schedule 2
Appendix K
ETHYLOESTRENOL
cross reference: ETHYLESTRENOL
ETHYNODIOL
cross reference: ETYNODIOL
ETICYCLIDINE
cross reference: PCE
Schedule 9
ETIDOCAINE
Schedule 4
ETIDRONIC ACID
cross reference: ETIDRONATE DISODIUM
Schedule 4
ETILEFRIN
Schedule 4
ETIPROSTON
Schedule 4
ETODOLAC
Schedule 4
ETOFENAMATE
Schedule 4
Schedule 2
ETOFENPROX
Appendix B, Part 3
ETONITAZENE
Schedule 9
ETONOGESTREL
Schedule 4
ETOPOSIDE
Schedule 4
ETORICOXIB
Schedule 4
ETORPHINE
Schedule 9
ETOXAZOLE
Appendix B, Part 3
ETOXERIDINE
Schedule 9
ETRAVIRINE
Schedule 4
ETRETINATE
Schedule 4
Appendix D, Item 5
Appendix F, Part 3
Appendix L, Part 2
ETRIDIAZOLE
Schedule 5
ETRIMFOS
Schedule 6
ETYNODIOL
cross reference: ETHYNODIOL
Schedule 4
EUBACTERIUM sp. strain DSM11798
Appendix B, Part 3
EUCALYPTUS OIL
Schedule 6
Appendix E, Part 2
EUGENOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
EUPATORIUM CANNABINUM
cross reference: HEMP AGRIMONY
Schedule 10
EVEROLIMUS
Schedule 4
EXEMESTANE
Schedule 4
EXENATIDE
Schedule 4
EXPLOSIVES
Appendix A
EXTRACT OF LEMON EUCALYPTUS
cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS
Schedule 5
EZETIMIBE
Schedule 4
F
FAMCICLOVIR
Schedule 4
Schedule 3
Appendix H
FAMOTIDINE
Schedule 4
Schedule 2,
Appendix F, Part 3
FAMPHUR
Schedule 7
Schedule 6
FARFUGIUM JAPONICUM
Schedule 10
FEBANTEL
Schedule 6
FEBUXOSTAT
Schedule 4
FELBINAC
Schedule 4
Schedule 2
FELODIPINE
Schedule 4
FELYPRESSIN
Schedule 4
FENAMIPHOS
Schedule 7
Schedule 6
FENARIMOL
Schedule 5
FENAZAFLOR
Schedule 6
FENBENDAZOLE
Schedule 5
FENBUCONAZOLE
Schedule 5
FENBUFEN
Schedule 4
FENBUTATIN OXIDE
Schedule 6
FENCAMFAMIN
Schedule 4
FENCHLORAZOLE-ETHYL
Schedule 5
FENCHLORPHOS
Schedule 6
FENCLOFENAC
Schedule 4
FENETYLLINE
Schedule 9
FENFLURAMINE
Schedule 4
Appendix K
FENFURAM
Appendix B, Part 3
FENHEXAMID
Appendix B, Part 3
FENITROTHION
Schedule 6
FENNEL OIL
Schedule 5
Appendix E, Part 2
FENOFIBRATE
Schedule 4
FENOLDOPAM
Schedule 4
FENOPROFEN
Schedule 4
FENOPROP
Schedule 5
FENOTEROL
Schedule 4
FENOXACRIM
Schedule 7
Schedule 6
FENOXAPROP-ETHYL
Schedule 5
FENOXAPROP-p-ETHYL
Schedule 5
FENOXYCARB
Appendix B, Part 3
FENPIPRAMIDE
Schedule 4
FENPIPRANE
Schedule 4
FENPROPOREX
Schedule 4
FENPROSTALENE
Schedule 4
FENPYRAZAMINE
Schedule 5
FENPYROXIMATE
Schedule 6
FENSON
Schedule 5
FENSULFOTHION
Schedule 7
FENTANYL
Schedule 8
FENTEROL
Appendix F, Part 3
FENTHION
Schedule 7
Schedule 6
Schedule 5
FENTHION-ETHYL
Schedule 7
FENVALERATE
Schedule 6
FERRIC DERISOMALTOSE
Schedule 4
FEXOFENADINE
Schedule 4
Schedule 2
FIBRINOLYSIN
Schedule 4
FIDAXOMICIN
Schedule 4
FILGRASTIM
Schedule 4
FINASTERIDE
Schedule 4
FINGOLIMOD
Schedule 4
Appendix L, Part 2
FIPRONIL
Schedule 6
Schedule 5
FIROCOXIB
Schedule 4
FLAMPROP-METHYL
Schedule 5
FLAMPROP-M-METHYL
Schedule 5
FLAVOXATE
Schedule 3
FLAZASULFURON
Schedule 5
FLECAINIDE
Schedule 4
FLEROXACIN
Schedule 4
FLOCOUMAFEN
Schedule 7
Schedule 6
FLOCTAFENINE
Schedule 4
FLONICAMID
Schedule 6
FLORASULAM
Schedule 5
FLORFENICOL
Schedule 4
FLORPYRAUXIFEN-BENZYL
Appendix B, Part 3
FLUANISONE
Schedule 4
FLUAZIFOP-BUTYL
Schedule 6
FLUAZIFOP-p-BUTYL
Schedule 6
FLUAZINAM
Schedule 6
FLUAZURON
Schedule 5
FLUBENDAZOLE
Schedule 5
FLUBENDIAMIDE
Schedule 5
FLUBROMAZEPAM
Schedule 9
FLUBROMAZOLAM
Schedule 9
FLUCHLORALIN
Schedule 5
FLUCLOROLONE
Schedule 4
FLUCLOXACILLIN
Schedule 4
FLUCOFURON
Schedule 7
Schedule 6
FLUCONAZOLE
Schedule 4
Schedule 3
Appendix F, Part 3
Appendix H
FLUCYTHRINATE
Schedule 7
FLUCYTOSINE
Schedule 4
FLUDARABINE
Schedule 4
FLUDIOXONIL
Schedule 5
FLUDROCORTISONE
Schedule 4
FLUENSULFONE
Schedule 6
FLUFENAMIC ACID
Schedule 4
FLUFENOXURON
Appendix B, Part 3
FLUMAZENIL
Schedule 4
FLUMETASONE
cross reference: FLUMETHASONE
Schedule 4
FLUMETHASONE
cross reference: FLUMETASONE
FLUMETHIAZIDE
Schedule 4
FLUMETHRIN
Schedule 6
Schedule 5
FLUMETSULAM
Appendix B, Part 3
FLUMICLORAC PENTYL
Schedule 5
FLUMIOXAZIN
Schedule 7
Schedule 6
FLUNISOLIDE
Schedule 4
FLUNITRAZEPAM
Schedule 8
Appendix D, Item 5 (Benzodiazepine derivatives)
Appendix K
FLUNIXIN MEGLUMINE
Schedule 4
FLUOCINOLONE
Schedule 4
FLUOCINONIDE
Schedule 4
FLUOCORTIN
Schedule 4
FLUOCORTOLONE
Schedule 4
FLUOMETURON
Appendix B, Part 3
FLUOPICOLIDE
Appendix B, Part 3
FLUOPYRAM
Schedule 5
FLUORESCEIN
Schedule 4
FLUORIDES
cross reference: SILICOFLUORIDES
Schedule 6
Schedule 5
Schedule 4
Schedule 3
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
Appendix H
FLUOROACETAMIDE
Schedule 7
FLUOROACETIC ACID
Schedule 7
Appendix J, Part 2
FLUOROMETHOLONE
Schedule 4
4-FLUORO-N-METHYLAMFETAMINE
cross reference: 4-FLUORO-N-METHYLAMPHETAMINE, 4-FLUORO-N-METHAMFETAMINE
Schedule 9
1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE
cross reference: AM-694
Schedule 9
FLUOROURACIL
Schedule 4
FLUOXETINE
Schedule 4
FLUOXYMESTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
FLUPENTIXOL
cross reference: FLUPENTHIXOL
Schedule 4
Appendix K
FLUPHENAZINE
Schedule 4
Appendix K
FLUPROPANATE
cross reference: TETRAPION
Schedule 6
FLUPROSTENOL
Schedule 4
FLUPYRADIFURONE
Schedule 6
FLUQUINCONAZOLE
Schedule 6
FLURALANER
cross-reference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE
Schedule 5
FLURANDRENOLONE
Schedule 4
FLURAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
Appendix K
FLURBIPROFEN
Schedule 4
Schedule 2
FLUOROACETAMIDE
Appendix J, Part 2
FLUROXENE
Schedule 4
FLUROXYPYR
Appendix B, Part 3
FLUSILAZOL
Schedule 6
FLUSPIRILENE
Schedule 4
FLUTAMIDE
Schedule 4
FLUTICASONE
cross reference: FLUTICASONE PROPIONATE, FLUTICASONE FUROATE
Schedule 4
FLUTICASONE FUROATE
cross reference FLUTICASONE
FLUTICASONE PROPIONATE
Schedule 4
Schedule 2
FLUTOLANIL
Appendix B, Part 3
FLUTRIAFOL
Schedule 6
FLUVALINATE
Schedule 6
Schedule 5
FLUVASTATIN
Schedule 4
FLUVOXAMINE
Schedule 4
FLUXAPYROXAD
Schedule 5
FOLIC ACID
Schedule 4
Schedule 2
FOLINIC ACID
cross reference: CALCIUM FOLINATE
Schedule 4
Schedule 2
FOLLICLE-STIMULATING HORMONE
Schedule 4
Appendix D, Item 1
FOLLISTATIN
Schedule 4
Appendix D, Item 5
FOLLITROPIN ALFA
cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
Schedule 4
Appendix D, Item 1
FOLLITROPIN BETA
cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
Schedule 4
Appendix D, Item 1
FOLLITROPIN DELTA
cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
Schedule 4
Appendix D, Item 1
FOLPET
Schedule 7
Appendix J, Part 2
FOMEPIZOLE
Schedule 4
FOMIVIRSEN
Schedule 4
FONDAPARINUX
Schedule 4
FOOD
Appendix A
FORAMSULFURON
Schedule 5
FORCHLORFENURON
Appendix B, Part 3
FORMALDEHYDE
cross reference: FORMALDEHYDE CONDENSATION PRODUCT, METACRESOLSULPHONIC ACID, FREE FORMALDEHYDE, METHYLENE GLYCOL
Schedule 10
Schedule 6
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
FORMALDEHYDE CONDENSATION PRODUCT
Schedule 6
FORMEBOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
FORMESTANE
Schedule 4
FORMETANATE
Schedule 7
FORMIC ACID
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
FORMOTEROL
Schedule 4
FORMOTHION
Schedule 6
FOSAMPRENAVIR
Schedule 4
FOSAPREPITANT
Schedule 4
FOSCARNET
Schedule 4
FOSFESTROL
cross reference: DIETHYLSTILBESTROL DIPHOSPHATE
Schedule 4
FOSFOMYCIN
Schedule 4
FOSINOPRIL
Schedule 4
FOSPHENYTOIN
Schedule 4
FOSPIRATE
Schedule 6
Schedule 5
FOSTHIAZATE
Schedule 7
FOTEMUSTINE
Schedule 4
FRAMYCETIN
Schedule 4
FRITTED GLAZING OR ENAMELLING PREPARATIONS
Appendix A
FULLERS EARTH
Appendix B, Part 3
FULVESTRANT
Schedule 4
FUMAGILLIN
Schedule 6
FUNGAL PROTEASE derived from Aspergillus niger
Appendix B, Part 3
FURALAXYL
Schedule 5
FURALTADONE
Schedule 4
FURATHIOCARB
Schedule 7
Schedule 5
FURAZABOL
Schedule 4
FURAZOLIDONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
FURETHIDINE
Schedule 9
FURFURAL
cross reference: 2-FURANCARBOXALDEHYDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
FUROSEMIDE
cross reference: FRUSEMIDE
Schedule 4
FUSIDIC ACID
Schedule 4
G
GABAPENTIN
Schedule 4
Appendix K
GALANTAMINE
Schedule 4
GALANTHUS spp.
Schedule 4
GALLAMINE
Schedule 4
GALSULFASE
Schedule 4
GAMMA BUTYROLACTONE
Schedule 10
GAMMA HYDROXYBUTYRATE
cross reference: 4-HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE
Schedule 9
GAMMA-CYHALOTHRIN
Schedule 5
Schedule 7
GANCICLOVIR
Schedule 4
GANIRELIX
Schedule 4
GATIFLOXACIN
Schedule 4
GEFITINIB
Schedule 4
GELSEMIUM SEMPERVIRENS
Schedule 2
Appendix G
GEMCITABINE
Schedule 4
Appendix K
GEMEPROST
Schedule 4
GEMFIBROZIL
Schedule 4
GEMIFLOXACIN
Schedule 4
GEMTUZUMAB OZOGAMICIN
Schedule 4
GENTAMICIN
Schedule 4
GENTIAN VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET
GERANIUM OIL
Appendix B, Part 3
GESTODENE
Schedule 4
GESTONORONE
Schedule 4
GESTRINONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
GHRH INJECTABLE PLASMID
Schedule 4
GIBBERELLIC ACID
Appendix B, Part 3
GITALIN
Schedule 4
GLASS
cross reference: CRYSTAL WARE
Appendix A
GLATIRAMER ACETATE
Schedule 4
GLAZED POTTERY
Appendix A
GLECAPREVIR
Schedule 4
GLIBENCLAMIDE
Schedule 4
GLIBORNURIDE
Schedule 4
GLICLAZIDE
Schedule 4
GLIMEPIRIDE
Schedule 4
GLIPIZIDE
Schedule 4
GLISOXEPIDE
Schedule 4
GLUCAGON
Schedule 3
Appendix G
Appendix H
α-GLUCANASE derived from Aspergillus niger
Appendix B, Part 3
GLUFOSINATE-AMMONIUM
Schedule 5
GLUTARAL
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
GLUTARALDEHYDE
cross reference: GLUTARAL
GLUTATHIONE
Schedule 4
GLUTETHIMIDE
Schedule 4
Appendix D, Item 5
Appendix K
GLYCERYL THIOGLYCOLLATE
Schedule 6
GLYCERYL TRINITRATE
Schedule 4
Schedule 3
Appendix G
GLYCOLIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
GLYCOPYRRONIUM
Schedule 4
Schedule 3
GLYCOSYLATED HYDROQUINONE
cross reference: HYDROQUINONE
GLYMIDINE
Schedule 4
GLYPHOSATE
Schedule 5
GnRH VACCINE
Schedule 4
GOLIMUMAB
Schedule 4
GONADORELIN
Schedule 4
GONADOTROPHIC HORMONES
Schedule 4
GOSERELIN
Schedule 4
GRAMICIDIN
Schedule 4
GRANISETRON
Schedule 4
GRAZOPREVIR
Schedule 4
GREPAFLOXACIN
Schedule 4
GRISEOFULVIN
Schedule 4
GROWTH HORMONE RELEASING HORMONES *(GHRHs)
Schedule 4
Appendix D, Item 5
GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6)
Schedule 4
Appendix D, Item 5
GROWTH HORMONE RELEASING PEPTIDE *(GHRPs)
Schedule 4
Appendix D, Item 5
GROWTH HORMONE SECRETAGOGUES *(GHSs)
Schedule 4
Appendix D, Item 5
GUAIFENESIN
cross reference: PARACETAMOL
Schedule 4
Schedule 2
GUAIPHENESIN
cross reference: GUAIFENESIN
GUANABENZ
Schedule 4
GUANACLINE
Schedule 4
GUANETHIDINE
Schedule 4
GUANFACINE
Schedule 4
Appendix K
GUANIDINE
Schedule 6
Schedule 4
Appendix E, Part 2
GUAZATINE
Schedule 6
GUSELKUMAB
Schedule 4
H
HACHIMYCIN
Schedule 4
HAEMATIN
Schedule 4
HAEMOPHILUS INFLUENZAE VACCINE
Schedule 4
HALAUXIFEN METHYL
Appendix B, Part 3
HALCINONIDE
Schedule 4
HALOFANTRINE
Schedule 4
HALOFENATE
Schedule 4
HALOFUGINONE
Schedule 7
Schedule 4
Appendix J, Part 2
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS
cross reference: DIBENZODIOXINS, HALOGENATED - DIBENZOFURANS, HALOGENATED, DIOXINS
Schedule 7
Appendix J, Part 2
HALOPERIDOL
cross reference: BUTYPHENONES
Schedule 4
Appendix G
Appendix K
HALOSULFURON-METHYL
Schedule 5
HALOTHANE
Schedule 4
HALOXON
Schedule 6
HALOXYFOP
Schedule 6
HARMALA ALKALOIDS
Schedule 9
HC RED 13
cross reference: 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL
HC VIOLET 1
cross reference: 2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
HCB
Schedule 7
Appendix J, Part 2
HELIOTROPIUM spp.
Schedule 10
HEMEROCALLIS
Schedule 4
HEPARINS
Schedule 4
HEPATITIS A VACCINE
Schedule 4
HEPATITIS B VACCINE
Schedule 4
HEPTACHLOR
Schedule 6
HEROIN
Schedule 9
HETACILLIN
Schedule 4
HEXACHLOROPHANE
cross reference: HEXACHLOROPHENE
HEXACHLOROPHENE
cross reference: HCB
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
HEXACONAZOLE
Schedule 5
HEXAFLURON
Appendix B, Part 3
HEXAMETHONIUM
Schedule 4
HEXARELIN
Schedule 4
Appendix D, Item 5
HEXAZINONE
Schedule 6
Schedule 5
HEXETIDINE
Schedule 4
HEXLOXYETHANOL
Appendix F, Part 3
HEXOBENDINE
Schedule 4
HEXOCYCLIUM
Schedule 4
HEXOPRENALINE
Schedule 4
HEXYL ACETATE
Appendix B, Part 3
HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)
Schedule 4
HEXYL CINNAMALDEHYDE
Appendix B, Part 3
3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN
cross reference: PARAHEXYL
Schedule 9
HEXYLOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
HEXYTHIAZOX
Appendix B, Part 3
HISTAMINE
Schedule 4
HMG-CoA REDUCTASE INHIBITORS
cross reference: STATINS
Schedule 4
HOMATROPINE
Schedule 4
HUMAN BLOOD PRODUCTS
cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA, PLATELETS, PROTEIN C, PROTHROMBIN COMPLEX CONCENTRATE (PCC), RED CELLS, THROMBIN, WHOLE BLOOD, STEM CELLS
Appendix A
HUMAN CHORIONIC GONADATROPHIN
Schedule 4
HUMAN OSTEOGENIC PROTEIN-1 (OP-1)
Appendix B, Part 3
HUMAN PAPILLOMAVIRUS VACCINE
Schedule 4
HYALURONIC ACID
Schedule 4
HYDRALAZINE
Schedule 4
HYDRAMETHYLNON
Schedule 6
Schedule 5
HYDRARGAPHEN
Schedule 4
HYDRAZINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
HYDROCARBONS LIQUID AROMATIC
cross reference: AROMATIC EXTRACT OILS,
Schedule 7
Appendix F, Part 3
HYDROCARBONS, LIQUID
cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID HYDROCARBONS, MINERAL OILS, MINERAL TURPENTINE, NAPHTHALENE, PARAFFIN OILS, PETROL, PETROLEUM OILS, REDUCERS, THINNERS, TOLUENE, WHITE SPIRIT, WHITE PETROLEUM SPIRIT, WHITE MINERAL OILS, XYLENE
Schedule 5
Appendix E, Part 2
Part 1 - Interpretation
HYDROCHLORIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
HYDROCHLOROTHIAZIDE
Schedule 4
HYDROCODONE
Schedule 8
Appendix K
HYDROCORTISONE
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3,
Appendix H
HYDROCORTISONE ACETATE
Schedule 3
Schedule 2
HYDROCYANIC ACID
cross reference: CYANIDES
Schedule 7
Schedule 4,
Appendix F, Part 3,
Appendix J, Part 2
HYDROFLUMETHIAZIDE
Schedule 4
HYDROFLUORIC ACID
cross reference: HYDROGEN FLUORIDE
Schedule 7
Schedule 6
Schedule 5
Appendix J, Part 2
HYDROGEN PEROXIDE
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
HYDROGEN SULFIDE
Schedule 7
HYDROMORPHINOL
Schedule 8
HYDROMORPHONE
Schedule 8
Appendix K
HYDROPRENE
Appendix B, Part 3
HYDROQUINONE
cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
HYDROSILICOFLUORIC ACID
cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID, HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
4-HYDROXYBUTANOIC ACID
Schedule 9
HYDROXYCARBAMIDE
Schedule 4
HYDROXYCHLOROQUINE
Schedule 4
2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL
cross reference: CANNABICYCLOHEXANOL, CP 47,497 C8 HOMOLOGUE, CP 47,497
Schedule 9
HYDROXYEPHEDRINE
Schedule 4
4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL
cross reference: 3-NITRO-p-HYDROXYETHYLAMINOPHENOL
2-HYDROXYETHYL METHACRYLATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
[7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0)
cross reference: BASIC RED 76 (CAS No. 68391-30-0)
HYDROXYPETHIDINE
Schedule 9
HYDROXYPHENAMATE
Schedule 4
HYDROXYPROGESTERONE
Schedule 4
HYDROXYPROPYL CELLULOSE
Appendix B, Part 3
2-HYDROXYPROPYL METHACRYLATE
Schedule 5
8-HYDROXYQUINOLINE
cross reference: OXYQUINOLINE
HYDROXYSTENOZOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
HYDROXYUREA
cross reference: HYDROXYCARBAMIDE
HYDROXYZINE
Schedule 4, Appendix K
HYGROMYCIN
Schedule 4
HYOSCINE
cross reference: HYOSCINE BUTYLBROMIDE
Schedule 4
Schedule 2
Appendix G
HYOSCINE BUTYLBROMIDE
Schedule 2
HYOSCYAMINE
Schedule 2
Appendix G
HYOSCYAMUS NIGER
Schedule 2
Appendix G
HYPOTHALAMIC RELEASING FACTORS
Schedule 4
Appendix G
HYPROMELLOSE
Schedule 4
I
IBAFLOXACIN
Schedule 4
IBANDRONIC ACID
Schedule 4
IBOGAINE
Schedule 4
IBRITUMOMAB
Schedule 4
IBRUTINIB
Schedule 4
IBUFENAC
Schedule 4
IBUPROFEN
cross reference: PARACETAMOL
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
IBUTAMOREN
cross reference: MK-677, Nutrobal
Schedule 4
Appendix D, Item 5
IBUTEROL
Schedule 4
IBUTILIDE
Schedule 4
ICATIBANT
Schedule 4
ICODEXTRIN
Appendix B, Part 3
IDARUBICIN
Schedule 4
IDARUCIZUMAB
Schedule 4
IDEBENONE
Schedule 4
IDOXURIDINE
Schedule 4
IDURSULFASE
Schedule 4
IFOSFAMIDE
Schedule 4
ILOPROST
Schedule 4
IMATINIB
Schedule 4
IMAZALIL
cross reference: ENILCONAZOLE
Schedule 5
IMAZAMOX
Schedule 5
IMAZAPIC
Schedule 5
IMAZAPYR
Schedule 5
IMAZETHAPYR
Schedule 5
IMEPITOIN
Schedule 4
IMIDACLOPRID
Schedule 6
Schedule 5
IMIDAPRIL
Schedule 4
IMIDOCARB
Schedule 6
IMIGLUCERASE
Schedule 4
IMINOCTADINE TRIALBESILATE
Schedule 6
IMIPENIM
Schedule 4
IMIPRAMINE
Schedule 4
Appendix K
IMIPROTHRIN
Schedule 6
Schedule 5
IMIQUIMOD
Schedule 4
IMMUNOGLOBULINS
cross reference: EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
Schedule 4
IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS
Appendix A
INDACATEROL
Schedule 4
INDANAZOLINE
Schedule 2
INDAPAMIDE
Schedule 4
INDAZIFLAM
Schedule 6
INDINAVIR
Schedule 4
INDOLE-3-ACETIC ACID
Appendix B, Part 3
INDOMETACIN
Schedule 4
Schedule 2
Appendix G
INDOMETHACIN
cross reference: INDOMETACIN
INDOPROFEN
Schedule 4
INDORAMIN
Schedule 4
INDOXACARB
Schedule 6
Schedule 5
INFLIXIMAB
Schedule 4
INFLUENZA AND CORYZA VACCINES
cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ
Schedule 4
INGENOL MEBUTATE
Schedule 4
INOTUZUMAB OZOGAMICIN
Schedule 4
INOSITOL NICOTINATE
Schedule 3
INSULIN DEGLUDEC
Schedule 4
INSULIN GLARGINE
Schedule 4
INSULIN-LIKE GROWTH FACTOR I
Schedule 4
INSULIN-LIKE GROWTH FACTORS
Schedule 4
Appendix D, Item 5
INSULINS
Schedule 4
INTERFERONS
Schedule 4
INTERLEUKINS
Schedule 4
INTRAOCULAR VISCOELASTIC PRODUCTS
Appendix A
IODINE
cross reference: IODOPHORS
Schedule 6
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
IODOMETHANE
Schedule 7
Appendix J, Part 2
IODOPHORS
cross reference: IODINE
Schedule 6
Appendix E, Part 2
3-IODO-2-PROPYNYL BUTYL CARBAMATE
cross reference: IODOCARB
Schedule 6
Schedule 5
IODOSULFURON-METHYL-SODIUM
Schedule 5
IODOTHIOURACIL
Schedule 4
IOXYNIL
Schedule 6
IPAMORELIN
Schedule 4,
Appendix D, Item 5
IPCONAZOLE
Schedule 6
Schedule 5
IPILIMUMAB
Schedule 4
IPRATROPIUM
Schedule 4
Schedule 2
IPRATROPIUM BROMIDE
Appendix F, Part 3
IPRIFLAVONE
Schedule 4
IPRINDOLE
Schedule 4
IPRODIONE
Appendix B, Part 3
IPRONIAZID
Schedule 4
IRBESARTAN
Schedule 4
IRINOTECAN
Schedule 4
IRON COMPOUNDS
cross reference: IRON OXIDES
Schedule 6
Schedule 5
Schedule 4
Schedule 2
ISETHIONATE
Appendix B, Part 3
ISOAMINILE
Schedule 4
ISOAMYL NITRITE
Schedule 4
ISOBUTYL NITRITE
Schedule 4
ISOCARBOPHOS
Schedule 7
ISOCARBOXAZID
Schedule 4
ISOCONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix H
ISOCYANATES
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ISOETARINE
Schedule 4
ISOEUGENOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
ISOFENPHOS
Schedule 7
ISOFETAMID
Appendix B, Part 3
ISOFLURANE
Schedule 4
ISOMETHADONE
Schedule 9
ISOMETHEPTENE
Schedule 4
ISONIAZID
Schedule 4
ISOPHORONE
Schedule 5
Appendix E, Part 2
ISOPRENALINE
Schedule 4
Appendix F, Part 3
ISOPRENE ALCOHOL
Appendix B, Part 3
ISOPRINOSINE
Schedule 4
ISOPROPAMIDE
Schedule 4
Schedule 2
ISOPROTURON
Schedule 7
ISOPYRAZAM
Schedule 6
ISOSORBIDE DINITRATE
Schedule 4
Schedule 3
ISOSORBIDE MONONITRATE
Schedule 4
ISOSTEARYL ALCOHOL ETHOXYLATE
Appendix B, Part 3
ISOTRETINOIN
Schedule 4
Appendix D, Item 5
Appendix F, Part 3
Appendix L, Part 2
ISOXABEN
Schedule 5
ISOXAFLUTOLE
Schedule 5
ISOXICAM
Schedule 4
ISOXSUPRINE
Schedule 4
ISRADIPINE
Schedule 4
ITRACONAZOLE
Schedule 4
IVABRADINE
Schedule 4
IVACAFTOR
Schedule 4
IVERMECTIN
Schedule 7
Schedule 5
Schedule 4
IXABEPILONE
Schedule 4
IXAZOMIB
Schedule 4
IXEKIZUMAB
Schedule 4
J
JAPANESE ENCEPHALITIS VACCINE
Schedule 4
JUNIPERUS SABINE
cross reference: SAVIN(E)
Schedule 10
K
KANAMYCIN
Schedule 4
KAOLIN
Appendix B, Part 3
KEROSENE
Appendix E, Part 2
KETAMINE
Schedule 8
KETANSERIN
Schedule 4
KETAZOLAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
KETOBEMIDONE
Schedule 9
KETOCONAZOLE
Schedule 4
Schedule 2
KETOPROFEN
Schedule 4
Schedule 3
Appendix H
KETOROLAC
Schedule 4
KETOTIFEN
Schedule 4
Schedule 2
KHELLIN
Schedule 4
KITASAMYCIN
Schedule 5
Schedule 4
KRESOXIM-METHYL
Appendix B, Part 3
KUNZEA OIL
Appendix B, Part 3
L
LABETALOL
Schedule 4
LACIDIPINE
Schedule 4
LACOSAMIDE
Schedule 4
LAMBDA-CYHALOTHRIN
Schedule 7
Schedule 6
Schedule 5
LAMIVUDINE
Schedule 4
LAMOTRIGINE
Schedule 4
Appendix K
LANADELUMAB
Schedule 4
LANATOSIDES
Schedule 4
LANREOTIDE
Schedule 4
LANSOPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
LANTHANUM
Schedule 4
LAPATINIB
Schedule 4
LARONIDASE
Schedule 4
LAROPIPRANT
Schedule 4
LASALOCID
Schedule 6
LASIODIPLODIA PSEUDOTHEOBROMAE
Schedule 5
LATAMOXEF
Schedule 4
LATANOPROST
Schedule 4
LAUDEXIUM
Schedule 4
LAURETH CARBOXYLIC ACIDS
Schedule 6
Appendix E, Part 2
LAURIC ACID
Appendix B, Part 3
LAUROMACROGOLS
cross reference: LAURETH-9
Schedule 4
LAURYL ALCOHOL
cross reference: 1-DODECANOL
Appendix B, Part 3
LAURYL ISOQUINOLINIUM BROMIDE
Schedule 6
Appendix E, Part 2
LAURYL SULFATE SALTS
cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES
Schedule 6
Appendix E, Part 2
LAVANDIN OIL
cross reference: CAMPHOR
Appendix B, Part 3
LAVENDER OIL
Appendix B, Part 3
LEAD
cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM
Schedule 4
LEAD COMPOUNDS
cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix F, Part 3
LEAD METALLIC
Appendix B, Part 3
LEDIPASVIR
Schedule 4
LEFETAMINE
Schedule 4
LEFLUNOMIDE
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
LEMON OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
LEMONGRASS OIL
Schedule 5
LENALIDOMIDE
Schedule 4
Appendix D, Item 4
Appendix F, Part 3
Appendix L
LENOGRASTIM
Schedule 4
LENVATINIB
Schedule 4
LEPIDOPTEROUS SEX PHEROMONES
Appendix B, Part 3
LEPIRUDIN
Schedule 4
LEPTAZOL
Schedule 4
LEPTOPHOS
Schedule 7
LEPTOSPERMUM SCOPARIUM OIL
cross reference: MANUKA OIL
Schedule 6
Appendix E, Part 2
LERCANIDIPINE
Schedule 4
LESINURAD
Schedule 4
LETERMOVIR
Schedule 4
LETROZOLE
Schedule 4
LEUPRORELIN
Schedule 4
LEVALLORPHAN
Schedule 4
LEVAMISOLE
Schedule 6
Schedule 5
Schedule 4
LEVAMFETAMINE
cross reference: LEVAMPHETAMINE
Schedule 8
LEVETIRACETAM
Schedule 4
Appendix K
LEVOBUNOLOL
Schedule 4
LEVOBUPIVACAINE
Schedule 4
LEVOCABASTINE
Schedule 4
Schedule 2
Appendix F, Part 3
Appendix L, Part 2
LEVOCETIRIZINE
Schedule 4
Schedule 2
Appendix K
LEVODOPA
Schedule 4
LEVOMEPROMAZINE
cross reference: METHOTRIMEPRAZINE
Schedule 4
LEVOMETHAMFETAMINE
cross reference: LEVOMETHAMPHETAMINE
Schedule 8
LEVOMETHORPHAN
Schedule 9
LEVOMILNACIPRAN
Schedule 4
LEVOMORAMIDE
Schedule 8
LEVONORGESTREL
Schedule 4
Schedule 3
Appendix H
LEVOPHENACYLMORPHAN
Schedule 9
LEVORPHANOL
Schedule 8
LEVOSIMENDAN
Schedule 4
LIDOCAINE
Schedule 5
Schedule 4
Schedule 2
LIDOFLAZINE
Schedule 4
LIFITEGRAST
Schedule 4
LIGNOCAINE
cross reference: LIDOCAINE
LIGULARIA DENTATA
Schedule 10
LIME OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
LIMONENE
cross reference: DIPENTENE
Appendix B, Part 3
LINAGLIPTIN
Schedule 4
LINCOMYCIN
Schedule 4
LINDANE
cross reference: BHC
Schedule 6
Schedule 5
Schedule 4
Schedule 2
LINEZOLID
Schedule 4
LINOLEIC ACID
Appendix B, Part 3
LINSEED FATTY ACIDS
Appendix B, Part 3
LINURON
Appendix B, Part 3
LIOTHYRONINE
cross reference: TRIIODOTHYRONINE
Schedule 4
LIPEGFILGRASTIM
Schedule 4
LIQUORICE, DEGLYCYRRHISINISED
Appendix B, Part 3
LIRAGLUTIDE
Schedule 4
LISDEXAMFETAMINE
Schedule 8
LISINOPRIL
Schedule 4
LISURIDE
Schedule 4
LITHIUM
Schedule 4
Schedule 2
LITHIUM PERFLUOROOCTANE SULFONATE
Schedule 7
LIXISENATIDE
Schedule 4
LOBELIA INFLATA
Schedule 2
LOBELINE
Schedule 2
LODOXAMIDE
Schedule 4
Schedule 2
LOFEXIDINE
Schedule 4
LOGIPARIN
Schedule 4
LOMEFLOXACIN
Schedule 4
LOMUSTINE
Schedule 4
LOPERAMIDE
Schedule 4
Schedule 2
Appendix F, Part 3
LOPINAVIR
Schedule 4
LOPRAZOLAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
LORACARBEF
Schedule 4
LORATADINE
Schedule 4
Schedule 2
LORAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
Appendix K
LORMETAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
LOSARTAN
Schedule 4
LOTEPREDNOL
Schedule 4
LOTILANER
Schedule 5
LOXAPINE
Schedule 4
LUBRICANTS
Appendix A
LUFENURON
Schedule 5
LUMACAFTOR
Schedule 4
LUMEFANTRINE
Schedule 4
LUMIRACOXIB
Schedule 4
LURASIDONE
Schedule 4
Appendix K
LUTEINISING HORMONE
Schedule 4
Appendix D, Item 1
LYMECYCLINE
Schedule 4
LYSERGIC ACID
Schedule 9
LYSERGIDE
Schedule 9
M
MACITENTAN
Schedule 4
Appendix D, Item 6
Appendix L, Part 2
MACROGOLS
Schedule 3
Schedule 2
MACROPHOMINA PHASEOLINA
Schedule 5
MADURAMICIN
Schedule 7
Schedule 5
Appendix J, Part 2
MAFENIDE
Schedule 6
Schedule 4
MAGNESIUM CHLORATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
MAGNESIUM SULFATE
Schedule 3
MALACHITE GREEN
Schedule 7
Schedule 5
MALATHION
cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS
Schedule 6
Schedule 5
Schedule 3
Appendix E, Part 2
MALEIC HYDRAZIDE
Appendix B, Part 3
MANCOZEB
Schedule 5
MANDESTROBIN
Schedule 5
MANDIPROPAMID
Schedule 5
MANDRAGORA OFFICINARUM
Schedule 4
MANGANESE DIOXIDE
Appendix B, Part 3
MANNITYL HEXANITRATE
Schedule 3
MANNOMUSTINE
Schedule 4
MAPROTILINE
Schedule 4
MARAVIROC
Schedule 4
MARBOFLOXACIN
Schedule 4
MARJORAM OIL
Schedule 5
Appendix E, Part 2
MAROPITANT
Schedule 4
MATCHES
Appendix A
MAVACOXIB
Schedule 4
MAZIDOX
Schedule 7
MAZINDOL
Schedule 4
Appendix K
MCPA
Schedule 6
Schedule 5
MCPB
Schedule 5
MEASLES VACCINE
Schedule 4
MEBANAZINE
Schedule 4
MEBENDAZOLE
Schedule 6
Schedule 5
Schedule 2
MEBEVERINE
Schedule 4
MEBHYDROLIN
Schedule 4
Appendix K
MEBOLAZINE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
MEBUTAMATE
Schedule 4
MECAMYLAMINE
Schedule 4
MECARBAM
Schedule 7
MECASERMIN
Schedule 4
MECILLINAM
Schedule 4
MECLOCYCLINE
Schedule 4
MECLOFENAMATE
Schedule 4
MECLOFENAMIC ACID
Schedule 5
MECLOFENOXATE
Schedule 4
MECLONAZEPAM
Schedule 9
MECLOQUALONE
Schedule 9
MECLOZINE
Schedule 4
Schedule 2
Appendix K
MECOPROP
Schedule 6
Schedule 5
MECOPROP-P
Schedule 6
MEDAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
Appendix K
MEDETOMIDINE
Schedule 4
MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS
Appendix A
MEDICAL DEVICES
cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS, INTRA-ARTICULAR FLUIDS, URINARY CATHETERS
Appendix A
MEDIGOXIN
cross reference: METHYLDIGOXIN
Schedule 4
MEDROXYPROGESTERONE
Schedule 4
MEDRYSONE
Schedule 4
MEFENAMIC ACID
Schedule 4
Schedule 2
Appendix F, Part 3
MEFENOREX
Schedule 4
MEFENPYR-DIETHYL
Schedule 5
MEFENTRIFLUCONAZOLE
Schedule 5
MEFLOQUINE
Schedule 4
MEFLUIDIDE
Schedule 6
MEFRUSIDE
Schedule 4
MEGASPHAERA ELSDENII strain 41125
Appendix B, Part 3
MEGESTROL
Schedule 4
MELAGATRAN
Schedule 4
MELALEUCA OIL
cross reference: TEA TREE OIL
Schedule 6
Appendix E, Part 2
MELANOTAN II
cross reference: α–MELANOCYTE STIMULATING HORMONE
Schedule 4
MELATONIN
Schedule 4
MELENGESTROL
Schedule 4
MELENGESTROL ACETATE
Schedule 6
MELIA AZEDARACH
Schedule 10
MELOXICAM
Schedule 4
MELPHALAN
Schedule 4
MEMANTINE
Schedule 4
MENAZON
Schedule 6
MENINGOCOCCAL VACCINE
Schedule 4
MENINGOCOCCAL GROUP B VACCINE
cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein
Schedule 4
MENOTROPHIN
Schedule 4
MEPACRINE
Schedule 4
MEPENZOLATE
Schedule 4
MEPHENESIN
Schedule 4
MEPHENTERMINE
Schedule 4
MEPINDOLOL
Schedule 4
MEPIQUAT
Schedule 5
MEPITIOSTANE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
MEPIVACAINE
Schedule 4
MEPROBAMATE
Schedule 4
Appendix K
MEPTAZINOL
Schedule 4
MEPYRAMINE
MEPYRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
MEQUITAZINE
Schedule 4
MERCAPTAMINE
cross reference: CYSTEAMINE
Schedule 6
Schedule 5
Schedule 4
Appendix K
MERCAPTOACETIC ACID
cross reference: THIOGLYCOLIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
2-MERCAPTOETHANOL
Schedule 6
MERCAPTOMERIN
Schedule 4
MERCAPTOPURINE
Schedule 4
MERCURIC CHLORIDE
cross reference: CALOMEL
Schedule 7
MERCURIC IODIDE
Appendix E, Part 2
MERCURIC NIRATE
Appendix E, Part 2
MERCURIC OXIDE
Schedule 6
Appendix E, Part 2
MERCURIC POTASSIUM IODIDE
Appendix E, Part 2
MERCURIC THIOCYANATE
Appendix E, Part 2
Appendix F, Part 3
MERCUROCHROME
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
MERCUROUS CHLORIDE
cross reference: CORROSIVE SUBLIMATE
Appendix E, Part 2
MERCURY
cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL MERCURIC CHLORIDE
Schedule 7
Schedule 4
Schedule 2
Appendix G
Appendix J, Part 2
MERCURY metallic
Appendix E, Part 2
MERCURY, organic compounds
Appendix E, Part 2
MEROPENEM
Schedule 4
MERSALYL
Schedule 4
MERCURIC CHLORIDE
Appendix E, Part 2
MESABOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
MESALAZINE
Schedule 4
MESNA
Schedule 4
MESOSULFURON-METHYL
Appendix B, Part 3
MESOTRIONE
Schedule 5
MESTANOLONE
cross reference: ANDROSTALONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
MESTEROLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
MESTRANOL
Schedule 4
METACRESOLSULPHONIC ACID
Schedule 6
Appendix F, Part 3
METAFLUMIZONE
Schedule 5
METALAXYL
Schedule 6
Schedule 5
METALDEHYDE
Schedule 6
Schedule 5
Appendix E, Part 2
METAMFETAMINE
cross reference: METHYLAMFETAMINE, METHYLAMPHETAMINE, METHAMFETAMINE, METHAMPHETAMINE
Schedule 8
METAMITRON
Schedule 6
METANDIENONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METARAMINOL
Schedule 4
METARHIZIUM ANISOPLIAE
Appendix B, Part 3
METAZACHLOR
Schedule 5
METAZOCINE
Schedule 9
METENOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METERGOLINE
Schedule 4
METFORMIN
Schedule 4
METHABENZTHIAZURON
Schedule 5
METHACHOLINE
Schedule 4
METHACRIFOS
Schedule 7
Schedule 6
Appendix J, Part 2
METHACYCLINE
Schedule 4
METHADONE
Schedule 8
Appendix K
METHALLENESTRIL
cross reference: METHALLENOESTRIL
Schedule 4
METHAM
cross reference: METHAM SODIUM
Schedule 6
METHAMIDOPHOS
Schedule 7
METHANDRIOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METHANOL
Schedule 5
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
METHANTHELINIUM
Schedule 4
METHAPYRILENE
Schedule 7
METHAQUALONE
Schedule 9
METHAZOLAMIDE
Schedule 4
METHAZOLE
Schedule 7
METHCATHINONE
Schedule 9
METHDILAZINE
Schedule 4
Schedule 3
Appendix K
METHENAMINE
cross reference: 1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE, HEXAMETHYLENETETRAMINE
Schedule 5
METHENOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METHICILLIN
Schedule 4
METHIDATHION
Schedule 7
METHIMAZOLE
cross reference: THIAMAZOLE
Schedule 4
METHIOCARB
Schedule 7
Schedule 6
Schedule 5
METHISAZONE
Schedule 4
METHIXENE
Schedule 4
METHOCARBAMOL
Schedule 4
Appendix K
METHOFLUTHRIN
Schedule 5
METHOHEXITONE
Schedule 4
METHOIN
Schedule 4
METHOMYL
cross reference: DENATONIUM BENZOATE
Schedule 7
Schedule 6
METHOPRENE
Appendix B, Part 3
METHOTREXATE
Schedule 4
METHOXAMINE
Schedule 4
Schedule 2
Appendix F, Part 3
METHOXSALEN
Schedule 4
METHOXYCHLOR
Schedule 5
2-METHOXYETHANOL
Schedule 7
Appendix F, Part 3
METHOXYETHYLMERCURIC ACETATE
Schedule 7
Appendix J, Part 2
METHOXYETHYLMERCURIC CHLORIDE
Schedule 7
Appendix J, Part 2
METHOXYFENOZIDE
Appendix B, Part 3
METHOXYFLURANE
Schedule 4
5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE
cross reference: 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE, MMDA
Schedule 9
4-METHOXY- α –METHYLPHENYLETHYLAMINE
cross reference: PMA
Schedule 9
5-METHOXY- α –METHYLTRYPTAMINE
cross reference: 5-MeO-AMT
Schedule 9
METHOXYPHENAMINE
Schedule 2
2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE
cross reference: JWH-250
Schedule 9
METHSUXIMIDE
Schedule 4
METHYCLOTHIAZIDE
Schedule 4
METHYL ACETATE
Appendix B, Part 3
METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE
cross reference: SALVINORIN A
Schedule 9
METHYL AMINOLEVULINATE
Schedule 4
p-METHYLAMINOPHENOL
Schedule 6
Appendix F, Part 3
4-METHYLAMINOREX
Schedule 9
METHYLANDROSTANOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METHYLATED SPIRIT(S)
cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
METHYL BENZOQUATE
Appendix B, Part 3
METHYL BROMIDE
Schedule 7
Appendix J, Part 2
METHYL CHLORIDE
Appendix F, Part 3
METHYLCHLOROISOTHIAZOLINONE
Schedule 6
Appendix F, Part 3
METHYLCLOSTEBOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL
Schedule 7
Schedule 6
1-METHYLCYCLOPROPENE
Appendix B, Part 3
METHYLDESORPHINE
Schedule 9
METHYLDIBROMO GLUTARONITRILE
Schedule 10
Schedule 6
Appendix F, Part 3
METHYLDIHYDROMORPHINE
Schedule 8
METHYLDOPA
Schedule 4
4,4’-METHYLENEBIS[2-CHLOROANILINE]
Schedule 7
Appendix J, Part 2
METHYLENE BISTHIOCYANATE
Schedule 6
Appendix F, Part 3
METHYLENE BLUE
Schedule 7
Schedule 5
Schedule 4
3,4-METHYLENEDIOXYAMFETAMINE
cross reference: 3,4-METHYLENEDIOXYAMPHETAMINE, MDA
Schedule 9
3,4-METHYLENEDIOXYPYROVALERONE
cross reference: MDPV
Schedule 9
METHYLEPHEDRINE
Schedule 2
METHYLERGOMETRINE
Schedule 4
METHYL ETHYL KETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Part 1 - Interpretation
METHYL ETHYL KETONE OXIME
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
METHYL ETHYL KETONE PEROXIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
METHYLEUGENOL
Schedule 6
Appendix E, Part 2,
Appendix F, Part 3
3-METHYLFENTANYL
Schedule 9
METHYL p-HYDROXYBENZOATE
Appendix B, Part 3
METHYL ISOAMYL KETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, Part 2
Part 1 - Interpretation
METHYL ISOBUTYL KETONE
cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S)
Schedule 5
Appendix E, Part 2
Part 1 - Interpretation
METHYL ISOTHIOCYANATE
Schedule 6
METHYLISOTHIAZOLINONE
Schedule 6
Appendix F, Part 3
METHYLMERCURY
Schedule 4
Appendix G
METHYL METHACRYLATE
Schedule 10
Schedule 6
Appendix F, Part 3
4-METHYLMETHCATHINONE
cross reference: MEPHEDRONE
Schedule 9
N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE
cross reference: MBDB
Schedule 9
N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE
cross reference: N-HYDROXY MDA
Schedule 9
2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID
cross reference: MORAMIDE INTERMEDIATE
Schedule 9
METHYLNALTREXONE
Schedule 4
METHYL NEODECANAMIDE
Schedule 6
METHYLNORBORNYLPYRIDINE
Schedule 6
METHYLONE *(MDMC)
Schedule 9
METHYLPENTYNOL
Schedule 4
METHYLPHENIDATE
Schedule 8
METHYLPHENOBARBITAL
cross reference: BARBITURATE METHYLPREDNISOLONE
Schedule 4
Appendix K
METHYLPHENOBARBITONE
cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE
cross reference: ACIDMPPP
Schedule 9
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID
cross reference: PETHIDINE INTERMEDIATE C
Schedule 8
METHYLPREDNISOLONE
Schedule 4
N-METHYL-2-PYRROLIDONE
Schedule 5
Schedule 6
Appendix E, Part 2
2-METHYLRESORCINOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
METHYLROSANILINIUM CHLORIDE
cross reference: CRYSTAL VIOLET, GENTIAN VIOLET
Schedule 10
Schedule 6
Schedule 4
METHYL SALICYLATE
Schedule 6
Schedule 5
Schedule 4
METHYL SALICYLATE LIQUID
Appendix E, Part 2
METHYLTESTOSTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
4-METHYLTHIOAMFETAMINE
cross reference: 4-METHYLTHIOAMPHETAMINE
Schedule 9
3-METHYLTHIOFENTANYL
Schedule 9
2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE
Schedule 5
METHYLTHIOURACIL
Schedule 4
METHYLTRIENOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METHYPRYLONE
Schedule 4
METHYSERGIDE
Schedule 4
METIRAM
Schedule 5
METOCLOPRAMIDE
Schedule 4
Schedule 3
METOFLUTHRIN
Schedule 6
Schedule 5
METOLACHLOR
Schedule 5
METOLAZONE
Schedule 4
METOPON
Schedule 9
METOPROLOL
Schedule 4
METOSULAM
Schedule 6
METRAFENONE
Schedule 6
Schedule 5
METRIBOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
METRIBUZIN
Schedule 6
METRIFONATE
cross reference: TRICHLORFON
Schedule 4
METRONIDAZOLE
cross reference: BENZOYL METRONIDAZOLE
Schedule 4
METSULFURONMETHYL
Appendix B, Part 3
METYRAPONE
Schedule 4
MEVINPHOS
Schedule 7
MEXILETINE
Schedule 4
MEZLOCILLIN
Schedule 4
MIANSERIN
Schedule 4
Appendix K
MIBEFRADIL
Schedule 4
MIBOLERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
MICAFUNGIN
Schedule 4
MICONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
MIDAZOLAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
MIDODRINE
Schedule 4
MIDOSTAURIN
Schedule 4
MIFEPRISTONE
Schedule 4
MIGALASTAT
Schedule 4
MIGLITOL
Schedule 4
MIGLUSTAT
Schedule 4
MILBEMECTIN
Schedule 6
Schedule 5
MILNACIPRAN
Schedule 4
MILBEMYCIN OXIME
Schedule 4
Schedule 5
MILRINONE
Schedule 4
MINOCYCLINE
Schedule 4
MINOXIDIL
Schedule 4
Schedule 2
MIPAFOX
Schedule 7
MIRABEGRON
Schedule 4
MIREX
Schedule 7
Appendix J, Part 2
MIRTAZAPINE
Schedule 4
Appendix K
MISOPROSTOL
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
MITOBRONITOL
Schedule 4
MITOMYCIN
Schedule 4
MITOTANE
Schedule 4
MITOXANTRONE
Schedule 4
MITRAGYNA SPECIOSA
Schedule 9
MITRAGYNINE
Schedule 9
MITRATAPIDE
Schedule 4
MIVACURIUM CHLORIDE
Schedule 4
MOCLOBEMIDE
Schedule 4
MODAFINIL
Schedule 4
MOLGRAMOSTIM
Schedule 4
MOLINATE
Schedule 7
Appendix J, Part 2
MOLINDONE
Schedule 4
MOMETASONE
Schedule 2
Schedule 4
MOMFLUOROTHRIN
Schedule 6
MONENSIN
Schedule 6
Schedule 5
Schedule 4
MONEPANTEL
Schedule 5
MONOBENZONE
cross reference: HYDROQUINONE
Schedule 4
MONOCLONAL ANTIBODIES
Schedule 4
MONOCROTOPHOS
Schedule 7
MONOETHANOLAMINE
Schedule 6
Schedule 5
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
MONTELUKAST
Schedule 4
MOPERONE
Schedule 4
MORANTEL
Schedule 6
Schedule 5
MORAZONE
Schedule 4
MORICIZINE
Schedule 4
MORPHERIDINE
Schedule 9
MORPHINE
Schedule 8
Appendix K
MORPHINE METHOBROMIDE
Schedule 8
MORPHINE-N-OXIDE
Schedule 8
(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1- YLMETHANONE
cross reference: JWH-200
Schedule 9
MOTOR, HEATING or FURNACE FUELS
cross reference: FUELS, FUELS, HOBBY - FUELS, TOY, KEROSENE, METHANOL, PETROL
Appendix A
MOTRAZEPAM
Schedule 4
MOTRETINIDE
Schedule 4
MOXIDECTIN
Schedule 7
Schedule 6
Schedule 5
Schedule 4
MOXIFLOXACIN
Schedule 4
MOXONIDINE
Schedule 4
MSMA
Schedule 7
Schedule 6
MUMPS VACCINE
Schedule 4
MUPIROCIN
Schedule 4
MURAGLITAZAR
Schedule 4
MUROMONAB
Schedule 4
MUSCIMOL
Schedule 9
MUSTINE
cross reference: NITROGEN MUSTARD
Schedule 4
MYCLOBUTANIL
Schedule 5
MYCOPHENOLIC ACID
cross reference: MYCOPHENOLATE MOFETIL
Schedule 4
MYRISTIC ACID
Appendix B, Part 3
MYROPHINE
Schedule 9
N
NAA
cross reference: NAPTHALENEACETIC ACID
Schedule 5
NABILONE
Schedule 8
NABIXIMOLS
cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID, CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS SATIVA, TETRAHYDROCANNABINOLIC ACID, TETRAHYDROCANNABINOLS, TETRAHYDROCANNABIVAROL
Schedule 8
Appendix D, Item 1
Appendix K
NABUMETONE
Schedule 4
NADOLOL
Schedule 4
NADROPARIN
Schedule 4
NAFARELIN
Schedule 4
NAFTIDROFURYL
Schedule 4
NALBUPHINE
Schedule 4
Appendix K
NALED
Schedule 6
Schedule 5
NALIDIXIC ACID
Schedule 4
NALMEFENE
Schedule 4
NALORPHINE
Schedule 4
NALOXEGOL
Schedule 4
NALOXONE
Schedule 4
Schedule 3
Appendix H
NALTREXONE
Schedule 4
NANDROLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
NAPHAZOLINE
Schedule 2
Appendix F, Part 3
NAPHTHALENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
Appendix G
1,5-NAPHTHALENEDIOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2,7-NAPTHALENEDIOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE
cross reference: JWH-073
Schedule 9
NAPHTHALOPHOS
Schedule 6
Schedule 7
1-NAPHTHOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NAPHTHOYLINDOLES
Schedule 9
NAPHTHOYLPYRROLES
Schedule 9
NAPHTHYLMETHYLINDENES
Schedule 9
NAPHTHYLMETHYLINDOLES
Schedule 9
NAPROPAMIDE
Appendix B, Part 3
NAPROXEN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
NAPTALAM
Schedule 5
NAPTHYL ACETAMIDE
Appendix B, Part 3
NARASIN
Schedule 6
Schedule 4
NARATRIPTAN
Schedule 4
NATALIZUMAB
Schedule 4
NATAMYCIN
cross reference: PIMARCIN
Schedule 4
NATEGLINIDE
Schedule 4
NEBACUMAB
Schedule 4
NEBIVOLOL
Schedule 4
NEDOCROMIL
Schedule 4
NEFAZODONE
Schedule 4
NEFOPAM
Schedule 4
NELFINAVIR
Schedule 4
NEOMYCIN
Schedule 4
NEOSCYTALIDIUM NOVAEHOLLANDIAE
Schedule 5
NEOSTIGMIN
Schedule 4
NEPAFENAC
Schedule 4
NERATINIB
Schedule 4
NERIUM OLEANDER
Schedule 4
Appendix G
NEROLI OIL
Appendix B, Part 3
NESIRITIDE
Schedule 4
NETILMICIN
Schedule 4
NETOBIMIN
Schedule 6
Schedule 5
NETUPITANT
Schedule 4
NEVIRAPINE
Schedule 4
NIALAMIDE
Schedule 4
NICARBAZIN
Appendix B, Part 3
NICARDIPINE
Schedule 4
NICERGOLINE
Schedule 4
NICKEL SULFATE
Schedule 6
NICLOSAMIDE
Schedule 2
NICOCODINE
Schedule 9
NICODICODINE
Schedule 9
NICOFURANOSE
Schedule 4
NICOMORPHINE
Schedule 9
NICORANDIL
Schedule 4
NICOTINE
Schedule 7
Schedule 6
Schedule 4
Appendix F, Part 3
Appendix J, Part 2
NICOTINIC ACID
cross reference: NICOTINAMIDE
Schedule 4
Schedule 3
NICOTINYL ALCOHOL
Schedule 3
NICOUMALONE
Schedule 4
NIFEDIPINE
Schedule 4
NIFENAZONE
Schedule 4
NIFOXIPAM
Schedule 9
NIKETHAMIDE
Schedule 4
NILOTINIB
Schedule 4
NILUTAMIDE
Schedule 4
NIMESULIDE
Schedule 4
NIMIDANE
Schedule 7
Schedule 6
NIMODIPINE
Schedule 4
NIMORAZOLE
Schedule 4
NINTEDANIB
Schedule 4
NIRIDAZOLE
Schedule 4
NISIN
Appendix B, Part 3
NISOLDIPINE
Schedule 4
NITENPYRAM
Schedule 6
NITISINONE
Schedule 4
NITRAZEPAM
Schedule 4
Appendix D, Item 5 (benzodiazepine derivatives)
Appendix K
NITRENDIPINE
Schedule 4
NITRIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
NITRIC OXIDE
Schedule 4
NITROBENZENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROFEN
Schedule 7
Appendix J, Part 2
NITROFURANTOIN
Schedule 4
NITROFURAZONE
Schedule 4
3-NITRO-p-HYDROXYETHYLAMINOPHENOL
cross reference: 4-[(2-hydroxyethyl)amino]-3-nitrophenol
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROPHENOLS
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROPRUSSIDES
Schedule 7
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROSCANATE
Schedule 5
2-NITROTOLUENE
Schedule 7
NITROUS OXIDE
Schedule 4
NITROXOLINE
Schedule 4
NITROXYNIL
Schedule 6
NIVOLUMAB
Schedule 4
NIZATIDINE
Schedule 4
Schedule 2
Appendix F, Part 3
NOMEGESTROL
Schedule 4
NOMIFENSINE
Schedule 4
NONANOIC ACID
Schedule 5
NONOXINOL 9
Schedule 6
Schedule 5
Appendix E, Part 2
NORACYMETHADOL
Schedule 9
NORADRENALINE
Schedule 4
Appendix F, Part 3
19-NORANDROSTENEDIOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
19-NORANDROSTENEDIONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
NORANDROSTENOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
NORBOLETHONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
NORBORMIDE
Schedule 5
NORCLOSTEBOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
NORCODEINE
Schedule 8
NORELGESTROMIN
Schedule 4
NOREPINEPHRINE
cross reference: NORADRENALINE
NORETHANDROLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
NORETHISTERONE
Schedule 4
NORFLOXACIN
Schedule 4
NORFLURAZON
Appendix B, Part 3
NORGESTREL
Schedule 4
NORIBOGAINE
Schedule 4
NORLEVORPHANOL
Schedule 9
NORMAL HUMAN IMMUNOGLOBULIN
Schedule 4
NORMETHADONE
Schedule 8
Appendix K
NORMETHANDRONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
NORMORPHINE
Schedule 9
NORPIPANONE
Schedule 9
NORTRIPTYLINE
Schedule 4
Appendix K
NOSCAPINE
Schedule 2
NOVALURON
Appendix B, Part 3
NOVOBIOCIN
Schedule 4
NOXIPTYLINE
Schedule 4
NUCLEAR POLYHEDROSIS VIRUS OF Helicoverpa armigera occlusion bodies
Appendix B, Part 3
NUSINERSEN
Schedule 4
NUTMEG OIL
Schedule 5
NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION
Appendix A
NYSTATIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
O
OBETICHOLIC ACID
Schedule 4
OCLACITINIB
Schedule 4
OCRELIZUMAB
Schedule 4
OCRIPLASMIN
Schedule 4
OCTAMYLAMINE
Schedule 4
OCTATROPINE
Schedule 4
1-OCTEN-3-OL
Schedule 6
OCTHILINONE
Schedule 6
OCTREOTIDE
Schedule 4
OCTYL ALCOHOLS
Appendix B, Part 3
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE
Schedule 5
OCTYL NITRITE
Schedule 4
N-(N-OCTYL)-2-PYRROLIDONE
cross reference: DESIGNATED SOLVENT, N-(N-DODECYL)-2-PYRROLIDONE, N-METHYL-2-PYRROLIDONE
Schedule 6
Schedule 5
Appendix E, Part 2
Part 1 - Interpretation
OESTRADIOL
cross reference: ESTRADIOL
OESTRIOL
cross reference: ESTRIOL
OESTROGENS
cross reference: ESTROGENS
OESTRONE
cross reference: ESTRONE
OFATUMUMAB
Schedule 4
OFLOXACIN
Schedule 4
OLANZAPINE
Schedule 4
Appendix K
OLAPARIB
Schedule 4
OLAQUINDOX
Schedule 6
OLARATUMAB
Schedule 4
OLEANDOMYCIN
Schedule 5
Schedule 4
OLEANDRIN
Schedule 4
OLEIC ACID
Appendix B, Part 3
N-OLEYL-1,3-DIAMINOPROPANE
Schedule 6
OLMESARTAN
Schedule 4
OLODATEROL
Schedule 4
OLOPATADINE
Schedule 4
OLSALAZINE
Schedule 4
OMBITASVIR
Schedule 4
OMALIZUMAB
Schedule 4
OMEGA-3-ACID ETHYL ESTERS
Schedule 4
OMEPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
OMETHOATE
Schedule 7
Schedule 6
Schedule 5
ONDANSETRON
Schedule 4
OPIPRAMOL
Schedule 4
OPIUM
cross reference: NOSCAPINE, PAPAVERINE
Schedule 8
Appendix K
ORANGE OIL (BITTER)
Schedule 5
Appendix E, Part 2
ORANGE OIL, SWEET
Appendix B, Part 3
ORBIFLOXACIN
Schedule 4
ORCIPRENALINE
Schedule 4
Appendix F, Part 3
ORGANOPHOSPHORUS COMPOUNDS
cross reference: MALATHION
Schedule 4
ORLISTAT
Schedule 4
Schedule 3
ORNIDAZOLE
Schedule 4
ORNIPRESSIN
Schedule 4
ORPHENADRINE
Schedule 4
o-DICHLOROBENZENE
Appendix F, Part 3
o-PHENYLPHENOL
Appendix E, Part 2
Appendix F, Part 3
4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER
cross reference: PETHIDINE INTERMEDIATE B
Schedule 8
o-PHTHALADEHYDE
Appendix F, Part 3
o-PHTHALALDEHYDE
Appendix E, Part 2
ORTHOPTERIN
Schedule 4
o-TOLIDINE
Appendix J, Part 2
OSELTAMIVIR
Schedule 4
OSIMERTINIB
Schedule 4
OUABAIN
Schedule 4
OVANDROTONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
OXABETRINIL
Appendix B, Part 3
OXABOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
OXACILLIN
Schedule 4
OXADIARGYL
Schedule 5
OXADIAZON
Schedule 6
OXADIXYL
Schedule 5
OXALATES
Appendix F, Part 3
OXALIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
OXALIPLATIN
Schedule 4
OXAMYL
Schedule 7
OXANDROLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
OXANTEL EMBONATE
Schedule 5
OXAPROZIN
Schedule 4
OXAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
Appendix K
OXCARBAZEPINE
Schedule 4
OXATHIAPIPROLIN
Appendix B, Part 3
OXEDRINE
cross reference: SYNEPHRINE
Schedule 4
OXETACAINE
cross reference: OXETHAZAINE
Schedule 4
Schedule 2
OXFENDAZOLE
Schedule 5
OXIBENDAZOLE
Schedule 5
OXICONAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
OXITROPIUM
Schedule 4
OXOLAMINE
Schedule 4
OXOLINIC ACID
Schedule 4
OXPENTIFYLLINE
cross reference: PENTOXIFYLLINE
OXPRENOLOL
Schedule 4
OXYBUPROCAINE
Schedule 4
OXYBUTYNIN
Schedule 4
OXYCARBOXIN
Schedule 5
OXYCLOZANIDE
Schedule 6
OXYCODONE
Appendix K
OXYCODONE
Schedule 8
OXYDEMETON METHYL
Schedule 7
OXYFLUORFEN
Appendix B, Part 3
OXYMESTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
OXYMETAZOLINE
Schedule 2
Appendix F, Part 3
OXYMETHOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
OXYMORPHONE
Schedule 8
OXYPHENBUTAZONE
Schedule 4
OXYPHENCYCLIMINE
Schedule 4
OXYPHENISATIN
Schedule 10
OXYPHENONIUM
Schedule 4
OXYQUINOLINE
Schedule 2
Appendix F, Part 3
OXYTETRACYCLINE
Schedule 5
Schedule 4
OXYTHIOQUINOX
Schedule 5
OXYTOCIN
Schedule 4
Appendix G
P
PACLITAXEL
Schedule 4
PACLOBUTRAZOL
Schedule 5
PAECILOMYCES LILACINUS STRAIN 251
Schedule 6
PAINT
Appendix F, Part 3
PALBOCICLIB
Schedule 4
PALIFERMIN
Schedule 4
PALIPERIDONE
Schedule 4
Appendix K
PALIVIZUMAB
Schedule 4
PALMAROSA OIL
Appendix B, Part 3
PALMITIC ACID
Appendix B, Part 3
PALONOSETRON
Schedule 4
PAMAQUIN
Schedule 4
PAMIDRONIC ACID
cross reference: PAMIDRONATE DISODIUM
Schedule 4
PANCREATIC ENZYMES
cross reference: LIPASE
Schedule 4
PANCURONIUM
Schedule 4
PANITUMUMAB
Schedule 4
PANOBINOSTAT
Schedule 4
PANTOPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
PAPAVERETUM
Appendix K
PAPAVERINE
cross reference: OPIUM
Schedule 4
Schedule 2
PAPER
Appendix A
PARA-AMINOPROPIOPHENONE (PAPP)
cross reference: 4-AMINOPROPIOPHENONE
PARACETAMOL
cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE, CAFFEINE
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
para-DICHLOROBENZENE
cross reference: PDB
Appendix F, Part 3
PARA-FLUOROFENTANYL
Schedule 9
PARAFORMALDEHYDE
cross reference: FREE FORMALDEHYDE
Schedule 10
Schedule 6
Schedule 2
Appendix E, Part 2
PARALDEHYDE
Schedule 4
PARAMETHADIONE
Schedule 4
PARAMETHASONE
Schedule 4
PARAQUAT
Schedule 7
PARATHION
Schedule 7
PARATHION-METHYL
Schedule 7
Schedule 6
PARBENDAZOLE
Schedule 6
PARECOXIB
Schedule 4
PARICALCITOL
Schedule 4
PARITAPREVIR
Schedule 4
PAROMOMYCIN
Schedule 4
PAROXETINE
Schedule 4
PASIREOTIDE
Schedule 4
PATCHOULI OIL
Appendix B, Part 3
PATIROMER SORBITEX CALCIUM
Schedule 4
PAZOPANIB
Schedule 4
PEBULATE
Schedule 6
PECAZINE
Schedule 4
PECTINASE derived from Aspergillus niger
Appendix B, Part 3
PEFLOXACIN
Schedule 4
PEGAPTANIB
Schedule 4
PEGASPARGASE
Schedule 4
PEGBOVIGRASTIM
Appendix B, Part 1
Appendix B, Part 2
PEGFILGRASTIM
Schedule 4
PEGINTERFERON
Schedule 4
PEGVISOMANT
Schedule 4
PERAMIVIR
Schedule 4
PHENOLS
Appendix E, Part 2
PEMBROLIZUMAB
Schedule 4
PEMETREXED
Schedule 4
PEMOLINE
Schedule 4
PEMPIDINE
Schedule 4
PENBUTOLOL
Schedule 4
PENCICLOVIR
Schedule 4
PENCONAZOLE
Schedule 5
PENCYCURON
Appendix B, Part 3
PENDIMETHALIN
Schedule 5
PENETHAMATE
Schedule 4
PENFLUFEN
Schedule 5
PENICILLAMINE
Schedule 4
PENNYROYAL OIL
Schedule 6
Appendix E, Part 2
PENTACHLOROPHENOL
Schedule 7
Schedule 6
Appendix F, Part 3
PENTADECANOIC ACID
Appendix B, Part 3
PENTAERYTHRITYL TETRANITRATE
Schedule 4
PENTAGASTRIN
Schedule 4
PENTAMETHONIUM
Schedule 4
PENTAMIDINE
Schedule 4
PENTAZOCINE
Schedule 8
Appendix K
PENTHIENATE
Schedule 4
PENTHIOPYRAD
Schedule 5
PENTOBARBITONE
cross refeference: PENTOBARBITAL
PENTOBARBITAL
Schedule 8
Schedule 4
Appendix K
PENTOLINIUM
Schedule 4
PENTOSAN POLYSULFATE SODIUM
Schedule 4
PENTOXIFYLLINE
Schedule 4
1-PENTYL-3-(1-NAPHTHOYL)INDOLE
cross reference: JWH-018
Schedule 9
1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE
cross reference: JWH-122
Schedule 9
PEPPERMINT OIL
Appendix B, Part 3
PERACETIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PERAMPANEL
Schedule 4
Appendix D, Item 5
Appendix K
PERFLUIDONE
Schedule 6
PERGOLIDE
Schedule 4
PERHEXILINE
Schedule 4
PERICIAZINE
Schedule 4
Appendix K
PERICYAZINE
cross reference: PERICIAZINE
PERINDOPRIL
Schedule 4
PERMANGANATES
cross reference: POTASSIUM PERMANGANATE
Schedule 6
Appendix F, Part 3
PERMETHRIN
Schedule 6
Schedule 5
Schedule 4
PERPHENAZINE
Schedule 4
Appendix K
PERTUSSIS ANTIGEN
Schedule 4
PERTUZUMAB
Schedule 4
PETASITES spp.
Schedule 10
PETHIDINE
Schedule 8
Appendix K
PETROL
Schedule 5
Appendix E, Part 2
PHEDRAZINE
Schedule 2
PHENACEMIDE
Schedule 4
PHENACETIN
Schedule 4
PHENADOXONE
Schedule 9
PHENAGLYCODOL
Schedule 4
PHENAMPROMIDE
Schedule 9
PHENAZOCINE
Schedule 9
PHENAZONE
Schedule 5
Schedule 4
Schedule 2
PHENAZOPYRIDINE
Schedule 4
PHENCYCLIDINE
cross reference: PCP
Schedule 9
PHENDIMETRAZINE
Schedule 8
PHENELZINE
Schedule 4
Appendix K
N-PHENETHYL-4-PIPERIDONE
Schedule 9
PHENETICILLIN
Schedule 4
PHENFORMIN
Schedule 4
PHENGLUTARIMIDE
Schedule 4
PHENIBUT
cross reference: BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID
Schedule 9
PHENINDIONE
Schedule 4
PHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
PHENISATIN
Schedule 4
PHENISOPHAM
Schedule 5
PHENMEDIPHAM
Appendix B, Part 3
PHENMETRAZINE
Schedule 8
PHENOBARBITAL
Schedule 4
Appendix K
PHENOBARBITONE
cross reference: PHENOBARBITAL
PHENOL
cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
PHENOLPHTHALEIN
Schedule 4
PHENOMORPHAN
Schedule 9
PHENOPERIDINE
Schedule 8
Appendix K
PHENOTHIAZINE
Schedule 6
d-PHENOTHRIN
Appendix B, Part 3
PHENOXYBENZAMINE
Schedule 4
2-PHENOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
PHENOXYMETHYL OXIRANE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
PHENOXYMETHYLPENICILLIN
Schedule 4
PHENSUXIMIDE
Schedule 4
PHENTERMINE
Schedule 4
Appendix D, Item 5
PHENTHIMENTONIUM
Schedule 4
PHENTOLAMINE
Schedule 4
PHENYLACETYLINDOLES
Schedule 9
PHENYLBUTAZONE
Schedule 4
PHENYLENEDIAMINES
cross reference: ALKYLATED PHENYLENEDIAMINES, DIETHYL-PARA-PHENYLENEDIAMINE, DIMETHYL-PARA-PHENYLENEDIAMINE
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
PHENYLEPHRINE
cross reference: CODEINE, IBUPROFEN, PARACETAMOL
Schedule 4
Schedule 2
Appendix F, Part 3
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE
cross reference: PEPAP
Schedule 9
PHENYLMERCURIC ACETATE
cross reference: MERCURY
Schedule 7
Appendix J, Part 2
PHENYL METHYL KETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, Part 2
Part 1 - Interpretation
PHENYLPHENOL
Schedule 5
PHENYLPROPANOLAMINE
Schedule 4
PHENYLTOLOXAMINE
Schedule 4
Appendix K
PHENYTOIN
Schedule 4
Appendix F, Part 3
PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract)
Schedule 4
PHOLCODINE
Schedule 8
Schedule 4
Schedule 2
Appendix K
PHORATE
Schedule 7
PHOSALONE
Schedule 6
PHOSFOLAN
Schedule 7
PHOSMET
Schedule 6
PHOSPHIDES, METALLIC
cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC PHOSPHIDE
Schedule 7
Appendix J, Part 2
PHOSPHINE
Schedule 7
Appendix J, Part 2
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Schedule 4
PHOSPHONIC ACID
cross reference: PHOSPHOURUS ACID
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PHOSPHORIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PHOSPHORUS
Appendix F, Part 3
Appendix G
PHOSPHORUS,
Appendix E, Part 2
PHOSPHORUS, YELLOW
Schedule 7
PHOTOGRAPHIC PAPER or FILM
Appendix A
PHOXIM
Schedule 6
PHTHALALDEHYDE
Schedule 6
Schedule 5
PHTHALYLSULFATHIAZOLE
Schedule 4
PHYSOSTIGMINE
Schedule 4
PHYTASE
Appendix B, Part 3
PIBRENTASVIR
Schedule 4
PICARIDIN
Schedule 5
PICLORAM
Appendix B, Part 3
PICOLINAFEN
Appendix B, Part 3
PICRIC ACID
Appendix E, Part 2
Appendix F, Part 3
PICROTOXIN
Schedule 4
PIGMENTS
Appendix A
PILOCARPINE
Schedule 4
PIMECROLIMUS
Schedule 4
PIMELIC ACID
Appendix B, Part 3
PIMINODINE
Schedule 9
PIMOBENDAN
Schedule 4
PIMOZIDE
Schedule 4
Appendix K
PINACIDIL
Schedule 4
PINDOLOL
Schedule 4
PINDONE
Schedule 6
PINE OILS
Schedule 6
Schedule 5
PINOXADEN
Schedule 6
Schedule 5
PIOGLITAZONE
Schedule 4
PIPECURONIUM
Schedule 4
PIPEMIDIC ACID
Schedule 4
PIPENZOLATE
Schedule 4
PIPER METHYSTICUM
cross reference: KAVA, KAVALACTONES
Schedule 4
PIPERACILLIN
Schedule 4
PIPERAZNE
Schedule 5
Schedule 2
PIPERIDINE
Schedule 4
PIPERIDOLATE
Schedule 4
PIPERONYL BUTOXIDE
Appendix B, Part 3
PIPEROPHOS
Schedule 6
PIPOBROMAN
Schedule 4
PIPOTHIAZINE
Schedule 4
PIPRADROL
Schedule 4
PIRACETAM
Schedule 4
PIRBUTEROL
Schedule 4
PIRENOXINE
cross reference: CATALIN
Schedule 4
PIRENZEPINE
Schedule 4
PIRETANIDE
Schedule 4
PIRFENIDONE
Schedule 4
PIRIMICARB
Schedule 5
Schedule 6
PIRIMIPHOS-ETHYL
Schedule 6
PIRIMIPHOS-METHYL
Schedule 6
PIRITRAMIDE
Schedule 8
PIROXICAM
Schedule 4
PIRPROFEN
Schedule 4
PITAVASTATIN
Schedule 4
PITUITARY HORMONES
Schedule 4
PIVAMPICILLIN
Schedule 4
PIZOTIFEN
Schedule 4
Appendix K
PLASMID DNA (rE. coli DH5α pINGhT)
cross reference: VACCINES – PLASMID DNA
PLERIXAFOR
Schedule 4
PLICAMYCIN
Schedule 4
PNEUMOCOCCAL VACCINE
Schedule 4
PODOPHYLLOTOXIN
cross reference: PODOPHYLLIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
PODOPHYLLUM EMODI
cross reference: PODOPHYLLIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
PODOPHYLLUM PELTATUM
cross reference: PODOPHYLLIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
PODOPHYLLUM RESIN
cross reference: PODOPHYLLIN
Appendix G
POLIDEXIDE
Schedule 4
POLIHEXANIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
POLIOMYELITIS VACCINE
Schedule 4
POLIXETONIUM SALTS
Schedule 6
Schedule 5
POLOXALENE
Appendix B, Part 3
POLY (GNRF) OVALBUMIN
Appendix B, Part 3
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE
cross reference: POLYDADMAC
Appendix B, Part 3
POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS
Schedule 5
Appendix E, Part 2
POLYACRYLAMIDE
Schedule 4
POLYCAPROLACTONE
Schedule 4
POLYESTRADIOL
Schedule 4
POLYETHANOXY (15) TALLOW AMINE
Schedule 5
Appendix E, Part 2
POLYHEDROSIS VIRUS of Helico zea occlusion bodies
Appendix B, Part 3
POLYLACTIC ACID
Schedule 4
POLYMYXIN
Schedule 4
POLYSORBATE 20
Appendix B, Part 3
POLYSULFATED GLYCOSAMINOGLYCANS
Schedule 4
POLYTHIAZIDE
Schedule 4
POMALIDOMIDE
Schedule 4
Appendix D, Item 4
Appendix F, Part 3
Appendix L, Part 2
PORACTANT
Schedule 4
PORCELAIN
Appendix A
PORCINE SOMATOTROPHIN
Appendix B, Part 3
POSACONAZOLE
Schedule 4
POTASSIUM AZELOYL DIGLYCINATE
Schedule 6
POTASSIUM BICARBONATE
Appendix B, Part 3
POTASSIUM BROMATE
Schedule 6
Appendix E, Part 2
POTASSIUM BROMIDE
Schedule 4
POTASSIUM CHLORATE
Schedule 5
Schedule 2
Appendix E, Part 2
POTASSIUM CHLORIDE
Schedule 4
POTASSIUM CYANATE
Schedule 6
Appendix E, Part 2
POTASSIUM HYDROXIDE
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
POTASSIUM METABISULPHITE
Schedule 5
Appendix F, Part 3
POTASSIUM NITRITE
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
POTASSIUM PERCHLORATE
Schedule 4
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT
Schedule 6
Schedule 5
POTASSIUM PERSULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
POTASSIUM SORBATE
Appendix B, Part 3
POTASSIUM SULFIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PRACTOLOL
Schedule 4
PRADOFLOXACIN
Schedule 4
PRALATREXATE
Schedule 4
PRALIDOXIME
Schedule 4
PRALLETHRIN
Schedule 6
Schedule 5
PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)
Schedule 4
Appendix D, Item 5
PRAMIPEXOLE
Schedule 4
PRAMOCAINE
Schedule 4
PRAMPINE
Schedule 4
PRASTERONE
cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
PRASUGREL
Schedule 4
PRAVASTATIN
Schedule 4
PRAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
Appendix K
PRAZIQUANTEL
Schedule 4
PRAZOSIN
Schedule 4
PREDNISOLONE
Schedule 4
PREDNISONE
Schedule 4
PREGABALIN
Schedule 4
Appendix K
PREGNENOLONE
Schedule 4
PRENALTEROL
Schedule 4
PRENYLAMINE
Schedule 4
PRILOCAINE
Schedule 4
Schedule 2
PRIMAQUINE
Schedule 4
PRIMIDONE
Schedule 4
PRINTING INKS or INK ADDITIVES
Appendix A
PROBENECID
Schedule 4
PROBUCOL
Schedule 4
PROCAINAMIDE
Schedule 4
PROCAINE
Schedule 4
PROCAINE BENZYLPENICILLIN
Schedule 4
PROCAINE PENICILLIN
cross reference: PROCAINE BENZYLPENICILLIN
PROCARBAZINE
Schedule 4
PROCHLORAZ
Schedule 6
PROCHLORPERAZINE
Appendix K
PROCHLORPERAZINE
Schedule 4
Schedule 3
PROCYCLIDINE
Schedule 4
Schedule 2
PROCYMIDONE
Schedule 7
PROFENOFOS
Schedule 6
PROFOXYDIM
Schedule 5
PROGESTERONE
Schedule 5
Schedule 4
Appendix G
PROGESTOGENS
Schedule 4
PROGLUMIDE
Schedule 4
PROGUANIL
Schedule 4
PROHEPTAZINE
Schedule 9
PROHEXADIONE CALCIUM
Schedule 5
PROLINTANE
Schedule 4
PROMACYL
Schedule 6
PROMAZINE
Schedule 4
Appendix K
PROMETHAZINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
PROMETRYN
Schedule 5
PROMOXOLANE
Schedule 4
PROPACHLOR
Schedule 6
PROPAFENONE
Schedule 4
PROPAMIDINE
Schedule 4
Schedule 2
PROPAMOCARB
Schedule 5
PROPANIDID
Schedule 4
PROPANIL
Schedule 5
PROPANTHELINE
Schedule 4
PROPAQUIZAFOP
Schedule 5
PROPARGITE
Schedule 6
PROPENTOFYLLINE
Schedule 4
PROPERIDINE
Schedule 9
PROPETAMPHOS
Schedule 6
PROPETANDROL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
PROPICONAZOLE
Schedule 6
Schedule 5
PROPINEB
Schedule 6
PROPIONIBACTERIUM ACNES
Schedule 4
PROPIONIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PROPIRAM
Schedule 8
PROPOFOL
Schedule 4
PROPOXUR
Schedule 6
Schedule 5
PROPRANOLOL
Schedule 4
Appendix G
PROPYL ACETATES
Appendix B, Part 3
n-PROPYL ALCOHOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PROPYLENE GLYCOL
Appendix B, Part 3
2-PROPYLENE GLYCOL 1-MONOMETHYL
Appendix B, Part 3
PROPYLENE OXIDE
Schedule 7
Appendix J, Part 2
PROPYLHEXEDRINE
Schedule 4
PROPYLTHIOURACIL
Schedule 4
PROPYPHENAZONE
Schedule 4
PROPYZAMIDE
Schedule 5
PROQUAZONE
Schedule 4
PROQUINAZID
Schedule 6
PROSCILLARIDIN
Schedule 4
PROSTAGLANDINS
Schedule 4
PROSTIANOL
Schedule 4
PROSULFOCARB
Schedule 6
PROSULFURON
Schedule 6
PROTAMINE
Schedule 4
PROTHIOCONAZOLE
Appendix B, Part 3
PROTHIOCONAZOLE-DESCHLORO
Schedule 5
PROTHIOCONAZOLE-TRIAZOLIDINETHIONE
Schedule 5
PROTHIOFOS
Schedule 6
PROTHIONAMIDE
Schedule 4
PROTHIPENDYL
Schedule 4
PROTIRELIN
Schedule 4
PROTOVERATRINES
Schedule 4
PROTRIPTYLINE
Appendix K
PROTRIPTYLINE
Schedule 4
PROXYMETACAINE
Schedule 4
PRUCALOPRIDE
Schedule 4
PSEUDOEPHEDRINE
Schedule 4
Schedule 3
PSEUDOMONAS FLUORESCENS
Appendix B, Part 3
PSILOCYBINE
Schedule 9
PTERIDIUM spp.
Schedule 10
d-PULEGONE
Schedule 6
Appendix E, Part 2
PULMONARIA spp.
Schedule 10
PYDIFLUMETOFEN
Appendix B, Part 3
PYMETROZINE
Schedule 5
PYRACLOFOS
Schedule 6
PYRACLOSTROBIN
Schedule 5
PYRAFLUFEN-ETHYL
Schedule 5
PYRANTEL
Schedule 2
PYRASULFOTOLE
Schedule 5
PYRAZINAMIDE
Schedule 4
PYRAZOLAM
Schedule 9
PYRAZOPHOS
Schedule 6
PYRETHRINS
cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE, PYRETHRIC ACIDS, PYRETHROLONE
Schedule 5
Schedule 2
PYRIDABEN
Schedule 6
Schedule 5
PYRIDALYL
Schedule 6
PYRIDATE
Schedule 6
PYRIDINOLCARBAMATE
Schedule 4
PYRIDOSTIGMINE
Schedule 4
PYRIDOXAL
Schedule 4
PYRIDOXAMINE
Schedule 4
PYRIDOXINE
Schedule 4
PYRIFENOX
Schedule 5
PYRIMETHAMINE
Schedule 4
PYRIMETHANIL
Appendix B, Part 3
PYRINURON
Schedule 7
Appendix J, Part 2
PYRIOFENONE
Schedule 6
Schedule 5
PYRIPROLE
Schedule 6
PYRIPROXYFEN
Appendix B, Part 3
PYRITHIOBAC SODIUM
Schedule 5
PYRITHIONE COPPER
Schedule 6
PYRITHIONE ZINC
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
PYROVALERONE
Schedule 4
PYROXASULFONE
Schedule 6
PYROXSULAM
Schedule 6
PYRVINIUM
cross reference: VIPRYNIUMA
Schedule 4
Q
QUASSIA
Appendix B, Part 3
QUATERNARY AMMONIUM COMPOUNDS
cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS
Schedule 6
Schedule 5
Appendix E, Part 5
QUAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
QUETIAPINE
Schedule 4
Appendix K
QUINAGOLIDE
Schedule 4
QUINALBARBITONE
cross reference: SECOBARBITAL
QUINAPRIL
Schedule 4
QUINBOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
QUINCLORAC
Schedule 5
QUINETHAZONE
Schedule 4
QUINIDINE
Schedule 4
QUININE
cross reference: QUININE (CAS No. 130-95-0), QUININE SULFATE (1:1) (CAS No. 549-56-4), QUININE SULFATE (2:1) (CAS No. 804-63-7), QUININE SULFATE (2:1) DIHYDRATE (CAS No. 6119-70-6), QUININE SULFATE (1:1) HEPTAHYDRATE (CAS No. 6183-68-2), QUININE DIHYDROCHLORIDE (CAS No. 60-93-5), QUININE MONOHYDROCHLORIDE (CAS No. 130-89-2), QUININE HYDROCHLORIDE DIHYDRATE (CAS No. 6119-47-7), QUININE HYDROCHLORIDE (UNSPECIFIED) (CAS No. 7549-43-1)
Schedule 7
Schedule 6
Schedule 5
Schedule 4
Appendix F, Part 3
QUINISOCAINE
cross reference: DIMETHISOQUINE
Schedule 4
QUINOLINE
cross reference: 2,3-BENZAPYRIDINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
QUINOXYFEN
Appendix B, Part 3
QUINTOZENE
cross reference: PENTACHLORONITROBENZENE
Schedule 5
QUINUPRISTIN
Schedule 4
QUIZALOFOP ETHYL
cross reference: QUIZALOFOP ETHYL (D + ISOMER)
Schedule 6
QUIZALOFOP-p-ETHYL
Schedule 6
Schedule 5
QUIZALOFOP-p-TEFURYL
Schedule 6
R
RABEPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
RABIES VACCINE
Schedule 4
RACEMETHORPHAN
Schedule 9
RACEMORAMIDE
Schedule 8
RACEMORPHAN
Schedule 9
RACTOPAMINE
Schedule 5
Schedule 4
RADIOGRAPHIC CONTRAST MEDIA
cross reference: RADIOPAQUES
Appendix A
RADIOISOTOPES
Appendix A
RALOXIFENE
Schedule 4
RALTEGRAVIR
Schedule 4
RALTITREXED
Schedule 4
RAMIPRIL
Schedule 4
RAMUCIRUMAB
Schedule 4
RANIBIZUMAB
Schedule 4
RANITIDINE
Schedule 4
Schedule 2
Appendix F, Part 3
RANOLAZINE
Schedule 4
RAPACURONIUM
Schedule 4
RASAGILINE
Schedule 4
RASBURICASE
Schedule 4
RAUWOLFIA SERPENTINA
Schedule 4
RAUWOLFIA VOMITORIA
Schedule 4
RAZOXANE
Schedule 4
REBOXETINE
Schedule 4
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
Schedule 4
RED YEAST RICE
Schedule 4
REGORAFENIB
Schedule 4
REMIFENTANIL
Schedule 8
REMOXIPRIDE
Schedule 4
REPAGLINIDE
Schedule 4
RESERPINE
Schedule 4
RESLIZUMAB
Schedule 4
RESMETHRIN
Schedule 6
Schedule 5
RESORCINOL
cross reference: 1,3-benzenediol
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
RETAPAMULIN
Schedule 4
RETEPLASE
Schedule 4
RETIGABINE
Schedule 4
Appendix K
RIBAVIRIN
Schedule 4
RIBOCICLIB
Schedule 4
RIDAFOROLIMUS
Schedule 4
RIFABUTIN
Schedule 4
RIFAMPICIN
Schedule 4
RIFAMYCIN
Schedule 4
RIFAPENTINE
Schedule 4
RIFAXIMIN
Schedule 4
RILPIVIRINE
Schedule 4
RILUZOLE
Schedule 4
RIMEXOLONE
Schedule 4
RIMITEROL
Schedule 4
RIMONABANT
Schedule 4
RIMSULFURON
Schedule 5
RIOCIGUAT
Schedule 4
Appendix D, Item 5
Appendix L, Part 2
RISEDRONIC ACID
Schedule 4
RISPERIDONE
Schedule 4
Appendix K
RITODRINE
Schedule 4
RITONAVIR
Schedule 4
RITUXIMAB
Schedule 4
RIVAROXABAN
Schedule 4
RIVASTIGMINE
Schedule 4
RIZATRIPTAN
Schedule 4
ROBENACOXIB
Schedule 4
ROBENIDINE
Schedule 5
ROFECOXIB
Schedule 4
ROFLUMILAST
Schedule 4
ROLICYCLIDINE
cross reference: PCPY, PHP
Schedule 9
ROLITETRACYCLINE
Schedule 4
ROMIDEPSIN
Schedule 4
ROMIFIDINE
Schedule 4
ROMIPLOSTIM
Schedule 4
ROMOSOZUMAB
Schedule 4
RONIDAZOLE
Schedule 4
ROPINIROLE
Schedule 4
ROPIVACAINE
Schedule 4
ROSEMARY OIL
Appendix B, Part 3
ROSIGLITAZONE
Schedule 4
ROSIN
cross reference: COLOPHONY
Schedule 5
ROSOXACIN
Schedule 4
ROSUVASTATIN
Schedule 4
ROTENONE
cross reference: CUBE
Schedule 6
ROTIGOTINE
Schedule 4
Appendix K
ROXIBOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ROXITHROMYCIN
Schedule 4
RUBELLA VACCINE
Schedule 4
RUBOXISTAURIN
Schedule 4
RUFINAMIDE
Schedule 4
Appendix K
Appendix L, Part 2
RUPATADINE
Schedule 4
Appendix K
RUXOLITINIB
Schedule 4
S
SACUBITRIL
Schedule 4
SAFINAMIDE
Schedule 4
SAFLUFENACIL
Schedule 7
Schedule 5
SAFROLE
cross reference: SASSAFRAS OIL
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SAGE OIL
cross reference: DALMATIAN, THUJONE
Schedule 6
Appendix E, Part 2
SAGE OIL (Spanish)
cross reference: CAMPHOR
Appendix B, Part 3
SALBUTAMOL
Schedule 4
Schedule 3
Appendix F, Part 3
SALCATONIN
cross reference: CALCITONIN SALMON
SALICYLAMIDE
cross reference: ASPIRIN, CAFFEINE, PARACETAMOL
Schedule 4
Schedule 2
Appendix F, Part 3
SALICYLANILIDE
Schedule 5
SALICYLIC ACID
cross reference: CHOLINE SALICYLATE
Schedule 3
Appendix H
SALINOMYCIN
Schedule 6
Schedule 4
SALMETEROL
Schedule 4
SALVIA DIVINORUM
Schedule 9
SANDALWOOD OIL
Appendix B, Part 3,
SANTONIN
Schedule 3
SAPROPTERIN
Schedule 4
SAQUINAVIR
Schedule 4
SARILUMAB
Schedule 4
SAROLANER
Schedule 5
Schedule 6
SASSAFRAS OIL
cross reference: SAFROLE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SAXAGLIPTIN
Schedule 4
SCHOENOCAULON OFFICINALE
cross reference: SABADILLA
Schedule 4
SCHRADAN
Schedule 7
SCOPOLIA CARNIOLICA
Schedule 4
SEAWEED
Appendix B, Part 3
SEBELIPASE ALFA
Schedule 4
SECBUTOBARBITAL
Schedule 8
Appendix K
SECBUTOBARBITONE
cross reference: SECBUTOBARBITAL
SECOBARBITAL
Schedule 8
Appendix K
SECUKINUMAB
Schedule 4
SEDAXANE
Schedule 5
SEEDS
Appendix A
SELAMECTIN
Schedule 5
SELECTIVE ANDROGEN RECEPTOR MODULATORS
cross reference: SARM
Schedule 4
Appendix D, Item 5
SELEGILINE
Schedule 4
SELENIUM
cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM ARSENIDE, SELENIUM SULFIDE
Schedule 7
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
Appendix G
SELEXIPAG
Schedule 4
SEMDURAMICIN
Schedule 7
Schedule 6
SENECIO spp.
Schedule 10
SERELAXIN
Schedule 4
SERMORELIN
Schedule 4
SERTINDOLE
Schedule 4
SERTRALINE
Schedule 4
SETHOXYDIM
Schedule 5
SEVELAMER
Schedule 4
SEVOFLURANE
Schedule 4
SEX HORMONES
Schedule 4
SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1
cross reference: EPIDERMAL GROWTH FACTOR
SIBUTRAMINE
Schedule 4
SIDURON
Schedule 5
SILANDRONE
Schedule 4
Appendix D, Item 5 (Anabolic steroidal agent)
SILDENAFIL
Schedule 4
SILICOFLUORIDES
cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES, HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE,
Schedule 6
Schedule 5
SILICONES
Schedule 10
Schedule 4
Appendix F, Part 3
SILODOSIN
Schedule 4
SILTUXIMAB
Schedule 4
SILVER
Schedule 2
SILVER NITRATE
cross reference: SILVER SALTS
Schedule 6
Appendix E, Part 2
SILVER OXIDE
Appendix B, Part 3
SILVER SULFADIAZINE
Schedule 4
SIMAZINE
Appendix B, Part 3
SIMEPREVIR
Schedule 4
SIMVASTATIN
Schedule 4
SINBIOALLETHRIN
Schedule 6
Schedule 5
SINGLE-USE TUBES
Appendix A
SIROLIMUS
Schedule 4
SISOMICIN
Schedule 4
SITAGLIPTIN
Schedule 4
SITAXENTAN
Schedule 4
Appendix D, Item 6
Appendix F, Part 3
Appendix L, Part 2
SLIMICIDES
Appendix A
SODIUM ALUMINATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SODIUM BICARBONATE
Appendix B, Part 3
SODIUM BROMATE
Schedule 6
Appendix E, Part 2
SODIUM BROMIDE
Schedule 4
SODIUM CELLULOSE PHOSPHATE
Schedule 4
SODIUM CHLORATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM CROMOGLYCATE
Schedule 4
Schedule 2
SODIUM DIACETATE
Schedule 5
Appendix E, Part 2
SODIUM DICHLOROISOCYANURATE
Appendix E, Part 2
SODIUM DODECYLBENZENE SULFONATE
Schedule 5
Appendix E, Part 2, Part
Appendix F, Part 3
SODIUM FLUORIDE
Appendix F, Part 3
SODIUM HYDROGEN SULFATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM HYDROSULFITE
Schedule 5
Appendix F, Part 3
SODIUM HYDROXIDE
cross reference: LYE WATER
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM LAURETH-6 CARBOXYLATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM METABISULPHITE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM MORRHUATE
Schedule 4
SODIUM NITRITE
Schedule 7
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
SODIUM NITROPRUSSIDE
Schedule 4
SODIUM OXYBATE
Schedule 8
Appendix D, Item 1
Appendix K
SODIUM PERCARBONATE
Schedule 6
Schedule 5
Appendix E, Part 2
SODIUM PERSULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SODIUM PHENYLBUTYRATE
Schedule 4
SODIUM PHOSPHATE
Schedule 4
Schedule 3
SODIUM PICOSULFATE
Schedule 3
SODIUM POLYSTYRENE SULPHONATE
Schedule 5
Schedule 4
SODIUM PROPIONATE
Appendix B, Part 3
SODIUM SALICYLATE
Schedule 4
SODIUM STANNATE
Schedule 5,
Appendix E, Part 2
SODIUM SULFIDE
Schedule 5, Schedule 6, Appendix E, Part 2, Appendix F, Part 3
SODIUM TETRADECYLSULFATE
Schedule 4
SODIUM TRICHLOROACETATE
Appendix E, Part 2
SODIUM ZIRCONIUM CYCLOSILICATE.
Schedule 4
SODIUMHYDROSULFITE
Appendix E, Part 2
SOFOSBUVIR
Schedule 4
SOLASODINE
Schedule 4
SOLIFENACIN
Schedule 4
SOMATOSTATIN
Schedule 4
SOMATOTROPIN EQUINE
Schedule 4
SOMATROPIN
cross reference: HUMAN GROWTH HORMONE
Schedule 4
Appendix D, Item 5
Appendix G
SONIDEGIB
Schedule 4
SONTOQUINE
Schedule 4
SORAFENIB
-Schedule 4
SOTALOL
Schedule 4
SPARFLOXACIN
Schedule 4
SPARTEINE
Schedule 4
SPECTINOMYCIN
Schedule 4
SPINETORAM
Schedule 5
SPINOSAD
Schedule 5
SPIRAMYCIN
Schedule 4
SPIRAPRIL
Schedule 4
SPIRONOLACTONE
Schedule 4
SPIROTETRAMAT
Schedule 6
SPIROXAMINE
Schedule 6
SQUILL
Schedule 2
STANOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
STANOZOLOL
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
STAR ANISE OIL
Schedule 5
STAVUDINE
Schedule 4
STENABOLIC (SR9009) and other synthetic REV-ERB agonists
cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667
Schedule 4
Appendix D, Item 5
STENBOLONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
STERIC ACID
Appendix B, Part 3
STEROID HORMONES
Schedule 4
STILBESTROL
cross reference: STILBOESTROL, DIETHYLSTILBESTROL
Schedule 4
STIRIPENTOL
Schedule 4
Appendix K
STREPTODORNASE
Schedule 4
STREPTOKINASE
Schedule 4
STREPTOMYCES LYDICUS WYEC 108
Appendix B, Part 3
STREPTOMYCIN
Schedule 4
STRONTIUM RANELATE
Schedule 4
STROPHANTHINS
Schedule 4
STROPHANTHUS spp.
Schedule 4
Appendix G
STRYCHNINE
cross reference: NUX VOMICA
Schedule 7
Schedule 4
Appendix E, Part 2
Appendix G
Appendix J, Part 2
STRYCHNOS spp.
Schedule 4
STYRAMATE
Schedule 4
STYRENE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Part 1 - Interpretation
SUCCIMER
Schedule 4
SUCRALFATE
Appendix B, Part 3
SUFENTANIL
Schedule 8
SUGAMMADEX
Schedule 4
SULBACTAM
Schedule 4
SULCOFURON
Schedule 7
Schedule 6
Appendix E, Part 2
Appendix J, Part 2
SULCONAZOLE
Schedule 4
Schedule 2,
SULESOMAB
Appendix B, Part 3
SULFACETAMIDE
Schedule 5
Schedule 4
Schedule 3
SULFADIAZINE
Schedule 5
Schedule 4
SULFADIMETHOXINE
Schedule 4
SULFADIMIDINE
Schedule 5
Schedule 4
SULFADOXINE
Schedule 4
SULFAFURAZOLE
Schedule 4
SULFAGUANIDINE
Schedule 4
SULFAMERAZINE
Schedule 5
Schedule 4
SULFAMETHIZOLE
Schedule 4
SULFAMETHOXAZOLE
Schedule 4
SULFAMETHOXYDIAZINE
Schedule 4
SULFAMETHOXYPYRIDAZINE
Schedule 4
SULFAMETROLE
Schedule 4
SULFAMIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SULFAMONOMETHOXINE
Schedule 4
SULFAMOXOLE
Schedule 4
SULFAPHENAZOLE
Schedule 4
SULFAPYRIDINE
Schedule 4
SULFAQUINOXALINE
Schedule 4
SULFASALAZINE
Schedule 4
SULFATHIAZOLE
Schedule 5
Schedule 4,
SULFATROXAZOLE
Schedule 4
SULFENTRAZONE
Schedule 7
SULFINPYRAZONE
Schedule 4
SULFLURAMID
Schedule 6
SULFOMETURON-METHYL
Schedule 5
SULFOMYXIN
Schedule 4
SULFONAMIDES
cross reference: SULFACETAMIDE, SULPHANILAMIDE
Schedule 4
SULFONMETHANE
cross reference: ALKYL SULFONALS, SULFONAL
Schedule 4
SULFOSULFURON
Appendix B, Part 3
SULFOTEP
Schedule 7
SULFOXAFLOR
Schedule 6
Schedule 5
SULFURIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SULFURYL FLUORIDE
Schedule 6
SULINDAC
Schedule 4
SULPHATED POLYSACCHARIDES
Appendix B, Part 3
SULPROFOS
Schedule 6
SULTAMICILLIN
Schedule 4
SULTHIAME
Schedule 4
SUMATRIPTAN
Schedule 4
SUNITINIB
Schedule 4
SUPROFEN
Schedule 4
SUTILAINS
Schedule 4
SUVOREXANT
Schedule 4
Appendix K
SUXAMETHONIUM
Schedule 4
SUXETHONIUM
Schedule 4
SYMPHYTUM spp.
cross reference: COMFREY
Schedule 10
Schedule 5
Appendix F, Part 3
SYNTHETIC CANNABINOMIMETICS
Schedule 9
T
2,4,5-T
Schedule 6
TACRINE
Schedule 4
TACROLIMUS
Schedule 4
TADALAFIL
Schedule 4
TAFENOQUINE SUCCINATE
Schedule 4
TAFLUPROST
Schedule 4
TALIGLUCERASE ALFA
Schedule 4
TALIMOGENE LAHERPAREPVEC
Schedule 4
TALLOW ALKYLAMINE ACETATES
Schedule 6
N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE
Schedule 6
TAMOXIFEN
Schedule 4
TAMSULOSIN
Schedule 4
TANACETUM VULGARE
cross reference: OIL OF TANSY, TANSY OIL
Schedule 4
TANNIC ACID
Appendix B, Part 3
TANNIC ACID/BENZYL ALCOHOL PRODUCT
Appendix B, Part 3
TAPENTADOL
Schedule 8
Appendix K
TAR ACIDS
Schedule 6
TASONERMIN
Schedule 4
TAZAROTENE
Schedule 4
Appendix F, Part 3
TAZOBACTAM
Schedule 4
2,3,6-TBA
Schedule 5
T-CELL RECEPTOR ANTIBODY
Schedule 4
TCMTB
cross reference: 2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE
Schedule 6
TDE
cross reference: 1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE
Schedule 6
Schedule5
TEBUCONAZOLE
cross reference: TERBUCONAZOLE
Schedule 5
TEBUFENOZIDE
Schedule 5
TEBUFENPYRAD
Schedule 6
TEBUTHIURON
Schedule 6
TEDUGLUTIDE
Schedule 4
TEFLUTHRIN
Schedule 7
Schedule 5
TEGAFUR
Schedule 4
TEGASEROD
Schedule 4
TEICOPLANIN
Schedule 4
TELAPREVIR
Schedule 4
TELBIVUDINE
Schedule 4
TELITHROMYCIN
Schedule 4
TELMISARTAN
Schedule 4
TELOTRISTAT ETHYL
Schedule 4
TEMAZEPAM
Schedule 4
Appendix D, Item 5 (Benzodiazepine derivatives)
TEMEPHOS
Schedule 6
Schedule 5
TEMOZOLOMIDE
Schedule 4
TEMSIROLIMUS
Schedule 4
TENECTEPLASE
Schedule 4
TENIPOSIDE
Schedule 4
TENOCYCLIDINE
cross reference: TCP
Schedule 9
TENOFOVIR
Schedule 4
TENOXICAM
Schedule 4
TEPOXALIN
Schedule 4
TEPP
Schedule 8
TEPRALOXYDIM
Schedule 5
TERAZOSIN
Schedule 4
TERBACIL
Appendix B, Part 3,Part 3
TERBINAFINE
Schedule 4
Schedule 2
TERBUFOS
Schedule 7
TERBUTALINE
Schedule 4
Schedule 3
Appendix F, Part 3
TERBUTHYLAZINE
Schedule 6
TERBUTRYN
Schedule 5
TERFENADINE
Schedule 4
Appendix F, Part 3
TERIFLUNOMIDE
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
TERIPARATIDE
Schedule 4
Appendix D, Item 1
TERLIPRESSIN
Schedule 4
TERMITE BARRIERS
Appendix A
TERODILINE
Schedule 4
TEROPTERIN
Schedule 4
TERPENES, CHLORINATED
cross reference: CHLORINATED TERPENES
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
TESTOLACTONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
TESTOSTERONE
Schedule 6
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
Appendix G
TETANUS ANTITOXIN
Schedule 4
TETANUS TOXOID
Schedule 4
1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE
cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE
Schedule 5
TETRABENAZINE
Schedule 4
TETRACAINE
cross reference: AMETHOCAINE
Schedule 4
Schedule 2
TETRACHLOROETHANE
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
TETRACHLOROETHYLENE
cross reference: DESIGNATED SOLVENT
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
Part 1 - Interpretation
TETRACHLORVINPHOS
Schedule 5
TETRACONAZOLE
Schedule 6
Schedule 5
TETRACOSACTIDE
Schedule 4
TETRACOSACTRIN
cross reference: TETRACOSACTIDE
TETRACYCLINE
Schedule 5
Schedule 4
TETRADIFON
Schedule 6
TETRAETHYLAMMONIUM
Schedule 4
TETRAHYDROCANNABINOLIC ACID
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS
TETRAHYDROCANNABINOLS
cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS
Schedule 9
Schedule 8
Appendix D, Item 1
Appendix K
TETRAHYDROCANNABIDIVAROL
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS
TETRAHYDROZOLINE
cross reference: TETRYZOLINE
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE
cross reference: STABAXOL
Schedule 6
Schedule 7
Appendix J, Part 2
TETRAMETHRIN
Schedule 5
TETRAMISOLE
Schedule 6
TETROXOPRIM
Schedule 4
TETRYZOLINE
cross reference: TETRAHYDROZOLINE
Schedule 2
Appendix F, Part 3
TEZACAFTOR
Schedule 4
THALIDOMIDE
Schedule 4
Appendix D, Item 2
Appendix F, Part 3
Appendix L, Part 2
THALLIUM
cross reference: THALLIUM SULFATE
Schedule 7
Appendix J, Part 2
THAUMATIN
Appendix B, Part 3
THEBACON
Schedule 8
THEBAINE
Schedule 8
THENYLDIAMINE
Schedule 4
Appendix K
THEOPHYLLINE
Schedule 4
Schedule 3
THEVETIA PERUVIANA
Schedule 4
THEVETIN
Schedule 4
THIABENDAZOLE
Schedule 5
Schedule 2
THIACETARSAMIDE
Schedule 4
THIACLOPRID
Schedule 6
THIAMBUTOSINE
Schedule 4
THIAMETHOXAM
Schedule 6
Schedule 5
THIAZAFLURON
Schedule 6
THIAZOPYR
Schedule 5
THIAZOSULFONE
Schedule 4
THIDIAZURON
Appendix B, Part 3
THIETHYLPERAZINE
Schedule 4
Appendix K
THIFENSULFURON
Schedule 5
THIOACETAZONE
Schedule 4
THIOBENCARB
Schedule 5
THIOCARLIDE
Schedule 4
THIODICARB
Schedule 6
Schedule 5
THIOFANOX
Schedule 7
THIOFENTANYL
Schedule 9
THIOGUANINE
cross reference: TIOGUANINE
THIOMESTERONE
cross reference: TIOMESTERONE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
THIOMETON
Schedule 6
THIOPENTAL
Schedule 4
THIOPENTONE
cross reference: THIOPENTAL
THIOPHANATE-METHYL
Schedule 6
Schedule 5
THIOPROPAZATE
Schedule 4
Appendix K
THIOPROPERAZINE
Schedule 4
THIORIDAZINE
Schedule 4
Appendix K
THIOSTREPTON
Schedule 4
THIOTEPA
cross reference: TRIETHYLENE THIOPHOSPHORAMIDE
Schedule 4
THIOTHIXENE
Schedule 4
Appendix K
THIOURACIL
Schedule 4
THIOUREA
cross reference: ALKYL THIOUREAS
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
THIRAM
Schedule 6
THUJONE
Schedule 6
Appendix E, Part 2
THYME OIL
Schedule 5
Appendix E, Part 2
THYMOL
Schedule 6
THYMOXAMINE
Schedule 4
THYROID
Schedule 4
THYROTROPHIN
cross reference: TSH
Schedule 4
THYROXINE
Schedule 4
Appendix G
TIAGABINE
Schedule 4
TIAMULIN
Schedule 4
TIANEPTINE
Schedule 4
Appendix D, Item 5TIAPROFENIC ACID
Schedule 4
TIARAMIDE
Schedule 4
TIBOLONE
Schedule 4
TICAGRELOR
Schedule 4
TICARCILLIN
Schedule 4
TICLOPIDINE
Schedule 4
TIEMONIUM
Schedule 4
TIENILIC ACID
Schedule 4
TIGECYCLINE
Schedule 4
TIGLOIDINE
Schedule 4
TILDIPIROSIN
Schedule 4
TILETAMINE
Schedule 4
TILIDINE
Schedule 8
TILMANOCEPT
Schedule 4
TILMICOSIN
Schedule 4
TILUDRONIC ACID
cross reference: DISODIUM TILUDRONATE
Schedule 4
TIMBER
cross reference: WALLBOARD
Appendix A
TIMOLOL
Schedule 4
TIMOTHY-GRASS POLLEN EXTRACT
cross reference: PHLEUM PRATENSE POLLEN EXTRACT
Schedule 4
TIN ORGANIC COMPOUNDS
cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TIN-COMPOUNDS, TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS, TRIPROPYL TIN COMPOUNDS
Schedule 7
TINIDAZOLE
Schedule 4
TINZAPARIN
Schedule 4
TIOCARBAZIL
Schedule 5
TIOCONAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
TIOGUANINE
cross reference: THIOGUANINE
Schedule 4
TIOTROPIUM
Schedule 4
TIPEPIDINE
Schedule 4
TIPIRACIL
Schedule 4
TIPRANAVIR
Schedule 4
TIRILAZAD
Schedule 4
TIROFIBAN
Schedule 4
TOBRAMYCIN
Schedule 4
TOCAINIDE
Schedule 4
TOCERANIB
Schedule 4
TOCILIZUMAB
Schedule 4
TOFACITINIB
Schedule 4
TOLAZAMIDE
Schedule 4
TOLAZOLINE
Schedule 4
TOLBUTAMIDE
Schedule 4
TOLCAPONE
Schedule 4
TOLCLOFOS-METHYL
Schedule 5
TOLFENAMIC ACID
Schedule 4
TOLIDINE
Schedule 4
Appendix E, Part 2
TOLMETIN
Schedule 4
TOLONIUM
Schedule 4
TOLPROPAMINE
Schedule 4
TOLRESTAT
Schedule 4
TOLTERODINE
Schedule 4
TOLTRAZURIL
Schedule 5
TOLUENE
cross reference: XYLENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2,4-TOLUENEDIAMINE
Schedule 10
TOLUENEDIAMINES
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
o-TOLUIDINE
Schedule 10
TOLVAPTAN
Schedule 4
TOLYLFLUANID
Schedule 6
TOPIRAMATE
Schedule 4
TOPOTECAN
Schedule 4
TOPRAMEZONE
Schedule 5
TORASEMIDE
Schedule 4
TOREMIFENE
Schedule 4
TOXOIDS
Schedule 4
TRALKOXYDIM
Schedule 5
TRAMADOL
Schedule 4
Appendix K
TRAMAZOLINE
Schedule 2
Appendix F, Part 3
TRAMETINIB DIMETHYL SULFOXIDE
Schedule 4
TRANDOLAPRIL
Schedule 4
TRANEXAMIC ACID
cross reference: CETYL TRANEXAMATE
Schedule 4
TRANSFLUTHRIN
Schedule 6
TRANYLCYPROMINE
Schedule 4
Appendix K
TRASTUZUMAB
Schedule 4
TRASTUZUMAB EMTANSINE
Schedule 4
TRAVOPROST
Schedule 4
TRAZODONE
Schedule 4
TRENBOLONE
cross reference: TRIENBOLONE, TRIENOLONE
Schedule 5
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
TREOSULPHAN
Schedule 4
TREPROSTINIL
Schedule 4
TRESTOLONE
Schedule 4
Appendix D, Item 5 (androgenic steroidal agents)
TRETAMINE
Schedule 4
TRETINOIN
Schedule 4
Appendix D, Item 4
Appendix F, Part 3
Appendix L, Part 2
TRIACETYLOLEANDOMYCIN
Schedule 4
TRIADIMEFON
Schedule 6
Schedule 5
TRIADIMENOL
Schedule 5
TRI-ALLATE
Schedule 5
TRIAMCINOLONE
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3, Part 2
Appendix H
TRIAMIPHOS
Schedule 7
TRIAMTERENE
Schedule 4
TRIASULFURON
Appendix B, Part 3
TRIAZBUTIL
Schedule 7
TRIAZIQUONE
Schedule 4
TRIAZOLAM
Schedule 4
Appendix D, Item 5 (benzodiazepine derivatives)
TRIBENURON-METHYL
Schedule 5
TRIBUFOS
cross reference: s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE
Schedule 7
TRICHLORFON
cross reference: METRIFONATE
Schedule 6
TRICHLORMETHIAZIDE
Schedule 4
TRICHLOROACETIC ACID
Schedule 6
Schedule 5
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
TRICHLOROACETIC ACID ALKALI SALTS
Schedule 5
Appendix E, Part 2
1,1,1-TRICHLOROETHANE
cross reference: DESIGNATED SOLVENT
Schedule 10
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Part 1 - Interpretation
TRICHLOROETHYLENE
cross reference: TRICHLOROETHENE
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
TRICHLOROISOCYANURIC ACID
cross reference: CHLORINATING COMPOUNDS
Appendix E, Part 2
TRICHLOROPHENOL
Schedule 6
Appendix F, Part 3
TRICHODERMA HARZIANUM
Appendix B, Part 3
TRICHODESMA AFRICANA
Schedule 10
TRICLABENDAZOLE
Schedule 6
TRICLOFOS
Schedule 4
TRICLOPYR
Schedule 6
TRICLOSAN
Schedule 6
TRICYCLAMOL
Schedule 4
TRIDEMORPH
Schedule 6
TRIDIHEXETHYL
Schedule 4
TRIDIPHANE
Schedule 5
TRIETAZINE
Schedule 5
TRIETHANOLAMINE
cross reference: TROLAMINE
TRIETHYL PHOSPHATE
Schedule 6
Appendix E, Part 2
TRIETHYLENE GLYCOL
Appendix B, Part 3
TRIFLOXYSTROBIN
Schedule 5
TRIFLOXYSULFURON
Appendix B, Part 3
TRIFLUMIZOLE
Schedule 5
TRIFLUMURON
Schedule 5
TRIFLUOPERAZINE
Schedule4
Appendix K
TRIFLUOROMETHANESULFONIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE
cross reference: TFMPP
Schedule 9
TRIFLUPERIDOL
Schedule 4
TRIFLUPROMAZINE
Schedule 4
TRIFLURALIN
Appendix B, Part 3
TRIFLURIDINE
Schedule 4
TRIFORINE
Appendix B, Part 3
TRIHEXYPHENIDYL
cross reference: BENZHEXOL
Schedule 4
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
TRILOSTANE
Schedule 4
TRIMEPERIDINE
Schedule 9
TRIMEPRAZINE
cross reference: ALIMEMAZINE
TRIMETAPHAN
Schedule 4
TRIMETHOPRIM
Schedule 4
3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE
cross reference: TMA
Schedule 9
3,4,5-TRIMETHOXYPHENETHYLAMINE
cross reference: MESCALINE, METHOXYPHENAMINE, METHOXY-PHENYLETHYLAMINE
Schedule 9
1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE
Schedule 9
TRIMIPRAMINE
Schedule 4
Appendix K
TRIMUSTINE
Schedule 4
TRINEXAPAC-ETHYL
Schedule 5
TRINITROPHENOL
Schedule 6
Schedule 4
3,6,9-TRIOXAUNDECANEDIOIC ACID
Schedule 5
Appendix F, Part 3
TRIOXYSALEN
Schedule 4
TRIPARANOL
Schedule 10
TRIPELENNAMINE
Schedule 4
TRIPLE ANTIGEN VACCINE
cross reference: DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID
Schedule 4
TRIPROLIDINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
TRIPTORELIN
Schedule 4
TRISODIUM NITRILOTRIACETATE
Schedule 6
TRITICONAZOLE
Schedule 5
TROGLITAZONE
Schedule 4
TROLAMINE
Schedule 5
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
TROMETAMOL
Schedule 4
TROPICAMIDE
Schedule 4
TROPISETRON
Schedule 4
TROVAFLOXACIN
Schedule 4
TROXIDONE
Schedule 4
TRYPTOPHAN
Schedule 4
TUAMINOHEPTANE
Schedule 2
TUBERCULIN
Schedule 4
TUBOCURARINE
Schedule 4
TULATHROMYCIN
Schedule 4
TULOBUTEROL
Schedule 4
TURPENTINE OIL
cross reference: OIL OF TURPENTINE
Schedule 5
Appendix E, Part 2
TUSSILAGO FARFARA
cross reference: COLTSFOOT
Schedule 10
TYLOSIN
Schedule 4
TYMAZOLINE
Schedule 4
Appendix F, Part 3
TYPHOID VACCINE
Schedule 4
U
ULIPRISTAL
Schedule 4
Schedule 3
Appendix H
ULOCLADIUM OUDEMANSII
Appendix B, Part 3
UMECLIDINIUM
Schedule 4
UNOPROSTONE
Schedule 4
URACIL
Schedule 4
URAPIDIL
Schedule 4
UREA
Appendix B, Part 3
URETHANE
Schedule 4
UROFOLLITROPIN
cross reference: FOLLICLE-STIMULATING HORMONE, HUMAN
Schedule 4
Appendix D, Item 1
UROKINASE
Schedule 4
URSODEOXYCHOLIC ACID
Schedule 4
USTEKINUMAB
Schedule 4
V
VACCINES
Schedule 4
VACCINES – PLASMID DNA
cross reference: PLASMID DNA (rE. coli DH5α pINGhT)
Schedule 4
VACCINIA VIRUS VACCINE
Schedule 4
VALACICLOVIR
Schedule 4
VALDECOXIB
Schedule 4
VALGANCICLOVIR
Schedule 4
VALNOCTAMIDE
Schedule 4
VALPROIC ACID
Schedule 4
VALSARTAN
Schedule 4
VAMIDOTHION
Schedule 6
VANCOMYCIN
Schedule 4
VANDETANIB
Schedule 4
VARDENAFIL
Schedule 4
VARENICLINE
Schedule 4
VARICELLA VACCINE
Schedule 4
VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT)
cross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
VASOPRESSIN
Schedule 4
VECURONIUM
Schedule 4
VEDAPROFEN
Schedule 4
VEDOLIZUMAB
Schedule 4
VELAGLUCERASE ALFA
Schedule 4
VELPATASVIR
Schedule 4
VEMURAFENIB
Schedule 4
VENETOCLAX
Schedule 4
VENLAFAXINE
Schedule 4
VERAPAMIL
Schedule 4
VERATRUM
Schedule 4
VERNAKALANT
Schedule 4
VERNOLATE
Schedule 5
VERTEPORFIN
Schedule 4
VETIVER OIL
Appendix B, Part 3
VIDARABINE
Schedule 4
VIGABATRIN
Schedule 4
VILANTEROL
Schedule 4
VILDAGLIPTIN
Schedule 4
VILOXAZINE
Schedule 4
VINBLASTINE
Schedule 4
VINCAMINE
Schedule 4
VINCLOZOLIN
Schedule 6
Appendix F, Part 3
VINCRISTINE
Schedule 4
VINDESINE
Schedule 4
VINFLUNINE
Schedule 4
VINORELBINE
Schedule 4
VINYL ACETATE MONOMER
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
VINYL CHLORIDE
Schedule 7
Appendix J, Part 2
VINYL ETHER
Schedule 4
VIRGINIAMYCIN
Schedule 5
Schedule 4
VISMODEGIB
Schedule 4
VISNADINE
Schedule 4
VITAMIN A
Schedule 4
VITAMIN D
cross reference: COLECALCIFEROL, ERGOCALCIFEROL
Schedule 4
Schedule 3
Appendix H
VITAMIN K
cross reference: PHYTOMENADIONE
Appendix B, Part 3
VITREOUS ENAMELS
Appendix A
VORAPAXAR
Schedule 4
VORICONAZOLE
Schedule 4
VORINOSTAT
Schedule 4
VORTIOXETINE
Schedule 4
VOXILAPREVIR
Schedule 4
W
WALLBOARD
cross reference: TIMBER
Appendix A
WARFARIN
Schedule 6
Schedule 5
Schedule 4
WRITING CORRECTION PENS
Appendix A
X
XAMOTEROL
Schedule 4
XANTHINOL NICOTINATE
Schedule 4
XANTHOPHYLL
cross reference: LUTEIN
Appendix B, Part 3
XIMELAGATRAN
Schedule 4
XIPAMIDE
Schedule 4
XYLANASE derived from Aspergillus niger
Appendix B, Part 3
XYLAZINE
Schedule 4
XYLENE
cross reference: TOLUENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
XYLOMETAZOLINE
Schedule 2
Appendix F, Part 3
Y
YLANG YLANG OIL
Appendix B, Part 3
YOHIMBINE
cross reference: ASPIDOSPERMA QUEBRACHO
Schedule 4
Z
(Z)-9-TRICOSENE
cross reference: TRICOSENE
Appendix B, Part 3
ZAFIRLUKAST
Schedule 4
ZALCITABINE
Schedule 4
ZALEPLON
Schedule 4
ZANAMIVIR
Schedule 4
ZERANOL
Schedule 6
Schedule4
ZETA-CYPERMETHRIN
Schedule 7
Schedule 6
ZIDOVUDINE
Schedule 4
ZILPATEROL
Schedule 4
ZIMELDINE
Schedule 4
ZINC BORATE
Schedule 6
ZINC CHLORIDE
Schedule4
Appendix E, Part 2
ZINC COMPOUNDS
Schedule 4
ZINC LACTATE
Schedule 6
Appendix F, Part 3
ZINC NAPHTHENATE
Appendix B, Part 3
ZINC para-PHENOLSULFONATE
Schedule 6
ZINC SULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ZINEB
cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM
Schedule 5
ZIPRASIDONE
Schedule 4
Appendix K
ZIRAM
Schedule 7
Schedule 6
ZOLAZEPAM
Schedule 4
ZOLEDRONIC ACID
Schedule 4
ZOLMITRIPTAN
Schedule 4
ZOLPIDEM
Schedule4
Appendix K
ZONISAMIDE
Schedule 4
Appendix K
ZOPICLONE
Schedule 4
Appendix K
ZOXAZOLAMINE
Schedule 4
ZUCLOPENTHIXOL
Schedule 4